FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Jaff, MR AF Jaff, Michael R. BE Mohler, ER GerhardHerman, M Jaff, MR TI Renal Artery Duplex Ultrasonography SO ESSENTIALS OF VASCULAR LABORATORY DIAGNOSIS LA English DT Article; Book Chapter ID NATURAL-HISTORY; RENOVASCULAR HYPERTENSION; ISCHEMIC NEPHROPATHY; VASCULAR-DISEASE; FOLLOW-UP; STENOSIS; ULTRASOUND; RISK; PREVALENCE; DIAGNOSIS C1 Massachusetts Gen Hosp, Vasc Ultrasound Core Lab, Boston, MA 02114 USA. RP Jaff, MR (reprint author), Massachusetts Gen Hosp, Vasc Ultrasound Core Lab, Boston, MA 02114 USA. NR 24 TC 1 Z9 2 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-98741-4 PY 2005 BP 75 EP 83 D2 10.1002/9780470987414 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA BYC25 UT WOS:000297921300009 ER PT J AU Marchini, S Marrazzo, E Bonomi, R Chiorino, G Zaffaroni, M Weissbach, L Hornicek, FJ Broggini, M Faircloth, GT D'Incalci, A AF Marchini, S Marrazzo, E Bonomi, R Chiorino, G Zaffaroni, M Weissbach, L Hornicek, FJ Broggini, M Faircloth, GT D'Incalci, A TI Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743 SO EUROPEAN JOURNAL OF CANCER LA English DT Article DE microarrays; ET-743; drug-resistant cells ID OVARIAN-CARCINOMA CELLS; ANTITUMOR-ACTIVITY; ECTEINASCIDIN-743 ET-743; MULTIDRUG TRANSPORTER; MICROARRAY DATA; LEUKEMIA-CELLS; P-GLYCOPROTEIN; EXPRESSION; COMPOUND; XENOGRAFTS AB ET-743 (Yondelis(TM), Trabectedin) isolated from the tunicate Ecteinascidia turbinata, is being tested in phase II clinical trials in Europe and the United States of America (USA). Studies with different solid tumours have shown antitumour activity in advanced, pre-treated sarcomas as well as in drug-resistant breast and ovarian cancer. The primary mechanism of action for ET-743 has not been fully elucidated and different models have been suggested to explain its molecular mechanism of action. ET-743 binds tightly to the minor groove of DNA and previous data have suggested that ET-743 acts by interfering with RNA transcription. To further investigate the mechanism of in vitro drug resistance, we evaluated the gene expression profile in ovarian and chondrosarcoma cell lines selected for resistance to ET-743. We found 70 genes whose expression was modulated in both drug-resistant cell lines when compared with their respective parental drug-sensitive cell lines. This pattern of gene expression seems to be selective for ET-743-resistant cells, since ovarian cancer cells resistant to paclitaxel did not share the same gene expression changes. Data presented in this study reveal different molecular pathways that could be involved in the cellular mechanism of ET-743 resistance. (C) 2004 Elsevier Ltd. All rights reserved. C1 Mario Negri Inst Pharmacol Res, Dept Oncol, Mol Pharmacol Lab, I-20157 Milan, Italy. Fondo Edo Tempia, I-13900 Biella, Italy. Massachusetts Gen Hosp, Orthopaed Res Labs, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. PharmaMar USA, Cambridge, MA 02139 USA. RP Marchini, S (reprint author), Mario Negri Inst Pharmacol Res, Dept Oncol, Mol Pharmacol Lab, Via Eritrea 62, I-20157 Milan, Italy. EM marchini@marionegri.it RI Chiorino, Giovanna/K-5037-2016; OI Chiorino, Giovanna/0000-0002-9502-6400; BROGGINI, MASSIMO/0000-0002-8138-9358; D'Incalci, Maurizio/0000-0001-8784-1360 NR 40 TC 21 Z9 21 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PD JAN PY 2005 VL 41 IS 2 BP 323 EP 333 DI 10.1016/j.ejca.2004.10.021 PG 11 WC Oncology SC Oncology GA 896WY UT WOS:000226966300028 PM 15661559 ER PT J AU Cannon, JP Lee, TA Bolanos, JT Danziger, LH AF Cannon, JP Lee, TA Bolanos, JT Danziger, LH TI Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES LA English DT Review ID VANCOMYCIN-RESISTANT LACTOBACILLI; LACTIC-ACID BACTERIA; INFECTIVE ENDOCARDITIS; ANTIMICROBIAL SUSCEPTIBILITY; ANTIBIOTIC SUSCEPTIBILITY; PLANTARUM ENDOCARDITIS; TRANSPLANT RECIPIENT; RHAMNOSUS SEPTICEMIA; NEUTROPENIC PATIENTS; TORULOPSIS-GLABRATA AB Given that Lactobacillus has been reported to be the causative pathogen in many types of infection despite debate regarding the organism's clinical significance, a literature review was conducted to investigate the treatments and outcomes of Lactobacillus infections reported to date. In this article, the characteristics of over 200 reported cases of Lactobacillus-associated infections are summarized. Lactobacillus was found to be frequently associated with endocarditis and bacteremia. Lactobacillus was also associated with a variety of other infections including, but not limited to, peritonitis, abscesses, and meningitis. The species casei and rhamnosus were the most common. The isolates tended to be most sensitive to erythromycin and clindamycin and most resistant to vancomycin. The species that was most sensitive to vancomycin was acidophilus. The overall mortality rate was nearly 30%. There was a significant association between mortality and polymicrobial infection (P=0.004). In the subset of patients with bacteremia, increased mortality was associated with inadequate treatment (P=0.001) and polymicrobial bacteremia (P=0.044). C1 Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60611 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Serv Pharm, Hines, IL 60141 USA. Northwestern Univ, Feinberg Sch Med, Dept Med, Div Gen Internal Med,Ctr Healthcare Studies, Chicago, IL 60611 USA. Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Chicago, IL 60612 USA. Univ Illinois, Dept Med, Infect Dis Sect, Chicago, IL 60612 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Midw Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. RP Danziger, LH (reprint author), Univ Illinois, Coll Pharm, Dept Pharm Practice, 833 S Wood St,Mail Code 886, Chicago, IL 60611 USA. EM danziger@uic.edu NR 113 TC 150 Z9 163 U1 3 U2 16 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0934-9723 J9 EUR J CLIN MICROBIOL JI Eur. J. Clin. Microbiol. Infect. Dis. PD JAN PY 2005 VL 24 IS 1 BP 31 EP 40 DI 10.1007/s10096-004-1253-y PG 10 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 889RD UT WOS:000226459200006 PM 15599646 ER PT J AU Linette, GP Carlson, JA Slominski, A Mihm, MC Ross, JS AF Linette, GP Carlson, JA Slominski, A Mihm, MC Ross, JS TI Biomarkers in melanoma: Stage III and IV disease SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS LA English DT Review DE biomarkers; investigational agents; melanoma; prognostic factors; Stage III; Stage IV; vaccines ID METASTATIC MALIGNANT-MELANOMA; AMERICAN JOINT COMMITTEE; TUMOR-INFILTRATING LYMPHOCYTES; TYROSINASE MESSENGER-RNA; N-RAS MUTATIONS; CUTANEOUS MELANOMA; PROGNOSTIC-FACTORS; LYMPH-NODE; ADJUVANT INTERFERON; LACTATE-DEHYDROGENASE AB The prognosis associated with Stage III melanoma Is variable (17-65% 5-year survival) and primarily Influenced by the number of lymph nodes Involved, the presence of ulceration In a primary lesion, and the tumor burden present In each lymph node. In patients with metastatic (Stage IV) melanoma, the prognosis remains dismal (6-18% 5-year survival) and Is Influenced primarily by the sites (and extent) of metastatic Involvement. Serum lactate dehydrogenase Is the only prognostic biomarker useful In metastatic melanoma and it has been Incorporated Into the 2002 American Joint Committee on Cancer tumor, node, metastasis staging system. In this review, the known prognostic factors In Stage III and IV melanoma are reviewed. Selected Investigational therapies and associated biomarkers are also discussed. C1 Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA. Albany Med Coll, Albany, NY 12208 USA. Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA. Massachusetts Gen Hosp, Div Dermatopathol, Boston, MA 02114 USA. Albany Med Coll Union Univ, Dept Pathol & Lab Med, Albany, NY 12208 USA. RP Linette, GP (reprint author), Washington Univ, Sch Med, Div Oncol, Campus Box 8056, St Louis, MO 63110 USA. EM glinette@im.wustl.edu; carlsona@mail.amc.edu; aslominski@utmem.edu; martin.mihm@mgh.harvard.edu; rossj@mail.amc.edu OI Carlson, John Andrew/0000-0002-6866-6314 NR 76 TC 14 Z9 14 U1 0 U2 0 PU FUTURE DRUGS LTD PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEYY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7159 J9 EXPERT REV MOL DIAGN JI Expert Rev. Mol. Diagn. PD JAN PY 2005 VL 5 IS 1 BP 65 EP 74 DI 10.1586/14737159.5.1.65 PG 10 WC Pathology SC Pathology GA 940SD UT WOS:000230163500008 PM 15723593 ER PT J AU Bandipalliam, P AF Bandipalliam, P TI Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations SO FAMILIAL CANCER LA English DT Review DE hematologic malignancies; hereditary nonpolyposis colon cancer; mismatch repair gene mutations; neurofibromatosis ID NONPOLYPOSIS COLORECTAL-CANCER; MUIR-TORRE-SYNDROME; MICROSATELLITE INSTABILITY; TRANSGENIC EXPRESSION; BETHESDA GUIDELINES; TURCOTS-SYNDROME; LYNCH-SYNDROME; HUMAN MGMT; MICE; PMS2 AB Hereditary nonpolyposis colon cancer (HNPCC) is the most common hereditary colon cancer syndrome. It is characterized by multiple colon as well as extracolonic cancers such as endometrial, ovarian and urinary tract cancers. In addition, it is well known that some cases of HNPCC can present with unique tumor spectrums such as sebaceous tumors, which is often referred to as the 'Muir-Torre' syndrome. In recent years there have been a few reports of families presenting with early onset of colon tumors along with cafe-au-lait spots and/or hematologic malignancies often associated with homozygous mutations involving one of the mismatch repair genes. In this article we have performed a comprehensive review of the entire medical literature to identify all cases with similar presentations reported in the literature and have summarized the clinical features and genetic test results of the same. The available data clearly highlight such presentations as a distinct clinical entity characterized by early onset of gastrointestinal tumors, hematologic malignancies as well as features of neurofibromatosis (easily remembered by the acronym 'CoLoN'; Colon tumors or/and Leukemia/Lymphoma or/and Neurofibromatosis features). Furthermore, there has also been some evidence that the neurofibromatosis type-1 gene is a mutational target of the mismatch repair deficiency that is seen in families with HNPCC, and that mlh1 deficiency can accelerate the development of leukemia in neurofibromatosis (Nf1) heterozygous mice. Recognition of this syndrome has significant importance in terms of earlier detection of cancers, cancer screening recommendations as well as genetic counseling offered to such families. C1 Dana Farber Canc Inst, Div Populat Sci, Dept Adult Oncol, Boston, MA 02115 USA. RP Bandipalliam, P (reprint author), Dana Farber Canc Inst, Div Populat Sci, Dept Adult Oncol, Boston, MA 02115 USA. NR 37 TC 62 Z9 65 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1389-9600 J9 FAM CANCER JI Fam. Cancer PY 2005 VL 4 IS 4 BP 323 EP 333 DI 10.1007/s10689-005-8351-6 PG 11 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA 012PQ UT WOS:000235351800011 PM 16341812 ER PT S AU Kleinman, RE AF Kleinman, RE BE Hernell, O Schmitz, J TI Chronic nonspecific diarrhea of childhood SO Feeding During Late Infancy and Early Childhood: Impact on Health SE NESTLE NUTRITION WORKSHOP SERIES PEDIATRIC PROGRAM LA English DT Proceedings Paper CT 56th Nestle Pediatric Nutrition Workshop CY NOV 14-18, 2004 CL Noordwijk, NETHERLANDS ID TODDLER DIARRHEA; CARBOHYDRATE-ABSORPTION; YOUNG-CHILDREN; FLUID INTAKE; FRUIT JUICE; APPLE JUICE; FRUCTOSE; INFANTS; LOPERAMIDE; STARCH C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02114 USA. RP Kleinman, RE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02114 USA. NR 26 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0742-2806 BN 3-8055-7906-3 J9 NESTLE NUTR WORKS SE PY 2005 VL 56 BP 73 EP 84 DI 10.1159/000086276 PG 12 WC Nutrition & Dietetics; Pediatrics SC Nutrition & Dietetics; Pediatrics GA BDD04 UT WOS:000232792000006 PM 16632945 ER PT J AU Gurmankin, AD Caplan, AL Braverman, AM AF Gurmankin, AD Caplan, AL Braverman, AM TI Screening practices and beliefs of assisted reproductive technology programs SO FERTILITY AND STERILITY LA English DT Article DE IVF; access; screening AB Objective: To explore assisted reproductive technology (ART) programs' beliefs about and practices for screening program candidates for the use of ART services. Design: An anonymous, self-administered, mailed questionnaire. Setting: U.S. ART programs. Participant(s): Director of U.S. ART programs. Main Outcome Measure(s): Screening practices and beliefs, agreement with statements about screening rights and responsibility, information collected about candidates, and likelihood of turning away hypothetical candidates. Result(s): The majority of programs do not have a formal policy for screening candidates. The majority of program directors agree that they have a right and responsibility to screen candidates. On average, programs turn away 4% of candidates each year. The majority of programs report being very to extremely likely to deny treatment to the couples described in various scenarios, such as physical abuse, positive HIV status, and single parenthood. Significant variation was seen across programs in their likelihood of turning away various hypothetical candidates. Conclusion(s): There is substantial variation in ART programs' screening practices. These results highlight the need for increased debate over what constitutes inappropriate denial of access to services, and what are prudent, social, ethical, and medical judgment. (C)2005 by American Society for Reproductive Medicine. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Univ Penn, Dept Med Eth, Philadelphia, PA 19104 USA. Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. Penn Reprod Associates, Philadelphia, PA USA. RP Gurmankin, AD (reprint author), Dana Farber Canc Inst, 44 Binney St,Smith 253, Boston, MA 02115 USA. EM adg11@cornell.edu NR 20 TC 29 Z9 31 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD JAN PY 2005 VL 83 IS 1 BP 61 EP 67 DI 10.1016/j.fertnstert.2004.06.048 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 889LT UT WOS:000226445200008 PM 15652888 ER PT J AU Fleming, R Harborne, L MacLaughlin, DT Ling, D Norman, J Sattar, N Seifer, DB AF Fleming, R Harborne, L MacLaughlin, DT Ling, D Norman, J Sattar, N Seifer, DB TI Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment SO FERTILITY AND STERILITY LA English DT Article; Proceedings Paper CT 17th Meeting of the Latin-American-Association-of-Researchers-in-Human-Reproduction CY MAY 28-31, 2003 CL Varadero, CUBA SP Latin Amer Assoc Researchers Human Reprod DE mullerian-inhibiting substance; PCOS; metformin; ovarian follicles ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; HORMONE; HIRSUTISM; FOLLICLES AB Objective: Assessment of ovarian responses to metformin treatment in obese women with polycystic ovary syndrome (PCOS). Design: Prospective treatment with randomization to two doses of metformin. Setting: University teaching hospital. Patient(s): Obese women (n = 82) with PCOS. Intervention(s): Markers of ovarian function were assessed after 4 and 8 months. Main Outcome Measure(s): Hormone (androgens and mullerian-inhibiting substance [MIS]) changes over time. Result(s): There was no difference in the reproductive hormone changes between the doses of metformin, and data were combined for further analyses. Significant responses to treatment were recorded for menstrual frequency and androstenediona (A) (reduction) within the first 4 months of treatment. However, suppression of the elevated circulation MIS concentrations required protracted treatment, because no change was observed in the first 4 months-only in the second 4-month assessment period. Conclusion(s): Metformin treatment PCOS leads to rapid suppression of A and improved menstrual frequency. Suppression of MIS is a delayed response that may be secondary to the development of a cohort of follicles that underwent initial recruitment in an environment of reduced insulin stimulation. (C)2005 by American Society for Reproductive Medicine. C1 Univ Glasgow, Royal Infirm, Dept Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland. Massachusetts Gen Hosp, Paediat Res Lab, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Reprod Endocrinol & Infertil, Dept Obstet Gynecol & Reprod Sci, New Brunswick, NJ USA. RP Fleming, R (reprint author), Univ Glasgow, Royal Infirm, Dept Obstet & Gynaecol, Level 3 QEB, Glasgow G31 2ER, Lanark, Scotland. EM gqta13@udcf.gla.ac.uk RI Norman, Jane/B-2347-2010; OI Seifer, David/0000-0003-3950-9341 NR 25 TC 51 Z9 61 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD JAN PY 2005 VL 83 IS 1 BP 130 EP 136 DI 10.1016/j.fertnstert.2004.05.098 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 889LT UT WOS:000226445200018 PM 15652898 ER PT J AU Rahman, I AF Rahman, I TI Redox regulation of chromatin modeling in response to cigarette smoke: Impact on pro-inflammatory gene transcription SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 12th Annual Meeting Society-for-Free-Radical-Biology-and-Medicine CY NOV 16-20, 2005 CL Austin, TX SP Soc Free Rad Biol & Med C1 Univ Colorado, Denver VAMC, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2005 VL 39 SU 1 BP S2 EP S2 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 985VL UT WOS:000233406700002 ER PT J AU Valencia, A Kochevar, IE AF Valencia, A Kochevar, IE TI Role of NADPH-oxidase in the UVA-photosensitivity in Smith-Lemli-Opitz syndrome SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 12th Annual Meeting Society-for-Free-Radical-Biology-and-Medicine CY NOV 16-20, 2005 CL Austin, TX SP Soc Free Rad Biol & Med C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2005 VL 39 SU 1 BP S108 EP S108 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 985VL UT WOS:000233406700314 ER PT S AU Gleason, CE Carlsson, CM Johnson, S Atwood, C Asthana, S AF Gleason, CE Carlsson, CM Johnson, S Atwood, C Asthana, S BE Singh, M Simpkins, JW TI Clinical pharmacology and differential cognitive efficacy of estrogen preparations SO FUTURE OF HORMONE THERAPY: WHAT BASIC SCIENCE AND CLINICAL STUDIES TEACH US SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on the Future of Estrogen and Hormone Therapy Postmenopausal Women CY NOV 05-07, 2004 CL Ft Worth, TX SP Univ N Texas Hlth Sci Ctr DE estrogens; conjugated equine estrogen; 17 beta-estradiol; Alzheimer's disease; cognition; memory ID HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL; HEALTHY POSTMENOPAUSAL WOMEN; CONJUGATED EQUINE ESTROGENS; SURGICALLY MENOPAUSAL WOMEN; CORONARY-HEART-DISEASE; BRAIN METABOLIC-CHANGE; BETA-AMYLOID TOXICITY; TRANSDERMAL ESTRADIOL; RECEPTOR MODULATORS AB Menopause is associated with a significant decline in levels of estrogen, which reportedly leads to several distressing symptoms and adverse health effects on various target tissues including those on bones, heart, and brain. Although effective, the long-term safety and feasibility of therapy with both unopposed and opposed oral conjugated equine estrogen has been questioned by the recent findings of both the Women's Health Initiative (WHI) and the Women's Health Initiative Memory Study (WHIMS). The findings of both these studies have raised several critical issues related to hormone therapy that need to be systematically evaluated in clinical studies. Specifically, these issues relate to the differential efficacy and adverse-effects profile of various forms of estrogen and progestins, the importance of the route of administration of estrogen, the best timing to initiate postmenopausal hormone therapy, and the efficacy of cyclic versus continuous hormone therapy. This article focuses on estrogen and discusses issues related to selecting the best form and route of administration of the hormone. It includes information on basic clinical pharmacology of various forms of estrogen, neuroendocrinology of the menopause, neurobiology of estradiol and estrone, and results of selected basic science and human intervention studies with relevance to identifying the best form and route of administration of estrogen. C1 William S Middleton Mem Vet Adm Med Ctr, GRECC 11G, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Sect Geriatr & Gerontol, Dept Med, Madison, WI 53706 USA. RP Gleason, CE (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC 11G, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ceg@medicine.wisc.edu NR 112 TC 33 Z9 33 U1 1 U2 3 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-584-2 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1052 BP 93 EP 115 DI 10.1196/annals.1347.007 PG 23 WC Endocrinology & Metabolism; Multidisciplinary Sciences; Obstetrics & Gynecology SC Endocrinology & Metabolism; Science & Technology - Other Topics; Obstetrics & Gynecology GA BDE44 UT WOS:000233076700007 PM 16024754 ER PT S AU Webber, KM Casadesus, G Marlatt, MW Perry, G Hamlin, CR Atwood, CS Bowen, RL Smith, MA AF Webber, KM Casadesus, G Marlatt, MW Perry, G Hamlin, CR Atwood, CS Bowen, RL Smith, MA BE Singh, M Simpkins, JW TI Estrogen bows to a new master: The role of gonadotropins in Alzheimer pathogenesis SO FUTURE OF HORMONE THERAPY: WHAT BASIC SCIENCE AND CLINICAL STUDIES TEACH US SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on the Future of Estrogen and Hormone Therapy Postmenopausal Women CY NOV 05-07, 2004 CL Ft Worth, TX SP Univ N Texas Hlth Sci Ctr DE Alzheimer disease; andropause; estrogen; gonadotropins; luprolide acetate; luteinizing hormone; menopause ID RANDOMIZED CONTROLLED-TRIAL; HEALTH INITIATIVE MEMORY; LUTEINIZING-HORMONE; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; PLUS PROGESTIN; DISEASE; DEMENTIA; RISK; PREVALENCE AB Epidemiological data showing a predisposition of women to develop Alzheimer disease (AD) led many researchers to investigate the role of sex steroids, namely estrogen, in disease pathogenesis. Although there is circumstantial support for the role of estrogen, the unexpected results of the Women's Health Initiative (WHI) Memory Study, which reported an increase in the risk for probable dementia and impaired cognitive performance in postmenopausal women treated with a combination of estrogen and progestin, have raised serious questions regarding the protective effects of estrogen. Although explanations for these surprising results vary greatly, the WHI Memory Study cannot be correctly interpreted without a complete investigation of the effects of the other hormones of the hypothalamic-pituitary-gonadal (HPG) axis on the aging brain. Certain hormones of the HPG axis, namely, the gonadotropins (luteinizing hormone and follicle-stimulating hormone), are not only involved in regulating reproductive function via a complex feedback loop but are also known to cross the blood-brain barrier. We propose that the increase in gonadotropin concentrations, and not the decrease in steroid hormone (e.g., estrogen) production following menopause/andropause, is a potentially primary causative factor for the development of AD. In this review, we examine how the gonadotropins may play a central and determining role in modulating the susceptibility to, and progression of, AD. On this basis, we suggest that the results of the WHI Memory Study are not only predictable but also avoidable by therapeutically targeting the gonadotropins instead of the sex steroids. C1 Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA. Univ Wisconsin, Sch Med, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53706 USA. Voyager Pharmaceut Corp, Raleigh, NC 27615 USA. RP Smith, MA (reprint author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA. EM mark.smith@case.edu RI Smith, Mark/A-9053-2009; Perry, George/A-8611-2009 OI Perry, George/0000-0002-6547-0172 NR 39 TC 25 Z9 26 U1 1 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-584-2 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1052 BP 201 EP 209 DI 10.1196/annals.1347.020 PG 9 WC Endocrinology & Metabolism; Multidisciplinary Sciences; Obstetrics & Gynecology SC Endocrinology & Metabolism; Science & Technology - Other Topics; Obstetrics & Gynecology GA BDE44 UT WOS:000233076700014 PM 16024763 ER PT B AU Podolsky, DK AF Podolsky, DK BE Adler, G Blum, AL Blum, HE Leuschner, U Manns, MP Mossner, J Sartor, RB Scholmerich, J TI Gastroenterology: history of the future SO Gastroenterology Yesterday - Today - Tomorrow: A Review and Preview SE FALK SYMPOSIUM LA English DT Proceedings Paper CT Falk Symposium 144 on Gastroenterology Yesterday, Today, Tomorrow CY OCT 16-17, 2004 CL Freiburg, GERMANY SP Falk Fdn C1 Massachusetts Gen Hosp, Gastrointestinal Unit GRJ 719, Boston, MA 02114 USA. RP Podolsky, DK (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit GRJ 719, 32 Fruit St, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 1-4020-2896-2 J9 FALK SYMP PY 2005 VL 144 BP 314 EP 321 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BDX53 UT WOS:000235957800030 ER PT J AU Strate, LL Syngal, S AF Strate, LL Syngal, S TI Predictors of utilization of early colonoscopy vs. radiography for severe lower intestinal bleeding SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID LOWER GASTROINTESTINAL HEMORRHAGE; URGENT COLONOSCOPY; DIAGNOSIS; ANGIOGRAPHY; MANAGEMENT; IMPACT AB Background: The management of acute lower intestinal bleeding is not standardized. This study assessed factors associated with early (within 24 hours of presentation) colonoscopy vs. radiographic evaluation of patients with severe acute lower intestinal bleeding in routine practice. Methods: A cohort of 252 patients admitted with acute lower intestinal bleeding to a teaching hospital (August 1996 to June 1999) was studied retrospectively Severe bleeding was defined as transfusion of two units of packed red blood cells and/or a greater than 20% decrease in hematocrit within 24 hours of presentation. If both colonoscopy and radiography were performed, the initial procedure was analyzed. Multivariable regression was used to identify independent factors related to each of the two initial interventions. Results: A total of 118 patients met criteria for severe bleeding; 33 (28%) underwent an initial, early colonoscopy and 20 (17%) underwent an initial, early radiographic procedure (17 radionuclide scintigraphy, 3 angiography). Independent factors related to early colonoscopy were post-polypectomy bleeding (OR 6.3: 95% CI[1.4, 28.0]), admission on a weekday (OR 3.0: 95% CI[1.0, 8.6]), and admission late in the day (OR 2.7: 95% CI[1.0, 7.0]). Independent factors related to early radiography were tachycardia (OR 5.1: 95% CI[1.7, 14.9]), syncope (OR 3.8: 95% CI[1.1, 13.2]) and bleeding during the first 4 hours after admission (OR 3.1: 95% CI[1.0, 9.0]). Colonoscopy was associated with shorter hospital stay (p = 0.025), increased diagnostic yield (p = 0.005), and fewer red blood cell transfusions (p = 0.024). Rates of therapeutic intervention, surgery; and death did not differ significantly between the two strategies. Conclusions: Logistical factors and the likelihood of a localized source of bleeding influence the performance of early colonoscopy for the evaluation of acute lower intestinal bleeding, whereas patients with clinical indicators of severe bleeding often undergo radiographic procedures. Because early colonoscopy may improve outcomes, further studies are needed to compare available strategies and to standardize the management of acute lower intestinal bleeding. C1 Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA. RP Strate, LL (reprint author), Dana Farber Canc Inst, Div Populat Sci, 44 Binney St, Boston, MA 02115 USA. FU AHRQ HHS [HS00020]; NIDDK NIH HHS [5T32DK0753315] NR 13 TC 24 Z9 25 U1 0 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2005 VL 61 IS 1 BP 46 EP 52 AR PII S0016-5107(04)02227-8 DI 10.1016/S0016-5107(04)02227-8 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 893RJ UT WOS:000226736600008 PM 15672055 ER PT S AU Solban, N Sznycer-Taub, N Benavides, JM Chang, S Georgakoudi, I Hasan, T AF Solban, N Sznycer-Taub, N Benavides, JM Chang, S Georgakoudi, I Hasan, T BE Bornhop, DJ Achilefu, SI Raghavachari, R Savitsky, AP TI The need for optical imaging in the understanding and optimization of photodynamic therapy. SO Genetically Engineered and Optical Probes for Biomedical Applications III SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Genetically Engineered and Optical Probes for Biomedical Applications III CY JAN 25-26, 2005 CL San Jose, CA SP SPIE DE photodynamic therapy; optical imaging; photo-immunotargeted therapies; treatment monitoring C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Solban, N (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-5678-0 J9 P SOC PHOTO-OPT INS PY 2005 VL 5704 BP 1 EP 9 DI 10.1117/12.604768 PG 9 WC Biochemical Research Methods; Engineering, Biomedical; Optics SC Biochemistry & Molecular Biology; Engineering; Optics GA BCH91 UT WOS:000229367600001 ER PT J AU Brodsky, AS Meyer, CA Swinburne, IA Giles, H Keenan, BJ Liu, XLS Fox, EA Silver, PA AF Brodsky, AS Meyer, CA Swinburne, IA Giles, H Keenan, BJ Liu, XLS Fox, EA Silver, PA TI Genomic mapping of RNA polymerase II reveals sites of co-transcriptional regulation in human cells SO GENOME BIOLOGY LA English DT Article ID TERMINAL DOMAIN; ELONGATION; DNA; HUMAN-CHROMOSOME-21; PHOSPHORYLATION; GENES AB Background: Transcription by RNA polymerase II is regulated at many steps including initiation, promoter release, elongation and termination. Accumulation of RNA polymerase II at particular locations across genes can be indicative of sites of regulation. RNA polymerase II is thought to accumulate at the promoter and at sites of co-transcriptional alternative splicing where the rate of RNA synthesis slows. Results: To further understand transcriptional regulation at a global level, we determined the distribution of RNA polymerase II within regions of the human genome designated by the ENCODE project. Hypophosphorylated RNA polymerase II localizes almost exclusively to 5' ends of genes. On the other hand, localization of total RNA polymerase II reveals a variety of distinct landscapes across many genes with 74% of the observed enriched locations at exons. RNA polymerase II accumulates at many annotated constitutively spliced exons, but is biased for alternatively spliced exons. Finally, RNA polymerase II is also observed at locations not in gene regions. Conclusion: Localizing RNA polymerase II across many millions of base pairs in the human genome identifies novel sites of transcription and provides insights into the regulation of transcription elongation. These data indicate that RNA polymerase II accumulates most often at exons during transcription. Thus, a major factor of transcription elongation control in mammalian cells is the coordination of transcription and pre-mRNA processing to define exons. C1 Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02155 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02155 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Brodsky, AS (reprint author), Harvard Univ, Sch Med, Dept Syst Biol, 44 Binney St, Boston, MA 02115 USA. EM alex_brodsky@dfci.harvard.edu FU NHGRI NIH HHS [K22 HG002488, K22 HG02488-01A1] NR 27 TC 58 Z9 59 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1474-7596 J9 GENOME BIOL JI Genome Biol. PY 2005 VL 6 IS 8 AR r64 DI 10.1186/gb-2005-6-8-r64 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 964HT UT WOS:000231870800006 PM 16086846 ER PT J AU Hackl, H Burkard, TR Sturn, A Rubio, R Schleiffer, A Tian, S Quackenbush, J Eisenhaber, F Trajanoski, Z AF Hackl, Hubert Burkard, Thomas Rainer Sturn, Alexander Rubio, Renee Schleiffer, Alexander Tian, Sun Quackenbush, John Eisenhaber, Frank Trajanoski, Zlatko TI Molecular processes during fat cell development revealed by gene expression profiling and functional annotation SO GENOME BIOLOGY LA English DT Review ID ACTIVATED-RECEPTOR-GAMMA; AMINO-ACID-COMPOSITION; REGULATES ADIPOCYTE DIFFERENTIATION; HUMAN XANTHINE DEHYDROGENASE; SECONDARY STRUCTURAL CONTENT; TRANSCRIPTION FACTOR FOXO1; COLONY-ENHANCING FACTOR; LEUCINE-ZIPPER PROTEIN; ACTIN-BUNDLING PROTEIN; NF-KAPPA-B AB Background: Large-scale transcription profiling of cell models and model organisms can identify novel molecular components involved in fat cell development. Detailed characterization of the sequences of identified gene products has not been done and global mechanisms have not been investigated. We evaluated the extent to which molecular processes can be revealed by expression profiling and functional annotation of genes that are differentially expressed during fat cell development. Results: Mouse microarrays with more than 27,000 elements were developed, and transcriptional profiles of 3T3-L1 cells (pre-adipocyte cells) were monitored during differentiation. In total, 780 differentially expressed expressed sequence tags ( ESTs) were subjected to in-depth bioinformatics analyses. The analysis of 3'-untranslated region sequences from 395 ESTs showed that 71% of the differentially expressed genes could be regulated by microRNAs. A molecular atlas of fat cell development was then constructed by de novo functional annotation on a sequence segment/ domain-wise basis of 659 protein sequences, and subsequent mapping onto known pathways, possible cellular roles, and subcellular localizations. Key enzymes in 27 out of 36 investigated metabolic pathways were regulated at the transcriptional level, typically at the rate-limiting steps in these pathways. Also, coexpressed genes rarely shared consensus transcription-factor binding sites, and were typically not clustered in adjacent chromosomal regions, but were instead widely dispersed throughout the genome. Conclusions: Large-scale transcription profiling in conjunction with sophisticated bioinformatics analyses can provide not only a list of novel players in a particular setting but also a global view on biological processes and molecular networks. C1 Graz Univ Technol, Inst Genom & Bioinformat, A-8010 Graz, Austria. Graz Univ Technol, Christian Doppler Lab Genom & Bioinformat, A-8010 Graz, Austria. Res Inst Mol Pathol, A-1030 Vienna, Austria. Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Trajanoski, Z (reprint author), Graz Univ Technol, Inst Genom & Bioinformat, Petersgasse 14, A-8010 Graz, Austria. EM zlatko.trajanoski@tugraz.at OI Schleiffer, Alexander/0000-0001-6251-2747; Hackl, Hubert/0000-0003-4055-3841 NR 159 TC 45 Z9 53 U1 1 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2005 VL 6 IS 13 AR R108 DI 10.1186/gb-2005-6-13-r108 PG 23 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 054WP UT WOS:000238409600011 PM 16420668 ER PT J AU Monticelli, S Ansel, KM Xiao, CC Socci, ND Krichevsky, AM Thai, TH Rajewsky, N Marks, DS Sander, C Rajewsky, K Rao, A Kosik, KS AF Monticelli, S Ansel, KM Xiao, CC Socci, ND Krichevsky, AM Thai, TH Rajewsky, N Marks, DS Sander, C Rajewsky, K Rao, A Kosik, KS TI MicroRNA profiling of the murine hematopoietic system SO GENOME BIOLOGY LA English DT Article ID T-CELL DIFFERENTIATION; GENE-EXPRESSION; COMPUTATIONAL IDENTIFICATION; MICROARRAY ANALYSIS; MAST-CELLS; TARGETS; BRAIN; PU.1; RNA AB Background: MicroRNAs ( miRNAs) are a class of recently discovered noncoding RNA genes that post-transcriptionally regulate gene expression. It is becoming clear that miRNAs play an important role in the regulation of gene expression during development. However, in mammals, expression data are principally based on whole tissue analysis and are still very incomplete. Results: We used oligonucleotide arrays to analyze miRNA expression in the murine hematopoietic system. Complementary oligonucleotides capable of hybridizing to 181 miRNAs were immobilized on a membrane and probed with radiolabeled RNA derived from low molecular weight fractions of total RNA from several different hematopoietic and neuronal cells. This method allowed us to analyze cell type-specific patterns of miRNA expression and to identify miRNAs that might be important for cell lineage specification and/or cell effector functions. Conclusion: This is the first report of systematic miRNA gene profiling in cells of the hematopoietic system. As expected, miRNA expression patterns were very different between hematopoietic and non-hematopoietic cells, with further subtle differences observed within the hematopoietic group. Interestingly, the most pronounced similarities were observed among fully differentiated effector cells (Th1 and Th2 lymphocytes and mast cells) and precursors at comparable stages of differentiation ( double negative thymocytes and pro-B cells), suggesting that in addition to regulating the process of commitment to particular cellular lineages, miRNAs might have an important general role in the mechanism of cell differentiation and maintenance of cell identity. C1 Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. CBR Inst Biomed Res, Boston, MA 02115 USA. Univ Milan, Dept Biol & Genet Med Sci, I-20133 Milan, Italy. Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA. Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NYU, Dept Biol, Ctr Funct Comparat Genom, New York, NY 10003 USA. Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA. RP Monticelli, S (reprint author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. EM monticel@cbr.med.harvard.edu RI sander, chris/H-1452-2011 NR 38 TC 245 Z9 271 U1 1 U2 17 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1474-7596 J9 GENOME BIOL JI Genome Biol. PY 2005 VL 6 IS 8 AR r71 DI 10.1186/gb-2005-6-8-r71 PG 15 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 964HT UT WOS:000231870800013 PM 16086853 ER PT J AU Greenberg, RA Rudolph, KL AF Greenberg, RA Rudolph, KL TI Telomere structural dynamics in genome integrity control and carcinogenesis SO GENOME INSTABILITY IN CANCER DEVELOPMENT SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Article ID DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; HUMAN-DIPLOID FIBROBLASTS; HUMAN COLORECTAL-CANCER; REPLICATIVE LIFE-SPAN; MOUSE CELLS LACKING; HUMAN SOMATIC-CELLS; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; CATALYTIC SUBUNIT C1 Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-3000 Hannover, Germany. RP Greenberg, RA (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. NR 224 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0065-2598 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2005 VL 570 BP 311 EP 341 PG 31 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Research & Experimental Medicine GA BEA26 UT WOS:000236407200011 PM 18727506 ER PT S AU Sever, S Skoch, J Bacskai, BJ Newmyer, SL AF Sever, S Skoch, J Bacskai, BJ Newmyer, SL BE Balch, WE Der, CJ Hall, A TI Assays and functional properties of auxilin-dynamin interactions SO GTPASES REGULATING MEMBRANE DYNAMICS SE Methods in Enzymology LA English DT Review; Book Chapter ID CLATHRIN-MEDIATED ENDOCYTOSIS; UNCOATING ATPASE; COATED VESICLES; GTPASE ACTIVITY; DISSOCIATION; PURIFICATION; ACTIVATION; EXPRESSION; RECEPTOR; CELLS AB The large GTPase dynamin is required for budding of clathrin-coated vesicles from the plasma membrane, but its mechanism of action is still not understood. Growing evidence indicates that the GTP-bound form of dynamin recruits downstream partners that execute the fission reaction. Recently, we reported nucleotide-dependent interactions between dynamin and auxilin, which suggested that auxilin cooperates with dynamin during vesicle formation. Here we describe three different in vitro assays that monitor auxilin-dynamin interactions, as well as fluorescence lifetime imaging microscopy that identify direct interactions between dynamin and auxilin in cells. C1 Harvard Univ, Sch Med, Dept Med, Renal Unit,Massechusetts Gen Hosp, Boston, MA 02115 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Alzheimers Dis Res Lab, Boston, MA 02115 USA. Univ Calif San Francisco, GW Hopper Fdn, San Francisco, CA 94143 USA. RP Sever, S (reprint author), Harvard Univ, Sch Med, Dept Med, Renal Unit,Massechusetts Gen Hosp, Boston, MA 02115 USA. NR 29 TC 3 Z9 4 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 0-12-182809-3 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2005 VL 404 BP 570 EP 585 DI 10.1016/S0076-6879(05)04050-4 PG 16 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BDO67 UT WOS:000234565700050 PM 16413301 ER PT J AU Thigpen, JT Aghajanian, CA Alberts, DS Campos, SM Gordon, AN Markman, M McMeekin, DS Monk, BJ Rose, PG AF Thigpen, JT Aghajanian, CA Alberts, DS Campos, SM Gordon, AN Markman, M McMeekin, DS Monk, BJ Rose, PG TI Role of pegylated liposomal doxorubicin in ovarian cancer SO GYNECOLOGIC ONCOLOGY LA English DT Review DE pegylated liposomal doxorubicin; ovarian cancer; gynecologic malignancies ID GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-II TRIAL; REDUCED CARDIOTOXICITY; PLATINUM-RESISTANT; REFRACTORY OVARIAN; WEEKLY PACLITAXEL; RANDOMIZED-TRIAL; CARCINOMA; CHEMOTHERAPY; TOPOTECAN AB Objectives. Safe, effective treatments are needed for relapsed ovarian cancer. Goals include improving symptoms, enhancing quality of life, and prolonging survival. The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin. Methods. A roundtable meeting of experts in the management of ovarian carcinoma was held to build consensus around the present and future role of pegylated liposomal doxorubicin for ovarian cancer and other gynecologic malignancies. Results. Pegylated liposomal doxorubicin is effective and well tolerated in relapsed ovarian cancer. When compared with topotecan in a phase III randomized trial, pegylated liposomal doxorubicin showed several advantages: improved quality of life, fewer severe adverse events, fewer dose modifications, less hematologic support, and lower total cost per patient. In platinum-sensitive patients, pegylated liposomal doxorubicin also produced a survival advantage. Results from prospective and retrospective studies further demonstrate the improved cardiac safety of pegylated liposomal doxorubicin compared to conventional anthracyclines. Conclusions. Based on survival and toxicity advantages and a once-monthly administration schedule, pegylated liposomal doxorubicin is the first-choice nonplatinum agent for relapsed ovarian cancer. Pegylated liposomal doxorubicin may also have clinical application in combination regimens for platinum-sensitive ovarian cancer, as consolidation/maintenance therapy for ovarian cancer, as a component of first-line therapy for ovarian cancer, and in the treatment of other gynecologic malignancies. Future clinical trials will further define and maximize the role of pegylated liposomal doxorubicin in the treatment of ovarian cancer and other gynecologic malignancies. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Mississippi, Med Ctr, Dept Med, Div Oncol, Jackson, MS 39216 USA. Cornell Univ, Mem Sloan Kettering Canc Ctr, Weill Med Coll, New York, NY USA. Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Arizona, Phoenix, AZ USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Oklahoma, Med Ctr, Oklahoma City, OK USA. Univ Calif Irvine, Irvine Med Ctr, Orange, CA 92668 USA. Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA. RP Thigpen, JT (reprint author), Univ Mississippi, Med Ctr, Dept Med, Div Oncol, 2500 N State St, Jackson, MS 39216 USA. EM jtthigpen@att.net NR 47 TC 77 Z9 79 U1 0 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD JAN PY 2005 VL 96 IS 1 BP 10 EP 18 DI 10.1016/j.ygyno.2004.09.046 PG 9 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 883UI UT WOS:000226040800002 PM 15589573 ER PT J AU Duska, LR Berkowitz, R Matulonis, U Muto, M Goodman, A Mcintyre, JF Klein, A Atkinson, T Seiden, MV Campos, S AF Duska, LR Berkowitz, R Matulonis, U Muto, M Goodman, A Mcintyre, JF Klein, A Atkinson, T Seiden, MV Campos, S CA Gynecologic Oncology Res program TI A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer SO GYNECOLOGIC ONCOLOGY LA English DT Article DE chemotherapy; radiotherapy; endometrial cancer ID GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-II TRIAL; PLUS CISPLATIN; STAGE-III; CARCINOMA; RADIATION; IV AB Objectives. To determine the toxicity, tolerability, and feasibility of delivering combination chemotherapy with subsequent radiation therapy to women with high-risk endometrial cancer and to evaluate the long-term bowel toxicity of this regimen. Methods. The trial was approved by the Dana Farber/Partners Cancer Care (DFPCC) Institutional Review Board (IRB). Patients with stage 3 or stage 4 endometrial cancer or patients with high-risk histology and any stage disease were prospectively entered. Complete surgical staging and a normal gated blood pool scan were required prior to entry. Patients were treated with three cycles of paclitaxel (160 mg/m(2)), doxorubicin (45 mg/m(2)) and carboplatin (AUC 5) (TAC) all on day 1 of a 21-day schedule as an outpatient with G-CSF support. At the conclusion of chemotherapy, patients received radiation therapy (4500 cGy to the whole pelvis) commencing within 35 days of the last cycle of chemotherapy. Paraaortic radiation and/or vaginal brachytherapy were allowed at the discretion of the treating radiation oncologist. Results. Twenty patients were entered onto the trial from November 2000 through February 2003. Eighteen patients successfully completed the trial, and two patients came off trial during chemotherapy (both later completed planned radiation therapy). Patients were initially stage 1 (n = 3), stage 3 (n = 14), and stage 4 (n = 3). Papillary serous was the dominant histology with 13 patients. Chemotherapy was given on average within 32 days of surgery (range 11-63 days) and radiation was initiated on average within 14 weeks of surgery (range 10-18 weeks). Chemotherapy was well tolerated, with 57 total cycles delivered of a planned 60 cycles. Two patients required dose modification in two cycles (two patients in cycle 3 secondary to hematologic toxicity). No grade 3 or grade 4 neurotoxicity was reported. There were six episodes of grade 3 short-term toxicity with radiation therapy reported in a single patient. Late radiotherapy toxicity included bowel obstruction requiring laparotomy in two patients and grade 3 constipation in one patient. Late radiation toxicity data are still being collected as follow-up continues. Conclusions. The TAC chemotherapy regimen is well tolerated and three cycles were delivered successfully with G-CSF support without evidence of the neurotoxicity or cardiac toxicity reported with the cisplatin containing TAP regimen. Standard radiation was deliverable following TAC therapy without excessive toxicity. Further study of this regimen with subsequent radiation therapy is warranted in patients at risk for systemic and regional recurrence of their malignancy. (C) 2004 Elsevier Inc. All rights reserved. C1 Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Div Gynecol Oncol, Boston, MA 02114 USA. Brigham & Womens Hosp, Div Gynecol Oncol, Boston, MA 02114 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02114 USA. N Shore Canc Ctr, Div Radiat Oncol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA. RP Duska, LR (reprint author), Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Div Gynecol Oncol, 100 Blossom St,Cox 501, Boston, MA 02114 USA. EM lduska@partners.org NR 11 TC 28 Z9 31 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD JAN PY 2005 VL 96 IS 1 BP 198 EP 203 DI 10.1016/j.ygyno.2004.09.022 PG 6 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 883UI UT WOS:000226040800030 PM 15589601 ER PT J AU Jackson, JA Telingator, CJ Pleak, RR Pollack, WS AF Jackson, JA Telingator, CJ Pleak, RR Pollack, WS TI Acting (to) out: Approaching homosexuality in a 15-year-old boy with anxiety and depression SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE adolescence; child psychiatry evaluation; gay; gender identity; homosexuality; Internet ID RISK C1 Massachusetts Gen Hosp, Div Child & Adolescent Psychiat, Dept Psychiat, Boston, MA 02114 USA. Cambridge Hosp, Dept Child & Adolescent Psychiat, Cambridge, MA 02139 USA. Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA. McLean Hosp, Ctr Men & Young Men, Belmont, MA 02178 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Albert Einstein Coll Med, New York, NY USA. RP Jackson, JA (reprint author), Massachusetts Gen Hosp, Dept Child & Adolescent Psychiat, Yawkey Ctr Outpatient Care, 55 Fruit St,YAW 6900, Boston, MA 02114 USA. EM jjackson14@partners.org NR 24 TC 1 Z9 1 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD JAN-FEB PY 2005 VL 13 IS 1 BP 43 EP 53 DI 10.1080/10673220590923173 PG 11 WC Psychiatry SC Psychiatry GA 913BZ UT WOS:000228126600004 PM 15804933 ER PT J AU Neumann, PJ Divi, N Beinfeld, MT Levine, BS Keenan, PS Halpern, EF Gazelle, GS AF Neumann, PJ Divi, N Beinfeld, MT Levine, BS Keenan, PS Halpern, EF Gazelle, GS TI Medicare's national coverage decisions, 1999-2003: Quality of evidence and review times SO HEALTH AFFAIRS LA English DT Review ID AMERICANS; POLICY AB In 1998 Medicare amended its procedures for making national coverage decisions for new technologies in an attempt to make the process more transparent and evidence based. We examined the quality of evidence for sixty-nine technologies reviewed by Medicare since then. Determinations by the Centers for Medicare and Medicaid Services (CMS) have generally been consistent with the strength of evidence. Good clinical evidence from rigorous studies is usually lacking for the technologies Medicare considers, although in most cases the CMS covers with conditions if there is at least fair evidence that benefits outweigh harms. Decisions referred to the external Medicare Coverage Advisory Committee (MCAC) have averaged eight months longer than non-MCAC decisions. C1 Harvard Univ Publ Hlth, Boston, MA 02115 USA. Massachusetts Gen Hosp, Cost Effectiveness Preventing AIDS Complicat Proj, Boston, MA USA. Fdn Informed Med Decis Making, Boston, MA USA. Childrens Hosp, Dept Endocrinol, Boston, MA USA. Natl Bur Econ Res, Cambridge, MA USA. RP Neumann, PJ (reprint author), Harvard Univ Publ Hlth, Boston, MA 02115 USA. EM pneumann@hsph.harvard.edu FU NIA NIH HHS [T32-AG00186] NR 31 TC 25 Z9 25 U1 1 U2 1 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2005 VL 24 IS 1 BP 243 EP 254 DI 10.1377/hlthaff.24.1.243 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 909CD UT WOS:000227835600033 PM 15647237 ER PT S AU Akashi, K AF Akashi, K BE Kanz, L Weisel, KC Orlic, D Fibbe, WE TI Lineage promiscuity and plasticity in hematopoietic development SO HEMATOPOIETIC STEM CELLS V SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 5th International Conference on Hematopoietic Stem Cells CY SEP 16-18, 2004 CL Univ Tubingen, Tubingen, GERMANY HO Univ Tubingen DE hematopoietic stem cells; hematopoietic lineages; transcription factors; lineage priming ID RETAIN LONG-TERM; STEM-CELLS; PROGENITOR CELLS; GENE-EXPRESSION; LYMPHOID PROGENITORS; PU.1; COMMITMENT; LEUKEMIA; RECEPTOR; C/EBP AB Hematopoiesis has provided a valuable model for understanding how genetic programs are established to decide cell fates in multipotent stem or progenitor cells. The identification of common myeloid and lymphoid progenitors has allowed us to directly assess the regulatory mechanisms of lineage commitment. Multiple genes of hematopoietic lineages, including transcription factors, are coexpressed in hematopoietic stem cells and progenitors, a phenomenon referred to as "lineage priming:'' The accessibility for multiple transcription factors promiscuously allows flexibility in cell fate commitments at the multipotent stages. The changes in the expression levels and timing of transcription factors can induce lineage conversion of committed cells, indicating that the regulation of transcription factors might be primarily critical for maintaining hierarchical hematopoietic development. C1 Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RP Akashi, K (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM koichi_akashi@dfci.harvard.edu FU NCI NIH HHS [CA78045]; NIDDK NIH HHS [DK61320] NR 29 TC 27 Z9 27 U1 0 U2 3 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-588-5 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1044 BP 125 EP 131 DI 10.1196/annals.1349.016 PG 7 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Multidisciplinary Sciences SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Science & Technology - Other Topics GA BCR23 UT WOS:000230894100015 PM 15958705 ER PT J AU Dominitz, JA Boyko, EJ Koepsell, TD Heagerty, PJ Maynard, C Sporleder, JL AF Dominitz, JA Boyko, EJ Koepsell, TD Heagerty, PJ Maynard, C Sporleder, JL CA VA Cooperative Study Grp 488 TI Elevated prevalence of hepatitis C infection in users of United States Veterans medical centers SO HEPATOLOGY LA English DT Article ID NON-B-HEPATITIS; VIRUS-INFECTION; NON-A; MULTIPLE IMPUTATION; VIRAL-HEPATITIS; RISK-FACTORS; EPIDEMIOLOGY; POPULATION AB Several studies suggest veterans have a higher prevalence of hepatitis C virus infection than nonveterans, possibly because of military exposures. The purpose of this study was to estimate the prevalence of anti-hepatitis C antibody and evaluate factors associated with infection among users of Department of Veterans Affairs medical centers. Using a two-staged cluster sample, 1,288 of 3,863 randomly selected veterans completed a survey and underwent home-based phlebotomy for serological testing. Administrative and clinical data were used to correct the prevalence estimate for nonparticipation. The prevalence of anti-hepatitis C antibody among serology participants was 4.0% (95% CI, 2.6%-5.5%). The estimated prevalence in the population of Veterans Affairs medical center users was 5.4% (95% CI, 3.3%-7.5%) after correction for sociodemographic and clinical differences between participants and nonparticipants. Significant predictors of seropositivity included demographic factors, period of military service (e.g., Vietnam era), prior diagnoses, health care use, and lifestyle factors. At least one traditional risk factor (transfusion or intravenous drug use) was reported by 30.2% of all subjects. Among those testing positive for hepatitis C antibody, 78% either had a transfusion or had used injection drugs. Adjusting for injection drug use and nonparticipation, seropositivity was associated with tattoos and incarceration. Military-related exposures were not found to be associated with infection in the adjusted analysis. In conclusion, the prevalence of hepatitis C in these subjects exceeds the estimate from the general US population by more than 2-fold, likely reflecting more exposure to traditional risk factors among these veterans. C1 VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, NW Hepatitis C Resource Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM jason.dominitz@med.va.gov RI Maynard, Charles/N-3906-2015; OI Maynard, Charles/0000-0002-1644-7814; Dominitz, Jason/0000-0002-8070-7086 NR 31 TC 137 Z9 137 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JAN PY 2005 VL 41 IS 1 BP 88 EP 96 DI 10.1002/hep.20502 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 886RC UT WOS:000226245000014 PM 15619249 ER PT J AU Bastepe, M Juppner, H AF Bastepe, M Juppner, H TI GNAS locus and pseudohypoparathyroidism SO HORMONE RESEARCH LA English DT Review DE pseudohypoparathyroidism; parathyroid hormone; Albright's hereditary osteodystrophy; GNAS locus ID STIMULATORY G-PROTEIN; GS-ALPHA GENE; PROGRESSIVE OSSEOUS HETEROPLASIA; PARATHYROID-HORMONE; HEREDITARY OSTEODYSTROPHY; MATERNAL TRANSMISSION; MOLECULAR-CLONING; SUBUNIT G(S)ALPHA; PARENTAL ORIGIN; IMPRINT MARK AB Pseudohypoparathyroidism (PHP) is characterized by hypocalcemia and hyperphosphatemia due to resistance to parathyroid hormone (PTH). Patients with PHP-Ia often present with additional hormonal resistance and show characteristic physical features that are collectively termed Albright's hereditary osteodystrophy (AHO). These features are also present in pseudopseudohypoparathyroidism (PPHP), but patients affected by this disorder do not show hormone resistance. PHP-Ib patients, on the other hand, present predominantly with renal PTH resistance and lack any features of AHO. Most of these PHP forms are caused by defects in GNAS (20q13.3), an imprinted gene locus with multiple transcriptional units. PHP-Ia and PPHP are caused by heterozygous inactivating mutations in those exons of GNAS encoding the alpha subunit of the stimulatory guanine nucleotide-binding protein (Gs alpha), and the autosomal dominant form of PHP-Ib (AD-PHP-Ib) is caused by heterozygous mutations disrupting a long-range imprinting control element of GNAS. Expressed nearly in all cells, Gs alpha plays essential roles in a multitude of physiological processes. Its expression in renal proximal tubules occurs predominantly from the maternal allele, and this tissue- and parent-specific imprinting of Gs alpha is an important determinant of hormone resistance in kindreds with PHP-Ia/PPHP and AD-PHP-Ib. Copyright (C) 2005 S. Karger AG, Basel. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Endocrine Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, MassGen Hosp Children, Boston, MA 02114 USA. RP Bastepe, M (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Endocrine Unit, Boston, MA 02114 USA. EM bastepe@helix.mgh.harvard.edu NR 66 TC 105 Z9 109 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2005 VL 63 IS 2 BP 65 EP 74 DI 10.1159/000083895 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 914VZ UT WOS:000228257400003 PM 15711092 ER PT J AU Hirsh, D Heinrichs, C Leenders, B Wong, ACK Cummings, DE Chanoine, JP AF Hirsh, D Heinrichs, C Leenders, B Wong, ACK Cummings, DE Chanoine, JP TI Ghrelin is suppressed by glucagon and does not mediate glucagon-related growth hormone release SO HORMONE RESEARCH LA English DT Article DE ghrelin; glucagon; growth hormone; glucose; insulin ID INSULIN-INDUCED HYPOGLYCEMIA; GH-DEFICIENT CHILDREN; CIRCULATING GHRELIN; STIMULATION TESTS; ACYLATED PEPTIDE; ENERGY-BALANCE; FOOD-INTAKE; SECRETION; STOMACH; GLUCOSE AB Background: Glucagon stimulation is routinely used as a provocative test to assess growth hormone (GH) sufficiency in pediatrics. Ghrelin also markedly stimulates GH secretion. Because glucagon stimulates the promoter of the ghrelin gene in vitro as well as ghrelin secretion by the perfused rat stomach, we sought to determine whether ghrelin mediates glucagon-induced GH secretion. Methods: We compared ghrelin, GH, insulin and glucose responses following administration of 0.03 mg/kg intravenously (iv; max. 1 mg) and 0.1 mg/kg intramuscularly (im; max. 2 mg) of glucagon in two groups (n = 10-11/group) of GH-sufficient children. We also measured ghrelin before and 6 min after iv administration of 1 mg glucagon in 21 adult subjects. Results: In children, glucagon caused a 26% decrease in ghrelin and a 72% increase in glucose concentrations that were independent of the dose or administration route of glucagon. In contrast, the insulin response was 2-3 times higher following administration of 0.1 mg/kg im compared to 0.03 mg/kg of glucagon iv. There was a significant correlation between the maximum decrease in ghrelin and increases in glucose (p = 0.03) but not in insulin. There was a significant correlation between ghrelin and GH area under the curve after controlling for the dose of glucagon ( p = 0.03) but not for the maximum increase in glucose. In normal adults, glucagon administration caused a 7% decrease in ghrelin concentrations after 6 min ( p = 0.0002). Conclusion: Ghrelin does not play a causal role in the GH response to pharmacological glucagon administration, which suppresses ghrelin levels starting a few minutes after injection. Copyright (C) 2005 S. Karger AG, Basel. C1 Univ British Columbia, British Columbia Childrens Hosp, Endocrinol & Diabet Unit, Vancouver, BC V6H 3V4, Canada. Free Univ Brussels, Hop Enfants Reine Fabiola, Unite Endocrinol Pediat, Brussels, Belgium. Univ Washington, VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. RP Chanoine, JP (reprint author), Univ British Columbia, British Columbia Childrens Hosp, Endocrinol & Diabet Unit, Room K4-212,4480 Oak St, Vancouver, BC V6H 3V4, Canada. EM jchanoine@cw.bc.ca FU NIDDK NIH HHS [R01 DK61516] NR 51 TC 16 Z9 16 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2005 VL 63 IS 3 BP 111 EP 118 DI 10.1159/000084569 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 922ON UT WOS:000228847400002 PM 15775713 ER PT J AU Oshima, M Deitiker, PR Mosier, DR Smith, RG Atassi, MZ AF Oshima, M Deitiker, PR Mosier, DR Smith, RG Atassi, MZ TI Responses in vitro of peripheral blood lymphocytes from patients with myasthenia gravis to stimulation with human acetylcholine receptor ot-chain peptides: Analysis in relation to age, thymic abnormality, and ethnicity SO HUMAN IMMUNOLOGY LA English DT Article DE acetylcholine receptor; autoimmunity; myasthenia gravis; T cell ID T-CELL RECOGNITION; ALPHA-SUBUNIT; EXTRACELLULAR PART; SYNTHETIC PEPTIDES; ANTIGENIC SITES; ANTIBODY; EPITOPES; CLONES; LINES; REPERTOIRE AB Peripheral blood lymphocytes (PBLs) were isolated from 24 patients with myasthenia gravis of three ethnic groups (Caucasian, African American, and Hispanic) and ten healthy individuals. We determined the in vitro proliferative responses of the PBL samples to each of 18 overlapping synthetic peptides corresponding to the entire main extracellular domain (residues 1-210) of the a-subunit of human acetylcholine receptor. The profiles of the T-cell responses (expressed in stimulation index [SI]) to the peptides varied among the 24 patient samples. There was a significant difference in the overall patient responses relative to controls toward 17 of 18 peptides. T cells from the patients gave responses greater than control mean SI + 4 standard deviation (Z(SI) > 4) to 2similar to9 peptides/sample. Six peptides, alpha23-38, alpha34-49, alpha78-93, alpha122-138, alpha146-162, and alpha182-198, were recognized with Z > 4 level by 42% to 58% of the patients' PBLs. The grouped patient responses, divided according to age, thymic diagnosis, or ethnicity, were compared with controls and with each other. Significant differences were observed between early- and late-onset cases in recognition of residues alpha34-49 (p = 0.015) and alpha78-93 (p = 0.053), and in recognition of residues alpha12-27, alpha56-71, alpha134-150, and alpha146-162 (0.0072 < p < 0.064) when two ethnic groups were compared with each other. Human Immunology 66, 32-42 (2005). (C) American Society for Histocompatibility and Immunogenetics, 2005. Published by Elsevier Inc. C1 Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. ME DeBakey VA Med Ctr, Neurol & Med Res Serv, Houston, TX USA. Univ Texas, Med Branch, Dept Neurol, Galveston, TX USA. RP Oshima, M (reprint author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA. NR 37 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PD JAN PY 2005 VL 66 IS 1 BP 32 EP 42 DI 10.1016/j.humimm.2004.09.015 PG 11 WC Immunology SC Immunology GA 894WG UT WOS:000226821700005 PM 15620460 ER PT J AU Delgado, JC Baena, A Thim, S Goldfeld, A AF Delgado, JC Baena, A Thim, S Goldfeld, A TI Aspartic acid homozygosity at codon 57 of HLA-DQ beta impairs the host immune response to tuberculosis SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract CT 31st Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics CY OCT 17-21, 2005 CL Washington, DC SP Amer Soc Histocompatibil & Immunogenet C1 CBR Inst Biomed Res, Boston, MA USA. Cambidian Hlth Comm, Phnom Phen, Cambodia. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 2005 VL 66 SU 1 BP S120 EP S121 PG 2 WC Immunology SC Immunology GA 983HF UT WOS:000233221400222 ER PT J AU Klitz, W Baxter-Lowe, LA Steere, A AF Klitz, W Baxter-Lowe, LA Steere, A TI The host population perspective in pathogen defense: Clues from borrelia burgdorferi and HLA SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract CT 31st Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics CY OCT 17-21, 2005 CL Washington, DC SP Amer Soc Histocompatibil & Immunogenet C1 Univ Calif Berkeley, Berkeley, CA 94720 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 2005 VL 66 SU 1 BP S121 EP S121 PG 1 WC Immunology SC Immunology GA 983HF UT WOS:000233221400223 ER PT J AU Moonsamy, PV Bonella, PL Sali, P Post, JL Bentley, LG Goodwin, G Erlich, HE AF Moonsamy, PV Bonella, PL Sali, P Post, JL Bentley, LG Goodwin, G Erlich, HE TI Genetic diversity within the HLA class II region: The identification of a new DPB 1 allele in a Type 1 Diabetes Genetics Consortium family SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract CT 31st Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics CY OCT 17-21, 2005 CL Washington, DC SP Amer Soc Histocompatibil & Immunogenet C1 Roche Mol Syst, Human Genet, Alameda, CA USA. Joslin Diabet Ctr, Sect Immunol & Immunogenet, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 2005 VL 66 SU 1 BP S41 EP S41 PG 1 WC Immunology SC Immunology GA 983HF UT WOS:000233221400076 ER PT J AU Saidman, SL Roth, AE Sonmez, T Unver, MU Delmonico, FL AF Saidman, SL Roth, AE Sonmez, T Unver, MU Delmonico, FL TI Computerized matching algorithms to optimize matches and increase opportunities for live donor kidney exchange SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract CT 31st Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics CY OCT 17-21, 2005 CL Washington, DC SP Amer Soc Histocompatibil & Immunogenet C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Cambridge, MA 02138 USA. Koc Univ, Istanbul, Turkey. New England Organ Bank Inc, Newton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 2005 VL 66 SU 1 BP S16 EP S16 PG 1 WC Immunology SC Immunology GA 983HF UT WOS:000233221400026 ER PT S AU Medoff, BD Thomas, SY Banerji, A Wain, JC Zhang, H Lilly, CM Ginns, LC Luster, AD AF Medoff, BD Thomas, SY Banerji, A Wain, JC Zhang, H Lilly, CM Ginns, LC Luster, AD BE Steinman, RM TI Pathogenic T-cell recruitment into the airway in human disease SO HUMAN IMMUNOLOGY: PATIENT-BASED RESEARCH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Human Immunology CY MAY 16-18, 2005 CL New York, NY SP NY Acad Sci, Dana Fdn DE T cells; lung inflammation; sarcoidosis; asthma; lung transplantation; chemokines; chemokine receptors ID BRONCHOALVEOLAR LAVAGE FLUID; BRONCHIOLITIS-OBLITERANS-SYNDROME; SEGMENTAL ALLERGEN CHALLENGE; CHEMOKINE-RECEPTOR EXPRESSION; INFLAMMATORY PROTEIN 3-ALPHA; HEART-LUNG TRANSPLANTATION; QUALITY-OF-LIFE; PULMONARY SARCOIDOSIS; EOSINOPHILIC PNEUMONIA; IFN-GAMMA AB Effector T cells significantly contribute to inflammatory diseases. These cells are recruited into tissue, where they orchestrate an inflammatory response that can either protect against infection or sometimes stimulate human disease. The recruitment of T cells into tissue from the blood and lymphoid compartments is an active process controlled by chemokines and the chemokine receptors expressed on distinct effector T-cell subsets. Thus, the chemokines secreted in the tissue will determine the specific types of T lymphocyte recruited into that tissue based on the chemokine receptors expressed on these cells. It follows that the chemokine receptor profile on T cells isolated from the lungs of patients with inflammatory pulmonary disease will define the subtype of pathogenic T lymphocytes mediating the disease process and will identify the mechanisms that recruit these cells into the lung. This article reviews data from both human and animal studies that define the chemokine receptors involved in the recruitment of T lymphocytes into the lung in various inflammatory pulmonary diseases, including asthma, obliterative bronchiolitis, sarcoidosis, and chronic eosinophilic pneumonia. We then speculate on the potential role of these chemokine receptors in the pathogenesis of these disorders and potential novel therapeutic approaches suggested by these data. C1 Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA. RP Luster, AD (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Bldg 149-8301,13th St, Charlestown, MA 02129 USA. EM luster.andrew@mgh.harvard.edu OI Thomas, Seddon/0000-0003-0075-0744 NR 111 TC 14 Z9 15 U1 0 U2 4 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-606-7 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1062 BP 220 EP 241 DI 10.1196/annals.1358.026 PG 22 WC Immunology; Multidisciplinary Sciences SC Immunology; Science & Technology - Other Topics GA BEA65 UT WOS:000236473100022 PM 16461804 ER PT S AU Means, TK Luster, AD AF Means, TK Luster, AD BE Steinman, RM TI Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus SO HUMAN IMMUNOLOGY: PATIENT-BASED RESEARCH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Human Immunology CY MAY 16-18, 2005 CL New York, NY SP NY Acad Sci, Dana Fdn DE toll-like receptors; plasmacytoid dendritic cells; systemic lupus erythematosus; autoimmune disease; chemokines; cytokines; immune complexes; autoantibodies ID PLASMACYTOID DENDRITIC CELLS; ALPHA-PRODUCING CELLS; FC-GAMMA-RIIA; MYD88-DEPENDENT SIGNALING PATHWAY; APOPTOTIC U937 CELLS; INTERFERON-ALPHA; IFN-ALPHA; MONONUCLEAR-CELLS; IMMUNE-COMPLEXES; DNA ANTIBODIES AB Systemic lupus erythematosus (SLE) is characterized by the production of pathogenic autoantibodies to nucleoproteins and DNA. The level of anti-DNA antibodies correlates with disease severity, and the deposition of these immune complexes (ICs) in the kidneys is thought to contribute to disease pathogenesis. Recent evidence suggests that the DNA component of ICs purified from SLE patients (SLE DNA-ICs) contributes to the development of SLE pathology. SLE DNA-ICs induce proliferation of self-reactive B cells and cytokine production by plasmacytoid dendritic cells (PDCs) in a TLR9-dependent manner. One of the cytokines induced by DNA-containing ICs is interferon alpha (IFN-alpha). Elevated serum levels of IFN-alpha and overexpression of interferon-induced genes have been observed in SLE patient blood and shown to correlate with disease severity. We have recently found that the mechanism of IFN-alpha production by PDCs depends on TLR9 and Fc gamma RIIa (CD32), and CD32 delivers SLE DNA-ICs to intracellular lysosomes containing TLR9. This CD32-TLR9 pathway, which is operative in PDCs, is distinct from the BCR/TLR9 pathway in B cells and may prove to be a novel target for future SLE therapies. In this article, the role of toll-like receptors, cytokines, and Fc receptors expressed by PDCs in the pathogenesis of SLE is summarized. C1 Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Means, TK (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, 149 13th St, Charlestown, MA 02129 USA. EM tmeans@partners.org NR 56 TC 37 Z9 45 U1 0 U2 3 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-606-7 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1062 BP 242 EP 251 DI 10.1196/annals.1358.027 PG 10 WC Immunology; Multidisciplinary Sciences SC Immunology; Science & Technology - Other Topics GA BEA65 UT WOS:000236473100023 PM 16461805 ER PT J AU Nishiguchi, KM Sandberg, MA Gorji, N Berson, EL Dryja, TP AF Nishiguchi, KM Sandberg, MA Gorji, N Berson, EL Dryja, TP TI Cone cGMP-gated channel mutations and clinical findings in patients with achromatopsia, macular degeneration, and other hereditary cone diseases SO HUMAN MUTATION LA English DT Article DE achromatopsia; photoreceptor; color blindness; macular degeneration; CNGA3; CNGB3; GNAT2; genotype-phenotype ID TRANSDUCIN ALPHA-SUBUNIT; RETINITIS PIGMENTOSA; TOTAL COLOURBLINDNESS; CATION CHANNEL; GNAT2; DYSTROPHY; CNGB3; ELECTRORETINOGRAMS; PHOTORECEPTORS; DYSFUNCTION AB Unrelated patients with achromatopsia, macular degeneration with onset under age 50 years, cone degeneration or dysfunction, cone,rod degeneration, or macular malfunction were screened for mutations in the three genes known to be associated with achromatopsia: the GNAT2 gene encoding the alpha subunit of cone transducin and the CNGA3 and CNGB3 genes encoding the alpha and beta subunits of the cone cGMPgated cation channel. We found no examples of patients with GNAT2 mutations. Out of 36 achromats, 12 (33%) had mutations in CNGA3 (13 different mutations including five novel mutations) and 12 (33%) had mutations in CNGB3 (six different mutations including four novel mutations). All achromats with CNG mutations had residual, presumably cone function as determined by computer-averaged 30-Hz electroretinograms (ERGs). There was considerable variability in acuity and color vision, with most patients having acuities of 20/200-20/400 and complete absence of color perception, and others having acuities of 20/25-20/40 and some color vision. Two pseudodominant achromatopsia cases were uncovered, both with CNGA3 mutations, including one family in which some compound heterozygotes with achromatopsia mutations were clinically unaffected. We found two novel CNGB3 changes in three patients with juvenile macular degeneration, a phenotype not previously associated with mutations in the cone channel subunits. These patients had subnormal acuity (20/30-20/60), normal to subnormal color vision, and normal to subnormal full-field cone ERG amplitudes. Our results indicate that some patients with channel protein mutations retain residual foveal cone function. Based on our findings, CNGB3 should be considered as a candidate gene to be evaluated in patients with forms of cone dysfunction, including macular degeneration. (C) 2005 Wiley-Liss, Inc. C1 Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ocular Mol Genet Inst, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Berman Gund Lab Study Retinal Degenerat, Boston, MA USA. RP Dryja, TP (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ocular Mol Genet Inst, 243 Charles St, Boston, MA 02114 USA. EM thaddeus_dryja@meei.harvard.edu FU NEI NIH HHS [EY00169, EY08683] NR 34 TC 71 Z9 78 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PY 2005 VL 25 IS 3 BP 248 EP 258 DI 10.1002/humu.20142 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 902NC UT WOS:000227362800004 PM 15712225 ER PT J AU Hansen, KR Thyer, AC Sluss, PM Bremner, WJ Soules, MR Klein, NA AF Hansen, KR Thyer, AC Sluss, PM Bremner, WJ Soules, MR Klein, NA TI Reproductive ageing and ovarian function: is the early follicular phase FSH rise necessary to maintain adequate secretory function in older ovulatory women? SO HUMAN REPRODUCTION LA English DT Article DE antral follicles; inhibin; ovarian ageing; ovarian reserve ID SPONTANEOUS MENSTRUAL CYCLES; STIMULATING-HORMONE RISE; IN-VITRO FERTILIZATION; ACTIVIN-A; DIMERIC INHIBIN; MENOPAUSAL TRANSITION; CYCLING WOMEN; AGE; SERUM; ESTRADIOL AB BACKGROUND: Serum FSH elevations and decreases in inhibin B have been consistently demonstrated in the early follicular phase of cycles in women of advanced reproductive age. However, secretory products of the dominant follicle (estradiol and inhibin A) in the serum of older ovulatory women are maintained at levels similar to those of their younger counterparts. The goal of this investigation was to determine if ovarian secretory capacity is dependent on relative FSH levels and if basal measures of ovarian reserve reflect ovarian secretory capacity. METHODS: We administered equivalent low, but effective doses of recombinant FSH for 5 days to a group of older subjects (40-45 years, n = 9) and younger controls (20-25 years, n = 10) after pituitary suppression with a GnRH agonist. Outcome measures included follicular development as determined by serial transvaginal ultrasound examinations and serum levels of estradiol, inhibin A and inhibin B. RESULTS: Serum levels of estiradiol and inhibin A were not statistically different between the two groups, while the number of large follicles formed was greater in the younger subjects. Basal parameters of ovarian reserve were not significantly correlated with ovarian secretory capacity, but did correlate with the number of follicles recruited in response to low-dose FSH. CONCLUSIONS: By providing equivalent serum levels of FSH in older and younger reproductive aged women, this study demonstrates that the secretory capacity of recruited follicles is maintained in older reproductive aged women. C1 Univ Washington, Dept Obstet & Gynecol, Div Reprod Endocrinol, Seattle, WA 98105 USA. Univ Washington, Dept Med, Seattle, WA 98105 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, Oklahoma City, OK USA. Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02114 USA. RP Klein, NA (reprint author), Univ Washington, Dept Obstet & Gynecol, Div Reprod Endocrinol, 4225 Roosevelt Way NE,Suite 305, Seattle, WA 98105 USA. EM nklein@u.washington.edu FU NIA NIH HHS [R01-AG-14579]; NICHD NIH HHS [U54-HD29164] NR 35 TC 19 Z9 23 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 J9 HUM REPROD JI Hum. Reprod. PD JAN PY 2005 VL 20 IS 1 BP 89 EP 95 DI 10.1093/humrep/deh544 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 886AP UT WOS:000226199000012 PM 15550499 ER PT B AU Piris, A Mihm, MC AF Piris, A Mihm, MC BE Wu, BQ TI Cutaneous vasculitis SO IAP 2005: Proceedings of the 4th Asia-Pacific International Academy of Pathology Congress LA English DT Proceedings Paper CT 4th Congress of the Asia-Pacific Division of the International-Academy-of-Pathology CY AUG 23-26, 2005 CL Beijing, PEOPLES R CHINA SP Int Acad Pathol, Int Acad Pathol, Chinese Div, Chinese Soc Pathol, China Med Assoc, Assoc Directors Pathol China, Hong Kong Coll Pathol, China Int Conf Ctr Sci & Technol ID SYSTEMIC-DISEASE; LESIONS; GRANULOMATOSIS; PATHOLOGY C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Piris, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. NR 22 TC 0 Z9 0 U1 0 U2 0 PU MEDIMOND S R L PI 40128 BOLOGNA PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY BN 88-7587-202-3 PY 2005 BP 153 EP 159 PG 7 WC Pathology SC Pathology GA BED81 UT WOS:000236897400023 ER PT B AU Tilles, AW Park, J AF Tilles, Arno W. Park, Jaesung GP ASME TI Engineering - A bioartificial liver device SO ICMM 2005, Proceedings of the 3rd International Conference on Microchannels and Minichannels, Pt A LA English DT Proceedings Paper CT 3rd International Conference on Microchannels and Minichannels CY JUN 13-15, 2005 CL Univ Toronto, Toronto, CANADA SP ASME HO Univ Toronto ID OXYGEN-UPTAKE RATES; CONTROLLED-TRIAL; PHASE-I; FAILURE; HEPATOCYTES; MULTICENTER; BIOREACTOR; SUPPORT; DESIGN; CELLS AB Fulminant hepatic failure is a clinical syndrome associated with a high mortality rate. Orthotopic liver transplantation is the only clinically proven effective treatment for patients with end-stage liver disease who do not respond to medical management. A major limitation of this treatment modality is the scarcity of donor organs available, resulting in patients dying while waiting for a donor liver. An extracorporeal bioartificial liver (BAL) device containing viable hepatocytes has the potential to provide temporary hepatic support to liver failure patients, serving as a bridge to transplantation while awaiting a suitable donor. In some patients, providing temporary hepatic support may be sufficient to allow adequate regeneration of the host liver, thereby eliminating the need for a liver transplant. Although the BAL device is a promising technology for the treatment of liver failure, there are several technical challenges that must be overcome in order to develop systems with sufficient processing capacity and of manageable size. In this overview, the authors describe the critical issues involved in developing a BAL device. They also discuss their experiences in hepatocyte culture optimization within the context of a microchannel flat-plate BAL device. C1 Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med, Boston, MA 02114 USA. RP Tilles, AW (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med, Boston, MA 02114 USA. NR 25 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MECHANICAL ENGINEERS PI NEW YORK PA THREE PARK AVENUE, NEW YORK, NY 10016-5990 USA BN 0-7918-4185-5 PY 2005 BP 119 EP 126 PG 8 WC Engineering, Mechanical SC Engineering GA BFM11 UT WOS:000243025300014 ER PT J AU Belcher, HME Butz, AM Wallace, P Hoon, AH Reinhardt, E Reeves, SA Pulsifer, MB AF Belcher, HME Butz, AM Wallace, P Hoon, AH Reinhardt, E Reeves, SA Pulsifer, MB TI Spectrum of early intervention services for children with intrauterine drug exposure SO INFANTS AND YOUNG CHILDREN LA English DT Article DE early intervention; growth outcome; intrauterine drug exposure; maternal substance abuse; neurobehavior; neuromotor ID PRENATAL COCAINE EXPOSURE; PRESCHOOL-CHILDREN; MARIJUANA EXPOSURE; HOME INTERVENTION; ALCOHOL EXPOSURE; SCHOOL READINESS; SUBSTANCE-ABUSE; AGE; INVENTORY; ATTENTION AB Intrauterine illicit drug exposure may lead to a variety of adverse neurobehavioral and neurodevelopmental outcomes. Providing early intervention to reduce the impact of maternal substance abuse on the developing fetus may have significant benefits for the child and family. In this article, we report on 3 promising intervention programs designed to improve the well-being of parents with drug dependence and their children. The initiation of these programs spans from pregnancy through early childhood. All 3 programs are community-based, using comprehensive culturally relevant developmental models. The first program was developed to provide comprehensive care for pregnant women with drug dependence and their newborns. Project STRIVE (Support, Trust, Rehabilitation, Initiative, Values, and Education) provided substance abuse treatment, intensive center- and home-based social work, and parent education onsite at a high-risk obstetric and pediatric clinic. The second program, the Early Infant Transition Center, enrolled newborns with a history of neonatal abstinence syndrome and their mothers. Based in a renovated rowhouse in East Baltimore, one block away from a major urban hospital, the Early Infant Transition Center provided 24-hour nursing care, oncall physicians and nurse practitioners, social workers, parent education, and onsite sleeping accommodation for parents during their infant's recovery. The third program, Home-U-Go Safely, used community-based nurses to give home-based health monitoring, education, and support to new mothers with a history of cocaine and/or opiate dependence. C1 Kennedy Krieger Inst, Dept Neurol & Dev Med, Baltimore, MD 21205 USA. Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21218 USA. Johns Hopkins Univ Nursing, Baltimore, MD USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Belcher, HME (reprint author), Kennedy Krieger Inst, Dept Neurol & Dev Med, 207 N Broadway, Baltimore, MD 21205 USA. EM belcher@kennedykrieger.org RI Sandall, Jane/D-4146-2009 OI Sandall, Jane/0000-0003-2000-743X NR 43 TC 4 Z9 4 U1 3 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0896-3746 J9 INFANT YOUNG CHILD JI Infants Young Child. PD JAN-MAR PY 2005 VL 18 IS 1 BP 2 EP 15 PG 14 WC Education, Special; Psychology, Developmental; Rehabilitation SC Education & Educational Research; Psychology; Rehabilitation GA 901EO UT WOS:000227266000002 ER PT J AU Matsunaga, J Sanchez, Y Xu, XY Haake, DA AF Matsunaga, J Sanchez, Y Xu, XY Haake, DA TI Osmolarity, a key environmental signal controlling expression of leptospiral proteins LigA and LigB and the extracellular release of LigA SO INFECTION AND IMMUNITY LA English DT Article ID OUTER-MEMBRANE; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; FILAMENTOUS HEMAGGLUTININ; BORDETELLA-PERTUSSIS; LOG-PHASE; INTERROGANS; GROWTH; SECRETION; DETERMINANTS AB The high-molecular-weight leptospiral immunoglobulin-like repeat (Lig) proteins are expressed only by virulent low-passage forms of pathogenic Leptospira species. We examined the effects of growth phase and environmental signals on the expression, surface exposure, and extracellular release of LigA and LigB. LigA was lost from stationary-phase cells, while LigB expression was maintained. The loss of cell-associated LigA correlated with selective release of a lower-molecular-weight form of LigA into the culture supernatant, while LigB and the outer membrane lipoprotein LipL41 remained associated with cells. Addition of tissue culture medium to leptospiral culture medium induced LigA and LigB expression and caused a substantial increase in released LigA. The sodium chloride component of tissue culture medium was primarily responsible for the enhanced release of LigA. Addition of sodium chloride, potassium chloride, or sodium sulfate to leptospiral medium to physiological osmolarity caused the induction of both cell-associated LigA and LigB, indicating that osmolarity regulates the expression of Lig proteins. Osmotic induction of Lig expression also resulted in enhanced release of LigA and increased surface exposure of LigB, as determined by surface immunofluorescence. Osmolarity appears to be a key environmental signal that controls the expression of LigA and LigB. C1 VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA USA. RP Matsunaga, J (reprint author), VA Greater Los Angeles Healthcare Syst, Div Infect Dis, B113-R225, Los Angeles, CA 90073 USA. EM jamesm@ucla.edu FU NIAID NIH HHS [R21 AI034431, AI-34431, R01 AI034431, R01 AI034431-08, R29 AI034431] NR 35 TC 62 Z9 62 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD JAN PY 2005 VL 73 IS 1 BP 70 EP 78 DI 10.1128/IAI.73.1.70-78.2005 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 883TD UT WOS:000226037700006 PM 15618142 ER PT J AU Behera, AK Hildebrand, E Scagliotti, J Steere, AC Hu, LT AF Behera, AK Hildebrand, E Scagliotti, J Steere, AC Hu, LT TI Induction of host matrix metalloproteinases by Borrelia burgdorferi differs in human and murine Lyme arthritis SO INFECTION AND IMMUNITY LA English DT Article ID SEVERE COMBINED IMMUNODEFICIENCY; RHEUMATOID-ARTHRITIS; HUMAN PLASMINOGEN; LABORATORY MICE; SYNOVIAL-FLUID; GELATINASE-B; DISEASE; EXPRESSION; TISSUE; MODEL AB Matrix metalloproteinases (MMPs) are induced from host tissues in response to Borrelia burgdorferi. Upregulation of MMPs may play a role in the dissemination of the organism through extracellular matrix tissues, but it can also result in destructive pathology. Although mice are a well-accepted model for Lyme arthritis, there are significant differences compared to human disease. We sought to determine whether MMP expression could account for some of these differences. MMP expression patterns following B. burgdorferi infection were analyzed in primary human chondrocytes, synovial fluid samples from patients with Lyme arthritis, and cartilage tissue from Lyme arthritis-susceptible and -resistant mice by using a gene array, real-time PCR, an enzyme-linked immunosorbent assay, and immunohistochemistry. B. burgdorferi infection significantly induced transcription of MMP-1, -3, -13, and -19 from primary human chondrocyte cells. Transcription of MMP-10 and tissue inhibitor of metalloprotease I was increased with B. burgdorferi infection, but protein expression was only minimally increased. The synovial fluid levels of MMPs from patients with high and low spirochete burdens were consistent with results seen in the in vitro studies. B. burgdorferi-susceptible C3H/HeN mice infected with B. burgdorferi showed induction of MMP-3 and MMP-19 but no other MMP or tissue inhibitor of metalloprotease. As determined by immunohistochemistry, MMP-3 expression was increased only in chondrocytes near the articular surface. The levels of MMPs were significantly lower in the more Lyme arthritis-resistant BALB/c and C57BL/6 mice. Differences between human and murine Lyme arthritis may be related to the lack of induction of collagenases, such MMP-1 and MMP-13, in mouse joints. C1 Tufts New England Med Ctr, Sch Med, Tupper Res Inst, Dept Infect Dis, Boston, MA 02111 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rhematol Allergy & Immunol,Ctr Immunol & Infl, Boston, MA USA. RP Hu, LT (reprint author), Tufts New England Med Ctr, Sch Med, Tupper Res Inst, Dept Infect Dis, 750 Washington St, Boston, MA 02111 USA. EM Lhu@tufts-nemc.org RI Hu, Linden/L-6314-2016 OI Hu, Linden/0000-0003-1659-5558 FU NIAID NIH HHS [R01 AI50043, R01 AI044240, R01 AI050043, R01AI44240, U01 AI058266, U01AI058266]; NIAMS NIH HHS [R01 AR020358, R01AR20358] NR 50 TC 33 Z9 35 U1 3 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD JAN PY 2005 VL 73 IS 1 BP 126 EP 134 DI 10.1128/IAI.73.1.126-134.2005 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 883TD UT WOS:000226037700011 PM 15618147 ER PT J AU Viray, M Linkin, D Maslow, JN Stieritz, DD Carson, LS Bilker, WB Lautenbach, E AF Viray, M Linkin, D Maslow, JN Stieritz, DD Carson, LS Bilker, WB Lautenbach, E TI Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: Emergence of fluoroquinolone resistance SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID SKILLED NURSING FACILITY; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; KLEBSIELLA-PNEUMONIAE; RISK-FACTORS; HOME RESIDENTS; INFECTION; COLONIZATION; BACTERIA; UNIT AB BACKGROUND Antibiotic resistance in the longterm-care facility (LTCF) setting is of increasing concern due to both the increased morbidity and mortality related to infections in this debilitated population and the potential for transfer of resistant organisms to other healthcare settings. Longitudinal trends in antibiotic resistance in LTCFs have not been well described. DESIGN: Correlational longitudinal survey study. SETTING: Four LTCFs in Pennsylvania. SUBJECTS: All clinical cultures of residents of the participating LTCFs (700 total beds) from 1998 through 2003. We assessed the annual prevalence of resistance to various antimicrobials of interest for the following organisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus, and enterococcus species. RESULTS: A total of 4,954 clinical isolates were obtained during the study. A high prevalence of antimicrobial resistance was noted for many organism-drug combinations. This was especially true for fluoroquinolone susceptibility among the Enterobacteriaceae (susceptibility range, 51.3% to 92.2%). In addition, the prevalence of resistance to various agents differed significantly across study sites. Finally, significant increasing trends in resistance were noted over time and were most pronounced for fluoroquinolone susceptibility among the Enterobacteriaceae. CONCLUSIONS: The prevalence of antimicrobial resistance has increased significantly in LTCFs, although trends have varied substantially across different institutions. These trends have been particularly pronounced for fluoroquinolone resistance among the Enterobacteriaceae. These findings demonstrate that antimicrobial resistance is widespread and increasing in LTCFs, highlighting the need for future studies to more clearly elucidate the risk factors for, and potential interventions against, emerging resistance in these settings. C1 Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Geriatr, Dept Med, Philadelphia, PA 19104 USA. RP Lautenbach, E (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 825 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM elautenb@cceb.med.upenn.edu FU AHRQ HHS [U18-HS10399]; NIDDK NIH HHS [DK-02987-01] NR 35 TC 46 Z9 46 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JAN PY 2005 VL 26 IS 1 BP 56 EP 62 DI 10.1086/502487 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 888JH UT WOS:000226369700008 PM 15693409 ER PT S AU Jonasson, L Hagmann, P Bresson, X Thiran, JP Wedeen, VJ AF Jonasson, L Hagmann, P Bresson, X Thiran, JP Wedeen, VJ BE Christensen, GE Sonka, M TI Representing diffusion MRI in 5D for segmentation of white matter tracts with a level set method SO INFORMATION PROCESSING IN MEDICAL IMAGING, PROCEEDINGS SE LECTURE NOTES IN COMPUTER SCIENCE LA English DT Article; Proceedings Paper CT 19th International Conference on Information Processing in Medical Imaging CY JUL 10-15, 2005 CL Glenwood Springs, CO SP Whitaker Fdn, Natl Inst Biomed Imaging & Bioengn, Univ Iowa, Obermann Ctr Adv Studies, Univ Iowa, Dept Elect Engn, Univ Iowa, Coll Engn ID MEAN-CURVATURE FLOW; ACTIVE CONTOURS AB We present a method for segmenting white matter tracts from high angular resolution diffusion MR, images by representing the data in a 5 dimensional space of position and orientation. Whereas crossing fiber tracts cannot be separated in 3D position space, they clearly disentangle in 5D position-orientation space. The segmentation is done using a 5D level set method applied to hyper-surfaces evolving in 5D position-orientation space. In this paper we present a methodology for constructing the position-orientation space. We then show how to implement the standard level set method in such a non-Euclidean high dimensional space. The level set theory is basically defined for N-dimensions but there are several practical implementation details to consider, such as mean curvature. Finally, we will show results from a synthetic model and a few preliminary results on real data of a human brain acquired by high angular resolution diffusion MRI. C1 Swiss Fed Inst Technol, Signal Proc Inst, CH-1015 Lausanne, Switzerland. Univ Lausanne Hosp, Dept Diagnost & Intervent Radiol, CH-1011 Lausanne, Switzerland. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA. RP Jonasson, L (reprint author), Swiss Fed Inst Technol, Signal Proc Inst, CH-1015 Lausanne, Switzerland. OI Thiran, Jean-Philippe/0000-0003-2938-9657 NR 17 TC 6 Z9 6 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 3-540-26545-7 J9 LECT NOTES COMPUT SC PY 2005 VL 3565 BP 311 EP 320 PG 10 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BCR05 UT WOS:000230871900026 ER PT S AU Sun, W Cetin, M Chan, R Reddy, V Holmvang, G Chandar, V Willsky, A AF Sun, W Cetin, M Chan, R Reddy, V Holmvang, G Chandar, V Willsky, A BE Christensen, GE Sonka, M TI Segmenting and tracking the left ventricle by learning the dynamics in cardiac images SO INFORMATION PROCESSING IN MEDICAL IMAGING, PROCEEDINGS SE Lecture Notes in Computer Science LA English DT Article; Proceedings Paper CT 19th International Conference on Information Processing in Medical Imaging CY JUL 10-15, 2005 CL Glenwood Springs, CO SP Whitaker Fdn, Natl Inst Biomed Imaging & Bioengn, Univ Iowa, Obermann Ctr Adv Studies, Univ Iowa, Dept Elect Engn, Univ Iowa, Coll Engn ID ACTIVE CONTOURS; LEVEL SETS; SEGMENTATION; INFORMATION; FRAMEWORK; MR AB Having accurate left ventricle (LV) segmentations across a cardiac cycle provides useful quantitative (e.g. ejection fraction) and qualitative information for diagnosis of certain heart conditions. Existing LV segmentation techniques are founded mostly upon algorithms for segmenting static images. In order to exploit the dynamic structure of the heart in a principled manner, we approach the problem of LV segmentation as a recursive estimation problem, In our framework, LV boundaries constitute the dynamic system state to be estimated, and a sequence of observed cardiac images constitute the data. By formulating the problem as one of state estimation, the segmentation at each particular time is based not only on the data observed at that instant, but also on predictions based on past segmentations. This requires a dynamical system model of the LV, which we propose to learn from training data through an information-theoretic approach. To incorporate the learned dynamic model into our segmentation framework and obtain predictions, we use ideas from particle filtering. Our framework uses a curve evolution method to combine such predictions with the observed images to estimate the LV boundaries at each time. We demonstrate the effectiveness of the proposed approach on a large set of cardiac images. We observe that our approach provides more accurate segmentations than those from static image segmentation techniques, especially when the observed data are of limited quality. C1 MIT, Informat & Decis Syst Lab, Cambridge, MA 02139 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc MR CT Program, Boston, MA USA. RP MIT, Informat & Decis Syst Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM waltsun@mit.edu NR 28 TC 25 Z9 25 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 3-540-26545-7 J9 LECT NOTES COMPUT SC PY 2005 VL 3565 BP 553 EP 565 PG 13 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BCR05 UT WOS:000230871900046 ER PT J AU Thoma, RJ Yeo, RA Gangestad, SW Halgren, E Sanchez, NM Lewine, JD AF Thoma, RJ Yeo, RA Gangestad, SW Halgren, E Sanchez, NM Lewine, JD TI Cortical volume and developmental instability are independent predictors of general intellectual ability SO INTELLIGENCE LA English DT Article DE developmental instability; Raven's Advanced Progressive Matrices; body fluctuating asymmetry ID FLUCTUATING ASYMMETRY; HUMAN BRAIN; INTELLIGENCE; LATERALIZATION; PERFORMANCE AB Measures of developmental instability (DI) reflect developmental disruptions due to genetic and environmental perturbations during normal development. DI might be expected to influence the developmental course of brain development and hence intelligence, and several studies indicate this to be the case. The factors that mediate this relationship are unknown. One possibility is that DI affects intelligence through effects on cortical size. To investigate this possibility; we assessed a measure of DI. body fluctuating asymmetry (FA), the Raven's Advanced Progressive Matrices (RAPM). and other cognitive tests on a group of 19 healthy male volunteers on whom cortical volume, white matter. overall brain volume, and cross-sectional areas of the corpus callosum and planum temporale were measured. Both FA and cortical volume significantly predicted RAPM scores, but were not significantly correlated themselves. Multiple regression analyses yielded effects of FA on RAPM scores and a general intelligence principal component independent of cortical volume. Hence, it appears that developmental instability affects intellectual functioning through pathways not involving cortical volume. Possible mediators include macro-organizational structure, neural integrity, or metabolic efficiency. (C) 2004 Elsevier Inc. All rights reserved. C1 New Mexico VA Hlth Care Syst, Albuquerque, NM USA. Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA. Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS USA. Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA. RP Thoma, RJ (reprint author), Univ New Mexico 1, Ctr Neuropsychol Serv, MSC 11 6094,915 Vassar NE, Albuquerque, NM 87131 USA. EM rjthoma@salud.unm.edu OI Gangestad, Steven/0000-0002-8879-4348 NR 35 TC 20 Z9 20 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0160-2896 J9 INTELLIGENCE JI Intelligence PD JAN-FEB PY 2005 VL 33 IS 1 BP 27 EP 38 DI 10.1016/j.intell.2004.08.004 PG 12 WC Psychology, Multidisciplinary SC Psychology GA 886LM UT WOS:000226228800003 ER PT J AU Worthington, JJ Kinrys, G Wygant, LE Pollack, MH AF Worthington, JJ Kinrys, G Wygant, LE Pollack, MH TI Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE anxiety; aripiprazole; augmentation; depression; SSRI ID TREATMENT-RESISTANT DEPRESSION; ANTIPSYCHOTIC ARIPIPRAZOLE; MAJOR DEPRESSION; RECEPTOR AB More than half of anxiety and depression patients treated with an adequate course of antidepressants fail to fully improve. We retrospectively examined whether treatment-resistant depression and anxiety disorder patients responded to and tolerated augmentation with the atypical antipsychotic, aripiprazole. We report on patients with depression and anxiety disorders, including panic disorder, generalized anxiety disorder, social anxiety and post-traumatic stress disorder, who had an incomplete response to a variety of selective serotonin reuptake inhibitors (SSRIs) and who received augmentation with aripiprazole. The primary outcome measure was the Clinical Global Impression of Improvement (CGI-I). In the intent-to-treat analysis, the mean +/-SD CGI-S was 3.8 +/- 1.3 at endpoint. Fifty-nine percent of subjects received CGI-I ratings of 1 or 2,'much improved' or 'very much improved,in terms of their depression and anxiety symptoms at the end of 12 weeks. Several patients showed an early (weeks 1-5), as well as sustained, response to augmentation with doses of aripiprazole between 15 and 30 mg/day. The results suggest that aripiprazole may be effective as an augmentation for patients with persistent depressive and anxiety disorders despite initial SSRI treatment. Because this is a retrospective case review, further prospective studies are required to confirm these findings. (C) 2005 Lippincott Williams Wilkins. C1 Harvard Univ, Sch Med, Dept Psychiat, Cambridge Hlth Alliance,Anxiety Disorders Res Pro, Cambridge, MA 02139 USA. Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, Boston, MA 02114 USA. RP Kinrys, G (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Cambridge Hlth Alliance,Anxiety Disorders Res Pro, 1493 Cambridge St, Cambridge, MA 02139 USA. EM gkinrys@challiance.org NR 16 TC 88 Z9 91 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0268-1315 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD JAN PY 2005 VL 20 IS 1 BP 9 EP 11 DI 10.1097/00004850-200501000-00002 PG 3 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 891PV UT WOS:000226593900002 PM 15602109 ER PT S AU Sisterson, JM AF Sisterson, JM BE Haight, RC Chadwick, MB Kawano, T Talou, P TI Cross-section measurements for proton- and neutron-induced reactions needed to understand cosmic-ray interactions on earth and in space SO International Conference on Nuclear Data for Science and Technology, Pts 1 and 2 SE AIP CONFERENCE PROCEEDINGS LA English DT Proceedings Paper CT International Conference on Nuclear Data for Science and Technology CY SEP 26-OCT 01, 2004 CL Santa Fe, NM SP OECD Nucl Energy Agcy, Int Atom Energy Agcy, US DOE, Los Alamos Natl Lab, Acqiris Corp, Amer Inst Phys, Canberra Ind Inc, Eljen Technologies, Goodfellow Corp, Inst Phys, St Gobain, Bicron, Scionix USA, Struck, Techsource, Thermoelectron, Wiener, Natl Nucl Data Ctr ID COSMOGENIC NUCLIDES; PRODUCTION-RATES; CU AB Primary cosmic rays interact directly with extraterrestrial bodies and cosmic-ray shower particles interact with the earth's surface to produce small quantities of radionuclides and stable isotopes, which are measured routinely using appropriate techniques. Theoretical models are used to analyze these measurements to team the history of the object or the cosmic rays that fell upon it. Cross sections for reactions producing these cosmogenic nuclides are essential input to these models. Most primary cosmic rays are protons, and good measurements of the cross sections for proton-induced reactions are essential. Most relevant cross sections are now well measured, but discrepancies still exist between the measurements and calculations. One explanation is that neutrons produced in primary cosmic-ray interactions also initiate spallation reactions contributing significantly to the cosmogenic nuclide inventory, but few of the relevant cross sections have been measured at energies > 30 MeV. We have measured many of these needed cross sections for neutron-induced reactions using two different techniques. Cross sections at selected unique neutron energies > 70 MeV are measured at iThemba LABS, South Africa (iTL) using quasi-monoenergetic neutron beams. Energy integrated (average) cross sections are measured at the Los Alamos Neutron Science Center (LANSCE), using 'white' neutron beams with an energy range of 0.1-750 MeV. C1 Massachusetts Gen Hosp, North East Proton Therapy Ctr, Boston, MA 02114 USA. RP Sisterson, JM (reprint author), Massachusetts Gen Hosp, North East Proton Therapy Ctr, 30 Fruit St, Boston, MA 02114 USA. NR 18 TC 0 Z9 0 U1 0 U2 0 PU AMER INST PHYSICS PI MELVILLE PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA SN 0094-243X BN 0-7354-0254-X J9 AIP CONF PROC PY 2005 VL 769 BP 1596 EP 1599 PN 1-2 PG 4 WC Nuclear Science & Technology; Physics, Applied; Physics, Nuclear SC Nuclear Science & Technology; Physics GA BCP35 UT WOS:000230511801119 ER PT J AU Bernal, SD AF Bernal, Samuel D. TI Biotherapy of Breast Cancer SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Meeting Abstract C1 [Bernal, Samuel D.] Univ Calif Los Angeles, VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. [Bernal, Samuel D.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PY 2005 VL 26 SU 1 BP S34 EP S34 PG 1 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA V79JE UT WOS:000205364200084 ER PT J AU Bernal, SD AF Bernal, Samuel D. TI Biotherapy of breast cancer SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Meeting Abstract C1 [Bernal, Samuel D.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Bernal, Samuel D.] Univ Calif Los Angeles, VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PY 2005 VL 26 SU 1 BP S34 EP S34 PG 1 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA V54FN UT WOS:000203664700083 ER PT J AU Bernal, SD AF Bernal, Samuel D. TI Lung Cancer Differentiation and Targeted Therapies SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Meeting Abstract C1 [Bernal, Samuel D.] Univ Calif Los Angeles, VA Greater Angeles Hlth Syst, Los Angeles, CA USA. [Bernal, Samuel D.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PY 2005 VL 26 SU 1 BP S47 EP S47 PG 1 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA V79JE UT WOS:000205364200126 ER PT J AU Skrabski, A Kopp, M Rozsa, S Rethelyi, J Rahe, RH AF Skrabski, A Kopp, M Rozsa, S Rethelyi, J Rahe, RH TI Life meaning: An important correlate of health in the Hungarian population SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE life meaning; premature oncological mortality; premature cardiovascular mortality; self-rated health; well-being; depression; self-efficacy; spirituality; religion; ways of coping; social support ID SELF-RATED HEALTH; CORONARY-ARTERY-DISEASE; CROSS-SECTIONAL ASSOCIATIONS; MALE MORTALITY-RATES; MIDDLE-AGED FEMALE; CHANGING SOCIETY; HEART-DISEASE; CARDIOVASCULAR-DISEASE; GENERAL-POPULATION; COPING INVENTORY AB One of the 5 coping scales in Rahe's Brief Stress and Coping Inventory, entitled Life Meaning, was examined in relation to demographic characteristics, other coping measures, and health status in a sample of 12,640 Hungarian participants, Participants were selected to represent the country's population according to sex, age, and place of residence. The study also explored the contribution of life meaning to the, explanation of variations of middle-aged (45-64 years) male and female mortality rates across 150 subregions in Hungary. On an ecological level life meaning proved to be inversely related to male and female oncological, female cardiovascular and total premature mortality rates in the 150 subregions of Hungary and on an individual level to participants' reported health status. In the total sample of individuals after controlling for gender age, and education, life meaning scores showed strong correlations with the World Health Organization well-being scale, with self-rated absence of depression, with self-rated health, and with self-rated absence of disability. Although relatively unrelated to age, gender, and education, life meaning was positively related to self-efficacy, importance of religion, problem-oriented coping, and social support. C1 Semmelweis Univ, Inst Behav Sci, H-1089 Budapest, Hungary. Eotvos Lorand Univ, Inst Psychol, Budapest, Hungary. Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA USA. RP Kopp, M (reprint author), Semmelweis Univ, Inst Behav Sci, H-1089 Budapest, Hungary. EM kopmar@net.sote.hu OI Rethelyi, Janos/0000-0002-3641-012X NR 52 TC 38 Z9 40 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 J9 INT J BEHAV MED JI Int. J. Behav. Med. PY 2005 VL 12 IS 2 BP 78 EP 85 DI 10.1207/s15327558ijbm1202_5 PG 8 WC Psychology, Clinical SC Psychology GA 933BE UT WOS:000229598100005 PM 15901216 ER PT J AU Hayes, AM Beevers, CG Feldman, GC Laurenceau, JP Perlman, C AF Hayes, AM Beevers, CG Feldman, GC Laurenceau, JP Perlman, C TI Avoidance and processing as predictors of symptom change and positive growth in an integrative therapy for depression SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE depression; avoidance; rumination; emotion regulation; emotional processing; cognitive processing; expressive writing ID POSTTRAUMATIC-STRESS-DISORDER; EMOTION REGULATION; MEDICAL ILLNESS; CARDIOVASCULAR-DISEASE; THOUGHT SUPPRESSION; COGNITIVE THERAPY; RATING-SCALE; HEALTH; PSYCHOTHERAPY; MECHANISMS AB Depression is a leading cause of disability worldwide and can worsen the course of a variety of medical illnesses. There is a clear need to develop more potent treatments for this, debilitating disorder and prevent its return. We are developing a promising psychotherapy that integrates components Of current, empirically supported therapies for depression and also teaches healthy lifestyle and emotion regulation habits to promote psychological health. In the 1st open trial, growth curve analyses revealed a significant linear decrease in symptoms of depression in a sample of 29 clients who completed the therapy. Participants wrote essays about their depression each week, and the content was analyzed using a new coding system of change processes. Hierarchical linear modeling (HLM) revealed that peak levels of processing in the essays were associated with more improvement in depression and with the expression of more hope and of both negative and positive views of the self, presumably as clients explored their depressive views of self Peak levels of avoidance were associated with less improvement in depression and with more hopelessness and negative views of the self These preliminary results suggest possible targets of change that can facilitate symptom reduction and perhaps also promote psychological health. C1 Univ Delaware, Dept Psychol, Newark, DE 19716 USA. Univ Texas, Dept Psychol, Austin, TX USA. Univ Miami, Dept Psychol, Coral Gables, FL 33146 USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Hayes, AM (reprint author), Univ Delaware, Dept Psychol, 108 Wolf Hall, Newark, DE 19716 USA. EM ahayes@psych.udel.edu FU NIMH NIH HHS [R21 MH62662] NR 90 TC 68 Z9 71 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 J9 INT J BEHAV MED JI Int. J. Behav. Med. PY 2005 VL 12 IS 2 BP 111 EP 122 DI 10.1207/s15327558ijbm1202_9 PG 12 WC Psychology, Clinical SC Psychology GA 933BE UT WOS:000229598100009 PM 15901220 ER PT J AU Ray, IB Reddy, VY AF Ray, IB Reddy, VY TI Implanted defibrillators and primary prevention of sudden cardiac death: where are we today? SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Review DE implantable defibrillator; sudden cardiac death; ventricular dysfunction; primary prevention ID RECENT MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR DYSFUNCTION; ANTIARRHYTHMIC-DRUG THERAPY; CARDIOVERTER-DEFIBRILLATOR; RANDOMIZED-TRIAL; HEART-FAILURE; HIGH-RISK; ARRHYTHMIAS; AMIODARONE; SURVIVAL AB Implanted defibrillators have become a mainstream therapy for the prevention of sudden cardiac death (SCD) from ventricular tachyarrhythmias in patients with chronic coronary artery disease. A decade of studies has confirmed the superiority of ICDs over antiarrhythmic drug therapy in prolonging the life of patients with a prior history of sustained VT or VF. Furthermore, recent studies have examined the role of ICD therapy in the primary prophylaxis against sudden death in patients considered at high risk for ventricular tachyarrhythmias. These studies have revealed that in selected patients with the substrate of chronic coronary artery disease and a ventricular scar, ICDs lead to important relative and absolute reductions in mortality in such patients without a prior history of VT or VF. Clinicians caring for patients with chronic coronary artery disease (CAD) and severe LV dysfunction, who are at a risk of sudden cardiac death, need to carefully consider this information when managing this patient population. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. RP Reddy, VY (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv, 55 Fruit St,Gray Bigelow 109, Boston, MA 02114 USA. EM VREDDY@PARTNERS.ORG RI Basu Ray, Indranill/D-3794-2011 NR 21 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0167-5273 J9 INT J CARDIOL JI Int. J. Cardiol. PD JAN PY 2005 VL 98 IS 1 BP 15 EP 20 DI 10.1016/j.ijcard.2003.10.032 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 896BE UT WOS:000226908800002 PM 15676160 ER PT J AU Eichenfield, LF Lucky, AW Langley, RGB Lynde, C Kaufmann, R Todd, G Lindsley, L Barbier, N Felser, JM AF Eichenfield, LF Lucky, AW Langley, RGB Lynde, C Kaufmann, R Todd, G Lindsley, L Barbier, N Felser, JM TI Use of pimecrolimus cream 1% (Elidel (R)) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome SO INTERNATIONAL JOURNAL OF DERMATOLOGY LA English DT Article ID ANTIINFLAMMATORY DRUG; SKIN DISEASES; SDZ-ASM-981; ECZEMA; PHARMACOLOGY; EFFICACY; SAFETY; LONDON AB Background Pimecrolimus cream 1%, a cell-selective inhibitor of inflammatory cytokines, has been shown to be effective in treating atopic dermatitis (AD). This report examines the effect of ethnic origin and baseline disease severity on treatment outcomes in pediatric patients with AD treated with pimecrolimus cream 1%. Methods The analysis included 589 patients aged 3 months to 17 years from three 6-week, randomized, multicenter studies of similar design. Patients were treated with pimecrolimus cream 1% or vehicle twice daily. Efficacy, safety and tolerability in Caucasian and non-Caucasian groups were compared. In addition, the effect of baseline disease severity on treatment outcome was investigated. Results A total of 321 Caucasian and 268 non-Caucasian patients [Blacks, Asians and others (including Hispanics)] with mild, moderate or severe disease at baseline were included. Baseline characteristics were comparable between the pimecrolimus and vehicle control groups and between Caucasian and non-Caucasian groups. Significantly higher efficacy [measured by Investigators' Global Assessment and Eczema Area and Severity Index (EASI) scores] was achieved in the pimecrolimus-treated group, compared with the vehicle group, irrespective of ethnic origin. Baseline disease severity had no effect on treatment outcome: patients with both mild and moderate AD responded well to pimecrolimus (absolute change from baseline in EASI score -2.60 and -5.48, respectively; both P < 0.001). Pimecrolimus cream 1% was safe and well tolerated in all ethnic groups and at all levels of disease severity. Conclusions Ethnic origin and baseline disease severity had no effect on treatment outcome with pimecrolimus cream 1% in patients with AD. C1 Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. Childrens Hosp, San Diego, CA USA. Dermatol Res Associates, Cincinnati, OH USA. Harvard Univ, Massachusetts Gen Hosp, Dermatol Clin Invest Unit, Boston, MA USA. Univ Toronto, Sch Med, Toronto Gen Hosp, Dept Med, Toronto, ON, Canada. Univ Toronto, Sch Med, Toronto Western Hosp, Toronto, ON, Canada. Univ Frankfurt, Ctr Dermatol & Venereol, D-6000 Frankfurt, Germany. Univ Cape Town, Dept Med, Div Dermatol, ZA-7925 Cape Town, South Africa. Groote Schuur Hosp Observ, Cape Town, South Africa. Novartis Pharmaceut Inc, E Hanover, NJ USA. Novartis Pharma AG, Basel, Switzerland. RP Eichenfield, LF (reprint author), 8010 Frost St,Ste 602, San Diego, CA 92123 USA. EM leichenfield@UCSD.edu NR 18 TC 14 Z9 19 U1 0 U2 1 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0011-9059 J9 INT J DERMATOL JI Int. J. Dermatol. PD JAN PY 2005 VL 44 IS 1 BP 70 EP 75 DI 10.1111/j.1365-4632.2004.02234.x PG 6 WC Dermatology SC Dermatology GA 882QG UT WOS:000225952800019 PM 15663667 ER PT J AU Becker, AE Thomas, JJ Franko, DL Herzog, DB AF Becker, AE Thomas, JJ Franko, DL Herzog, DB TI Interpretation and use of weight information in the evaluation of eating disorders: Counselor response to weight information in a national eating disorders educational and screening program SO INTERNATIONAL JOURNAL OF EATING DISORDERS LA English DT Article ID SELF-REPORTED WEIGHT; BODY-MASS INDEX; ANOREXIA-NERVOSA; BULIMIA-NERVOSA; FOLLOW-UP; PREDICTORS; ACCURACY AB Objective: Eating disorders are frequently undetected and inadequately treated in clinical settings. The current study investigated whether weight data were used appropriately in making recommendations for further care in the first National Eating Disorders Screening Program (NEDSP), Method: Accuracy of counselors' assessment of appropriateness of weight for height and adherence to an algorithm using weight to determine need for further evaluation were assessed for the 5,684 adult participants in a two-stage screening program held on college campuses. Results: In 95% of cases, the counselors correctly used the algorithm developed for the NEDSP to assign participants to weight categories ranging from normal to extremely underweight. However. counselors were poorly adherent to an algorithm directing them to recommend urgent evaluation to all extremely underweight participants-that is, those with a weight at or below 75% of expected weight. Of the extremely underweight participants (n = 32), only 25.0% (n = 8) received an appropriate recommendation for urgent evaluation, whereas 59.4% (n = 19) received a recommendation for further (but nonurgent) evaluation, and 15.6% (n = 5) did not receive a recommendation to seek any evaluation. Discussion: Clinicians appeared not to use weight data appropriately to make clinical recommendations for extremely underweight individuals. These results suggest that further specific emphasis on the health risks of extreme underweight may be helpful in training clinicians to manage patients with eating disorders. (C) 2004 by Wiley Periodicals, Inc. C1 Massachusetts Gen Hosp, Harvard Eating Disorders Ctr, Dept Psychiat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA. Yale Univ, Dept Psychol, New Haven, CT 06520 USA. Northeastern Univ, Dept Counseling & Appl Educ Psychol, Boston, MA 02115 USA. RP Franko, DL (reprint author), Massachusetts Gen Hosp, Harvard Eating Disorders Ctr, Dept Psychiat, WACC 725,15 Parkman ST, Boston, MA 02114 USA. EM d.franko@neu.edu NR 22 TC 5 Z9 5 U1 1 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0276-3478 J9 INT J EAT DISORDER JI Int. J. Eating Disord. PD JAN PY 2005 VL 37 IS 1 BP 38 EP 43 DI 10.1002/eat.20063 PG 6 WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology SC Psychology; Nutrition & Dietetics; Psychiatry GA 899IM UT WOS:000227138100006 PM 15690464 ER PT J AU Cogan, JC Franko, DL Herzog, DB AF Cogan, JC Franko, DL Herzog, DB TI Federal advocacy for anorexia nervosa: An American model SO INTERNATIONAL JOURNAL OF EATING DISORDERS LA English DT Article DE advocacy; eating disorders; federal policy AB Advocacy efforts aimed at influencing federal policy are needed to strenghten accessible resources for anorexia nervosa (AN) and to improve treatment prevention. Federal advocacy in the United States is spearheaded by the Eating Disorders Coalition for Research, Policy, and Action (EDC) whose mission is to advance the federal recognition of eating disorders as a public healthy priority. © 2005 by Wiley Periodicals, Inc. C1 Eating Disorders Coalit, Washington, DC 20003 USA. Northeastern Univ, Dept Counseling & Educ Psychol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Cogan, JC (reprint author), Eating Disorders Coalit, 611 Penn Ave SE,423, Washington, DC 20003 USA. EM EDCoalition@aol.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0276-3478 J9 INT J EAT DISORDER JI Int. J. Eating Disord. PY 2005 VL 37 SU S BP S101 EP S102 DI 10.1002/eat.20127 PG 2 WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology SC Psychology; Nutrition & Dietetics; Psychiatry GA 924LS UT WOS:000228980900024 PM 15852332 ER PT J AU Baker, PM Oliva, E AF Baker, PM Oliva, E TI Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: An update SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Review DE surface epithelial carcinomas; sex cord-stromal tumors; germ cell tumors; differential diagnosis; immunohistochemistry; new antibodies ID CORD-STROMAL TUMORS; RENAL-CELL CARCINOMA; METHYLACYL-COA RACEMASE; TRANSCRIPTION FACTOR-I; FEMALE GENITAL-TRACT; MULLERIAN-INHIBITING SUBSTANCE; METASTATIC MUCINOUS CARCINOMAS; PARAFFIN-SECTION DETECTION; DISEASE FLUID PROTEIN-15; SMOOTH-MUSCLE TUMORS AB Immunohistochemistry has become an important tool in the diagnosis of ovarian tumors. This article reviews the role of immumohistochernistry in the differential diagnosis of the three main categories of ovarian tumors, with emphasis on recently developed antibodies. In the surface epithelial stromal category the most common problem is its discernment from metastasis. The use of differential cytokeratins, primarily CK7 and CK20, as well as Cdx-2, beta-catenin, and P504S in differentiating between metastatic adenocarcinoma, particularly of colorectal origin, and primary ovarian carcinoma is discussed. Dpc4 may be useful in distinguishing pancreatic from ovarian mucinous carcinomas, because up to 55% of pancreatic carcinomas lack Dpc4 expression, whereas the differential expression of mucin genes may be helpful in distinguishing between primary ovarian mucinous and metastatic tumors. Urothelial markers (thrombomodulin and uroplakin III) and renal cell carcinoma markers (CD 10 and renal cell carcinoma marker) can be helpful in the diagnosis of metastatic urothelial and renal cell tumors to the ovary. The roles of inhibin, calretinin, CD99, and other recently described markers in the diagnosis of sex cord-stromal tumors are reviewed. The uses of OCT-4 (POU5F1) (a new highly sensitive and specific marker of dysgerminoma and embryonal carcinoma), CD30, and e-kit are also discussed. C1 Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Hlth Sci Ctr, Dept Pathol, Winnipeg, MB, Canada. RP Oliva, E (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 2, Boston, MA 02114 USA. EM eoliva@partners.org NR 206 TC 62 Z9 68 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-1691 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD JAN PY 2005 VL 24 IS 1 BP 39 EP 55 DI 10.1097/01.pgp.0000151556.46561.e7 PG 17 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA 885GY UT WOS:000226146300004 PM 15626916 ER PT J AU Scully, RE Cajander, S Falkmer, SE Young, RH AF Scully, RE Cajander, S Falkmer, SE Young, RH TI History of gynecological pathology - XVII. Dr. Lars Santesson (1901-1971) SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Biographical-Item C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA USA. Univ Uppsala, Fac Med, Dept Pathol, Uppsala, Sweden. Norwegian Univ Sci & Technol, St Olavs Univ Hosp, Fac Med, Dept Lab Med,Morphol Pathol Unit, N-7034 Trondheim, Norway. RP Young, RH (reprint author), 55 Fruit St, Boston, MA 02114 USA. EM RHYoung@partners.org NR 1 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-1691 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD JAN PY 2005 VL 24 IS 1 BP 93 EP 99 DI 10.1097/01.pgp.0000151558.92302.34 PG 7 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA 885GY UT WOS:000226146300012 PM 15626923 ER PT J AU Young, RH AF Young, RH TI Dusting off another shelf: Further comments on classic gynecologic pathology books of yesteryear SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Article DE old books; gynecologic pathology; Carl Abel; Robert T. Frank; Magnus Haines; Claud W. Taylor; Hans Motlik; Gunnar Teilum AB Selected outstanding books from the older literature on gynecologic pathology are reviewed with emphasis on drawing attention to the abundant helpful information and often outstanding illustrations that are worthy of review by present-day pathologists. This represents a follow up to a previous similar essay that appeared in Volume 19:67-84, 2000. The first three books cover general gynecological pathology: Gynecological Pathology by Carl Abel; Gynecological and Obstetrical Pathology by Robert T. Frank; and Haines and Taylor's Gynaecological Pathology by Magnus Haines and Claud W. Taylor. Each of them emphasizes the time-honored problem of mimicry of malignancy by diverse benign lesions or even aspects of normal histology. Awareness of the clinical background and cooperation between the clinician and pathologist are emphasized. The other three books considered are all devoted largely or exclusively to the ovary: Ovarian Tumors by Hans Selye, Ovarian Neoplasms, Morphology, and Classification by Karel Motlik, and Special Tumors of Ovary and Testis and Related Extragonadal Lesions by Gunnar Teilum. The book of Selye has a truly remarkable encyclopedic coverage of the older literature, the references being so comprehensive that they are presented in a separate volume. A number of aspects of the histopathology of ovarian tumors that have been emphasized in recent years are noted in Selye's book. Dr. Motlik's book presents a very high quality consideration of the differential diagnosis of ovarian tumors. Teilum's book contains a masterful account of the histopathology of germ cell tumors emphasizing a neoplasm with which his name will always be associated, the yolk sac tumor (endodermal sinus tumor). Numerous beautiful and refreshingly large illustrations are provided, and Dr. Teilum's interest in comparative pathology is evident in the pages, his linking of the famous Schiller-Duval bodies with the endodermal sinuses of the rat placenta, being the most notable example. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA 02114 USA. RP Young, RH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA 02114 USA. EM RHYoung@partners.org NR 15 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-1691 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD JAN PY 2005 VL 24 IS 1 BP 100 EP 110 DI 10.1097/01.pgp.0000151557.54184.e0 PG 11 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA 885GY UT WOS:000226146300013 PM 15626924 ER PT J AU Di Giannantonio, M Frydas, S Kempuraj, D Karagouni, E Hatzistilianou, M Conti, CMV Boucher, W Papadopoulou, N Donelan, J Cao, J Madhappan, B Boscolo, P Petrarca, C Castellani, L Quartesan, R Doyle, R Ferro, FM AF Di Giannantonio, M Frydas, S Kempuraj, D Karagouni, E Hatzistilianou, M Conti, CMV Boucher, W Papadopoulou, N Donelan, J Cao, J Madhappan, B Boscolo, P Petrarca, C Castellani, L Quartesan, R Doyle, R Ferro, FM TI Cytokines in stress SO INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY LA English DT Editorial Material DE cytokine; stress; inflammation ID ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; INFLAMMATORY CYTOKINES; SOCIOECONOMIC-STATUS; CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; MESSENGER-RNA; EXPRESSION C1 Univ Chieti, Div Psychiat, I-66013 Chieti, Italy. Aristotle Univ Thessaloniki, Sch Vet, Dept Psychiat, Thessaloniki, Greece. Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA. Hellenic Pasteur Inst, Parasitol Lab, Athens, Greece. Aristotle Univ, Dept Pediat 2, Thessaloniki, Greece. Univ Chieti, Dept Med & Sci Aging, I-66013 Chieti, Italy. Univ Chieti, Div Immunol, I-66013 Chieti, Italy. Univ Perugia, Dept Psychiat, I-06100 Perugia, Italy. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Di Giannantonio, M (reprint author), Univ Chieti, Div Psychiat, Via Vestini, I-66013 Chieti, Italy. EM digiannantonio@unich.it NR 55 TC 25 Z9 25 U1 7 U2 7 PU BIOLIFE SAS PI SILVA MARINA (TE) PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY SN 0394-6320 J9 INT J IMMUNOPATH PH JI Int. J. Immunopathol. Pharmacol. PD JAN-MAR PY 2005 VL 18 IS 1 BP 1 EP 5 PG 5 WC Immunology; Pathology; Pharmacology & Pharmacy SC Immunology; Pathology; Pharmacology & Pharmacy GA 902VG UT WOS:000227384200001 PM 15698505 ER PT J AU Loughrey, JPR Yao, N Datta, S Segal, S Pian-Smith, M Tsen, LC AF Loughrey, JPR Yao, N Datta, S Segal, S Pian-Smith, M Tsen, LC TI Hemodynamic effects of spinal anesthesia and simultaneous intravenous bolus of combined phenylephrine and ephedrine versus ephedrine for cesarean delivery SO INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA LA English DT Article DE ephedrine; phenytephrine; cesarean delivery; spinal anesthesia; hypotension ID PROPHYLACTIC EPHEDRINE; MATERNAL HYPOTENSION; SECTION; MANAGEMENT; PREVENTION; INFUSION AB Background: Hypotension following spinal anesthesia for cesarean delivery can produce adverse maternal symptoms and neonatal acid-base effects. Single-agent prophylaxis, most notably with ephedrine, does not reliably prevent spinal anesthesia-induced hypotension; recently, however, the prophylactic use of phenylephrine with ephedrine as an infusion was observed to be effective. We postulated that this combination, when given as an intravenous bolus for prophylaxis and rescue treatment, could be similarly effective. Method: Forty-three term parturients were randomized to receive a bolus of ephedrine 10 mg phenylephrine 40 mug (groups E and EP, respectively) simultaneously with spinal anesthesia. Hypotension was defined as a systolic blood pressure below 100 mmHg or a decrease of 20% from a baseline value. Rescue boluses comprised of ephedrine 5 mg phenylephrine 20 mug. Results: For groups E and EP, respectively, the incidence of hypotension was 80% vs. 95% (P = 0.339), with the mean number of rescue boluses being 3.85 +/- 3.7 and 3.05 +/- 1.7 and the mean umbilical artery pH being 7.246 +/- 0.081 vs. 7.244 +/- 0.106. All comparisons were not significant (NS). Conclusion: The combination of ephedrine and phenylephrine given as an intravenous bolus at the doses selected is not superior to ephedrine alone in preventing or treating hypotension in healthy parturients undergoing cesarean delivery. (C) 2004 Elsevier Ltd. All rights reserved. C1 Brigham & Womens Hosp, Dept Anesthesia Pain & Periopat Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesiol, Boston, MA 02115 USA. RP Tsen, LC (reprint author), Brigham & Womens Hosp, Dept Anesthesia Pain & Periopat Med, CWN-L1,75 Francis St, Boston, MA 02115 USA. EM ltsen@zeus.bwh.harvard.edu OI Tsen, Lawrence/0000-0002-1964-723X NR 26 TC 24 Z9 27 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0959-289X J9 INT J OBSTET ANESTH JI Int. J. Obstet. Anesth. PD JAN PY 2005 VL 14 IS 1 BP 43 EP 47 DI 10.1016/j.ijoa.2004.07.011 PG 5 WC Anesthesiology; Obstetrics & Gynecology SC Anesthesiology; Obstetrics & Gynecology GA 891HN UT WOS:000226572000009 PM 15627538 ER PT J AU Yeung, A Kung, WW Murakami, JL Mischoulon, D Alpert, JE Nierenberg, AA Fava, M AF Yeung, A Kung, WW Murakami, JL Mischoulon, D Alpert, JE Nierenberg, AA Fava, M TI Outcomes of recognizing depressed Chinese American patients in primary care SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE depression recognition; outcomes; primary care; Chinese Americans ID RANDOMIZED CONTROLLED-TRIAL; TREATING MAJOR DEPRESSION; MENTAL-HEALTH; NEURASTHENIA; INVENTORY; FAMILIES; VERSION AB Purpose: This study aims to examine the effect of identifying Chinese American patients as having major depressive disorder (MDD) to their primary care physicians (PCPs) on the latter's attention given to the treatment of depression. Methodology: Forty Chinese American patients from a primary care clinic were identified as having major depressive disorder (MDD), and their primary care physicians (PCPs) were notified of the diagnosis by letter. Three months later, medical records of subjects in the study were reviewed to see if their PCPs had intervened through referral and/or initiated treatment of depression. Results: PCPs documented intervention in 19 patients (47%) regarding their depression. Two of these patients (11%) were started on an antidepressant. Four (21%) accepted and 13 (68%) declined referral to mental health services. No intervention was recorded for 21 (53%) patients. Conclusion: We conclude that recognition alone of MDD among Chinese Americans in the community primary care setting does not lead to adequate initiation of treatment for depression by PCPs. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA USA. Fordham Univ, Bronx, NY 10458 USA. RP Yeung, A (reprint author), MGH Depress Clin & Res Program, 50 Staniford St,Suite 401, Boston, MA 02114 USA. EM ayeung@partners.org OI Alpert, Jonathan/0000-0002-4332-908X FU NIMH NIH HHS [5T32MH19126-10] NR 40 TC 10 Z9 10 U1 0 U2 0 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2005 VL 35 IS 3 BP 213 EP 224 DI 10.2190/11DA-XNQR-WYXR-AGXK PG 12 WC Psychiatry SC Psychiatry GA 002OS UT WOS:000234621400001 PM 16480237 ER PT J AU Haidet, P O'Malley, KJ Sharf, BF Gladney, AP Tran, AN Greisinger, AJ Ashton, CM Street, RL AF Haidet, P O'Malley, KJ Sharf, BF Gladney, AP Tran, AN Greisinger, AJ Ashton, CM Street, RL TI Associations between the impact of terrorism and health perceptions of patients SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article; Proceedings Paper CT 25th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 01-05, 2002 CL ATLANTA, GA SP Soc Gen Internal Med DE terrorism; chronic disease; health status; internal-external control; physician-patient relations; primary health care; patient-centered care; health behavior ID ILLNESS; SCALES AB Objective: Previous studies have demonstrated the effects of the September 11th 2001 terrorist attacks on anxiety and anxiety-related conditions in Americans. However, data regarding associations between the attacks and patients' health perceptions are lacking. The objective of this study was to explore associations between the personal impact of the September 11th attacks and patients' perceptions of health and illness. Method: We performed a cross-sectional survey of 303 adult African-American, Caucasian, and Hispanic patients at primary care clinics in Houston, Texas. Data were collected between October 15, 2001 and March 11 2002. We developed items to measure the impact of the September 11th attacks and patients' quality of life. Previously validated scales were used to measure health status, health locus of control, preferences regarding the patient-physician relationship, and patients' explanatory models of illness. Results: Twenty-two percent of patients reported no impact from the attacks, 41% reported mildly negative impact, 22% reported moderately negative impact, and 15% reported extremely negative impact in their lives. In multivariate analysis, demographic characteristics were not associated with impact from the attacks. However, patients who perceived a more external locus of control with respect to health and patients who reported greater meaning of illness in their lives also reported more negative impact from the September 11th attacks. Conclusions: The September 11th terrorist attacks had at least a somewhat negative impact for a majority of patients far from the site of the nearest attack, and regardless of their demographic backgrounds. The amount of negative impact that patients perceived as a result of the terrorist attacks correlates with certain illness perceptions, including an external health locus of control and a perception of greater meaning of illness in one's life. Such correlations may indicate an effect of terrorism on patients' illness behaviors. Further research is needed to better understand effects of the threat of terror-ism on the general health and illness behaviors of patients. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Texas A&M Univ, College Stn, TX USA. Kelsey Res Fdn, Houston, TX USA. Kelsey Seybold Clin, Houston, TX USA. RP Haidet, P (reprint author), 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM phaidet@bcm.tmc.edu FU AHRQ HHS [P01 HS10876] NR 16 TC 0 Z9 0 U1 5 U2 7 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2005 VL 35 IS 3 BP 249 EP 258 DI 10.2190/DW00-WCKK-8B37-BJA6 PG 10 WC Psychiatry SC Psychiatry GA 002OS UT WOS:000234621400004 PM 16480240 ER PT J AU Abi Raad, R Chen, Y Goldberg, S Gioso, C Taghian, A AF Abi Raad, R Chen, Y Goldberg, S Gioso, C Taghian, A TI Location and control of local disease predict overall survival and distant metastasis free survival in patients with ipsilateral breast tumor recurrence after breast conserving therapy for stage I/II breast cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 009 BP S5 EP S5 DI 10.1016/j.ijrobp.2005.07.015 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300012 ER PT J AU Albert, M Song, JS Schultz, D Cormack, R Tempany-Afdhal, C Haker, S Szot-Barnes, A Beard, C Hurwitz, M Suh, W Jolesz, F D'Amico, AV AF Albert, M Song, JS Schultz, D Cormack, R Tempany-Afdhal, C Haker, S Szot-Barnes, A Beard, C Hurwitz, M Suh, W Jolesz, F D'Amico, AV TI Defining the rectal dose constraint for permanent radioactive seed implantation of the prostate SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Millersville Univ Pennsylvania, Millersville, PA 17551 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2120 BP S300 EP S300 DI 10.1016/j.ijrobp.2005.07.514 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301032 ER PT J AU Bellon, JR Gover, MT Burstein, HJ Harris, JR Harris, LN AF Bellon, JR Gover, MT Burstein, HJ Harris, JR Harris, LN TI Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 6 Z9 6 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 091 BP S55 EP S56 DI 10.1016/j.ijrobp.2005.07.097 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300094 ER PT J AU Boldea, V Sarrut, D Sharp, G Jiang, S Choi, N AF Boldea, V Sarrut, D Sharp, G Jiang, S Choi, N TI Study of motion in a 4D-CT using deformable registration SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Univ Lyon 2, CNRS, UMR 5205, LIRIS, Lyon, France. Ctr Leon Berard, F-69373 Lyon, France. Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Sarrut, David/F-4849-2010 OI Sarrut, David/0000-0002-4854-4141 NR 0 TC 0 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2455 BP S499 EP S500 DI 10.1016/j.ijrobp.2005.07.850 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301364 ER PT J AU Chakravarti, A Desilvio, M Zhang, M Grignon, D Rosenthal, S Asbell, S Hanks, G Sandler, H Pollack, A Zhai, G Shipley, W AF Chakravarti, A Desilvio, M Zhang, M Grignon, D Rosenthal, S Asbell, S Hanks, G Sandler, H Pollack, A Zhai, G Shipley, W TI The prognostic value of p16 expression in locally advanced prostate cancer: A study based on RTOG 92-02 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. Amer Coll Radiol, Philadelphia, PA USA. Wayne State Univ, Harper Hosp, Detroit, MI USA. Radiol Associates Sacramento, Sacramento, CA USA. Albert Einstein Coll Med, New York, NY USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 030 BP S17 EP S18 DI 10.1016/j.ijrobp.2005.07.036 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300033 ER PT J AU Chen, Y Padera, T Hagendoorn, J Jain, R AF Chen, Y Padera, T Hagendoorn, J Jain, R TI A quantitative in vivo model of irradiation effect on lymphatic function and lymphangiogenesis: Implications for radiation induced secondary lymphedema SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Edwin L Steele Lab, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2386 BP S458 EP S459 DI 10.1016/j.ijrobp.2005.07.781 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301295 ER PT J AU Choi, NC Wolfgang, J Flampouri, S Patel, A Jiang, S Niemierko, A Chen, GT AF Choi, NC Wolfgang, J Flampouri, S Patel, A Jiang, S Niemierko, A Chen, GT TI 4D CT planning improves tumor control probability (TCP) when compared with helical CT scan in 3D Conformal radiation therapy (CRT) in lung cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2284 BP S398 EP S398 DI 10.1016/j.ijrobp.2005.07.678 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301193 ER PT J AU Coen, JJ Zietman, AL Grocela, JA Heney, NM Babayan, RK AF Coen, JJ Zietman, AL Grocela, JA Heney, NM Babayan, RK TI Defining biochemical control after prostate brachytherapy: Can we use a target PSA? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Boston Univ, Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2137 BP S309 EP S310 DI 10.1016/j.ijrobp.2005.07.531 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301049 ER PT J AU Coen, JJ Bermudez, S Suzuki, Y Wu, C Zhang, M Zietman, AL Shipley, WU Chakravarti, A AF Coen, JJ Bermudez, S Suzuki, Y Wu, C Zhang, M Zietman, AL Shipley, WU Chakravarti, A TI VEGF-D expression predicts biochemical outcome in localized prostate cancer treated with external radiation: A ten year cohort analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2109 BP S294 EP S295 DI 10.1016/j.ijrobp.2005.07.503 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301021 ER PT J AU Den, R Baldini, EH Sugarbaker, DJ Wong, J Johnson, BE Janne, PA Bueno, R Allen, AM AF Den, R Baldini, EH Sugarbaker, DJ Wong, J Johnson, BE Janne, PA Bueno, R Allen, AM TI Radiotherapy following extrapleural pneumonectomy(EPP) for mesothelioma: The Brigham and women's hospital experience SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2289 BP S401 EP S401 DI 10.1016/j.ijrobp.2005.07.683 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301198 ER PT J AU Dimitroyannis, DA AF Dimitroyannis, DA TI Prostate external beam radiotherapy post permanent seed implantation: Dosimetric implications SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Univ, Sch Med, BIDMC, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2531 BP S550 EP S550 DI 10.1016/j.ijrobp.2005.07.926 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301440 ER PT J AU Donaldson, S Tarbell, N Weinstein, H Link, M Kun, L Billett, A Marcus, K Hurwitz, C Young, J Brain, S Hudson, M AF Donaldson, S Tarbell, N Weinstein, H Link, M Kun, L Billett, A Marcus, K Hurwitz, C Young, J Brain, S Hudson, M TI End results of a prospective clinical trial with VAMP and low-dose, involved-field radiation for pediatric patients with favorable, early-stage Hodgkin's disease SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Stanford Univ, Stanford, CA 94305 USA. St Jude Childrens Res Hosp, Memphis, TN 38105 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02115 USA. Barbara Bush CHildrens Hosp, Maine Med Ctr, Portland, ME USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 036 BP S21 EP S21 DI 10.1016/j.ijrobp.2005.07.042 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300039 ER PT J AU Doppke, KP Kozak, KR Katz, A Taghian, AG AF Doppke, KP Kozak, KR Katz, A Taghian, AG TI A dosimetric comparison of two external beam conformal treatment techniques for the delivery of accelerated partial breast irradiation (APBI) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 1056 BP S177 EP S178 DI 10.1016/j.ijrobp.2005.07.310 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300301 ER PT J AU Gierga, DP Turcotte, JC Sharp, GC Jiang, SB Doppke, KP Katz, AB Taghian, AG Chen, GT AF Gierga, DP Turcotte, JC Sharp, GC Jiang, SB Doppke, KP Katz, AB Taghian, AG Chen, GT TI Target registration error with three-dimensional surface imaging in setup of image-guided partial breast irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2511 BP S536 EP S537 DI 10.1016/j.ijrobp.2005.07.906 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301420 ER PT J AU Goldberg, S Ancukiewicz, M Niemierko, A AF Goldberg, S Ancukiewicz, M Niemierko, A TI The impact of data entry errors on the findings in radiation oncology research SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 1078 BP S191 EP S192 DI 10.1016/j.ijrobp.2005.07.332 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300323 ER PT J AU Guadagnolo, BA Punglia, RS Kuntz, KM Mauch, PM Ng, AK AF Guadagnolo, BA Punglia, RS Kuntz, KM Mauch, PM Ng, AK TI Cost-effectiveness of routine computerized tomography in follow-up of patients with complete response after primary treatment for Hodgkin's disease SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Joint Ctr Radiat Therapy, Boston, MA 02115 USA. Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 188 BP S114 EP S115 DI 10.1016/j.ijrobp.2005.07.194 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300191 ER PT J AU Haddad, R Posner, M Wirth, L Sonis, S Goguen, L Norris, C Sullivan, C Weeks, L Costello, R Tishler, R AF Haddad, R Posner, M Wirth, L Sonis, S Goguen, L Norris, C Sullivan, C Weeks, L Costello, R Tishler, R TI Concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous arnifostine in the treatment of locally advanced squamous cell carcinoma of the head and neck SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. Brigham & Womens Hosp, Div Otolaryngol Head & Neck Surg, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2229 BP S365 EP S365 DI 10.1016/j.ijrobp.2005.07.623 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301139 ER PT J AU Hurwitz, MD Kaplan, ID Hansen, JL Prokopios-Davos, S Topulos, GP Wishnow, K Manola, J Bornstein, BA Hynynen, K AF Hurwitz, MD Kaplan, ID Hansen, JL Prokopios-Davos, S Topulos, GP Wishnow, K Manola, J Bornstein, BA Hynynen, K TI Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favorable toxicity profile SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2164 BP S325 EP S325 DI 10.1016/j.ijrobp.2005.07.558 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301076 ER PT J AU Kalapurakal, JA Breslow, NE Ritchey, ML Shamberger, RC Haase, GM Grundy, P Green, DM Thomas, DR D'Angio, GJ AF Kalapurakal, JA Breslow, NE Ritchey, ML Shamberger, RC Haase, GM Grundy, P Green, DM Thomas, DR D'Angio, GJ TI Influence of radiation therapy and doxorubicin on abdominal tumor recurrence following tumor spillage among patients with favorable histology Wilms tumor in NWTS-3 and-4 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Northwestern Univ, Chicago, IL 60611 USA. Univ Washington, Seattle, WA 98195 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Ctr, Boston, MA USA. Denver Childrens Hosp, Denver, CO USA. Cross Canc Inst, Alberta, AB, Canada. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Bayfront Canc Care Ctr, St Petersburg, FL USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 039 BP S22 EP S23 DI 10.1016/j.ijrobp.2005.07.045 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300042 ER PT J AU Kepka, L Suit, HD Goldberg, SI Hornicek, FJ Gebhardt, MC Mankin, HJ Yoon, SS Rosenberg, AL Nielsen, GP DeLaney, TF AF Kepka, L Suit, HD Goldberg, SI Hornicek, FJ Gebhardt, MC Mankin, HJ Yoon, SS Rosenberg, AL Nielsen, GP DeLaney, TF TI Radiation therapy for control of soft tissue sarcomas resected with positive margins SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Ctr Oncol MSKL Curie, Warsaw, Poland. NR 0 TC 0 Z9 1 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 078 BP S47 EP S48 DI 10.1016/j.ijrobp.2005.07.084 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300081 ER PT J AU Kirsch, DG Haigis, K Santiago, P Tukeshia, O Korsmeyer, S Jacks, T AF Kirsch, DG Haigis, K Santiago, P Tukeshia, O Korsmeyer, S Jacks, T TI Using mouse genetics to dissect the cellular target of radiation in the GI syndrome SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. MIT, Canc Res Ctr, Cambridge, MA 02139 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2402 BP S469 EP S469 DI 10.1016/j.ijrobp.2005.07.797 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301311 ER PT J AU Kozak, KR Doppke, KP Katz, A Gadd, M Smith, BL Habin, K Kachnic, LA Recht, A Powell, SN Taghian, AG AF Kozak, KR Doppke, KP Katz, A Gadd, M Smith, BL Habin, K Kachnic, LA Recht, A Powell, SN Taghian, AG TI Feasibility of simple 3D conformal external-beam accelerated partial breast irradiation (APBI): Initial dosimetric experience SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA. Boston Med Ctr, Dept Radiat Oncol, Boston, MA USA. Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 017 BP S10 EP S10 DI 10.1016/j.ijrobp.2005.07.023 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300020 ER PT J AU Kuban, DA Levy, L Potters, L Beyer, D Blasko, J Moran, B Ciezki, J Zietman, A Zelefsky, M Pisansky, T Elshaikh, M Horwitz, E AF Kuban, DA Levy, L Potters, L Beyer, D Blasko, J Moran, B Ciezki, J Zietman, A Zelefsky, M Pisansky, T Elshaikh, M Horwitz, E TI Comparison of biochemical failure definitions for permanent prostate brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. New York Prostate Inst, Oceanside, NY USA. Arizona Oncol Serv, Scottsdale, AZ USA. Seattle Prostate Inst, Seattle, WA USA. Chicago Prostate Inst, Chicago, IL USA. Cleveland Clin, Cleveland, OH 44106 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Mayo Clin, Rochester, MN USA. Univ Michigan, Ann Arbor, MI 48109 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 057 BP S33 EP S34 DI 10.1016/j.ijrobp.2005.07.063 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300060 ER PT J AU Landis, DM Luo, W Song, J Bellon, J Punglia, R Wong, J Harris, J Killoran, J Gelman, R AF Landis, DM Luo, W Song, J Bellon, J Punglia, R Wong, J Harris, J Killoran, J Gelman, R TI Variability among breast radiation oncologists in delineation of the post-surgical breast lumpectomy cavity volume SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 014 BP S8 EP S8 DI 10.1016/j.ijrobp.2005.07.020 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300017 ER PT J AU Lawton, CA DeSilvio, M Roach, M Uhl, V Krisch, R Seider, M Rotman, M Jones, C Asbell, S Valicenti, R Han, S Thomas, CR AF Lawton, CA DeSilvio, M Roach, M Uhl, V Krisch, R Seider, M Rotman, M Jones, C Asbell, S Valicenti, R Han, S Thomas, CR TI An update of the phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): Updated analysis of RTOG 94-13 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Med Coll Wisconsin, Milwaukee, WI 53226 USA. RTOG, Philadelphia, PA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Summit Med Ctr, Concord, CA USA. Univ Penn, Philadelphia, PA 19104 USA. Akron City Hosp, Akron, OH USA. SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA. Sutter Community Hosp, Sacramento, CA USA. Albert Einstein Med Ctr, Philadelphia, PA 19141 USA. TJU, Philadelphia, PA USA. WSU, Detroit, MI USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 032 BP S19 EP S19 DI 10.1016/j.ijrobp.2005.07.038 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300035 ER PT J AU Lee, EK Cha, K Bortfeld, T Deasy, J Wu, T AF Lee, EK Cha, K Bortfeld, T Deasy, J Wu, T TI Multistage treatment planning optimization for managing organ motion in radiotherapy planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Georgia Inst Technol, Ctr Operat Res Med, Atlanta, GA 30332 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Washington Univ, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 1107 BP S209 EP S210 DI 10.1016/j.ijrobp.2005.07.361 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300352 ER PT J AU Mamon, HJ Niedzwiecki, D Hollis, DR Tan, B Smith, J Blackstock, AW Tepper, JE Goldberg, RM Mayer, RJ Fuchs, CS AF Mamon, HJ Niedzwiecki, D Hollis, DR Tan, B Smith, J Blackstock, AW Tepper, JE Goldberg, RM Mayer, RJ Fuchs, CS TI Preliminary analysis of cancer and leukemia group B (CALGB) 80003: A phase II trial of gemcitabine, 5-fluorouracil (5FU), and radiation therapy (RT) in locally advanced non-metastatic pancreatic adenocarcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. CALGB Stat Off, Durham, NC USA. Washington Univ, Sch Med, St Louis, MO 63130 USA. Roswell Pk Canc Ctr, Buffalo, NY USA. Wake Forest Univ, Med Ctr, Winston Salem, NC 27109 USA. Univ N Carolina, Chapel Hill, NC 27515 USA. RI Goldberg , Richard/M-1311-2013 NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 022 BP S13 EP S13 DI 10.1016/j.ijrobp.2005.07.028 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300025 ER PT J AU Mutyala, S Stewart, AJ Cormack, RA O'Farrell, DA Kazakin, J Devlin, PM AF Mutyala, S Stewart, AJ Cormack, RA O'Farrell, DA Kazakin, J Devlin, PM TI Toxicity of permanent 1-125 interstitial planar seed brachytherapy for close or positive margins for thoracic malignancies SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10467 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2277 BP S392 EP S393 DI 10.1016/j.ijrobp.2005.07.671 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301186 ER PT J AU Ng, A Li, S Neuberg, D Silver, B Stevenson, MA Mauch, PM AF Ng, A Li, S Neuberg, D Silver, B Stevenson, MA Mauch, PM TI Long-term results of a prospective trial of mantle irradiation (RT) alone for early-stage Hodgkin's disease SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 075 BP S45 EP S46 DI 10.1016/j.ijrobp.2005.07.081 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300078 ER PT J AU Niemierko, A Pommier, P Adams, J Fullerton, B Lopes, V Moulton, G Thornton, A Loeffler, J Chan, A AF Niemierko, A Pommier, P Adams, J Fullerton, B Lopes, V Moulton, G Thornton, A Loeffler, J Chan, A TI Dose-volume characteristics of brain lobe late response following proton-photon radiotherapy of paranasal sinus cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2064 BP S267 EP S267 DI 10.1016/j.ijrobp.2005.07.458 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300449 ER PT J AU Ozsahin, M Olszyk, O Karakoyun-Celik, O Pehlivan, B Azria, D Roelandts, M Kaanders, M Cengiz, M Krengli, M Zouhair, A AF Ozsahin, M Olszyk, O Karakoyun-Celik, O Pehlivan, B Azria, D Roelandts, M Kaanders, M Cengiz, M Krengli, M Zouhair, A TI Outcome and prognostic factors in olfactory neuroblastoma: A multicenter rare cancer network study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 CHU Vaudois, CH-1011 Lausanne, Switzerland. Ctr Oscar Lambret, F-59020 Lille, France. Massachusetts Gen Hosp, Boston, MA 02114 USA. Inst Gustave Roussy, Villejuif, France. CRLC Val Aurelle, Montpellier, France. Inst Jules Bordet, B-1000 Brussels, Belgium. UMC St Radboud, Radiat Oncol, Nijmegen, Netherlands. Univ Hacettepe, Sch Med, TR-06100 Ankara, Turkey. Univ Studi Piemonte Orientale, Novara, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2214 BP S355 EP S356 DI 10.1016/j.ijrobp.2005.07.608 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301124 ER PT J AU Paganetti, H AF Paganetti, H TI Dose rate effects on tumor cell response to intensity modulated fractionated radiation therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2400 BP S467 EP S468 DI 10.1016/j.ijrobp.2005.07.795 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301309 ER PT J AU Sher, DJ Wolfgang, J Niemierko, A Choi, N AF Sher, DJ Wolfgang, J Niemierko, A Choi, N TI Quantification of mediastinal lymph node movement using 4D CT scan: Implications for radiation treatment planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 1127 BP S222 EP S223 DI 10.1016/j.ijrobp.2005.07.381 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300372 ER PT J AU Stewart, AJ Cormack, RA Xiong, L Lee, H Hansen, JL Devlin, PM Viswanathan, AN AF Stewart, AJ Cormack, RA Xiong, L Lee, H Hansen, JL Devlin, PM Viswanathan, AN TI Bladder dosimetry in high dose rate vaginal cuff brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2187 BP S339 EP S340 DI 10.1016/j.ijrobp.2005.07.581 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301098 ER PT J AU Suh, W Loffredo, MJ Schultz, D Cormack, RA Tempany, CM Beard, CJ Hurwitz, MD Albert, M D'Amico, AV AF Suh, W Loffredo, MJ Schultz, D Cormack, RA Tempany, CM Beard, CJ Hurwitz, MD Albert, M D'Amico, AV TI Late toxicity and early prostate-specific antigen outcome following salvage prostate brachytherapy for select patients following primary radiation therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2101 BP S290 EP S290 DI 10.1016/j.ijrobp.2005.07.495 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301013 ER PT J AU Suit, HD AF Suit, HD TI 50th anniversary of T. T. Puck's development of technique for use of colony forming ability as measure of reproductive viability SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2265 BP S385 EP S385 DI 10.1016/j.ijrobp.2005.07.659 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301174 ER PT J AU Taghian, AG Kozak, KR Adams, J Doppke, KP Nyamwanda, JA Crowley, EM Smith, BL Gadd, MA Habin, K Katz, A Powell, SN Lu, H AF Taghian, AG Kozak, KR Adams, J Doppke, KP Nyamwanda, JA Crowley, EM Smith, BL Gadd, MA Habin, K Katz, A Powell, SN Lu, H TI Accelerated partial-breast irradiation (APBI) using protons for patients with early-stage breast cancer: A comparison with 3D conformal photon/electron based treatment SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 015 BP S8 EP S9 DI 10.1016/j.ijrobp.2005.07.021 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300018 ER PT J AU Treszezamsky, A Feng, Z Junran, Z Tokadjian, C Kachnic, LA Powell, SN AF Treszezamsky, A Feng, Z Junran, Z Tokadjian, C Kachnic, LA Powell, SN TI BRCA1 and BRCA2 deficient cells are sensitive to etoposide-induced DNA double strand breaks via topoisomerase II SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Washington Univ, Sch Med, St Louis, MO 63108 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2421 BP S479 EP S480 DI 10.1016/j.ijrobp.2005.07.816 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301330 ER PT J AU Truong, M Liebsch, NJ Busse, PM McIntyre, JF Deschler, DG Lin, DT Adams, JA Lopes, VV Thornton, AF Chan, AW AF Truong, M Liebsch, NJ Busse, PM McIntyre, JF Deschler, DG Lin, DT Adams, JA Lopes, VV Thornton, AF Chan, AW TI Patterns of neck relapse after elective nodal irradiation for sinonasal tumors: Implications for nodal volume delineation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 1005 BP S150 EP S150 DI 10.1016/j.ijrobp.2005.07.255 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300252 ER PT J AU Tsai, HK Katz, MS Coen, JJ Zietman, AL Kaufman, DS Shipley, WU AF Tsai, HK Katz, MS Coen, JJ Zietman, AL Kaufman, DS Shipley, WU TI Association of statin use with local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2179 BP S334 EP S335 DI 10.1016/j.ijrobp.2005.07.573 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301090 ER PT J AU Willers, H Feng, Z Bouffard, KE Powell, SN AF Willers, H Feng, Z Bouffard, KE Powell, SN TI Upregulated homologous recombination upon loss of p53 function dose not improve cell survival following treatment with DNA damaging agents SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Washington Univ, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2387 BP S459 EP S459 DI 10.1016/j.ijrobp.2005.07.782 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301296 ER PT J AU Wong, JS Taghian, A Powell, S Smith, BL Kaelin, CM O'Neill, A Silver, B Harris, JR AF Wong, JS Taghian, A Powell, S Smith, BL Kaelin, CM O'Neill, A Silver, B Harris, JR TI Tangential radiation therapy without axillary surgery in early-stage breast cancer: Results of a prospective trial SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Dana Farber Canc Inst Brigham & Women, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 090 BP S55 EP S55 DI 10.1016/j.ijrobp.2005.07.096 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300093 ER PT J AU Yock, TI Oberg, J Yeap, B Tarbell, NJ AF Yock, TI Oberg, J Yeap, B Tarbell, NJ TI Preliminary report of proton radiotherapy for pediatric low-grade gliomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2361 BP S442 EP S443 DI 10.1016/j.ijrobp.2005.07.756 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301270 ER PT J AU Zelefsky, MJ Kuban, DA Levy, LB Potters, L Beyer, DC Blasko, JC Moran, BJ Ciezki, JP Zietman, AL Pisansky, T Elshaikh, M Horwitz, EM AF Zelefsky, MJ Kuban, DA Levy, LB Potters, L Beyer, DC Blasko, JC Moran, BJ Ciezki, JP Zietman, AL Pisansky, T Elshaikh, M Horwitz, EM TI Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with permanent brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. New York Prostate Inst, Oceanside, NY USA. Arizona Oncol Serv, Scottsdale, AZ USA. Seattle Prostate Inst, Seattle, WA USA. Chicago Prostate Inst, Chicago, IL USA. Cleveland Clin, Cleveland, OH 44106 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, MN USA. Univ Michigan, Ann Arbor, MI 48109 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 056 BP S33 EP S33 DI 10.1016/j.ijrobp.2005.07.062 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300059 ER PT J AU Zhai, G Ho, A Hammond, E Fontanesi, J Rotman, M Pilepich, M Shipley, W Sandler, H Pollack, A Zhan-, M Chakravarti, A AF Zhai, G Ho, A Hammond, E Fontanesi, J Rotman, M Pilepich, M Shipley, W Sandler, H Pollack, A Zhan-, M Chakravarti, A TI Phospho-AKT expression and prognosis of locally advanced prostate cancer: A study based on RTOG 8610 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Amer Coll Radiol, Philadelphia, PA USA. Latter Day St Hosp, Salt Lake City, UT 84143 USA. Michigan Canc Res Inst, Michigan, MI USA. SUNY Hlth Ctr, Brooklyn Inst, New York, NY USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 2152 BP S319 EP S319 DI 10.1016/j.ijrobp.2005.07.546 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083301064 ER PT J AU Zhang, M Ho, A Hammond, E Roach, M Sause, W Pilepich, M Shipley, W Sandler, H Pollack, A Chakravarti, A AF Zhang, M Ho, A Hammond, E Roach, M Sause, W Pilepich, M Shipley, W Sandler, H Pollack, A Chakravarti, A TI The prognostic value of surviving in locally advanced prostate cancer: A study based on RTOG 8610 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. Amer Coll Radiol, Philadelphia, PA USA. Intermt Hlth Care, LDS Hosp, Salt Lake City, UT USA. Univ Calif San Francisco Institut, San Francisco, CA USA. Univ Calif Los Angeles, Los Angeles, CA 90032 USA. Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2005 VL 63 IS 2 SU 1 MA 031 BP S18 EP S18 DI 10.1016/j.ijrobp.2005.07.037 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 967HW UT WOS:000232083300034 ER PT J AU Schwartz, DL Ford, E Rajendran, J Yueh, B Coltrera, MD Virgin, J Anzai, Y Haynor, D Lewellyn, B Mattes, D Meyer, J Phillips, M Leblanc, M Kinahan, P Krohn, K Eary, J Laramore, GE AF Schwartz, DL Ford, E Rajendran, J Yueh, B Coltrera, MD Virgin, J Anzai, Y Haynor, D Lewellyn, B Mattes, D Meyer, J Phillips, M Leblanc, M Kinahan, P Krohn, K Eary, J Laramore, GE TI FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT 45th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 19-23, 2003 CL Salt Lake City, UT SP Amer Soc Therapeut Radiol & Oncol DE head-and-neck cancer; positron emission tomography; multimodality imaging; image-guided radiotherapy; cancer staging ID POSITRON-EMISSION-TOMOGRAPHY; LYMPH-NODE METASTASES; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; COMPUTED-TOMOGRAPHY; LUNG-CANCER; NASOPHARYNGEAL CARCINOMAS; EXTRACRANIAL HEAD; RANDOMIZED-TRIAL; RADIOTHERAPY AB Purpose: Image localization of head-and-neck squamous cell carcinoma lags behind current techniques to deliver a precise radiation dose with intensity-modulated radiotherapy. This pilot study prospectively examined the use of registered 18-F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT for preradiotherapy staging of the neck. Methods and Materials: Sixty-three patients with squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx were enrolled into an institutional FDG-PET imaging protocol between September 2000 and June 2003. Of these patients, 20 went on to immediate neck dissection surgery and were studied further. Of these 20, 17 (85%) had American Joint Committee on Cancer Stage III or IV disease. All patients underwent preoperative FDG-PET and contrast-enhanced CT of the head and neck. FDG-PET/CT images were created using a nonrigid image registration algorithm developed at the University of Washington. Alternate primary and nodal gross tumor volumes were contoured with radiotherapy treatment planning software, blinded to each other and to the pathology results. One set of volumes was designed with CT guidance alone and the other with the corresponding FDG-PET/CT images. Neck dissection specimens were subdivided into surgical nodal levels intraoperatively, and the histopathologic findings were correlated with the CT and FDG-PET/CT nodal level findings. Results: FDG-PET/CT detected 17 of 17 heminecks and 26 of 27 nodal zones histologically positive by dissection (100% and 96% sensitivity, respectively). The nodal level staging sensitivity and specificity for FDG-PET/CT was 96% (26 of 27) and 98.5% (68 of 69), respectively. FDG-PET/CT correctly detected nodal disease in 2 patients considered to have node-negative disease by CT alone. Agreement between the imaging results and pathology findings was stronger for FDG-PET/CT (kappa 0.95, 95% confidence interval 0.82-0.99) than for CT alone (kappa 0.81, 95% confidence interval 0.63-0.91; p = 0.06 by two-sided McNemar's testing). Conclusion: These early findings suggest that FDG-PET/CT is superior to CT alone for geographic localization of diseased neck node levels. Confirmatory trials to substantiate the accuracy of FDG-PET/CT neck staging should be prioritized. (C) 2005 Elsevier Inc. C1 Univ Washington, Sch Med, Dept Radiat Oncol 174, Seattle, WA 98108 USA. Univ Washington, Dept Radiol, Seattle, WA 98195 USA. Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Div Nucl Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Radiat Oncol, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Surg & Perioperat Care, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Hlth Sci Res & Dev, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Pathol, Seattle, WA USA. RP Schwartz, DL (reprint author), Univ Washington, Sch Med, Dept Radiat Oncol 174, 1660 S Columbian Way, Seattle, WA 98108 USA. EM docdls@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053; Meyer, Juergen/0000-0003-4350-2222; Kinahan, Paul/0000-0001-6461-3306 FU NCI NIH HHS [CA42045] NR 55 TC 122 Z9 138 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2005 VL 61 IS 1 BP 129 EP 136 DI 10.1016/j.ijrobp.2004.03.040 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 886LV UT WOS:000226229700020 PM 15629603 ER PT J AU Ng, AK Bernardo, MVP Silver, B Van Den Abbeele, A Stevenson, MA Fisher, DC Mauch, PM AF Ng, AK Bernardo, MVP Silver, B Van Den Abbeele, A Stevenson, MA Fisher, DC Mauch, PM TI Mid- and POST-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT 44th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 06-10, 2002 CL NEW ORLEANS, LA SP Amer Soc Therapeut Radiol & Oncol DE Hodgkin's disease; doxorubicin; bleomycin; adriamycin; vinblastine; dacarbazine; gallium scannings ID PROGNOSTIC-FACTORS; MEDIASTINAL IRRADIATION; PULMONARY-FUNCTION; CARDIOPULMONARY TOXICITY; COMBINATION CHEMOTHERAPY; PLUS RADIOTHERAPY; DACARBAZINE ABVD; MOPP/ABV HYBRID; 3 COURSES; BLEOMYCIN AB Purpose: To determine the efficacy of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for patients with Hodgkin's disease and to identify predictors of outcome with this regimen. Methods: Between 1987 and 1998, 175 patients with Stage I-IV Hodgkin's disease received ABVD as part of initial treatment. Overall survival (OS), freedom-from-treatment-failure (FFTF), and progression-free survival (PFS) were calculated using the Kaplan-Meier technique. Log-rank tests were used to identify univariate predictors of OS, FFTF, and PFS. Specifically, restaging gallium scan results and clinical response after chemotherapy were separately evaluated. Results: The median follow-up time was 64 months. The 5-year OS, FFTF, and PFS rates were 90%, 85%, and 82%, respectively. For Stage I-II patients, restaging gallium scan results and clinical response after chemotherapy were highly predictive of OS, FFTF, and PFS (p < 0.0001). Other significant predictors for higher OS included age <50 (p = 0.002), female gender (p = 0.047), and absence of B symptoms (p = 0.043). Of the 20 patients with a positive restaging gallium scan, 4 received high-dose therapy and 16 continued with conventional-dose therapy or received no further treatment. Of these 16 patients, 11 (69%) were disease-free at last follow-up. Conclusions: Although a positive mid- or postchemotherapy gallium scan was an adverse prognostic factor for OS, FFTF, and PFS, continued treatment with conventional-dose therapy may be adequate in selected patients with positive scans. (C) 2005 Elsevier Inc. C1 Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Dept Biostat Sci, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA. Harvard Univ, Dept Nucl Med, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Radiat Oncol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA. RP Mauch, PM (reprint author), 75 Francis St,ASB1-L2, Boston, MA 02115 USA. EM pmauch@lroc.harvard.edu NR 41 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2005 VL 61 IS 1 BP 175 EP 184 DI 10.1016/j.ijrobp.2004.05.019 PG 10 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 886LV UT WOS:000226229700026 PM 15629609 ER PT J AU Srivastava, A Rosenberg, AE Selig, M Rubin, BP Nielsen, GP AF Srivastava, A Rosenberg, AE Selig, M Rubin, BP Nielsen, GP TI Keratin-positive Ewing's sarcoma: An ultrastructural study of 12 cases SO INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE Ewing's sarcoma; peripheral primitive neuroectodermal tumor; PNET; ultrastructure; electron microscopy; keratin ID PRIMITIVE NEUROECTODERMAL TUMOR; PARAFFIN-EMBEDDED TISSUE; FUSION TRANSCRIPTS; IMMUNOHISTOCHEMICAL DETECTION; CYTOKERATIN IMMUNOREACTIVITY; EWS GENE; TRANSLOCATION; ADAMANTINOMA; EXPRESSION; DIFFERENTIATION AB Ewing's sarcoma/primitive neuroectodermal tumor (EWS/PNET) is an aggressive neoplasm of bone and soft tissue. Histologically, it is characterized by the presence of small round blue cells, which usually express MIC-2 and FLI-1 immunohistochemically. The most specific feature for diagnosis, however, is cytogenetic or molecular evidence of a consistent abnormality, the t(11;22) (q24;q12), or variants thereof. The immunohistochemical expression of keratins in a significant proportion of these cases has been highlighted in several recent studies. The ultrastructural features of these keratin-positive tumors have not, however, been characterized in detail. In this study we analyzed the ultrastructural features of 12 well-documented EWS/PNETs that stained strongly for pankeratin by immunohistochemistry. Ultrastructurally, the tumor cells contained a few organelles, which included a small number of mitochondria, poorly developed Golgi complexes, free ribosomes, and inconspicuous rough-endoplasmic reticulum. Rudimentary cell junctions were seen in 2 tumors while prominent junctions were observed in the remaining 10. Five tumors contained intracytoplasmic filaments, and definite tonofibrils were identified in 2. Well-developed basal lamina around tumor cells were also demonstrated in 2 tumors. Follow-up information was available for all cases. Seven patients died of disease, 2 are alive with disease, and 3 have no current evidence of disease. The cohort includes 5 patients with a type-1 translocation, which has been associated with a better prognosis in some studies; 4 of these patients have died of their disease, and I is alive with recurrent disease. This study shows that keratin-positive EWS/PNETs have evidence of epithelial differentiation ultrastructurally, and may possibly represent a more aggressive subset of the EWS/PNET group of tumors. C1 Massachusetts Gen Hosp, Dept Pathol, James Homer Wright Lab, Boston, MA 02114 USA. Tufts Univ, New England Med Ctr, Dept Pathol, Boston, MA 02111 USA. Univ Washington, Med Ctr, Seattle, WA 98195 USA. RP Nielsen, GP (reprint author), Massachusetts Gen Hosp, Dept Pathol, James Homer Wright Lab, 55 Fruit St, Boston, MA 02114 USA. RI Srivastava, Amitabh/A-9386-2009 NR 35 TC 18 Z9 20 U1 0 U2 0 PU WESTMINSTER PUBL INC PI GLEN HEAD PA 708 GLEN COVE AVE, GLEN HEAD, NY 11545 USA SN 1066-8969 J9 INT J SURG PATHOL JI Int. J. Surg. Pathol. PD JAN PY 2005 VL 13 IS 1 BP 43 EP 50 DI 10.1177/106689690501300106 PG 8 WC Pathology; Surgery SC Pathology; Surgery GA 898JV UT WOS:000227074000006 PM 15735854 ER PT J AU Craft, S Watson, GS Baker, L Cholerton, B Reger, M Plymate, S Fishel, M Kahn, S AF Craft, S Watson, GS Baker, L Cholerton, B Reger, M Plymate, S Fishel, M Kahn, S TI Treatment with the insulin-sensitizing PPAR-? agonist rosiglitazone preserves cognition and modulates plasma a-amyloid in patients with AD and amnestic MCI SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Meeting Abstract C1 Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Sch Med, VA Puget Sound, Dept Psychiat Geriatr Res, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 1041-6102 J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PY 2005 VL 17 SU 2 BP 104 EP 104 PG 1 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA 984RQ UT WOS:000233322400196 ER PT J AU Streim, J Barg, F Tomcho, T Kinosian, B AF Streim, J Barg, F Tomcho, T Kinosian, B TI Factors affecting glycemic control in aging diabetics with serious mental illness SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Meeting Abstract C1 Philadelphia VA Med Ctr, Sect Geriatr Psychiat, MIRECC, Philadelphia, PA USA. Univ Penn, Dept Family Med, Philadelphia, PA 19104 USA. Mental Illness Res Educ & Clin Ctr, Med Ctr, Philadelphia, PA USA. Philadelphia VA Med Ctr, MIRECC, Div Geriatr Med, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 1041-6102 J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PY 2005 VL 17 SU 2 BP 282 EP 283 PG 2 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA 984RQ UT WOS:000233322400528 ER PT J AU Ring, D AF Ring, D TI Surgical techniques for the repair of a fracture of the distal humerus in athletes SO INTERNATIONAL SPORTMED JOURNAL LA English DT Review DE distal humerus fracture; internal fixation; sports injury; olecranon osteotomy; capitellum fracture ID TOTAL ELBOW ARTHROPLASTY; INTERNAL-FIXATION; SUPRACONDYLAR FRACTURES; OPERATIVE TREATMENT; CAPITULUM HUMERI; T-FRACTURES; CAPITELLUM; PART; COMPLICATIONS; NONUNIONS AB Distal humerus fractures are relatively uncommon in athletes, but are becoming more common in sports such as snowboarding. Recognition of injury pattern is particularly important as complex articular comminution may be present even when the fracture looks like a simple capitellum fracture. Techniques of internal fixation continue to evolve, particularly for these more complex fractures. C1 Massachusetts Gen Hosp, Dept Orthopaed Surg, Orthopaed Trauma Serv, Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Orthopaed Trauma Serv, Hand & Upper Extrem Serv, ACC 525,15 Parkman St, Boston, MA 02114 USA. EM dring@partners.org NR 56 TC 0 Z9 0 U1 0 U2 0 PU INTERNATIONAL FEDERATION OF SPORTS MEDICINE PI NEWLANDS PA UCT/MRC RES UNIT EXERC SCI SPORTS MED, U CAPETOWN, BOUNDARY ROAD, NEWLANDS, 7700, SOUTH AFRICA SN 1528-3356 J9 INT SPORTMED J JI Int. Sportmed. J. PY 2005 VL 6 IS 2 BP 99 EP 123 PG 25 WC Sport Sciences SC Sport Sciences GA 019LP UT WOS:000235837700004 ER PT J AU Poulaki, V Mitsiades, CS McMullan, C Fanourakis, G Negri, J Goudopoulou, A Halikias, IX Voutsinas, G Tseleni-Balafouta, S Miller, JW Mitsiades, N AF Poulaki, V Mitsiades, CS McMullan, C Fanourakis, G Negri, J Goudopoulou, A Halikias, IX Voutsinas, G Tseleni-Balafouta, S Miller, JW Mitsiades, N TI Human retinoblastoma cells are resistant to apoptosis induced by death receptors: Role of caspase-8 gene silencing SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID MULTIPLE-MYELOMA CELLS; FAS-MEDIATED APOPTOSIS; LIGAND-INDUCED APOPTOSIS; FLICE-INHIBITORY PROTEIN; DR5 MONOCLONAL-ANTIBODY; NF-KAPPA-B; THERAPEUTIC APPLICATIONS; POTENTIAL MECHANISM; IMMUNE SURVEILLANCE; SODIUM-BUTYRATE AB PURPOSE. Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L are members of the TNFalpha family that can trigger apoptosis in susceptible cells via respective death receptors (DRs). FasL cross-links its receptor Fas, resulting in recruitment and proteolytic activation of caspase-8, which initiates the downstream apoptotic cascade. TRAIL signals through its receptors DR4 and DR5, which can activate caspase-8 as well. This study was undertaken to investigate the functional status of the FasL and TRAIL apoptotic pathways in retinoblastoma (Rb) cells. METHODS. The human Rb cell lines Y79 and WERI-Rb1 were evaluated for their response to the Fas cross-linking antibody CH11 and recombinant TRAIL, as well as for cell surface presence and mutational status of Fas, DR4, and DR5 by flow cytometry and genomic DNA sequencing, respectively. The expression of caspase-8 and its inhibitor FLIP, as well as their recruitment to the DR signaling complex were studied by immunoblot analysis. RESULTS. Rb cells express Fas, DR4, and DR5 on their surfaces, yet were resistant to DR-mediated apoptosis. This was not due to DR mutations or secretion of the soluble decoy Fas, antiapoptotic NF-kappaB activity, or FLIP overexpression, but to the absence of caspase-8 expression. The demethylating agent 5-aza-2'-deoxycytidine restored caspase-8 expression and sensitivity to DR-mediated apoptosis. CONCLUSIONS. Rb cells are resistant to DR-mediated apoptosis because of a deficiency in caspase-8 expression secondary to epigenetic gene silencing by overmethylation. The data help delineate the apoptotic pathways in Rb cells and suggest that the combination of demethylating agents with DR-activating modalities, such as TRAIL receptor monoclonal antibodies, may benefit patients with retinoblastoma. C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA. Univ Athens, Dept Pathol, Athens, Greece. Evangelismos Gen Hosp, Dept Gen Surg 4, Athens, Greece. NCSR Demokritos, Inst Biol, Lab Environm Mutagenesis & Carcinogenesis, Athens, Greece. RP Poulaki, V (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Lab, 325 Cambridge St, Boston, MA 02114 USA. EM poulakiv@hotmail.com NR 63 TC 25 Z9 33 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 2005 VL 46 IS 1 BP 358 EP 366 DI 10.1167/iovs.04-0324 PG 9 WC Ophthalmology SC Ophthalmology GA 889UV UT WOS:000226469100052 PM 15623796 ER PT J AU Chew, EY Clemens, T Bressler, S Klein, M Ruby, A Seddon, J AF Chew, EY Clemens, T Bressler, S Klein, M Ruby, A Seddon, J CA AREDS Res Grp TI Serum nutrient levels as risk factors for neovascular AMD SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO 2005) CY MAY 01-05, 2005 CL Ft Lauderdale, FL SP Assoc Res Vision Ophthalmol C1 NEI, AREDS Res Grp, NIH, Bethesda, MD 20892 USA. EMMES Corp, Rockville, MD USA. Wilmer Eye Inst, Baltimore, MD USA. Devers Eye Inst, Portland, OR USA. Associated Retina Consultants, Royal Oak, MI USA. Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PY 2005 VL 46 SU S MA 3303 PG 1 WC Ophthalmology SC Ophthalmology GA 911CZ UT WOS:000227980403501 ER PT J AU de Leon, JS Dagianis, JJ Latina, MA AF de Leon, JS Dagianis, JJ Latina, MA TI Efficacy of multiple selective laser trabeculoplasty treatments in open angle glaucoma SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO 2005) CY MAY 01-05, 2005 CL Ft Lauderdale, FL SP Assoc Res Vision Ophthalmol C1 Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. Nashua Eye Assoc, Nashua, NH USA. Tufts Univ, Medford, MA 02155 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PY 2005 VL 46 SU S MA 108 PG 1 WC Ophthalmology SC Ophthalmology GA 911CZ UT WOS:000227980400101 ER PT J AU Dharmaraj, S Silva, E Raymond, G Sunness, J Maumenee, I AF Dharmaraj, S Silva, E Raymond, G Sunness, J Maumenee, I TI Retinal findings and docosahexanoic acid (DHA) therapy in peroxisomal disorders SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO 2005) CY MAY 01-05, 2005 CL Ft Lauderdale, FL SP Assoc Res Vision Ophthalmol C1 Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. IBILI, Largo Dr Mota Pinto, Coimbra, Portugal. Kennedy Krieger Inst, Baltimore, MD USA. Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PY 2005 VL 46 SU S MA 4083 PG 1 WC Ophthalmology SC Ophthalmology GA 911CZ UT WOS:000227980404374 ER PT J AU Hovland, PG Menke, MN Branagan, A Hunter, Z Treon, SP McMeel, JW Feke, GT AF Hovland, PG Menke, MN Branagan, A Hunter, Z Treon, SP McMeel, JW Feke, GT TI Effect of plasmapheresis on retinal hemodynamics in patients with Waldenstrom's macroglobulinemia SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO 2005) CY MAY 01-05, 2005 CL Ft Lauderdale, FL SP Assoc Res Vision Ophthalmol C1 Harvard Univ, Sch Med, Schepens Retina Associates Fdn, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Bing Program Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PY 2005 VL 46 SU S MA 3925 PG 1 WC Ophthalmology SC Ophthalmology GA 911CZ UT WOS:000227980404215 ER PT J AU Kiss, S Rizzo, JF Mukai, S AF Kiss, S Rizzo, JF Mukai, S TI Peripapillary choroidal neovascularization in children SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO 2005) CY MAY 01-05, 2005 CL Ft Lauderdale, FL SP Assoc Res Vision Ophthalmol C1 Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PY 2005 VL 46 SU S MA 4084 PG 1 WC Ophthalmology SC Ophthalmology GA 911CZ UT WOS:000227980404377 ER PT J AU Kociok, N Poulaki, V Gavranic, C Kirchhof, B Joussen, AM AF Kociok, N Poulaki, V Gavranic, C Kirchhof, B Joussen, AM TI Geldanamycin treatment reduces neovascularization in a mouse model of Retinopathy of Prematurity SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO 2005) CY MAY 01-05, 2005 CL Ft Lauderdale, FL SP Assoc Res Vision Ophthalmol C1 Univ Cologne, Cologne, Germany. Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PY 2005 VL 46 SU S MA 4105 PG 1 WC Ophthalmology SC Ophthalmology GA 911CZ UT WOS:000227980404397 ER PT J AU Warden, SM Christoforidis, JB D'Amico, DJ AF Warden, SM Christoforidis, JB D'Amico, DJ TI Successful redirection of retinal blood flow in vivo following vascular cannulation in rabbits SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO 2005) CY MAY 01-05, 2005 CL Ft Lauderdale, FL SP Assoc Res Vision Ophthalmol C1 Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PY 2005 VL 46 SU S MA 4053 PG 1 WC Ophthalmology SC Ophthalmology GA 911CZ UT WOS:000227980404346 ER PT J AU Wiggs, JL Figueiredo, D Auguste, J Elizabeth, D Haines, J AF Wiggs, JL Figueiredo, D Auguste, J Elizabeth, D Haines, J TI Evaluation of MTHFR polymorphisms in patients with pseudoexfoliation syndrome SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO 2005) CY MAY 01-05, 2005 CL Ft Lauderdale, FL SP Assoc Res Vision Ophthalmol C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PY 2005 VL 46 SU S MA 37 PG 1 WC Ophthalmology SC Ophthalmology GA 911CZ UT WOS:000227980400027 ER PT J AU Yang, J Gao, J Adamian, M Wen, XH Pawlyk, B Zuo, J Makino, CL Li, T AF Yang, J Gao, J Adamian, M Wen, XH Pawlyk, B Zuo, J Makino, CL Li, T TI The ciliary rootlet provides structural support for photoreceptor outer segments SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY APR 30-MAY 05, 2005 CL Ft Lauderdale, FL SP Assoc Res Vis & Ophthalmol C1 Harvard Univ, Sch Med, Berman Gund Lab Study Retinal Degenerat, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Howe Lab,Dept Ophthalmol, Boston, MA 02115 USA. St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PY 2005 VL 46 SU S MA 3974 PG 1 WC Ophthalmology SC Ophthalmology GA 911CZ UT WOS:000227980404265 ER PT J AU Schmidt, S Messamore, E AF Schmidt, S Messamore, E TI Acamprosate joins short list of drugs for alcoholism SO JOURNAL OF ADDICTIONS NURSING LA English DT Editorial Material ID DEPENDENT PATIENTS; PLACEBO; MULTICENTER C1 Hazelden Fdn, Springbrook, OR USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. RP Schmidt, S (reprint author), Hazelden Fdn, Springbrook, OR USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1088-4602 J9 J ADDICT NURS JI J. Addict. Nurs. PY 2005 VL 16 IS 3 BP 147 EP 147 DI 10.1080/10884600500197949 PG 1 WC Substance Abuse; Nursing SC Substance Abuse; Nursing GA 048WY UT WOS:000237978400009 ER PT J AU Kulig, CC Beresford, TP AF Kulig, CC Beresford, TP TI Hepatitis C in alcohol dependence: Drinking versus disulfiram SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article DE hepatitis-C; disulfiram; alcohol dependence ID LIVER-DISEASE; SUPERVISED DISULFIRAM; INTERFERON THERAPY; VIRUS-INFECTION; RISK-FACTORS; MAINTENANCE; PREVALENCE; NALTREXONE; ANTIBODIES; CIRRHOSIS AB Hepatitis C virus (HCV) infects alcohol dependent (AD) individuals disproportionately. Disulfiram for timely abstinence in HCV+ AD cases remains controversial. Our literature review suggests that (1) active drinking accelerates HCV-related liver damage and that abstinence is associated both (2) with a slower course of HCV+ hepatic deterioration and (3) with enhanced response to antiviral HCV treatment. Further, (4) the risk of disulfiram liver injury appears much lower than that from alcohol, (5) HCV+AD individuals require close monitoring during the first 6 months of disulfiram treatment, and (6) early discontinuation of disulfiram usually reverses harmful effects when these occur. Although systematic data are sparse, continued drinking appears much more liver toxic than does disulfiram in this group. Disulfiram therapy may allow (I) prolonged abstinence leading to successful antiviral therapy for HCV, and (2) time to begin behavioral treatments that facilitate long-term abstinence. Sizeable prospective studies of HCV+ AD treatment are badly needed. C1 Denver VA Med Ctr, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA. RP Beresford, TP (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM thomas.beresford@uchsc.edu FU NIAAA NIH HHS [AA 14010, AA 12095] NR 46 TC 5 Z9 5 U1 1 U2 1 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1055-0887 J9 J ADDICT DIS JI J. Addict. Dis. PY 2005 VL 24 IS 2 BP 77 EP 89 DI 10.1300/J069v24n02_07 PG 13 WC Substance Abuse SC Substance Abuse GA 919JP UT WOS:000228614600007 PM 15784525 ER PT J AU Page, ST Herbst, KL Amory, JK Coviello, AD Anawalt, BD Matsumoto, AM Bremner, WJ AF Page, ST Herbst, KL Amory, JK Coviello, AD Anawalt, BD Matsumoto, AM Bremner, WJ TI Testosterone administration suppresses adiponectin levels in men SO JOURNAL OF ANDROLOGY LA English DT Article DE androgen; hypogonadal; leptin ID HEALTHY-YOUNG MEN; HORMONE-BINDING GLOBULIN; ADIPOSE-SPECIFIC PROTEIN; INSULIN SENSITIVITY; OLDER MEN; PROSTATE-CANCER; PLASMA-CONCENTRATIONS; ARTERIAL STIFFNESS; ANDROGEN RECEPTOR; BODY-COMPOSITION AB Testosterone (T) administration to men increases lean body mass and decreases fat mass. Adiponectin is produced by adipocytes and is thought to influence insulin sensitivity. In this study, we sought to determine whether experimental alterations in serum T change adiponectin levels in normal men. We measured adiponectin levels in 28 healthy men ages 18-35 years before and during treatment with a potent gonadotropin-releasing-hormone (GnRH) antagonist, acyline. Decreased T levels led to increased serum adiponectin within 7 days; maximal adiponectin levels were reached on day 21 (baseline 8.6 +/- 0.9 compared with 12.2 +/- 1.0 mug/mL on day 21, P (.)<05) and persisted through day 30, despite no significant changes in body mass index (BMI) and an increase in leptin. The addition of T to acyline, maintaining serum T levels within the normal range, prevented the increase in adiponectin following acyline alone. In a second study, 25 men aged 55-85 years were treated with 3 weeks of high-dose T (testosterone enanthate [TE], 600 mg/wk intramuscularly). With high serum T levels, adiponectin levels decreased significantly by day 21 of treatment (baseline 14.3 +/- 1.9 compared with 10.8 +/- 1.5 mug/mL, P <.05 vs baseline and placebo), BMI slightly increased, and leptin levels were decreased. We conclude that adiponectin levels increase within days of experimental T deficiency in normal men, and the increase in adiponectin is prevented by T replacement. Furthermore, supraphysiologic T administration results in decreased adiponectin levels. Our data support the hypothesis that T, its metabolites, or both directly suppress adipocyte production of adiponectin. C1 Univ Washington, Med Ctr, Div Endocrinol & Metab, Sch Med,Geriatr Res Educ & Clin Ctr, Seattle, WA 98915 USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Calif Los Angeles, Charles Drew Univ, Dept Med, Los Angeles, CA USA. RP Page, ST (reprint author), Univ Washington, Med Ctr, Div Endocrinol & Metab, Sch Med,Geriatr Res Educ & Clin Ctr, 1959 NE Pacific,Box 357138, Seattle, WA 98915 USA. EM page@u.washington.edu FU NCRR NIH HHS [M01-RR-00037]; NHLBI NIH HHS [HL007028]; NIA NIH HHS [K23 AG027238]; NICHD NIH HHS [U54-HD-12629] NR 45 TC 99 Z9 107 U1 0 U2 2 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 J9 J ANDROL JI J. Androl. PD JAN-FEB PY 2005 VL 26 IS 1 BP 85 EP 92 PG 8 WC Andrology SC Endocrinology & Metabolism GA 880WA UT WOS:000225819300014 PM 15611571 ER PT J AU Huppert, JD Moser, JS Gershuny, BS Riggs, DS Spokas, M Filip, J Hajcak, G Parker, HA Baer, L AF Huppert, JD Moser, JS Gershuny, BS Riggs, DS Spokas, M Filip, J Hajcak, G Parker, HA Baer, L TI The relationship between obsessive-compulsive and posttraumatic stress symptoms in clinical and non-clinical samples SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE obsessive--compulsive disorder; posttraumatic stress disorder; symptom overlap and depression ID DSM-IV ANXIETY; VIETNAM VETERANS; TRAUMATIC EVENTS; MOOD DISORDERS; COMORBIDITY; SCALE; RELIABILITY; PREVALENCE; COMMUNITY; POPULATION AB Although case reports suggest, the existence of a unique relationship between obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD), results from large-scale epidemiological and clinical studies have been. more equivocal. Furthermore, symptom overlap may artificially inflate the significance of the relationship between OCD and PTSD. Utilizing the Obsessive-Compulsive Inventory [OCI; Psychol. Assess. 10 (1998) 206] and the Posttraumatic Diagnostic Scale [PDS; Psychol. Assess. 9 (1997) 445], this study examined the relationship between OCD and PTSD symptoms in 128 patients diagnosed with OCD, 109 patients diagnosed with PTSD, 63 patients diagnosed with another anxiety disorder, and 40 college students. Experts in OCD and PTSD independently rated items on the OCI and PDS for the degree of overlap across the disorders. On the basis of these ratings, we created a scale from each measure that included only non-overlapping items. Results revealed that overall symptoms of OCD and PTSD were related in all samples. However, after controlling for depression and overlapping symptoms simultaneously, this relationship was no longer significant in the OCD and PTSD samples, although it remained significant in the anxious and college student comparison groups. These results support the presence of a relationship between symptoms of OCD and PTSD that may be largely accounted for by a combination of symptom overlap and depression. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Penn, Ctr Treatment & Study Anxiety, Philadelphia, PA 19104 USA. Skidmore Coll, Saratoga Springs, NY 12866 USA. Univ Delaware, Newark, DE 19716 USA. Harvard Univ, Cambridge, MA 02138 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Huppert, JD (reprint author), Univ Penn, Ctr Treatment & Study Anxiety, 3535 Market St,Suite 600N, Philadelphia, PA 19104 USA. EM huppert@mail.med.upenn.edu RI Moser, Jason/N-8218-2013; OI Huppert, Jonathan/0000-0002-0537-4701 NR 35 TC 34 Z9 35 U1 3 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2005 VL 19 IS 1 BP 127 EP 136 DI 10.1016/j.janxdis.2004.01.001 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 867WZ UT WOS:000224874800008 PM 15488372 ER PT J AU Eng, W Coles, ME Heimberg, RG Safren, SA AF Eng, W Coles, ME Heimberg, RG Safren, SA TI Domains of life satisfaction in social anxiety disorder: relation to symptoms and response to cognitive-behavioral therapy SO JOURNAL OF ANXIETY DISORDERS LA English DT Article; Proceedings Paper CT 21st Annual Conference of the Anxiety-Disorders-Association-of-America CY MAR, 2001 CL ATLANTA, GA SP Anxiety Disorders Assoc America DE life satisfaction; social anxiety; cognitive-behavioral treatment ID QUALITY-OF-LIFE; BECK DEPRESSION INVENTORY; NEGATIVE EVALUATION SCALE; PHOBIA; DISABILITY; FEAR; INSTRUMENTS AB A general sense of satisfaction with life has been shown to be discriminable from symptom levels and disability in clinical populations. The current study focused on the utility of identifying domains of life satisfaction in social anxiety disorder and differential changes in these domains following cognitive-behavioral group therapy (CBGT). An exploratory principal axis factor analysis of the items of the Quality of Life Inventory in clients with a principal diagnosis of social anxiety disorder (N = 138) yielded four domains of life satisfaction: (1) Achievement, (2) Social Functioning, (3) Personal Growth, and (4) Surroundings. Prior to treatment, clients reported dissatisfaction in the Achievement and Social Functioning domains. Further, levels of satisfaction in these domains were significantly related to severity of social anxiety and depressive symptoms. Finally, analyses of a subsample of clients completing 12-weeks of cognitive-behavioral group therapy revealed significant improvements in the Achievement and Social Functioning factors. These findings provide further support for the assertion that social anxiety disorder has important. implications for clients' quality of life and that CBGT can successfully impact several domains of satisfaction. (C) 2004 Elsevier Inc. All rights reserved. C1 Temple Univ, Dept Psychol, Adult Anxiety Clin, Philadelphia, PA 19122 USA. SUNY Binghamton, Binghamton, NY USA. CUNY Coll Staten Isl, Staten Isl, NY 10314 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Heimberg, RG (reprint author), Temple Univ, Dept Psychol, Adult Anxiety Clin, Weiss Hall 419,1701 N 13th St, Philadelphia, PA 19122 USA. EM heimberg@temple.edu FU PHS HHS [44119] NR 37 TC 56 Z9 57 U1 2 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2005 VL 19 IS 2 BP 143 EP 156 DI 10.1016/j.janxdis.2004.01.007 PG 14 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 874XF UT WOS:000225383200001 PM 15533701 ER PT J AU Zygmanski, P Hacker, F Friesen, S Rodenbush, R Lu, HM Chin, L AF Zygmanski, Piotr Hacker, Fred Friesen, Scott Rodenbush, Robin Lu, Hsiao-Ming Chin, Lee TI Maximum MLC opening effect in dynamic delivery of IMRT: leaf-positional analysis SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE IMRT delivery; quality assurance AB The analysis of dynamic multileaf collimator (MLC) positions for the delivered intensity-modulated radiotherapy (IMRT) plans is crucial in that it may capture dose delivery problems otherwise difficult to observe and quantify in the conventional dosimetric measurements with film or with an ionization chamber. In some IMRT systems, delivery of IMRT fields starts with a maximum MLC opening ( roughly the shape of the target in the beam's-eye view) and then proceeds to the subsequent dynamic MLC subfields. No irradiation is required in going from the initial segment ( maximum opening) to the next one, and theoretically, no dose should be delivered in that initial moment. However, due to a finite sampling time of the MLC controller, the finite speed of the MLC, and a finite leaf tolerance, there may be some dose delivered between the first and the second segment. The amount of the excess dose is higher for larger dose rates and for a smaller number of the total monitor units per IMRT field. The magnitude of the dose errors could be in the order of a few percent. Effects similar to the maximum MLC opening may occur in other situations as well, for instance, when leaves are forced to move over large distances in a short time. Confounding this are dose errors due to the uncertainty in the MLC transmission. The analysis of the actual leaf positions recorded in the dynamic MLC log file is helpful in differentiating between the two types of errors and in determining the optimal dynamic MLC delivery parameters. C1 Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Zygmanski, P (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM pzygmanski@LROC.harvard.edu NR 12 TC 7 Z9 7 U1 0 U2 4 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2005 VL 6 IS 2 BP 33 EP 43 DI 10.1120/jacmp.2024.25335 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA V43PP UT WOS:000202947300005 PM 15940210 ER PT J AU Lu, HM AF Lu, Hsiao-Ming TI A 3D digitization system for conventional radiation therapy simulation SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE radiation therapy; conventional simulation; 3D digitizer; body contour AB While the majority of patients receiving external beam radiation therapy treatment are planned by CT simulation, a significant number of them are still planned using conventional simulators for various reasons. The information- collection process in a conventional simulation is often fragmented and done with primitive tools. For example, in many institutions body contours are still acquired using solder wires and tracing paper, a time- consuming and error- prone procedure. We have developed a 3D digitization system to assist the information- acquisition process at conventional simulations. The system consists of an infrared camera assembly, a wireless digitizer probe, and Windows- based software. The system can provide 3D coordinates of any points in space accessible by the probe with submillimeter accuracy. It can be used to capture body contours, to record the coordinates of portal points, and to take various measurements for dose calculations as well as for patient setup. The software can display all the captured data together with the planned treatment fields, providing a comprehensive geometric verification of the treatment configuration. The system can also transfer all the information to dose-planning programs in DICOM- RT format, providing an integrated information flow from simulation to dose planning. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA. RP Lu, HM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02115 USA. EM hmlu@partners.org NR 9 TC 1 Z9 1 U1 0 U2 1 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2005 VL 6 IS 3 BP 108 EP 117 DI 10.1120/jacmp.2025.25350 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA V43PQ UT WOS:000202947400010 PM 16143795 ER PT J AU Serrador, JM Sorond, FA Vyas, M Gagnon, M Iloputaife, ID Lipsitz, LA AF Serrador, JM Sorond, FA Vyas, M Gagnon, M Iloputaife, ID Lipsitz, LA TI Cerebral pressure-flow relations in hypertensive elderly humans: transfer gain in different frequency domains SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE orthostasis; cerebral autoregulation; aging ID CARBON-DIOXIDE REACTIVITY; SHY-DRAGER SYNDROME; BLOOD-FLOW; AUTO-REGULATION; TRANSCRANIAL DOPPLER; CEREBROVASCULAR REACTIVITY; AUTOREGULATION; DYNAMICS; HEMODYNAMICS; HYPOCAPNIA AB The dynamics of the cerebral vascular response to blood pressure changes in hypertensive humans is poorly understood. Because cerebral blood flow is dependent on adequate perfusion pressure, it is important to understand the effect of hypertension on the transfer of pressure to flow in the cerebrovascular system of elderly people. Therefore, we examined the effect of spontaneous and induced blood pressure changes on beat-to-beat and within-beat cerebral blood flow in three groups of elderly people: normotensive, controlled hypertensive, and uncontrolled hypertensive subjects. Cerebral blood flow velocity (transcranial Doppler), blood pressure (Finapres), heart rate, and end-tidal CO2 were measured during the transition from a sit to stand position. Transfer function gains relating blood pressure to cerebral blood flow velocity were assessed during steady-state sitting and standing. Cerebral blood flow regulation was preserved in all three groups by using changes in cerebrovascular resistance, transfer function gains, and the autoregulatory index as indexes of cerebral autoregulation. Hypertensive subjects demonstrated better attenuation of cerebral blood flow fluctuations in response to blood pressure changes both within the beat (i.e., lower gain at the cardiac frequency) and in the low-frequency range ( autoregulatory, 0.03 - 0.07 Hz). Despite a better pressure autoregulatory response, hypertensive subjects demonstrated reduced reactivity to CO2. Thus otherwise healthy hypertensive elderly subjects, whether controlled or uncontrolled with antihypertensive medication, retain the ability to maintain cerebral blood flow in the face of acute changes in perfusion pressure. Pressure regulation of cerebral blood flow is unrelated to cerebrovascular reactivity to CO2. C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Hebrew Rehabil Ctr Aged, Boston, MA 02131 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Serrador, JM (reprint author), Beth Israel Deaconess Med Ctr Gerontol Palmer 117, 1 Deaconess Rd, Boston, MA 02215 USA. EM serrador@hms.harvard.edu RI Serrador, Jorge/A-9172-2009 FU NIA NIH HHS [AG 00294, AG 04390, AG 05134, AG 08812, P01 AG004390-21A1, P01 AG004390-21A10015, R37 AG025037-02] NR 33 TC 64 Z9 64 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JAN PY 2005 VL 98 IS 1 BP 151 EP 159 DI 10.1152/japplphysiol.00471.2004 PG 9 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 878PM UT WOS:000225658900019 PM 15361517 ER PT J AU Gronau, N Ben-Shakhar, G Cohen, A AF Gronau, N Ben-Shakhar, G Cohen, A TI Behavioral and physiological measures in the detection of concealed information SO JOURNAL OF APPLIED PSYCHOLOGY LA English DT Article ID GUILTY KNOWLEDGE TEST; EVENT-RELATED POTENTIALS; PROCESSING RESOURCES; ORIENTING RESPONSE; INTERMODALITY CHANGE; PSYCHOPHYSIOLOGICAL DETECTION; INDIVIDUAL-DIFFERENCES; SKIN-CONDUCTANCE; DECEPTION; ALLOCATION AB The authors examined the incremental validity of the reaction time (RT) measure beyond that of skin conductance response (SCR) in the detection of concealed information. Participants performed a Stroop-like task in which they named the color of critical and neutral words. Results show that the SCR highly differentiated between the relevant and neutral words. However, the RT demonstrated a significant differentiation only when the critical words denoted personally significant items (e.g., one's own name) and not when they denoted crime-relevant items related to a simulated crime. In both cases, combining the 2 measures yielded no advantage over the use of SCR alone. Thus, although behavioral measures may differentiate between relevant and neutral information in some cases, their practical use is questionable. C1 Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel. RP Gronau, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Nucl Magnet Resonance Ctr, Charlestown, MA 02129 USA. EM gronau@nmr.mgh.harvard.edu NR 70 TC 41 Z9 42 U1 3 U2 22 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-9010 J9 J APPL PSYCHOL JI J. Appl. Psychol. PD JAN PY 2005 VL 90 IS 1 BP 147 EP 158 DI 10.1037/0021-9010.90.1.147 PG 12 WC Psychology, Applied; Management SC Psychology; Business & Economics GA 887QF UT WOS:000226319900010 PM 15641895 ER PT J AU Burroughs, BR Hallstrom, B Golladay, GJ Hoeffel, D Harris, WH AF Burroughs, BR Hallstrom, B Golladay, GJ Hoeffel, D Harris, WH TI Range of motion and stability in total hip arthroplasty with 28-, 32-, 38-, and 44-mm femoral head sizes - An in vitro study SO JOURNAL OF ARTHROPLASTY LA English DT Article DE total hip arthroplasty; impingement; range of motion; femoral head ID MOLECULAR-WEIGHT POLYETHYLENE; DISLOCATION; REPLACEMENT; COMPLICATIONS; IMPINGEMENT; INSTABILITY; DESIGN; VOLUME; RATES AB The purpose of this study was to evaluate, via experimental models, the effect of larger head sizes for total hip arthroplasty on the type of impingement, range of motion (ROM), and joint stability. Testing was conducted using an anatomic full-size hip model (anatomic goniometer) and a novel anatomic dislocation simulator with 28-, 32-, 38-, and 44-mm diameter femoral heads within a 61-mm acetabular shell. Femoral heads >32-mm provided greater ROM and virtually complete elimination of component-to-component impingement. A significant increase in both flexion before dislocation and displacement between the femoral head and acetabulum to produce dislocation Occurred with femoral heads >32-mm in diameter. These data indicate that larger femoral heads offer potential in providing greater hip ROM and joint stability. C1 Massachusetts Gen Hosp, Orthoped Biomech & Biomat Lab, Boston, MA 02114 USA. RP Harris, WH (reprint author), Massachusetts Gen Hosp, Orthoped Biomech & Biomat Lab, Jackson 1126,55 Fruit St, Boston, MA 02114 USA. NR 37 TC 157 Z9 174 U1 2 U2 9 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 J9 J ARTHROPLASTY JI J. Arthroplast. PD JAN PY 2005 VL 20 IS 1 BP 11 EP 19 DI 10.1016/j.arth.2004.07.008 PG 9 WC Orthopedics SC Orthopedics GA 896FK UT WOS:000226919800003 PM 15660054 ER PT J AU Cook, J Scott, RD AF Cook, J Scott, RD TI Bony ankylosis following total knee arthroplasty - A case report SO JOURNAL OF ARTHROPLASTY LA English DT Article DE ankylosis; knee; arthroplasty; heterotopic ossification AB While bony ankylosis secondary to heterotopic ossification (HO) following total hip arthroplasty (THA) is well known to produce disability in the hip, much less has been written about the development of heterotopic ossification about the knee after total knee arthroplasty (TKA). Additionally, to our knowledge, there has been no published case of complete bony ankylosis of the knee following total knee arthroplasty. We present such a case in a 53 year old mate who underwent a primary total knee arthroplasty after resolution of septic arthritis. C1 Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA. Brigham & Womens Hosp, Dept Orthopaed, Boston, MA USA. RP Cook, J (reprint author), Massachusetts Gen Hosp, Dept Orthopaed, 55 Fruit St, Boston, MA 02114 USA. NR 14 TC 1 Z9 1 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 J9 J ARTHROPLASTY JI J. Arthroplast. PD JAN PY 2005 VL 20 IS 1 BP 122 EP 124 DI 10.1016/j.arth.2004.04.014 PG 3 WC Orthopedics SC Orthopedics GA 896FK UT WOS:000226919800019 PM 15660070 ER PT J AU Downing, BR Cornwell, K Toner, M Pins, GD AF Downing, BR Cornwell, K Toner, M Pins, GD TI The influence of microtextured basal lamina analog topography on keratinocyte function and epidermal organization SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A LA English DT Article DE microfabrication; skin; tissue engineering ID SKIN-SUBSTITUTES; GROWTH-FACTOR; DIFFERENTIATION; COLLAGEN; BURNS; REGENERATION; FIBROBLASTS; SUBSTRATE; TISSUE AB The rational design of future bioengineered skin substitutes requires an understanding of the mechanisms by which the three-dimensional microarchitecture of tissue scaffolds modulates keratinocyte function. Microtextured basal lamina analogs were developed to investigate the relationship between the characteristic topography at the dermal-epidermal interface of native skin and keratinocyte function. Microfabrication techniques were used to create master patterns, negative replicates, and collagen membranes with ridges and channels of length scales (e.g., grooves of 50-200 mum in depth and width) similar to the invaginations found in basal lamina at the dermal-epidermal junction of native skin. Keratinocytes were seeded on the surfaces of basal lamina analogs, and histological analyses were performed after 7 days of tissue culture at the air-liquid interface. The keratinocytes formed a differentiated and stratified epidermis that conformed to the features of the microtextured membranes. Morphometric analyses of immunostained skin equivalents suggest that keratinocyte stratification and differentiation increases as channel depth increases and channel width decreases. This trend was most pronounced in channels with the highest depth-to-width ratios (i.e., 200 mum deep, 50 mum wide). It is anticipated that the findings from these studies will elucidate design parameters to enhance the performance of future bioengineered skin substitutes. (C) 2004 Wiley Periodicals, Inc. C1 Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA. Univ Massachusetts, Sch Med, Worcester, MA 01655 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA. Shriners Hosp Children, Boston, MA 02114 USA. RP Pins, GD (reprint author), Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA. EM gpins@wpi.edu OI Cornwell, Kevin/0000-0002-9732-1788 FU NIBIB NIH HHS [P41 EB02503] NR 29 TC 25 Z9 27 U1 1 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9304 J9 J BIOMED MATER RES A JI J. Biomed. Mater. Res. Part A PD JAN 1 PY 2005 VL 72A IS 1 BP 47 EP 56 DI 10.1002/jbm.a.30210 PG 10 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 879MB UT WOS:000225720800006 PM 15543632 ER PT J AU Boas, DA Frostig, RD AF Boas, DA Frostig, RD TI Optics in neuroscience SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Editorial Material C1 Harvard Univ, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. Univ Calif Irvine, Irvine, CA 92717 USA. RP Boas, DA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU SPIE-INT SOCIETY OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2005 VL 10 IS 1 AR 011001 DI 10.1117/1.1851511 PG 2 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 927PZ UT WOS:000229208100001 ER PT J AU D'Arceuil, HE Hotakainen, MP Liu, C Themelis, G de Crespigny, AJ Franceschini, MA AF D'Arceuil, HE Hotakainen, MP Liu, C Themelis, G de Crespigny, AJ Franceschini, MA TI Near-infrared frequency-domain optical spectroscopy and magnetic resonance imaging: a combined approach to studying cerebral maturation in neonatal rabbits SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE magnetic resonance imaging; diffusion; brain maturation; hemoglobin concentration; hemoglobin saturation; frequency-domain; optical spectroscopy; near infrared ID POSITRON-EMISSION-TOMOGRAPHY; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; STRONGLY SCATTERING MEDIA; BLOOD OXYGENATION CHANGES; DEVELOPING HUMAN BRAIN; NEWBORN-INFANTS; PIGLET BRAIN; GLUCOSE-UTILIZATION; ABSORPTION-SPECTRA; PREMATURE-INFANTS AB The neonatal rabbit brain shows prolonged postnatal development both structurally and physiologically. We use noninvasive near-IR frequency-domain optical spectroscopy (NIRS) and magnetic resonance imaging (MRI) to follow early developmental changes in cerebral oxygenation and anatomy, respectively. Four groups of animals are measured: NIRS in normals, MRI in normals, and both NIRS and MRI with hypoxia-ischemia (HI) (diffusion MRI staging). NIRS and/or MRI are performed from P3 (postnatal day=P) up to P76. NIRS is performed on awake animals with a frequency-domain tissue photometer. Absolute values of oxyhemoglobin concentration ([HbO(2)]), deoxyhemoglobin concentration ([HbR]), total hemoglobin concentration (HbT), and hemoglobin saturation (StO(2)) are calculated. The brains of all animals appeared to be maturing as shown in the diffusion tensor MRL Mean optical coefficients (reduced scattering) remained unchanged in all animals throughout. StO(2) increased in all animals (40% at P9 to 65% at P43) and there are no differences between normal, HI controls, and HI brains. The measured increase in StO(2) is in agreement with the reported increase in blood flow during which reflects blood volume, the first 2 months of life in rabbits. HbT, peaked at postnatal day P17, as expected since the capillary density increases up to P17 when the microvasculature matures. (c) 2005 Society of Photo-Optical Instrumentation Engineers. C1 Martinos Ctr Biomed Imaging, Neuroradiol Sect, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Dept Radiol, Martinos Ctr Biomed Imaging, Neuroradiol Sect, Charlestown, MA USA. Univ Helsinki, Cognit Brain Res Unit, Dept Psychol, FIN-00014 Helsinki, Finland. RP D'Arceuil, HE (reprint author), Martinos Ctr Biomed Imaging, Neuroradiol Sect, Room 2301,Bldg 149,13th St, Charlestown, MA 02129 USA. EM helen@nmr.mgh.harvard.edu OI Liu, Christina/0000-0002-5723-177X FU NICHD NIH HHS [R01 HD042908, R01 HD042908-01, R01 HD042908-02, R01-HD42908] NR 58 TC 10 Z9 10 U1 0 U2 1 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2005 VL 10 IS 1 AR 011011 DI 10.1117/1.1852554 PG 9 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 927PZ UT WOS:000229208100011 PM 15847577 ER PT J AU Selb, J Franceschini, MA Sorensen, AG Boas, DA AF Selb, J Franceschini, MA Sorensen, AG Boas, DA TI Improved sensitivity to cerebral hemodynamics during brain activation with a time-gated optical system: analytical model and experimental validation SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE light propagation in tissues; diffuse optical tomography; time-domain system; depth-resolved imaging; functional brain imaging ID NEAR-INFRARED SPECTROSCOPY; MAGNETIC-RESONANCE; ADULT HEAD; NONINVASIVE MEASUREMENT; OXYGENATION; TOMOGRAPHY; STIMULATION; ABSORPTION; LIGHT; REFLECTANCE AB Time domain (TD) diffuse optical measurement systems are being applied to neuroimaging, where they can detect hemodynamics changes associated with cerebral activity. We show that TD systems can provide better depth sensitivity than the more traditional continuous wave (CW) systems by gating late photons, which carry information about deep layers of the brain, and rejecting early light, which is sensitive to the superficial physiological signal clutter. We use an analytical model to estimate the contrast due to an activated region of the brain, the instrumental noise of the systems, and the background signal resulting from superficial physiological signal clutter. We study the contrast-to-noise ratio and the contrast-to-background ratio as a function of the activation depth and of the source-detector separation. We then present experimental results obtained with a time-gated instrument on the motor cortex during finger-tapping exercises. Both the model and the experimental results show a similar contrast-to-noise ratio for CW and TD, but that estimation of the contrast is experimentally limited by background fluctuations and that a better contrast-to-background ratio is obtained in the TD case. Finally, we use the time-gated measurements to resolve in depth the brain activation during the motor stimulus. (c) 2005 Society of Photo-Optical Instrumentation Engineers. C1 Massachusetts Gen Hosp, Athinoula A Martinos Ctr, Photon Migrat Imaging Lab, Charlestown, MA 02129 USA. RP Selb, J (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr, Photon Migrat Imaging Lab, Bldg 149,13th St, Charlestown, MA 02129 USA. EM juliette@nmr.mgh.harvard.edu FU NCRR NIH HHS [P41-RR14075]; NIBIB NIH HHS [R01 EB001954-07, R01 EB001954, R01 EB001954-06, R01-EB002482]; NICHD NIH HHS [R01 HD 42908]; NINDS NIH HHS [2P01-NS35611] NR 39 TC 96 Z9 96 U1 1 U2 7 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2005 VL 10 IS 1 AR 011013 DI 10.1117/1.1852553 PG 12 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 927PZ UT WOS:000229208100013 PM 15847579 ER PT J AU Skoch, J Dunn, A Hyman, BT Bacskai, BJ AF Skoch, J Dunn, A Hyman, BT Bacskai, BJ TI Development of an optical approach for noninvasive imaging of Alzheimer's disease pathology SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE amyloid-beta; spectroscopy; microscopy; positron emission tomography ligand; Alzheimer's disease; near infrared; noninvasive imaging ID TRANSGENIC MICE; IN-VIVO; NEUROFIBRILLARY TANGLES; AMYLOID PLAQUES; BRAIN ACTIVITY; TURBID MEDIA; TOMOGRAPHY; PROTEIN; CLEARANCE; DIAGNOSIS AB Alzheimer's disease (AD) is characterized by the presence of aggregates of the amyloid-beta (A beta) peptide in the brain. These aggregates manifest themselves as senile plaques and cerebrovascular amyloid angiopathy (CAA). While traditional histochemical approaches can easily identify these deposits in postmortem tissue, only recently have specific ligands been developed to target A beta in living patients using positron emission tomography (PET). Successful detection of A beta pathology in patients will enable definitive preclinical diagnosis of A beta and enable quantitative evaluation of the efficacy of anti-Ale therapeutics developed to treat the disease. PET scanning, however, has several disadvantages including high cost, low availability, and the requirement for radioactive tracers. We describe recent progress in the development of techniques for imaging A beta deposits noninvasively using optical approaches. Successful development of an optical detection platform would enable inexpensive, accessible, nonradioactive detection of the A beta deposits found in AD. (c) 2005 Society of Photo-Optical Instrumentation Engineers. C1 Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Dept Neurol, Alzheimers Dis Res Unit, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Dept Radiol, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Bacskai, BJ (reprint author), Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Dept Neurol, Alzheimers Dis Res Unit, 114 16th St, Charlestown, MA 02129 USA. EM bbacskai@partners.org NR 30 TC 21 Z9 21 U1 0 U2 1 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2005 VL 10 IS 1 AR 011007 DI 10.1117/1.1846075 PG 7 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 927PZ UT WOS:000229208100007 PM 15847573 ER PT J AU Wilcox, T Bortfeld, H Woods, R Wruck, E Boas, DA AF Wilcox, T Bortfeld, H Woods, R Wruck, E Boas, DA TI Using near-infrared spectroscopy to assess neural activation during object processing in infants SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE spectroscopy; optics; imaging; object processing; infants ID CEREBRAL OXYGENATION CHANGES; INFERIOR TEMPORAL CORTEX; FEATURAL INFORMATION; VISUAL-STIMULATION; BRAIN ACTIVATION; NEWBORN-INFANTS; INFEROTEMPORAL CORTEX; HEMODYNAMIC-RESPONSES; OPTICAL TOPOGRAPHY; OCCLUSION EVENTS AB The capacity to represent the world in terms of numerically distinct objects (i.e., object individuation) is a milestone in early cognitive development and forms the foundation for more complex thought and behavior. Over the past 10 to 15 yr, infant researchers have expended a great deal of effort to identify the origins and development of this capacity. In contrast, relatively little is known about the neural mechanisms that underlie the ability to individuate objects, in large part because there are a limited number of noninvasive techniques available to measure brain functioning in human infants. Recent research suggests that near-IR spectroscopy (NIRS), an optical imaging technique that uses relative changes in total hemoglobin concentration and oxygenation as an indicator of neural activation, may be a viable procedure for assessing the relation between object processing and brain function in human infants. We examine the extent to which increased neural activation, as measured by NIRS, could be observed in two neural areas known to be involved in object processing, the primary visual cortex and the inferior temporal cortex, during an object processing task. Infants aged 6.5 months are presented with a visual event in which two featurally distinct objects emerge successively to opposite sides of an occluder and neuroimaging data are collected. As predicted, increased neural activation is observed in both the primary visual and inferior cortex during the visual event, suggesting that these neural areas support object processing in the young infant. The outcome has important implications for research in cognitive development, developmental neuroscience, and optical imaging. (c) 2005 Society of Photo-Optical Instrumentation Engineers. C1 Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Anthinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Wilcox, T (reprint author), Texas A&M Univ, Dept Psychol, MX-4235 TAMU,MS-4235, College Stn, TX 77843 USA. EM tgw@psyc.tamu.edu OI Bortfeld, Heather/0000-0002-3545-5449 FU NCRR NIH HHS [P41-RR14075, P41 RR014075]; NICHD NIH HHS [R03 HD046533] NR 85 TC 78 Z9 78 U1 1 U2 6 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2005 VL 10 IS 1 AR 011010 DI 10.1117/1.1852551 PG 9 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 927PZ UT WOS:000229208100010 PM 15847576 ER PT J AU Yaroslavsky, AN Barbosa, J Neel, V DiMarzio, C Anderson, RR AF Yaroslavsky, AN Barbosa, J Neel, V DiMarzio, C Anderson, RR TI Combining multispectral polarized light imaging and confocal microscopy for localization of nonmelanoma skin cancer SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE multispectral imaging; confocal microscopy; skin cancer; dyes ID IN-VIVO; EXCISIONS; TISSUES; CELLS AB Multispectral polarized light imaging (MSPLI) enables rapid inspection of a superficial tissue layer over large surfaces, but does not provide information on cellular microstructure. Confocal microscopy (CM) allows imaging within turbid media with resolution comparable to that of histology, but suffers from a small field of view. In practice, pathologists use microscopes at low and high power to view tumor margins and cell features, respectively. Therefore, we study the combination of CM and MSPLI for demarcation of nonmelanoma skin cancers. Freshly excised thick skin samples with nonmelanoma cancers are rapidly stained with either toluidine or methylene blue dyes, rinsed in acetic acid, and imaged using MSPLI and CM. MSPLI is performed at 630, 660, and 750 nm. The same specimens are imaged by reflectance CM at 630, 660, and 830 nm. Results indicate that CM and MSPLI images are in good correlation with histopathology. Cytological features are identified by CM, and tumor margins are delineated by MSPLI. A combination of MSPLI and CM appears to be complementary. This combined in situ technique has potential to guide cancer surgery more rapidly and at lower cost than conventional histopathology. (c) 2005 Society of Photo-Optical Instrumentation Engineers. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Labs Photomed,Dept Dermatol, Boston, MA 02114 USA. Northeastern Univ, Dept Elect & Comp Engn, Boston, MA 02115 USA. RP Yaroslavsky, AN (reprint author), Wellman Labs Photomed, MGH BHX 630,55 Fruit St, Boston, MA 02114 USA. EM yaroslav@helix.mgh.harvard.edu FU NIBIB NIH HHS [R01 EB002423-01] NR 13 TC 28 Z9 28 U1 0 U2 6 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2005 VL 10 IS 1 AR 014011 DI 10.1117/1.1854173 PG 6 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 927PZ UT WOS:000229208100026 PM 15847592 ER PT J AU Zhang, YH Brooks, DH Franceschini, MA Boas, DA AF Zhang, YH Brooks, DH Franceschini, MA Boas, DA TI Eigenvector-based spatial filtering for reduction of physiological interference in diffuse optical imaging SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE diffuse optical imaging; interference reduction; eigenvector filtering; principle component analysis ID NEAR-INFRARED SPECTROSCOPY; CEREBRAL HEMODYNAMICS; OXYGEN-SATURATION; BRAIN-FUNCTION; HUMAN ADULTS; ARTERIAL; BLOOD; TIME; FLUCTUATIONS; OSCILLATIONS AB Diffuse optical imaging is an effective technique for noninvasive functional brain imaging. However, the measurements respond to systemic hemodynamic fluctuations caused by the cardiac cycle, respiration, and blood pressure, which may obscure or overwhelm the desired stimulus-evoked response. Previous work on this problem employed temporal filtering, estimation of systemic effects from background pixels, or modeling of interference signals with predefined basis functions, with some success. However, weak signals are still lost in the interference, and other complementary methods are desirable. We use the spatial behavior of measured baseline signals to identify the interference subspaces. We then project signals components in this subspace out of the stimulation data. In doing so, we assume that systemic interference components will be more global spatially, with higher energy, than the stimulus-evoked signals of interest. Thus, the eigenvectors corresponding to the largest eigenvalues of an appropriate correlation matrix form the basis for an interference subspace. By projecting the data onto the orthogonal nullspace of these eigenvectors, we can obtain more localized response, as reflected in improved contrast-to-noise ratio and correlation coefficient maps. (c) 2005 Society of Photo-Optical Instrumentation Engineers. C1 Northeastern Univ, ECE Dept, Boston, MA 02115 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr, Charlestown, MA 02129 USA. RP Zhang, YH (reprint author), Northeastern Univ, ECE Dept, 442 DA, Boston, MA 02115 USA. EM yizhang@ece.neu.edu FU NCRR NIH HHS [P41-RR14075]; NIBIB NIH HHS [R01 EB001954, R01 EB001954-06, R01 EB001954-07]; NICHD NIH HHS [R01-HD42908]; NIMH NIH HHS [R01-MH62854] NR 26 TC 104 Z9 105 U1 1 U2 9 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2005 VL 10 IS 1 AR 011014 DI 10.1117/1.1852552 PG 11 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 927PZ UT WOS:000229208100014 PM 15847580 ER PT J AU Lee, MLT Whitmore, GA Bjorkbacka, H Freeman, MW AF Lee, MLT Whitmore, GA Bjorkbacka, H Freeman, MW TI Nonparametric methods for microarray data based on exchangeability and borrowed power SO JOURNAL OF BIOPHARMACEUTICAL STATISTICS LA English DT Article DE distribution-free; exchangeable random variables; false discovery rate; gene expression; microarray; multiple testing; nonparametric methods; normalization; rank methods; SAM; statistical analysis ID GENE-EXPRESSION; STATISTICAL-METHODS; NORMALIZATION; REPLICATION; MODELS AB This article proposes nonparametric inference procedures for analyzing microarray gene expression data that are reliable, robust, and simple to implement. They are conceptually transparent and require no special-purpose software. The analysis begins by normalizing gene expression data in a unique way. The resulting adjusted observations consist of gene-treatment interaction terms ( representing differential expression) and error terms. The error terms are considered to be exchangeable, which is the only substantial assumption. Thus, under a family null hypothesis of no differential expression, the adjusted observations are exchangeable and all permutations of the observations are equally probable. The investigator may use the adjusted observations directly in a distribution-free test method or use their ranks in a rank-based method, where the ranking is taken over the whole data set. For the latter, the essential steps are as follows: 1. Calculate a Wilcoxon rank-sum difference or a corresponding Kruskal-Wallis rank statistic for each gene. 2. Randomly permute the observations and repeat the previous step. 3. Independently repeat the random permutation a suitable number of times. Under the exchangeability assumption, the permutation statistics are independent random draws from a null cumulative distribution function (c.d.f.) approximated by the empirical c.d.f. Reference to the empirical c.d.f. tells if the test statistic for a gene is outlying and, hence, shows differential expression. This feature is judged by using an appropriate rejection region or computing a p-value for each test statistic, taking into account multiple testing. The distribution-free analog of the rank-based approach is also available and has parallel steps which are described in the article. The proposed nonparametric analysis tends to give good results with no additional refinement, although a few refinements are presented that may interest some investigators. The implementation is illustrated with a case application involving differential gene expression in wild-type and knockout mice of an E. coli lipopolysaccharide (LPS) endotoxin treatment, relative to a baseline untreated condition. C1 Brigham & Womens Hosp, Channing Lab, HMS, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. McGill Univ, Montreal, PQ, Canada. Lund Univ, Wallenberg Lab, Univ Hosp MAS, S-22101 Lund, Sweden. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Lee, MLT (reprint author), Brigham & Womens Hosp, Channing Lab, HMS, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA. EM meiling@channing.harvard.edu OI Bjorkbacka, Harry/0000-0003-3918-0857 FU NHGRI NIH HHS [HG02510]; NHLBI NIH HHS [HL72358, HL66678]; NIDDK NIH HHS [DK63665] NR 16 TC 7 Z9 7 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1054-3406 J9 J BIOPHARM STAT JI J. Biopharm. Stat. PY 2005 VL 15 IS 5 BP 783 EP 797 DI 10.1081/BIP-200067778 PG 15 WC Pharmacology & Pharmacy; Statistics & Probability SC Pharmacology & Pharmacy; Mathematics GA 024YR UT WOS:000236233000003 PM 16078385 ER PT J AU Schultz, K Rosenberg, AE Ebb, DH Mankin, HJ AF Schultz, K Rosenberg, AE Ebb, DH Mankin, HJ TI Lower-extremity lymphangiomatosis - A case report with a seventeen-year follow-up SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID CYSTIC HYGROMA; THORACIC LYMPHANGIOMATOSIS; INTERFERON; CHYLOTHORAX; RADIOTHERAPY; ALPHA C1 Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Pediat Hematol Oncol Serv, Boston, MA 02114 USA. RP Schultz, K (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St, Boston, MA 02114 USA. EM hmankin@partners.org NR 26 TC 7 Z9 7 U1 0 U2 0 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD JAN PY 2005 VL 87A IS 1 BP 162 EP 167 DI 10.2106/JBJS.D.01892 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 887OR UT WOS:000226315900025 PM 15634828 ER PT J AU Bhattacharyya, T Yeon, H AF Bhattacharyya, T Yeon, H TI "Doctor, was this surgery done wrong?" Ethical issues in providing second opinions SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Editorial Material C1 Massachusetts Gen Hosp, Partners Orthopaed Trauma Serv, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02114 USA. RP Bhattacharyya, T (reprint author), Massachusetts Gen Hosp, Partners Orthopaed Trauma Serv, 55 Fruit St,Yawkey 3600, Boston, MA 02114 USA. EM tbhattacharyya@partners.org NR 11 TC 2 Z9 2 U1 0 U2 0 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD JAN PY 2005 VL 87A IS 1 BP 223 EP 225 DI 10.2106/JBJS.D.02119 PG 3 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 887OR UT WOS:000226315900034 PM 15634836 ER PT J AU Anderson, KC AF Anderson, KC TI Targeting myeloma in the bone marrow microenvironment SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 4th North American Symposium on Skeleted Complications of Malignancy CY APR 28-30, 2005 CL Bethesda, MD SP Natl Inst Hlth C1 Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PY 2005 VL 20 SU 2 BP P11 EP P12 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 017JT UT WOS:000235690600024 ER PT J AU Smith, MR AF Smith, MR TI Treatment-related osteoporosis in men with prostate cancer SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 4th North American Symposium on Skeleted Complications of Malignancy CY APR 28-30, 2005 CL Bethesda, MD SP Natl Inst Hlth C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PY 2005 VL 20 SU 2 BP P19 EP P19 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 017JT UT WOS:000235690600037 ER PT J AU Yang, M Jiang, P Mitsiades, CS Hoffman, RM AF Yang, M Jiang, P Mitsiades, CS Hoffman, RM TI Imaging of cellular trafficking and growth of cancer cells in the bone of live mice SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 4th North American Symposium on Skeleted Complications of Malignancy CY APR 28-30, 2005 CL Bethesda, MD SP Natl Inst Hlth C1 AntiCanc Inc, San Diego, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PY 2005 VL 20 SU 2 BP P51 EP P51 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 017JT UT WOS:000235690600096 ER PT J AU Prelack, K Dwyer, J Sheridan, R Yu, YM Lydon, M Petras, L Dolnikowski, G Kehayias, JJ AF Prelack, K Dwyer, J Sheridan, R Yu, YM Lydon, M Petras, L Dolnikowski, G Kehayias, JJ TI Body water in children during recovery from severe burn injury using a combined tracer dilution method SO JOURNAL OF BURN CARE & REHABILITATION LA English DT Article ID SEVERE SEPSIS; BLUNT TRAUMA; MASS; MALNUTRITION; HYDRATION; ENERGY; DEPLETION; DISEASE; VOLUME; MODEL AB Useful information about hydration and the size of the body cell mass (BCM) can be obtained by monitoring changes in the amount of total body water (TBW) and its components, extracellular water (ECW) and intracellular water (ICW). A combined tracer dilution method with deuterium to measure TBW and bromide to measure ECW was used to assess changes in ICW (as a proxy for the BCM) and in the ECW/ICW ratio (an indicator of water distribution) over the course of recovery in nine severely burned children. During the acute phase of recovery, ICW losses averaged (mean +/- SD) 2.2 +/- 2.0 liters (P =.02) or 18.5 +/- 0.4%. During the rehabilitative phase, mean ICW increased by 3.4 +/- 3.7 liters or 31.9 +/- 14%. The ECW/ICW ratio varied widely both between patients and during the course of the study. During the acute phase of recovery, the mean ECW/ICW ratio increased from 1.06 +/- 0.15 liters to 1.20 +/- 0.14 liters because the ECW compartment had expanded relative to the ICW compartment. During rehabilitation, the ECW/ICW ratio decreased from 1.20 +/- 0.14 liters to 0.86 +/- 0.20 liters, with a recoup of 1CW and continued ECW losses. Tracking ICW and the ECW/ICW ratio using the combined tracer dilution method is practical for monitoring BCM and water distribution in severely burned children. Taken together, the indices provide useful information about hydration and nutritional status in individuals recovering from severe burn injury. C1 Shriners Hosp Crippled Children, Shriners Hosp Children, Boston, MA 02114 USA. Tufts Univ, USDA, Human Nutr Res Ctr Aging, Medford, MA 02155 USA. Tufts Univ, Freidman Sch Nutr Sci & Policy, Medford, MA 02155 USA. Tufts Univ, Sch Med, Medford, MA 02155 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Tufts New England Med Ctr Hosp, Frances Stern Nutr Ctr, Boston, MA 02114 USA. RP Prelack, K (reprint author), Shriners Hosp Crippled Children, Shriners Hosp Children, 51 Blossom St, Boston, MA 02114 USA. OI Dwyer, Johanna/0000-0002-0783-1769; Dolnikowski, Gregory/0000-0001-5886-2656 NR 31 TC 3 Z9 4 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0273-8481 J9 J BURN CARE REHABIL JI J. Burn Care Rehabil. PD JAN-FEB PY 2005 VL 26 IS 1 BP 67 EP 74 DI 10.1097/01.BCR.0000150300.16237.47 PG 8 WC Emergency Medicine; Rehabilitation; Surgery SC Emergency Medicine; Rehabilitation; Surgery GA 893HG UT WOS:000226709300013 PM 15640738 ER PT J AU Harris, BS Gourdie, RG O'Brien, TX AF Harris, BS Gourdie, RG O'Brien, TX TI Atrioventricular conduction system and transcription factors Nkx2.5 and Msx2 SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Editorial Material ID CONGENITAL HEART-DISEASE; MUTATIONS; LINEAGE; MICE; EXPRESSION; PATHWAYS C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Off Res & Dev, Charleston, SC USA. RP O'Brien, TX (reprint author), Med Univ S Carolina, Dept Med, 135 Rutledge Ave,Suite 1201 Cardiol, Charleston, SC 29425 USA. EM obriente@musc.edu NR 17 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL FUTURA PUBLISHING, INC PI MALDEN PA 350 MAIN STREET, MALDEN, MA 01248-5018 USA SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD JAN PY 2005 VL 16 IS 1 BP 86 EP 87 DI 10.1046/j.1540-8167.2005.04667.x PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 888UC UT WOS:000226398700019 PM 15673395 ER PT J AU Saam, T Kerwin, WS Chu, BC Cai, JM Kampschulte, A Hatsukami, TS Zhao, XQ Polissar, NL Neradilek, B Yarnykh, VL Flemming, K Huston, J Insull, W Morrisett, JD Rand, SD Demarco, KJ Yuan, C AF Saam, T Kerwin, WS Chu, BC Cai, JM Kampschulte, A Hatsukami, TS Zhao, XQ Polissar, NL Neradilek, B Yarnykh, VL Flemming, K Huston, J Insull, W Morrisett, JD Rand, SD Demarco, KJ Yuan, C TI Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis SO JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE LA English DT Article DE carotid arteries; atherosclerosis; magnetic resonance imaging ID INTIMA-MEDIA THICKNESS; HIGH-RESOLUTION MRI; RANDOMIZED CONTROLLED-TRIAL; IN-VIVO; CORONARY ATHEROSCLEROSIS; PLAQUE COMPOSITION; FIBROUS CAP; EX-VIVO; ACCURACY; ARTERY AB Purpose. To provide sample size calculation for the quantitative assessment of carotid atherosclerotic plaque using non-invasive magnetic resonance imaging in multi-center clinical trials. Methods. As part of a broader double-blind randomized trial of an experimental pharmaceutical agent, 20 asymptomatic placebo-control subjects were recruited from 5 clinical sites for a multi-center study. Subjects had 4 scans in 13 weeks on GE 1.5 T scanners, using TOF, T1-/PD-/T2- and contrast-enhanced T1-weighted images. Measurement variability was assessed by comparing quantitative data from the index carotid artery over the four time points. The wall/outer wall (W/OW) ratio was calculated as wall volume divided by outer wall Volume. The percent lipid-rich/necrotic core (%LR/NC) and calcification (%Ca) were measured as a proportion of the vessel wall. For %LR/NC and %Ca, Only those Subjects that exhibited LR/NC or Ca components were used in the analysis. Results. Measurement error was 5.8% for wall volume, 3.2% for W/OW ratio, 11.1%, for %LR/NC volume and 18.6% for %Ca volume. Power analysis based on these values shows that a Study with 14 participants in each group could detect a 5% change in W/OW ratio, 10% change in wall volume, and 20% change in %LR/NC volume (power = 80%, p < .05). The calculated measurement errors presume any true biological changes were negligible over the 3 months that subjects received placebo. Conclusion. In vivo MRI is capable of quantifying plaque volume and plaque composition, such as %lipid-rich/necrotic core and %calcification, in the clinical setting of a multi-center trial with low inter-scan variability. This Study provides the basis for sample size calculation Of future MRI trials. C1 Univ Washington, Dept Radiol, Seattle, WA 98195 USA. Univ Washington, Dept Surg, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA USA. Mt Whisper Light Stat Consulting, Seattle, WA USA. Mayo Clin, Dept Neurol, Rochester, MN USA. Mayo Clin, Dept Radiol, Rochester, MN USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA. Michigan State Univ, Dept Radiol, E Lansing, MI 48824 USA. RP Yuan, C (reprint author), Univ Washington, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM cyuan@u.washington.edu RI Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014 OI Yarnykh, Vasily/0000-0002-1583-8979; NR 24 TC 75 Z9 76 U1 1 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1097-6647 J9 J CARDIOV MAGN RESON JI J. Cardiov. Magn. Reson. PY 2005 VL 7 IS 5 BP 799 EP 808 DI 10.1080/10976640500287703 PG 10 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 989HN UT WOS:000233663600009 PM 16353440 ER PT J AU Kowalski, JR Egile, C Gil, S Snapper, SB Li, R Thomas, SM AF Kowalski, JR Egile, C Gil, S Snapper, SB Li, R Thomas, SM TI Cortactin regulates cell migration through activation of N-WASP SO JOURNAL OF CELL SCIENCE LA English DT Article DE cortactin; N-WASP; SH3 domain; cell migration; actin polymerization ID ALDRICH-SYNDROME PROTEIN; FILAMENT NETWORK FORMATION; ACTIN-BASED MOTILITY; ARP2/3 COMPLEX; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POLYMERIZATION; CDC42; NUCLEATION; MECHANISM; PHOSPHORYLATION AB Cortactin is an actin-associated scaffolding protein that regulates cell migration. Amplification of the human gene, EMS1, has been detected in breast, head and neck tumors, where it correlates with increased invasiveness. Cortactin can regulate actin dynamics directly via its N-terminal half, which can bind and activate the Arp2/3 complex. The C-terminal portion of cortactin, however, is thought to have limited function in its regulation of the actin polymerization machinery. In this report, we identify a role for the cortactin C-terminus in regulating cell migration and, more specifically, actin dynamics. Overexpression of either full-length cortactin or cortactin C-terminus is sufficient to enhance migration of mammary epithelial cells. In vitro, cortactin binds to and activates, via its SH3 domain, a regulator of the Arp2/3 complex, neural Wiskott Aldrich Syndrome protein (N-WASP). This in vitro activation of N-WASP is likely to be important in vivo, as cortactin-enhanced migration is dependent upon N-WASP Thus, our results suggest that cortactin has multiple mechanisms by which it can recruit and modulate the actin machinery and ultimately regulate cell migration. C1 Harvard Univ, Sch Med, Canc Biol Program, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA. Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02215 USA. RP Thomas, SM (reprint author), Harvard Univ, Sch Med, Canc Biol Program, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. EM sthomas@bidmc.harvard.edu FU NCI NIH HHS [CA75621]; NHLBI NIH HHS [HL059561]; NIGMS NIH HHS [GM057063] NR 51 TC 78 Z9 82 U1 0 U2 2 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0021-9533 J9 J CELL SCI JI J. Cell Sci. PD JAN 1 PY 2005 VL 118 IS 1 BP 79 EP 87 DI 10.1242/jcs.01586 PG 9 WC Cell Biology SC Cell Biology GA 896JX UT WOS:000226931500008 PM 15585574 ER PT J AU Sooy, K Sabbagh, Y Demay, MB AF Sooy, K Sabbagh, Y Demay, MB TI Osteoblasts lacking the vitamin D receptor display enhanced osteogenic potential in vitro SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE vitamin D; receptor; osteoblast; differentiation; knockout ID MINERAL ION HOMEOSTASIS; RAT OSTEOCALCIN GENE; CALVARIA CELLS; ABLATED MICE; D DEFICIENCY; BONE; DIFFERENTIATION; 1,25-DIHYDROXYVITAMIN-D3; EXPRESSION; PHENOTYPE AB 1,25-Dihydroxyvitamin D plays an important role in the regulation of osteoblast gene expression, regulating the expression of bone matrix proteins as well as that of Runx2, a key regulator of osteoblast differentiation. Studies in mice lacking the vitamin D receptor (VDR) have revealed that the actions of the VDR on the skeleton are not required in the setting of normal mineral ion homeostasis. Since paracrine and endocrine factors can compensate for gene defects in vivo, studies were performed to determine whether ablation of the VDR alters the program of osteoblast differentiation in vitro. Studies in primary calvarial cultures revealed that ablation of the VDR enhanced osteoblast differentiation. The cells from the VDR null mice exhibited an earlier onset and increased magnitude of alkaline phosphatase activity, as well as an earlier and sustained increase in mineralized matrix formation, demonstrating that this enhancement persists throughout the program of osteoblast differentiation. The expression of bone sialoprotein, which enhances mineralization, was also increased in the VDR null cultures. To determine whether the increase in osteoblast differentiation was associated with an increase in the number of osteogenic progenitors, the number of osteoblastic colony forming units (CFU-OB) was evaluated. There was a twofold increase in the number of CFU-OB in the cultures isolated from the VDR null mice. Furthermore, the VDR null CFU-OB demonstrated an earlier onset and higher magnitude of expression of alkaline phosphatase activity when compared to the CFU-OB from their wild-type control littermates. These studies demonstrate that the VDR attenuates osteoblast differentiation in vitro and suggest that other endocrine and paracrine factors modulate the effect of the VDR on osteoblast differentiation in vivo. (C) 2004 Wiley-Liss, Inc. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA. RP Demay, MB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Wellman 501,50 Blossom St, Boston, MA 02114 USA. EM demay@helix.mgh.harvard.edu OI Sabbagh, Yves/0000-0001-5339-6705 FU NIDDK NIH HHS [R01-DK46974, F32-DK10136, R01 DK046974] NR 33 TC 43 Z9 48 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD JAN 1 PY 2005 VL 94 IS 1 BP 81 EP 87 DI 10.1002/jcb.20313 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 881GZ UT WOS:000225852700008 PM 15517598 ER PT J AU Makhijani, NS Bischoff, DS Yamaguchi, DT AF Makhijani, NS Bischoff, DS Yamaguchi, DT TI Regulation of proliferation and migration in retinoic acid treated C3H10T1/2 cells by TGF-beta Isoforms SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID GROWTH-FACTOR-BETA; BONE MORPHOGENETIC PROTEIN-2; MESENCHYMAL PROGENITOR CELLS; OSTEOBLAST-LIKE CELLS; PLATELET ALPHA-GRANULES; FETAL-RAT CALVARIA; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-EXPRESSION; MC3T3-E1 CELLS; IN-VITRO AB Proliferation of mesenchymal precursors of osteogenic and chondrogenic cells and migration of these precursors to repair sites are important early steps in bone repair. Transforming growth factor-beta (TGF-P) has been implicated in the promotion of bone repair and may have a role in these processes. Three isoforms of TGF-beta, TGF-Pbeta1, -beta2, and -beta3, are expressed in fracture healing, however, their specific roles in the repair process are unknown. Differential actions of the TGF-P isoforms on early events of bone repair were explored in the multipotent mesenchymal precursor cell line, C3H10TI/2. Cell migration was determined using a modified Boyden chamber in response to concentrations of each isoform ranging from 10(-12) to 10(-9) g/ml. All three isoforms demonstrated a dose-dependent chemotactic stimulation of untreated C3H10T1/2 cells. Checkerboard assays indicated that all three isoforms also stimulated chemokinesis of the untreated cells. C3H10T1/2 cells treated with all-trans-retinoic acid (ATRA) and expressing relatively higher levels of osteoblastic gene markers such as alkaline phosphatase and collagen type 1, lower levels of chondrocytic gene markers collagen type 11 and aggrecan, and unchanged levels of the adipose marker adipsin did not demonstrate significant chemokinesis or chemotaxis in response to TGF-beta1 or-beta3 at concentrations ranging from 10-12 to 10-9 g/ml. In the ATRA-treated cells, TGF-beta2 stimulated a significant increase in chemotaxis only at the highest concentration tested. Cell proliferation was assessed by mitochondrial dehydrogenase activity and cell counts at TGF-beta concentrations from 10(-11) to 10(-8) g/ml. None of the TGF-beta isoforms stimulated cell proliferation in untreated or ATRA-treated C3H10T1/2 cells. Analysis of TGF-P receptors (TGF-PRI, -betaR2, and -betaR3) showed a 1.6- to 2.8-fold decrease in mRNA expression of these receptors in ATRA-treated cells. In conclusion: (1) while all three TGF-beta isoforms stimulate chemotaxis/chemokinesis of multipotent C3H10T1/ 2 cells, TGF-P] and -beta3 do not stimulate chemotaxis in C3H10TI/2 cells treated with ATRA while TGF-beta2 stimulated chemotaxis only at the highest concentration tested. (2) TGF-beta isoforms do not appear to stimulate cell proliferation in C3H10T1/ 2 cells in either a multipotent state or after ATRA treatment when expressing higher levels of alkaline phosphatase and collagen type I gene markers. (3) Decrease in mRNA expression for TGF-betaRI, -betaR2, and -betaR3 upon ATRA treatment could potentially explain the lack of chemotaxis/chemokinesis in these cells expressing higher levels of alkaline phosphatase and collagen type 1. J. Cell. Physiol. 202: 304-313, 2005. Published 2004 Wiley-Liss, lnc. C1 VA Greater Los Angeles Healthcare Syst, Res Serv 151, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Yamaguchi, DT (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dean.yamaguchi@med.va.gov NR 60 TC 13 Z9 17 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD JAN PY 2005 VL 202 IS 1 BP 304 EP 313 DI 10.1002/jcp.20128 PG 10 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 876RF UT WOS:000225514300032 PM 15389595 ER PT J AU Butz, AM Pulsifer, MB Belcher, HME Leppert, M Donithan, M Zeger, S AF Butz, AM Pulsifer, MB Belcher, HME Leppert, M Donithan, M Zeger, S TI Infant head growth and cognitive status at 36 months in children with In-Utero drug exposure SO JOURNAL OF CHILD & ADOLESCENT SUBSTANCE ABUSE LA English DT Article DE head growth; in-utero drug exposure; cognitive development ID PRENATAL COCAINE EXPOSURE; SUBSTANCE-ABUSE TREATMENT; ADDICTION SEVERITY INDEX; BIRTH-WEIGHT INFANTS; CASE-MANAGEMENT; TERM INFANTS; FOLLOW-UP; INTELLIGENCE; MECHANISMS; RETENTION AB Previous Studies of children with in-utero drug exposure (IUDE) raise concerns that decreased head circumference (HC) at birth increases the child's risk for later compromised cognitive functioning The purpose ofthis StUdy was to determine il'HC at birth and HC growth change are associated with cognitive. functioning (IQ) at 36 months of age in children with IUDE. In-utero drug exposed infants (N = 204) identified following delivery at two Urban hospitals were cornpared with a group of non-exposed children (N = 34) matched for maternal ape, gestational age and socioeconomic status. The IUDE infants had significantly smaller HC at birth than the non-exposed infants. however, by age 36 months the HC was comparable between the two groups. At age 36 months, there was no difference detected in the IQ between the IUDE and non-exposed groups, yet both groups scored almost one standard deviation below the mean for IQ and both groups were below but approached the US standard HC mean at the same age. Further Studies of the more subtle effects of prenatal drug exposure such as attention, impulse control and state regulation oil developmental outcomes are recommended as these children mature. C1 Johns Hopkins Univ, Sch Med, Div Gen Pediat, Dept Pediat, Baltimore, MD 21287 USA. Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21287 USA. Harvard Univ, Massachusetts Gen Hosp, Dept Psychol Assessment, Boston, MA 02115 USA. Kennedy Krieger Inst, Dept Neurol & Dev Med, Baltimore, MD USA. Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD 21287 USA. Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21287 USA. RP Butz, AM (reprint author), Johns Hopkins Univ, Sch Med, Div Gen Pediat, Dept Pediat, 600 N Wolfe St, Baltimore, MD 21287 USA. EM abutz@jhmi.edu NR 52 TC 2 Z9 2 U1 0 U2 0 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1067-828X J9 J CHILD ADOLES SUBST JI J. Child Adolesc. Subst. Abus. PY 2005 VL 14 IS 4 BP 15 EP 39 DI 10.1300/J029vl4n04_02 PG 25 WC Substance Abuse SC Substance Abuse GA 956TJ UT WOS:000231322400002 ER PT J AU Koutkia, P Canavan, B Breu, J Grinspoon, S AF Koutkia, P Canavan, B Breu, J Grinspoon, S TI Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID HIV-INFECTED PATIENTS; BODY-COMPOSITION; BINDING-PROTEIN; OBESE SUBJECTS; FACTOR-I; PERIPHERAL LIPODYSTROPHY; CONSENSUS GUIDELINES; INSULIN-RESISTANCE; RESEARCH SOCIETY; PLUS ARGININE AB Prior studies suggest reduced overnight GH secretion in association with excess visceral adiposity among patients with HIV lipodystrophy (LIPO, i.e. with fat redistribution). We now investigate GH responses to standardized GHRH-arginine in LIPO patients (n = 39) in comparison with body mass index- and age-matched control groups [HIV patients without fat distribution (NONLIPO, n = 17)] and healthy subjects (C, n = 16). IGF-I [242 +/- 17; 345 +/- 38; 291 +/- 27 ng/ml (P < 0.05 vs. NONLIPO)] was lowest in the LIPO group. Our data demonstrate failure rates of 18% for the LIPO group vs. 5.9% for the NONLIPO group and 0% for the C group, using a stringent criterion of 3.3 ng/ml for peak GH response to GHRH-arginine (P < 0.05 LIPO vs. C). Using less stringent cutoffs, the failure rate in the LIPO group rises to 38.5% at 7.5 ng/ml. Among the LIPO patients, the peak GH response to GHRH-arginine was significantly predicted by visceral adipose tissue (P = 0.008), free fatty acid (P = 0.04), and insulin level (P = 0.007) in regression modeling controlling for age, body mass index, sc fat area, and triglyceride level. These data demonstrate increased failure rates to standardized stimulation testing with GHRH-arginine in LIPO patients, in association with increased visceral adiposity. The effects of low-dose GH should be assessed in the large subset of LIPO patients with abnormal GH stimulation testing. C1 Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Neuroendocrine Unit, Boston, MA 02114 USA. MIT, Gen Clin Res Ctr, Cambridge, MA 02139 USA. RP Grinspoon, S (reprint author), Massachusetts Gen Hosp, Program Nutr Metab, 55 Fruit St,LON 207, Boston, MA 02114 USA. EM sgrinspoon@partners.org FU NCRR NIH HHS [M01-RR01066]; NIDDK NIH HHS [R01 DK063639] NR 33 TC 27 Z9 28 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2005 VL 90 IS 1 BP 32 EP 38 DI 10.1210/jc.2004-1342 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 886ME UT WOS:000226230700008 PM 15483073 ER PT J AU Jepson, C Asch, DA Hershey, JC Ubel, PA AF Jepson, C Asch, DA Hershey, JC Ubel, PA TI In a mailed physician survey, questionnaire length had a threshold effect on response rate SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE data collection health care surveys; questionnaire design AB Objective: To examine the association between questionnaire length and response rate in a mailed survey of generalist physicians randomly selected from the American Medical Association master file. Study Design and Setting: In a pilot study, otherwise similar questionnaires of 30 different lenghts (849 to 1,867 words) were mailed to 192 physicians in April 1999. In the main study, questionnaires of 16 different lengths (564, to 988 words) were mailed to 1,700 physicians between June 1999 and January 2000. Results: In the pilot study, response rate decreased from 60% for questionnaires 849 words in length to 16.7%, for questionnaires over 1,800 words in length. Logistic regression revealed an odds ratio of 0.887 (95%CI 0.813, 0.968; p = 0.006) for word count, expressed in units of 100 words. In the main study, response rate varied between 51.5% and 71.4%. Logistic regression showed no association between response and word count (OR 0.988; 95%CI 0.896, 1.090; p = 0.81). Conclusion: There appears to have been a threshold in these studies of approximately 1,000 words. Questionnaires above the threshold had lower response rates than those below it (38.0% vs. 59.4%). (C) 2005 Elsevier Inc. All rights reserved. C1 Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. Univ Michigan, Div Gen Internal Med, Ann Arbor, MI 48109 USA. Vet Affairs Med Ctr, Ann Arbor, MI USA. Program Improving Hlth Care Decis, Ann Arbor, MI USA. RP Jepson, C (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St,Room 4017, Philadelphia, PA 19104 USA. EM cjepson@mail.med.upenn.edu OI Asch, David/0000-0002-7970-286X FU NCI NIH HHS [R01-CA78052-01] NR 3 TC 100 Z9 100 U1 1 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD JAN PY 2005 VL 58 IS 1 BP 103 EP 105 DI 10.1016/j.jclinepi.2004.06.004 PG 3 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 892WV UT WOS:000226681600014 PM 15649678 ER PT J AU Pisegna, JR Martindale, RG AF Pisegna, JR Martindale, RG TI Acid suppression in the perioperative period SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Review DE aspiration pneumonitis; acid suppression; perioperative period; intravenous proton pump inhibitor ID GASTROESOPHAGEAL-REFLUX DISEASE; PROTON-PUMP INHIBITORS; INTRAVENOUS PANTOPRAZOLE; PULMONARY ASPIRATION; MECHANICAL VENTILATION; CONTINUOUS-INFUSION; GENERAL-ANESTHESIA; ELECTIVE SURGERY; GASTRIC CONTENTS; INTRAGASTRIC PH AB Aspiration of oropharyngeal and gastric contents during surgery, although infrequent, is a recognized complication of general anesthesia that carries significant risk for serious complications. Complications of aspiration have been reported to cause 10% to 30% of anesthesia-related deaths. Unconsciousness interferes with multiple biologic mechanisms that guard the airway against aspiration, and this is compounded in surgery by anesthesia- induced neurologic impairment and the risks related to placement of nasogastric and endotracheal tubes. Consequences of anesthesia-related aspiration include aspiration pneumonia, acute respiratory distress syndrome, pulmonary edema, and long-term complications such as laryngotracheal damage and decreased lung compliance. Therefore, averting aspiration, particularly in the elderly and other high-risk patients, should be part of the perioperative plan. Although antacids and histamine(2)-receptor antagonists have been used perioperatively with some success, they are limited by short duration of action and systemic side effects, among other factors. Proton pump inhibitors are currently being investigated in surgical patients at risk for aspiration or stress ulcers and seem to be potent, extremely effective, and well tolerated. This article reviews the risks for, and potential outcomes of, anesthesia-related aspiration, identifies high-risk populations, and outlines the experience to date with available preventive treatments. C1 VA Greater Los Angeles Hlth Care Syst, Div Gastroenterol & Hepatol, Los Angeles, CA USA. Med Coll Georgia, Gastrointestinal Surg Serv, Augusta, GA 30912 USA. RP Pisegna, JR (reprint author), W Los Angeles VA Med Ctr, GI Div, Digest Dis Res Ctr, Bldg 115,Rm 316,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu NR 72 TC 9 Z9 11 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD JAN PY 2005 VL 39 IS 1 BP 10 EP 16 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 881YD UT WOS:000225904500004 PM 15599203 ER PT J AU Frost, JD Hrachovy, RA AF Frost, JD Hrachovy, RA TI Pathogenesis of infantile spasms: A model based on developmental desynchronization SO JOURNAL OF CLINICAL NEUROPHYSIOLOGY LA English DT Article DE infantile spasms; epilepsy; encephalopathy; pathogenesis ID CORTICOTROPIN-RELEASING HORMONE; HUMAN BRAIN-STEM; WEST-SYNDROME; CEREBROSPINAL-FLUID; DELAYED MYELINATION; PARTIAL SEIZURES; SEROTONIN RECEPTORS; SURGICAL-TREATMENT; BETA-ENDORPHIN; REDUCED ACTH AB Infantile spasms is a severe epileptic encephalopathy of infancy. The fundamental cause is unknown, although a number of predisposing conditions are recognized. In this article, the authors critically review current knowledge concerning the pathophysiologic basis of infantile spasms and propose a new model based on developmental desynchronization. It is suggested that infantile spasms may result from a particular temporal desynchronization of two or more central nervous system developmental processes, resulting in a specific disturbance of brain function. The disturbance of function is postulated to be crucially dependent on an unbalanced maturational pattern, in which certain brain systems become dysfunctional owing to divergent developmental status. An important aspect of this model is the idea that disturbed function of a specific kind can result from multiple causative factors, and so can be associated with a variety of different anatomic and/or biochemical abnormalities. Thus, this concept is compatible with the observed diversity of pathologic findings and multiplicity of etiological associations observed in infantile spasms patients. C1 Methodist Hosp, Dept Neurophysiol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Texas Childrens Hosp, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurol, Peter Kellaway Sect Neurophysiol, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA. RP Frost, JD (reprint author), Methodist Hosp, Dept Neurophysiol, Michael E DeBakey Vet Affairs Med Ctr, 6565 Fannin,MS M587, Houston, TX 77030 USA. EM jamesf@bcm.tmc.edu NR 85 TC 54 Z9 59 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0736-0258 J9 J CLIN NEUROPHYSIOL JI J. Clin. Neurophysiol. PD JAN-FEB PY 2005 VL 22 IS 1 BP 25 EP 36 DI 10.1097/01.WNP.0000149893.12678.44 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 895SM UT WOS:000226883600003 PM 15689710 ER PT J AU Bellon, JR Harris, JR AF Bellon, JR Harris, JR TI Chemotherapy and radiation therapy for breast cancer: What is the optimal sequence? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID EARLY-STAGE; CONSERVATIVE SURGERY; ADJUVANT CHEMOTHERAPY; LOCAL-CONTROL; RADIOTHERAPY; IRRADIATION; RECURRENCE; IMPACT; MASTECTOMY; LUMPECTOMY C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Harvard Univ, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA. RP Bellon, JR (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. NR 23 TC 16 Z9 16 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2005 VL 23 IS 1 BP 5 EP 7 DI 10.1200/JCO.2005.09.962 PG 3 WC Oncology SC Oncology GA 888ND UT WOS:000226380600002 PM 15545662 ER PT J AU McDermott, DF Regan, MM Clark, JI Flaherty, LE Weiss, GR Logan, TF Kirkwood, JM Gordon, MS Sosman, JA Ernstoff, MS Tretter, CPG Urba, WJ Smith, JW Margolin, KA Mier, JW Gollob, JA Dutcher, JP Atkins, MB AF McDermott, DF Regan, MM Clark, JI Flaherty, LE Weiss, GR Logan, TF Kirkwood, JM Gordon, MS Sosman, JA Ernstoff, MS Tretter, CPG Urba, WJ Smith, JW Margolin, KA Mier, JW Gollob, JA Dutcher, JP Atkins, MB TI Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 37th Annual Meeting of the American-Society-of-Clinical-Oncology CY MAY 12-15, 2001 CL SAN FRANCISCO, CA SP Amer Soc Clin Oncol ID RECOMBINANT HUMAN INTERLEUKIN-2; CLINICAL-TRIALS; HOME-THERAPY; CANCER; SURVIVAL; NEPHRECTOMY; ALPHA-2A; TOXICITY AB Purpose The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma. Patients and Methods Patients were stratified for bone and liver metastases, primary tumor in place, and Eastern Cooperative Oncology Group performance status 0 or 1 and then randomly assigned to receive either IL-2 (5 MIU/m(2) subcutaneously every 8 hours for three doses on day 1, then daily 5 days/wk for 4 weeks) and IFN (5 MIU/m(2) subcutaneously three times per week for 4 weeks) every 6 weeks or HD IL-2 (600,000 U/kg/dose intravenously every 8 hours on days I through 5 and 15 to 19 [maximum 28 closes]) every 12 weeks. Results One hundred ninety-two patients were enrolled between April 1997 and July 2000. Toxicities were as anticipated for these regimens. The response rate was 23.2% (22 of 95 patients) for HD IL-2 versus 9.9% (nine of 91 patients) for IL-2/IFN (P = .018). Ten patients receiving HD IL-2 were progression-free at 3 years versus three patients receiving IL-2 and IFN (P = .082). The median response durations were 14 and 7 months (P = .14), and median survivals were 17.5 and 13 months (P = .24). For patients with bone or liver metastases (P = .001) or a primary tumor in place (P = .040), survival was superior with HD IL-2. Conclusion This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma. C1 Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Loyola Univ, Maywood, IL 60153 USA. Univ Illinois, Chicago, IL USA. Wayne State Univ, Detroit, MI USA. Univ Texas San Antonio, San Antonio, TX 78285 USA. Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA. Indiana Univ, Indianapolis, IN 46204 USA. Dartmouth Hitchcock Med Ctr, Hanover, NH USA. Earle Chiles Canc Ctr, Portland, OR USA. City Hope Comprehens Canc Ctr, Duarte, CA USA. Our Lady Mercy, Bronx, NY USA. RP McDermott, DF (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, 330 Brookline Ave,E-KS-153, Boston, MA 02215 USA. EM dmcdermo@bidmc.harvard.edu NR 22 TC 394 Z9 421 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2005 VL 23 IS 1 BP 133 EP 141 DI 10.1200/JCO.2005.03.206 PG 9 WC Oncology SC Oncology GA 888ND UT WOS:000226380600019 PM 15625368 ER PT J AU Hoang, T Xu, RH Schiller, JH Bonomi, P Johnson, DH AF Hoang, T Xu, RH Schiller, JH Bonomi, P Johnson, DH TI Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 39th Annual Meeting of the American-Society-of-Clinical-Oncology CY MAY 31-JUN 03, 2003 CL CHICAGO, IL SP Amer Soc Clin Oncol ID PROGNOSTIC-FACTORS; PROSTATE-CANCER; COMBINATION CHEMOTHERAPY; RANDOMIZED TRIAL; CISPLATIN; NOMOGRAM; ETOPOSIDE; STAGE AB Purpose (1) Identify clinical factors that can be used to predict survival in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) treated with third-generation chemotherapy regimens, and (2) build a clinical model to predict survival in this patient population. Patients and Methods Using data from two randomized, phase III Eastern Cooperative Oncology Group (ECOG) trials (E5592/E1594), we performed univariate and multivariate stepwise Cox regression analyses to identify survival prognostic factors. We used 75% of randomly sampled data to build a prediction model for survival, and the remaining 25% of data to validate the model. Results 436 patients with stage IV or IIIB NSCLC with effusion were treated From 1993 to 1999,, with platinum-based doublets (involving either paclitaxel, docetaxel, or gemcitabine). The response rate and median survival time were 20% and 8.2 months, respectively. One- and 2-year survivals were 33% and 11%, respectively. In multivariate analysis, six independent poor prognostic factors were identified: skin metastasis (hazard ratio [HR], 1.88), lower HR, 1.46), loss of appetite (HR, 1.62), liver metastasis (HR, performance status (ECOG I or 2, 1.32), greater than or equal to four metastatic sites (HR, 1.20), and no prior surgery (HR, 1.16). A nomogram using six pretreatment prognostic factors was built to predict 1- and 2-year survival. Conclusion Six pretreatment factors can be used to predict survival in chemotherapy-naive NSCLC patients treated with standard chemotherapy. Using our prognostic nomogram, 1- and 2-year survival probability of NSCLC patients can be estimated before treatment. This prognostic model may help clinicians and patients in clinical decision making, as well as investigators in research planning. C1 Univ Wisconsin, Ctr Comprehens Canc, Sch Med, Madison, WI 53792 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA. Vanderbilt Univ, Nashville, TN USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Hoang, T (reprint author), Univ Wisconsin, Ctr Comprehens Canc, Sch Med, 600 Highland Ave,K4-562, Madison, WI 53792 USA. EM txh@medicine.wisc.edu RI Johnson, David/A-7437-2009 FU NCI NIH HHS [K12 CA087718, K12-CA87718] NR 22 TC 137 Z9 147 U1 2 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2005 VL 23 IS 1 BP 175 EP 183 DI 10.1200/JCO.2005.04.177 PG 9 WC Oncology SC Oncology GA 888ND UT WOS:000226380600023 PM 15625371 ER PT J AU Lilenbaum, RC Herndon, JE List, MA Desch, C Watson, DM Miller, AA Graziano, SL Perry, MC Saville, W Chahinian, P Weeks, JC Holland, JC Green, MR AF Lilenbaum, RC Herndon, JE List, MA Desch, C Watson, DM Miller, AA Graziano, SL Perry, MC Saville, W Chahinian, P Weeks, JC Holland, JC Green, MR TI Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 38th Annual Meeting of the American-Society-of-Clinical-Oncology CY MAY 18-21, 2002 CL ORLANDO, FL SP Amer Soc Clin Oncol ID PHASE-III TRIAL; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; CISPLATIN; VINORELBINE; IFOSFAMIDE; DOCETAXEL; SURVIVAL; REGIMENS AB Purpose We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer. Patients and Methods A total of 561 eligible patients were randomly assigned to receive paclitaxel alone or in combination with carboplatin. Results The response rate was 17% in the paclitaxel arm and 30% in the carboplatin-paclitaxel. arm (P < .0001). Median failure-free survival was 2.5 months in the paclitaxel arm and 4.6 months in the carboplatin-paclitaxel arm (P = .0002). Median survival times were 6.7 months (95% CI, 5.8 to 7.8) and 8.8 months (95% CI, 8.0 to 9.9), and 1-year survival rates were 32% (95% CI, 27% to 38%), and 37% (95% CI, 32% to 43%), respectively. The overall survival distributions were not statistically different: hazard ratio = 0.91 (95% CI, 0.77 to 1.17; P = .25). Hematological toxicity and nausea were more frequent in the combination arm, but febrile neutropenia and toxic deaths were equally low in both arms. There was no significant survival difference in elderly patients. Performance status 2 patients treated with combination chemotherapy had a better survival rate than those treated with single-agent therapy (P = .019). Conclusion Combination chemotherapy improves response rate and failure-free survival compared with single-agent therapy, but there was no statistically significant difference in the primary end point of overall survival. The results in elderly patients were similar to younger patients. Performance status 2 patients had a superior outcome when treated with combination chemotherapy. C1 Mt Sinai Comprehens Canc Ctr, Miami Beach, FL 33140 USA. Canc & Leukemia Grp B Stat Ctr, Durham, NC USA. Univ Chicago, Res Ctr, Chicago, IL USA. Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA. Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. SUNY Upstate Med Univ, Syracuse, NY USA. Univ Missouri, Ellis Fischel Canc Ctr, Columbia, MO USA. Univ Calif San Diego, San Diego, CA 92103 USA. Mt Sinai Sch Med, New York, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Med Univ S Carolina, Charleston, SC 29425 USA. RP Lilenbaum, RC (reprint author), Mt Sinai Comprehens Canc Ctr, 4306 Alton Rd, Miami Beach, FL 33140 USA. EM Rlilenba@salick.com FU NCI NIH HHS [CA12046, CA03927, CA04457, CA11789, CA21060, CA31946, CA32291, CA33601, CA41287, CA45564, CA52784, CA77651] NR 15 TC 286 Z9 298 U1 0 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2005 VL 23 IS 1 BP 190 EP 196 DI 10.1200/JCO.2005.07.172 PG 7 WC Oncology SC Oncology GA 888ND UT WOS:000226380600025 PM 15625373 ER PT J AU Cho, D Kocher, O Tenen, DG Halmos, B Lee, JC Meyerson, ML Janne, PA AF Cho, D Kocher, O Tenen, DG Halmos, B Lee, JC Meyerson, ML Janne, PA TI Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer - Case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID TRIAL; COMBINATION C1 Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA. RP Cho, D (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA. RI Meyerson, Matthew/E-7123-2012; OI Tenen, Daniel/0000-0002-6423-3888 NR 8 TC 9 Z9 9 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2005 VL 23 IS 1 BP 235 EP 237 DI 10.1200/JCO.2005.07.169 PG 3 WC Oncology SC Oncology GA 888ND UT WOS:000226380600031 PM 15625379 ER PT J AU Haffajee, AD Japlit, M Bogren, A Kent, RL Goodson, JM Socransky, SS AF Haffajee, AD Japlit, M Bogren, A Kent, RL Goodson, JM Socransky, SS TI Differences in the subgingival microbiota of Swedish and USA subjects who were periodontally healthy or exhibited minimal periodontal disease SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE biofilm; geographic location; periodontal health; plaque; subgingival microbiota ID PORPHYROMONAS-GINGIVALIS; BACTEROIDES-FORSYTHUS; GINGIVITIS; PLAQUE AB Background: Previous studies have shown differences in the mean proportions of subgingival species in samples from periodontitis subjects in different countries, which may relate to differences in diet, genetics, disease susceptibility and manifestation. The purpose of the present investigation was to determine whether there were differences in the subgingival microbiotas of Swedish and American subjects who exhibited periodontal health or minimal periodontal disease. Method: One hundred and fifty eight periodontally healthy or minimally diseased subjects (N Sweden=79; USA=79) were recruited. Subjects were measured at baseline for plaque, gingivitis, BOP, suppuration, pocket depth and attachment level at 6 sites per tooth. Subgingival plaque samples taken from the mesial aspect of each tooth at baseline were individually analyzed, in one laboratory, for their content of 40 bacterial species using checkerboard DNA-DNA hybridization (total samples=4345). % DNA probe counts comprised by each species was determined for each site and averaged across sites in each subject. Significance of differences in proportions of each species between countries was determined using ANCOVA adjusting for age, mean pocket depth, gender and smoking status. p values were adjusted for multiple comparisons. Cluster analysis was performed to group subjects based on their subgingival microbial profiles using a chord coefficient and an average unweighted linkage sort. Results: On average, all species were detected in samples from subjects in both countries. After adjusting for multiple comparisons, 5 species were in significantly higher adjusted mean percentages in Swedish than American subjects: Actinomyces naeslundii genospecies 1 (9.7, 3.3); Streptococcus sanguis (2.5, 1.2); Eikenella corrodens (1.7, 1.0); Tannerella forsythensis (3.5, 2.3) and Prevotella melaninogenica (6.3, 1.8). Leptotrichia buccalis was in significantly higher adjusted mean percentages in American (5.5) than Swedish subjects (3.0). Cluster analysis grouped 121 subjects into 8 microbial profiles. Twenty four of the 40 test species examined differed significantly among cluster groups. Five clusters were dominated by American subjects and 2 clusters by Swedish subjects. Fifty eight of 79 (73%) of the Swedish subjects fell into 1 cluster group dominated by high proportions of A. naeslundii genospecies 1, Prevotella nigrescens, T. forsythensis and P. melaninogenica. Other clusters were characterized by high proportions of Actinomyces gerencseriae, Veillonella parvula, Capnocytophaga gingivalis, Prevotella intermedia, Eubacterium saburreum, L. buccalis and Neisseria mucosa. Conclusions: The microbial profiles of subgingival plaque samples from Swedish and American subjects who exhibited periodontal health or minimal disease differed. The heterogeneity in subgingival microbial profiles was more pronounced in the American subjects, possibly because of greater genetic and microbiologic diversity in the American subjects sampled. C1 Forsyth Inst, Dept Periodontol, Boston, MA 02115 USA. Univ Gothenburg, Dept Periodontol, Gothenburg, Sweden. RP Haffajee, AD (reprint author), Forsyth Inst, Dept Periodontol, Boston, MA 02115 USA. EM ahaffajee@forsyth.org FU NIDCR NIH HHS [DE-12861, DE-12108, DE-10977, DE-13232] NR 23 TC 34 Z9 35 U1 1 U2 5 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0303-6979 J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD JAN PY 2005 VL 32 IS 1 BP 33 EP 39 DI 10.1111/j.1600-051X.2004.00624.x PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 888AS UT WOS:000226347200007 PM 15642056 ER PT J AU Rosenbaum, JF AF Rosenbaum, JF TI Attitudes toward benzodiazepines over the years SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID TERM THERAPEUTIC USE; ANXIETY DISORDERS; PANIC DISORDER; PSYCHOTHERAPEUTIC MEDICATIONS; PHARMACOLOGICAL TREATMENT; EXPERT JUDGMENT; SOCIAL PHOBIA; WITHDRAWAL; DISCONTINUATION; DEPENDENCE AB Benzodiazepines have been used extensively for the treatment of anxiety and related disorders since the 1960s. Although they have been proven to be effective as first-line treatment for anxiety disorders, during the 1980s public perception and concern for abuse liability and physical dependence with long-term use gave rise to a great deal of controversy. Negative perceptions toward the use of benzodiazepines for treating anxiety not only caused severely ill patients to go untreated or under-treated but also called into question whether the illness itself was worthy of treatment. Although new pharmacologic and psychological treatments for anxiety are available, psychopharmacologists continue to endorse benzodiazepines as primary or adjunct treatment for anxiety disorders. The intent of this article is to provide a historic overview of these issues and to offer some general clinical principles to help minimize the risk of abuse and dependence with benzodiazepine use. C1 Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Rosenbaum, JF (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St,ACC 812, Boston, MA 02114 USA. EM jrosenbaum@partners.org NR 40 TC 21 Z9 24 U1 0 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 2 BP 4 EP 8 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 904SS UT WOS:000227518600001 PM 15762813 ER PT J AU Shores, MM Moceri, VM Sloan, KL Matsumoto, AM Kivlahan, DR AF Shores, MM Moceri, VM Sloan, KL Matsumoto, AM Kivlahan, DR TI Low testosterone levels predict incident depressive illness in older men: Effects of age and medical morbidity SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID PLACEBO-CONTROLLED TRIAL; BONE-MINERAL DENSITY; REPLACEMENT THERAPY; HYPOGONADAL MEN; MAJOR DEPRESSION; REFRACTORY DEPRESSION; HEALTH-SERVICES; SYMPTOMS; DISORDER; MOOD AB Objective: Prior studies found that chronic low testosterone levels are associated with an increased risk of depression. We investigated whether low testosterone levels in older men predict depressive illness over 2 years, while controlling for age and medical morbidity. Method: Participants were 748 men, aged 50 years or older, without prior ICD-9-diagnosed depressive illness, with a testosterone level obtained between 1995 and 1997. Measures were age, mean total testosterone levels (low: less than or equal to 2.5 ng/mL), medical morbidity, and incidence and time to depressive illness. Results: Men with low testosterone levels had a greater 2-year incidence of depressive illness (18.5% vs. 10.4%, df = 1. p = .006) and a shorter time to onset of depressive illness (log-rank chi(2) = 8.1. df = 1, p = .004). The unadjusted hazard ratio (HR) for depressive illness in men with low testosterone levels was 1.9 (95% confidence interval [CI] = 1.2 to 3.0, p = .005). After adjustment for age and medical morbidity, men with low testosterone levels continued to have a shorter time to depressive illness (adjusted HR = 2.1; 95% CI = 1.3 to 3.2, p = .002). Due to a significant interaction between age and medical morbidity, we conducted stratified Cox regression analyses and found that low testosterone levels and high medical morbidity or an age of 50 to 65 years were associated with increased depressive illness (p = .002). Conclusion: Low testosterone levels are associated with an earlier onset and greater incidence of depressive illness. Men with low testosterone levels who had high medical morbidity or were aged 50 to 65 years had an increased risk for depressive illness. Further prospective studies are needed to examine the role of testosterone in depressive illness in older men. C1 Univ Washington, Dept Psychiat & Behav Sci, VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98108 USA. RP Shores, MM (reprint author), Univ Washington, Dept Psychiat & Behav Sci, VA Puget Sound Hlth Care Syst, GRECC, 1660 S Columbian Way,S-182, Seattle, WA 98108 USA. EM molly_shores@med.va.gov NR 52 TC 69 Z9 71 U1 3 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2005 VL 66 IS 1 BP 7 EP 14 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 890DZ UT WOS:000226493200002 PM 15669883 ER PT J AU Simon, NM Fischmann, D AF Simon, NM Fischmann, D TI The implications of medical and psychiatric comorbidity with panic disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Roundtable Conference on New Insights Into the Nature and Treatment of Panic Disorder CY JAN 23, 2004 CL Boston, MA ID HEART-RATE-VARIABILITY; GENERALIZED ANXIETY DISORDER; EPIDEMIOLOGIC CATCHMENT-AREA; BIPOLAR-I DISORDER; LIFE EVENTS; MAJOR DEPRESSION; CHEST-PAIN; PRIMARY-CARE; RESPIRATORY IRREGULARITY; UNIPOLAR DEPRESSION AB The frequent presentation of patients with panic disorder in medical settings may, in part, be explained by the physical symptoms inherent in panic disorder. However, a number of medical disorders have symptoms that overlap with panic disorder symptoms, and elevated panic disorder prevalence is comorbid with a number of medical illnesses, including respiratory disorders, vestibular dysfunction, and hyperthyroidism and hypothyroidism. The presence of medical comorbidity complicates the identification, presentation, and treatment of panic disorder. In addition, comorbid mood disorders occur commonly and result in greater severity, poorer quality of life, and greater impairment. Recent work suggests that panic disorder occurs more commonly with bipolar disorder than major depressive disorder, resulting in substantial impairment, as well as poorer response to treatment. The implications of mood disorder and its medical comorbidity for the identification and treatment of panic disorder are discussed. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Simon, NM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, WAC 815,15 Parkman St, Boston, MA 02114 USA. EM nsimon@partners.org NR 98 TC 22 Z9 24 U1 2 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 4 BP 8 EP 15 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 923IE UT WOS:000228902800002 PM 15842182 ER PT J AU Stewart, SA AF Stewart, SA TI The effects of benzodiazepines on cognition SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID PERFORMANCE; WITHDRAWAL; IMPAIRMENT; METAANALYSIS; PSYCHOMOTOR; MEMORY; USERS AB Initially thought to be virtually free of negative effects, benzodiazepines are now known to carry risks of dependence, withdrawal, and negative side effects. Among the most controversial of these side effects are cognitive effects. Long-term treatment with benzodiazepines has been described as causing impairment in several cognitive domains, such as visuospatial ability, speed of processing, and verbal learning. Conversely, long-term benzodiazepine use has also been described as causing no chronic cognitive impairment, with any cognitive dysfunction in patients ascribed to sedation or inattention or considered temporary and associated with peak plasma levels. Complicating the issue are whether anxiety disorders themselves are associated with cognitive deficits and the extent to which patients are aware of their own cognitive problems. In an attempt to settle this debate, meta-analyses of peer-reviewed studies were conducted and found that cognitive dysfunction did in fact occur in patients treated long term with benzodiazepines, and although cognitive dysfunction improved after benzodiazepines were withdrawn, patients did not return to levels of functioning that matched benzodiazepine-free controls. Neuroimaging studies have found transient changes in the brain after benzodiazepine administration but no brain abnormalities in patients treated long term with benzodiazepines. Such findings suggest that patients should be advised of potential cognitive effects when treated long term with benzodiazepines, although they should also be informed that the impact of such effects may be insignificant in the daily functioning of most patients. C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Stewart, SA (reprint author), McLean Hosp, 115 Mill St, Belmont, MA 02478 USA. EM sastewart@partners.org NR 17 TC 136 Z9 139 U1 3 U2 23 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 2 BP 9 EP 13 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 904SS UT WOS:000227518600002 PM 15762814 ER PT J AU Henderson, DC AF Henderson, DC TI Schizophrenia and comorbid metabolic disorders SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID INDUCED WEIGHT-GAIN; SERUM TRIGLYCERIDE LEVELS; ATYPICAL ANTIPSYCHOTIC AGENTS; TYPE-2 DIABETES-MELLITUS; D-2 RECEPTOR OCCUPANCY; OLANZAPINE; CLOZAPINE; QUETIAPINE; RISPERIDONE; LEPTIN AB Comorbid metabolic disorders in patients with schizophrenia are underrecognized by many health care professionals and patients. That lack of awareness can contribute to serious morbidity and mortality in patients with schizophrenia. Patients with schizophrenia may be at greater risk for metabolic disorders such as insulin resistance, lipid abnormalities, and weight gain. In addition, although the use of atypical antipsychotics in the treatment of schizophrenia offers many positive benefits and may reduce some of the factors related to the morbidity and mortality of the disorder, these drugs appear to be associated with varying degrees of comorbid metabolic disorders, such as metabolic syndrome, and more serious consequences, such as cardiovascular disease. Recent consensus guidelines recommend that metabolic risks be considered when initiating therapy with atypical antipsychotics. Thus, baseline screening and routine monitoring of patient weight, fasting lipid profile, and fasting plasma glucose are essential. In addition, optimal treatment for patients with schizophrenia and comorbid metabolic disorders is best achieved when all parties involved with patient care (mental health and medical community, caregiver/family, and patient) communicate and work together. With proper awareness and cooperation on the part of the medical community, caregivers, and patients, the detrimental consequences that may result from the metabolic disorders addressed in this article can be at least partially offset. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Schizophrenia Program,Freedom Trail Clin, Boston, MA 02114 USA. RP Henderson, DC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Schizophrenia Program,Freedom Trail Clin, 25 Staniford St, Boston, MA 02114 USA. EM dchenderson@partners.org NR 84 TC 66 Z9 67 U1 2 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 6 BP 11 EP 20 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 961ON UT WOS:000231671800003 PM 16107179 ER PT J AU Wozniak, J AF Wozniak, J TI Recognizing and managing bipolar disorder in children SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Teleconference on New Perspectives in Treating Bipolar Disorder CY MAY 26, 2004 CL ELECTR NETWORK SP GlaxoSmithKline ID DEFICIT HYPERACTIVITY DISORDER; ADOLESCENT MANIA; ONSET MANIA; PHARMACOLOGICAL-TREATMENT; DEVELOPMENTAL SUBTYPE; PRESCHOOL-CHILDREN; DIVALPROEX SODIUM; CONDUCT DISORDER; JUVENILE MANIA; FOLLOW-UP AB Bipolar disorder affects people of all ages, including preschool-aged children. Two major difficulties in diagnosing children with bipolar disorder are its overlap with attention-deficit/hyperactivity disorder (ADHD) and its developmentally distinct presentation from that in adults, with high rates of irritability, chronicity, and mixed states. Comorbid conditions are common in bipolar disorder and, in addition to ADHD, include depression, anxiety disorders, oppositional defiant disorder, and conduct disorder. Family studies have helped to confirm the validity of bipolar disorder in children. In terms of treatment, children do not appear to respond well to conventional mood stabilizers alone. However, using an atypical antipsychotic either alone or in addition to another mood stabilizer has shown utility in treating manic symptoms, depression in mixed states, and aggression. Amphetamine salts have been helpful in treating bipolar children with comorbid ADHD, but no data are available on treating comorbid depression in bipolar children. Because childhood-onset mania is commonly chronic rather than episodic, highly comorbid, and characterized by high rates of irritability, future clinical trials should examine the overlap of mania with other disorders in children to determine routes to accurate diagnosis and treatment. C1 Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Cambridge, MA 02138 USA. RP Wozniak, J (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, 185 Alewife Brook Pkwy,Suite 2000, Cambridge, MA 02138 USA. EM jwozniak@partners.org NR 52 TC 30 Z9 30 U1 6 U2 7 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 1 BP 18 EP 23 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 902ET UT WOS:000227337700004 PM 15693748 ER PT J AU Stevens, JC Pollack, MH AF Stevens, JC Pollack, MH TI Benzodiazepines in clinical practice: Consideration of their long-term use and alternative agents SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID GENERALIZED ANXIETY DISORDER; POSTTRAUMATIC-STRESS-DISORDER; PANIC DISORDER; ALPRAZOLAM TREATMENT; EXTENDED-RELEASE; DRUG-THERAPY; DOUBLE-BLIND; OPEN-LABEL; RECEPTOR; RISK AB Despite increasing focus on the use of antidepressants and other agents for the treatment of anxiety, benzodiazepines have remained a mainstay of anxiolytic pharmacotherapy due to their robust efficacy, rapid onset of therapeutic effect, and generally favorable side effect profile. In this article, we examine issues related to the long-term use of benzodiazepines, including concerns about the development of therapeutic tolerance, dose escalation, and adverse cognitive effects. We also consider currently available alternatives to benzodiazepines and novel mechanisms of action that may prove fruitful in the development of future generations of anxiolytics. C1 Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, Boston, MA 02114 USA. RP Pollack, MH (reprint author), Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, WAC-812,15 Parkman St, Boston, MA 02114 USA. EM mpollack@partners.org NR 54 TC 27 Z9 29 U1 1 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 2 BP 21 EP 27 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 904SS UT WOS:000227518600004 PM 15762816 ER PT J AU Pollack, MH AF Pollack, MH TI Comorbid anxiety and depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Roundtable Meeting on New Therapies for Treatment-Resistant Depression and Anxiety CY SEP 28-29, 2003 CL Atlanta, GA ID SEROTONIN REUPTAKE INHIBITORS; POSTTRAUMATIC-STRESS-DISORDER; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; MAJOR DEPRESSION; DOUBLE-BLIND; SOCIAL ANXIETY; OPEN-LABEL; GENERALIZED ANXIETY; BIPOLAR DISORDER AB Anxiety and depressive disorders often occur as comorbid illnesses and share many common symptoms. Risk factors for these disorders most likely include interactions of environmental and genetic factors. The presence of comorbid anxiety and depression adversely affects clinical and treatment outcomes. Selective serotonin reuptake inhibitors are usually considered first-line treatment for patients with these disorders, although alternative antidepressants or additional therapies are often necessary. Studies suggest that benzodiazepines, anticonvulsants, and atypical antipsychotics may be effective as augmentation therapy to optimize outcome, with buspirone and beta-blockers useful in some patients as well. Cognitive-behavioral therapy is also an effective therapeutic alternative for affected patients. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Related Disorders, Boston, MA 02114 USA. RP Pollack, MH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Related Disorders, WAC 812,15 Parkman St, Boston, MA 02114 USA. EM mpollack@partners.org NR 86 TC 76 Z9 82 U1 5 U2 9 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 8 BP 22 EP 29 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 991HP UT WOS:000233803500004 PM 16336033 ER PT J AU Pollack, MH AF Pollack, MH TI The pharmacotherapy of panic disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Roundtable Conference on New Insights Into the Nature and Treatment of Panic Disorder CY JAN 23, 2004 CL Boston, MA ID PLACEBO-CONTROLLED TRIAL; GENERALIZED ANXIETY DISORDER; QUALITY-OF-LIFE; DOUBLE-BLIND; HEALTH-CARE; PSYCHOLOGICAL-PROBLEMS; PSYCHIATRIC-DISORDERS; IMIPRAMINE THERAPY; OPEN-LABEL; PAROXETINE AB Panic disorder is common and associated with significant morbidity and dysfunction. The pharmacologic treatment of panic disorder is aimed at reducing or eliminating panic attacks, avoidance behavior, anticipatory anxiety, and comorbid conditions-and substantially improving and normalizing overall function and quality of life. Antidepressants and benzodiazepines remain the current mainstays of pharmacotherapy for panic disorder, although other novel agents and strategies are becoming available and may add effective alternatives to the therapeutic armamentarium. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Anxiety & Traumat Stress Related Disorders, Boston, MA 02114 USA. RP Pollack, MH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Anxiety & Traumat Stress Related Disorders, 15 Parkman St,WAC-815, Boston, MA 02114 USA. EM mpollack@partners.org NR 54 TC 20 Z9 23 U1 0 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 4 BP 23 EP 27 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 923IE UT WOS:000228902800004 PM 15842184 ER PT J AU O'Brien, CP AF O'Brien, CP TI Benzodiazepine use, abuse, and dependence SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID TERM THERAPEUTIC USE; CLINICAL PHARMACOKINETICS; PANIC DISORDER; WITHDRAWAL; DIAZEPAM; ALPRAZOLAM; DISCONTINUATION; LIABILITY; CARBAMAZEPINE; CLONAZEPAM AB Although benzodiazepines are invaluable in the treatment of anxiety disorders, they have some potential for abuse and may cause dependence or addiction. It is important to distinguish between addiction to and normal physical dependence on benzodiazepines. Intentional abusers of benzodiazepines usually have other substance abuse problems. Benzodiazepines are usually a secondary drug of abuse-used mainly to augment the high received from another drug or to offset the adverse effects of other drugs. Few cases of addiction arise from legitimate use of benzodiazepines. Pharmacologic dependence, a predictable and natural adaptation of a body system long accustomed to the presence of a drug, may occur in patients taking therapeutic doses of benzodiazepines. However, this dependence, which generally manifests itself in withdrawal symptoms upon the abrupt discontinuation of the medication, may be controlled and ended through dose tapering, medication switching, and/or medication augmentation. Due to the chronic nature of anxiety, long-term low-dose benzodiazepine treatment may be necessary for some patients; this continuation of treatment should not be considered abuse or addiction. C1 Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP O'Brien, CP (reprint author), Univ Penn, Dept Psychiat, 3900 Chestnut St 6178, Philadelphia, PA 19104 USA. EM obrien@mail.trc.upenn.edu NR 42 TC 165 Z9 171 U1 9 U2 37 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 2 BP 28 EP 33 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 904SS UT WOS:000227518600005 PM 15762817 ER PT J AU Otto, MW Deveney, C AF Otto, MW Deveney, C TI Cognitive-behavioral therapy and the treatment of panic disorder: Efficacy and strategies SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Roundtable Conference on New Insights Into the Nature and Treatment of Panic Disorder CY JAN 23, 2004 CL Boston, MA ID ANXIETY DISORDERS; MAJOR DEPRESSION; CONTROLLED-TRIAL; FEAR EXTINCTION; CONTEXT; EXPOSURE; DISCONTINUATION; PSYCHOTHERAPY; RELAPSE; PHOBIA AB In this article, we review the efficacy and applications of cognitive-behavioral therapy (CBT) for panic disorder. Research supports CBT as an effective first-line treatment of panic disorder that offers relatively quick onset of action and long-term maintenance of treatment benefits. These characteristics, plus the acceptability, tolerability, and cost-efficacy of CBT, make it an especially attractive treatment option for panic disorder. We review these findings as well as some newer developments in the field including research on emotional acceptance, the importance of context in extinction learning, and the use of CBT in combination with pharmacotherapy. C1 Harvard Univ, Sch Med, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Dept Psychol, Boston, MA 02115 USA. RP Otto, MW (reprint author), Boston Univ, Ctr Anxiety & Related Disorders, 648 Beacon St,Fl 6, Boston, MA 02215 USA. NR 39 TC 43 Z9 44 U1 24 U2 37 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 4 BP 28 EP 32 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 923IE UT WOS:000228902800005 PM 15842185 ER PT J AU Otto, MW Bruce, SE Deckersbach, T AF Otto, MW Bruce, SE Deckersbach, T TI Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: Issues in the treatment of a patient in need SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SUBSTANCE-ABUSE TREATMENT; PANIC DISORDER; SOCIAL PHOBIA; CASE SERIES; ALPRAZOLAM; DISCONTINUATION; AGORAPHOBIA; MEDICATION; METAANALYSIS; EXPOSURE AB Cognitive-behavioral therapy (CBT) is effective in the treatment of anxiety disorders when used in conjunction with benzodiazepine pharmacotherapy and when used as a monotherapy. Patients using CBT alone have dropout rates similar to or lower than those patients undergoing other forms of therapy, including benzodiazepines. CBT also works well with patients who do not respond adequately to pharmacotherapy. Combined CBT and benzodiazepine treatment has additive effects when compared with benzodiazepine monotherapy; however, patients receiving combined therapy who subsequently discontinue benzodiazepine treatment experience a loss of efficacy compared with CBT and placebo, perhaps due to fear extinction being context dependent. To avoid this loss of efficacy, CBT may be administered alone or as a bridge between benzodiazepine use and discontinuation during a medication taper. The case report upon which this supplement is based questions the value of CBT for patients experiencing cognitive impairment due to an anxiety disorder, benzodiazepine medication., substance abuse, or a combination of these factors. This article addresses this concern and asserts that CBT is a valuable treatment option in these cases. C1 Boston Univ, Ctr Anxiety & Related Disorders, Waltham, MA 02254 USA. Boston Univ, Dept Psychol, Waltham, MA 02254 USA. Brown Univ, Dept Psychiat & Human Behav, Providence, RI 02912 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Otto, MW (reprint author), Boston Univ, Ctr Anxiety & Related Disorders, 648 Beacon St,6th Floor, Waltham, MA 02254 USA. NR 48 TC 15 Z9 15 U1 1 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 2 BP 34 EP 38 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 904SS UT WOS:000227518600006 PM 15762818 ER PT J AU Perlis, RH AF Perlis, RH TI The role of pharmacologic treatment guidelines for bipolar disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID CLINICAL-PRACTICE GUIDELINES; DOUBLE-BLIND; FOLLOW-UP; LITHIUM TREATMENT; SUBSTANCE-ABUSE; WEIGHT-GAIN; I DISORDER; MANIA; DEPRESSION; PLACEBO AB With the growth in the number of pharmacologic options available for the treatment of bipolar disorder, clinicians face a challenge in appropriately selecting and sequencing newer and older treatments. Because evidence-based practice has been suggested as a way to improve outcomes across specialties in medicine, a number of practice guidelines and treatment algorithms for bipolar disorder have been developed to aid clinical decision-making. Most of these guidelines and algorithms are based on detailed reviews of the medical literature, with an emphasis on systematic reviews and randomized, controlled trials. Some guidelines incorporate a consensus of expert opinion when the literature does not provide clear evidence. This review examines areas of overlap and discordance in practice guidelines issued by the American Psychiatric Association and the British Association for Psychopharmacology, as well as treatment algorithms developed by the Expert Consensus Guideline Series and the Texas Medical Algorithm Project. C1 Massachusetts Gen Hosp, Bipolar Clin & Res Program, Boston, MA 02114 USA. RP Perlis, RH (reprint author), Massachusetts Gen Hosp, Bipolar Clin & Res Program, 50 Staniford St,5thh Floor, Boston, MA 02114 USA. EM RPERLIS@PARTNERS.ORG NR 51 TC 15 Z9 16 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2005 VL 66 SU 3 BP 37 EP 47 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 909EL UT WOS:000227842900006 PM 15762833 ER PT J AU Fava, M Thase, ME DeBattista, C AF Fava, M Thase, ME DeBattista, C TI A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND; INDUCED WAKEFULNESS; DAYTIME SLEEPINESS; RESIDUAL SYMPTOMS; RANDOMIZED-TRIAL; CLINICAL-TRIALS; TERM TREATMENT; FLUOXETINE; STRATEGIES AB Background: Up to one half of depressed patients have partial or no response to antidepressant monotherapy. This multicenter, placebo-controlled study evaluated the efficacy of modafinil augmentation in major depressive disorder (MDD) patients with fatigue and excessive sleepiness despite selective serotonin reuptake inhibitor (SSRI) monotherapy. Method: Patients (18-65 years) with a DSM-IV diagnosis of MDD and partial response to SSRI monotherapy (greater than or equal to 8 weeks) at a stable dose for greater than or equal to 4 weeks were eligible. Patients had screening/baseline 31-item Hamilton Rating Scale for Depression (HAM-D) scores of 14 to 26, Epworth Sleepiness Scale (ESS) scores greater than or equal to 10, and Fatigue Severity Scale (FSS) scores greater than or equal to 4. Patients were randomly assigned to augmentation therapy with modafinil 200 mg/day or placebo for 8 weeks. Assessments included the ESS. Clinical Global Impressions-Improvement scale (CGI-I). 31- and 17-item HAM-D, FSS, Brief Fatigue Inventory (BFI), and Montgomery-Asberg Depression Rating Scale (MADRS). Results: Of 311 enrolled patients who received 1 dose of study drug. 158 were randomly assigned to modafinil (70% women) and 153 to placebo (72% women); 85% of each treatment group completed the study. At final visit, modafinil significantly improved patients' overall clinical condition compared with placebo on the basis of CGI-I scores (p = .02), and there were trends toward greater mean reductions in ESS. 31- and 17-item HAM-D, and MADRS scores versus placebo. Modafinil significantly reduced BFI scores for worst fatigue at final visit (p < .05 vs. placebo). There were no significant differences between modafinil and placebo at final visit in FSS or BFI total scores. Adverse events significantly more common during modafinil compared with placebo treatment were nausea (9% vs. 2%; p = .01) and feeling jittery (4% vs. 1%; p = .03). Conclusion: These findings suggest that modafinil is a well-tolerated and potentially effective augmenting agent for SSRI partial responders with fatigue and sleepiness. C1 Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Stanford Univ, Med Ctr, Stanford, CA 94305 USA. RP Fava, M (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 15 Parkman St,ACC 812, Boston, MA 02114 USA. EM MFava@Parmers.org NR 50 TC 129 Z9 132 U1 4 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2005 VL 66 IS 1 BP 85 EP 93 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 890DZ UT WOS:000226493200012 PM 15669893 ER PT J AU Green, MF Glahn, D Engel, SA Nuechterlein, KH Sabb, F Strojwas, M Cohen, MS AF Green, MF Glahn, D Engel, SA Nuechterlein, KH Sabb, F Strojwas, M Cohen, MS TI Regional brain activity associated with visual backward masking SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Article ID SCHIZOPHRENIC-PATIENTS; CORTEX; FMRI; AREAS; PERFORMANCE; ATTENTION; REGISTRATION; RECOGNITION; ACTIVATION; MECHANISMS AB In visual backward masking, the visibility of a briefly presented visual target is disrupted by a mask that is presented shortly thereafter. The goal of the current study was to identify regions in the human cortex that may provide the neural basis of visual masking. We searched for areas whose activity correlated with perception as we systematically varied the strength of masking. A total of 13 subjects performed a backward masking task during functional magnetic resonance imaging. Target and mask were presented at three delay intervals ( 34, 68, and 102 msec) and behavioral measures confirmed that the targets were more visible at longer masking intervals. Two sets of regions of interest were identified: Distinct regions in the visual cortex (V1/V2, LO, hMT+) were segregated using scans to localize visual processing drawn from the existing literature. Additional cortical regions were selected in a data-driven approach based on their activity during the backward masking task. For each set, we determined the regions whose magnitude of activation increased at longer masking intervals. Nine of the subjects provided valid behavioral performance data on the visual masking task and imaging data from these subjects were used for subsequent analysis. The scans of visual processing areas identified four regions, including: early visual areas (V1 and V2), the motion-sensitive regions in the lateral occipital (LO) lobe (hMT+), and two components ( dorsal and ventral) of the object-sensitive region, LO. Of these, the ventral and dorsal LO regions were sensitive to the strength of the mask. For the data-driven approach, six regions were identified on the basis of a difference map in which all masking intervals were contrasted with rest. These included the inferior parietal, anterior cingulate, precentral, insula, thalamic, and occipital areas. The predicted effects of more activity with weaker masking were seen in the thalamus, inferior parietal, and anterior cingulate. This study isolated three types of visual processing areas. The first included regions that subserve key stages of vision ( including object and motion processing). The second type responded to the presentation of briefly presented visual stimuli, regardless of masking interval. The third type ( selected from the first two) included regions sensitive to the interval between the target and mask. These latter regions ( including ventral LO, inferior parietal, anterior cingulate, and thalamus) may form the neural substrate of backward masking. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. RP Green, MF (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Med Plaza 300,Rm 2263, Los Angeles, CA 90095 USA. EM mgreen@ucla.edu RI Cohen, Mark/C-6610-2011 OI Cohen, Mark/0000-0001-6731-4053 FU NEI NIH HHS [EY12722]; NIMH NIH HHS [MH43293] NR 52 TC 34 Z9 34 U1 0 U2 1 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PD JAN PY 2005 VL 17 IS 1 BP 13 EP 23 DI 10.1162/0898929052880011 PG 11 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 890WT UT WOS:000226542500002 PM 15701236 ER PT J AU Caplan, D Chen, E West, WC Waters, G Robakis, D AF Caplan, D Chen, E West, WC Waters, G Robakis, D TI The effect of task on the bold signal localization of syntactic processing SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Boston Univ, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 26 EP 26 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700084 ER PT J AU Chen, E Caplan, D West, WC Waters, G AF Chen, E Caplan, D West, WC Waters, G TI Event-related examination of animacy effects on the localization of syntactic processing SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Boston Univ, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 26 EP 26 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700083 ER PT J AU DeDe, G Waters, G Alpert, N Kennedy, D Makris, N Michaud, J Reddy, A Caplan, D AF DeDe, G Waters, G Alpert, N Kennedy, D Makris, N Michaud, J Reddy, A Caplan, D TI A study of syntactic processing in aphasia SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA. Massachusetts Gen Hosp, Martinos Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Neuropsychol Lab, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 27 EP 27 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700087 ER PT J AU StancGzak, L Caplan, D Waters, G AF StancGzak, L Caplan, D Waters, G TI Similar and different patterns of activation in fast and slow sentence processors: An FMRI study SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Boston Univ, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 27 EP 27 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700086 ER PT J AU Kuperberg, G Kreher, D Blais, K Caplan, D Holcomb, P AF Kuperberg, G Kreher, D Blais, K Caplan, D Holcomb, P TI Semantic influences on syntactic processing: evidence from event-related potentials SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Tufts Univ, Medford, MA 02155 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 29 EP 29 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700095 ER PT J AU Davalos, D Martin, L Freedman, R AF Davalos, D Martin, L Freedman, R TI Nicotine effects on mismatch negativity in schizophrenia SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 78 EP 78 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700321 ER PT J AU Aminoff, E Schacter, DL Bar, M AF Aminoff, E Schacter, DL Bar, M TI The role of contextual associations and the parahippocampal cortex in creating false memories SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Harvard Univ, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 97 EP 97 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700410 ER PT J AU Sitnikova, T Cotton, J West, CW Holcomb, PJ Kuperberg, GR AF Sitnikova, T Cotton, J West, CW Holcomb, PJ Kuperberg, GR TI Comprehension of real-world events in schizophrenia: An electrophysiological perspective. SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Tufts Univ, Medford, MA 02155 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 118 EP 118 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700505 ER PT J AU Olson, IR Chatterjee, A Page, K Verfaellie, M AF Olson, IR Chatterjee, A Page, K Verfaellie, M TI Binding in visual short term memory is impaired in patients with medial temporal lobe amnesia SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Univ Penn, Ctr Cognit Neurosci, Philadelphia, PA 19104 USA. Boston Univ, Sch Med, Boston, MA 02215 USA. Boston VA Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 131 EP 131 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700561 ER PT J AU Chua, E Schacter, D Depeau, K Celone, K Miller, S Sperling, R AF Chua, E Schacter, D Depeau, K Celone, K Miller, S Sperling, R TI Functional MRI of metamemory processes: Comparing feeling-of-knowing to post-recognition confidence judgments SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Harvard Univ, Brigham & Womens Hosp, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 134 EP 134 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700576 ER PT J AU Schnyer, D Nicholls, L Deason, R Verfaellie, M Marsolek, C AF Schnyer, D Nicholls, L Deason, R Verfaellie, M Marsolek, C TI Visual anti-priming: Tests of amnesic patients and older controls SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Boston VA Healthcare Syst, Memory Disorders Res Ctr, Boston, MA USA. Boston Univ, Sch Med, Boston, MA 02215 USA. Univ Minnesota, Minneapolis, MN 55455 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 137 EP 137 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878700590 ER PT J AU Neta, M Bar, M AF Neta, M Bar, M TI First impressions: How visual features shape our preference SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, NMR, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 170 EP 170 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878701111 ER PT J AU Pearlmutter, N Stanczak, L Caplan, D Waters, G AF Pearlmutter, N Stanczak, L Caplan, D Waters, G TI Neural correlates of semantic plausibility in sentence comprehension with high and low working memory groups SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Northeastern Univ, Boston, MA 02115 USA. Boston Univ, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 175 EP 175 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878701133 ER PT J AU Holt, D Lynn, S Kreher, D Rauch, S Holcomb, P Kuperberg, G AF Holt, D Lynn, S Kreher, D Rauch, S Holcomb, P Kuperberg, G TI Neurophysiological correlates of reading emotional sentences SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Ctr Mental Hlth & Media, Cambridge, MA 02138 USA. Tufts Univ, Medford, MA 02155 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 176 EP 176 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878701139 ER PT J AU Kreher, D Holcomb, P Kuperberg, G AF Kreher, D Holcomb, P Kuperberg, G TI Neural correlates of indirect semantic priming: An event-related potential study. SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Tufts Univ, Medford, MA 02155 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 176 EP 176 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878701140 ER PT J AU Righart, R de Gelder, B AF Righart, R de Gelder, B TI Threatening contexts enhance early perceptual analysis of faces. An electrophysiological study. SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Cognit & Affect Neurosci Lab, Tilburg, Netherlands. Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 201 EP 201 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878701249 ER PT J AU Wehner, D Ahlfors, S Mody, M AF Wehner, D Ahlfors, S Mody, M TI Neural patterns of semantic interference during reading in children: An MEG study SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 MIT, Cambridge, MA 02139 USA. Massachusetts Gen Hosp, Martinos Ctr, Boston, MA 02114 USA. RI Ahlfors, Seppo/P-3644-2016 NR 0 TC 0 Z9 0 U1 0 U2 1 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 209 EP 209 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878701287 ER PT J AU Kuperberg, G Gulabani, D Cotton, J Blais, K Caplan, D Holcomb, P AF Kuperberg, G Gulabani, D Cotton, J Blais, K Caplan, D Holcomb, P TI Making sense of discourse: An event-related fMRI study SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 12th Annnual Meeting of the Cognitive-Neuroscience-Society CY APR 09-12, 2005 CL New York, NY SP Cognit Neurosci Soc C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Tufts Univ, Medford, MA 02155 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2005 SU S BP 229 EP 229 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 909RP UT WOS:000227878701376 ER PT J AU Klose, AD Ntziachristos, V Hielscher, AH AF Klose, AD Ntziachristos, V Hielscher, AH TI The inverse source problem based on the radiative transfer equation in optical molecular imaging SO JOURNAL OF COMPUTATIONAL PHYSICS LA English DT Review DE fluorescence tomography; fluorescence imaging; inverse source problem; molecular imaging; equation of radiative transfer; discrete ordinates method; adjoint differentiation; algorithmic differentiation; scattering media; tissue optics ID DISCRETE-ORDINATES METHOD; DOMAIN PHOTON MIGRATION; SCATTERING MEDIA; CONTRAST AGENTS; TURBID MEDIA; AUTOMATIC DIFFERENTIATION; FLUORESCENCE TOMOGRAPHY; RECONSTRUCTION SCHEME; DIFFUSION TOMOGRAPHY; ADJOINT MODEL AB We present the first tomographic reconstruction algorithm for optical molecular imaging that is based on the equation of radiative transfer. The reconstruction code recovers the spatial distribution of fluorescent sources in highly scattering biological tissue. An objective function, which describes the discrepancy of measured near-infrared light with predicted numerical data on the tissue surface, is iteratively minimized to find a solution of the inverse source problem. At each iteration step the predicted data are calculated by a forward model for light propagation based on the equation of radiative transfer. The unknown source distribution is updated along a search direction that is provided by an adjoint differentiation technique. (C) 2004 Elsevier Inc. All rights reserved. C1 Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA. Columbia Univ, Dept Radiol, New York, NY 10027 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. RP Klose, AD (reprint author), Columbia Univ, Dept Biomed Engn, ET 351,Mudd Bldg,MC 8904,500 W 120th St, New York, NY 10027 USA. EM ak2083@columbia.edu NR 101 TC 131 Z9 137 U1 2 U2 17 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0021-9991 J9 J COMPUT PHYS JI J. Comput. Phys. PD JAN 1 PY 2005 VL 202 IS 1 BP 323 EP 345 DI 10.1016/j.jcp.2004.07.008 PG 23 WC Computer Science, Interdisciplinary Applications; Physics, Mathematical SC Computer Science; Physics GA 877NX UT WOS:000225578400015 ER PT J AU Chuang, SK Cai, T Douglass, CW Wei, LJ Dodson, TB AF Chuang, SK Cai, T Douglass, CW Wei, LJ Dodson, TB TI Frailty approach for the analysis of clustered failure time observations in dental research SO JOURNAL OF DENTAL RESEARCH LA English DT Article DE survival analysis; dental implants; risk factors; follow-up study; Cox regression analysis; clustered survival data; frailty approach; gamma distribution ID ASYMPTOTIC THEORY; MODEL; SURVIVAL; STRATEGY AB Because dental implant failure patterns tend to cluster within subjects, we hypothesized that the risk of implant failure varies among subjects. To address this hypothesis in the setting of clustered, correlated observations, we considered a retrospective cohort study where we identified a cohort having at least one implant placed. The cohort was composed of 677 patients who had 2349 implants placed. To test the hypothesis, we applied an innovative analytic method, i.e., the Cox proportional hazards model with frailty, to account for correlation within subjects and the heterogeneity of risk, i.e., frailty, among subjects for implant failure. Consistent with our hypothesis, risk for implant failure among subjects varied to a statistically significantly degree (p = 0.041). In addition, the risk for implant failure is significantly associated with several factors, including tobacco use, implant length, immediate implant placement, staging, well size, and proximity of adjacent implants or teeth. C1 Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. Harvard Univ, Sch Dent Med, Boston, MA 02114 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA USA. Harvard Univ, Sch Dent Med, Dept Oral & Maxillofacial Surg, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Chuang, SK (reprint author), POB 67376,Chestnut Hill Stn, Chestnut Hill, MA 02467 USA. EM schuang@hsph.harvard.edu FU NIAID NIH HHS [R01 AI052817, R37 AI024643-15]; NIDCR NIH HHS [K16 DE000275, K24 DE000448] NR 25 TC 35 Z9 35 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PD JAN PY 2005 VL 84 IS 1 BP 54 EP 58 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 895AV UT WOS:000226834000009 PM 15615876 ER PT J AU Klein, RL McHenry, MB Lok, KH Hunter, SJ Le, NA Jenkins, AJ Zheng, DJ Semler, A Page, G Brown, WV Lyons, TJ Garvey, WT AF Klein, RL McHenry, MB Lok, KH Hunter, SJ Le, NA Jenkins, AJ Zheng, DJ Semler, A Page, G Brown, WV Lyons, TJ Garvey, WT CA DCCTEDIC Res Grp TI Apolipoprotein C-III protein concentrations and gene polymorphisms in type I diabetes - Associations with microvascular disease complications in the DCCT/EDIC cohort SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article ID CORONARY-ARTERY DISEASE; FAMILIAL COMBINED HYPERLIPIDEMIA; FRAGMENT-LENGTH-POLYMORPHISMS; LIPOPROTEIN-LIPASE ACTIVITY; INSULIN-RESPONSE ELEMENT; A-I; TRIGLYCERIDE-RICH; HEART-DISEASE; APO-CIII; HYPERTRIGLYCERIDEMIA AB Aim: We investigated the associations of apolipoprotein C-III (apoCIII) protein and apoCIII gene variation with microvascular disease complications in Type 1 diabetes. Methods: The serum apoCIII concentration, and both a T-455-->C and a SacI gene polymorphisms were determined in 409 patients in the DCCT/EDIC cohort of patients with Type 1 diabetes. Correlations with albumin excretion rate (AER) and the severity of retinopathy were investigated. Results: Higher apoCIII concentrations were associated (P < .0001) with increased triglycerides (r = .78), total (r = .61) and LDL (r = .40) cholesterol, apoAI (r = .26), and apoB (r = .50), AER (r = .08), and the severity of retinopathy (ETDRS score, r = .11), and these relationships persisted after controlling for age, gender, body mass index (BMI), and HbA1c level. The apoCIII concentration was significantly higher in the group of patients with macroalbuminuria (AERs 300 mg/24 h) compared to the groups with microalbuminuria (AER 40-299 mg/24 h; P < .0001) or normoalbuminuria (AER < 40 mg/24 h) (P < .0001). The apoCIII concentration also was significantly higher in the group of patients with severe retinopathy (ETDRS 10-23) compared to those with moderate (ETDRS 4-9: P < .02) or mild retinopathy (ETDRS 1-3; P < .0001). Neither the T-455-->C polymorphism nor a SacI polymorphism in the 3' UTR were associated with circulating apoCIII concentrations, nor the severity of nephropathy or retinopathy. Conclusions: Elevated apoCIII levels have been associated with increased macrovascular disease risk. In the DCCT/EDIC cohort of patients, there was an independent positive association of apoCIII level with microvascular complications of Type 1 diabetes. Published by Elsevier Inc. C1 Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Med Genet, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs, Med Ctr, Res Serv, Charleston, SC USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA. Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. Emory Univ, Div Atherosclerosis & Lipid Metab, Atlanta, GA 30322 USA. Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia. Univ Oklahoma, Hlth Sci Fdn, Sect Endocrinol Diabet & Hypertens, Oklahoma City, OK USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Box NDIC DCCT, Bethesda, MD USA. RP Klein, RL (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Med Genet, 114 Doughty St,POB 250770, Charleston, SC 29425 USA. EM kleinrl@musc.edu RI Jenkins, Alicia/N-2482-2015 FU NHLBI NIH HHS [P01-HL55782] NR 49 TC 16 Z9 18 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD JAN-FEB PY 2005 VL 19 IS 1 BP 18 EP 25 DI 10.1016/j.jdiacomp.2004.04.005 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 896VF UT WOS:000226961400003 PM 15642486 ER PT J AU Rivera, ML Nadel, ES Brown, DFM AF Rivera, ML Nadel, ES Brown, DFM TI Exertional chest pain SO JOURNAL OF EMERGENCY MEDICINE LA English DT Editorial Material ID CREATINE-KINASE-MB; CARDIAC TROPONIN-T; ASYMPTOMATIC MARATHON RUNNERS; PROLONGED STRENUOUS EXERCISE; ACUTE MYOCARDIAL-INFARCTION; NATRIURETIC-PEPTIDE; ISOENZYME LEVELS; INJURY; DIAGNOSIS; MARKERS C1 Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Div Emergency Med, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Nadel, ES (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. NR 22 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD JAN PY 2005 VL 28 IS 1 BP 69 EP 73 DI 10.1016/j.jemermed.2004.10.008 PG 5 WC Emergency Medicine SC Emergency Medicine GA 890SY UT WOS:000226532300013 PM 15657008 ER PT J AU Rashid, RM Achille, NJ Lee, JM Lathers, DMR Young, MRI AF Rashid, RM Achille, NJ Lee, JM Lathers, DMR Young, MRI TI Decreased T-cell proliferation and skewed immune responses in LLC-bearing mice SO JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY LA English DT Article DE cancer; Lewis lung carcinoma; T cells; dendritic cells; splenocytes; APC; Con A; anti-CD3; cytokines ID MURINE DENDRITIC CELLS; LUNG-CANCER PATIENTS; IMMUNOLOGICAL DYSFUNCTION; ANTITUMOR IMMUNITY; NITRIC-OXIDE; NECK-CANCER; IN-VIVO; TUMOR; ANTIGEN; TH2 AB Deficits in immune cell responses have been reported in cancer patients. We used the murine Lewis lung carcinoma (LLC) model to better understand these deficits. The goal of this study was to determine if the immune responses of LLC tumor-bearing (TB) mice differ from control mice and whether the difference could be attributed to either antigen-presenting cells (APC) or to T cells. Tumors were first allowed to grow in vivo for approximately 2 weeks. Splenocytes were then isolated for in vitro proliferation and cytokine release studies. The results showed a decrease in mitogen-stimulated proliferation by unfractionated splenocyte cultures from TB mice when compared to control mice in response to concanavalin A (Con A), a T-cell mitogen. Decreased responses were also observed when the APC spleen cell fraction from TB mice was cultured with normal T cells, although proliferation was more prominently reduced in cultures of TB T cells plus normal APC. Also, splenocytes from TB mice secreted significantly increased levels of IFN-gamma, IL-4, and IL-10. Admixing APC from control mice with TB T cells significantly decreased levels of IL-4 and IL-10 secretion as compared to the levels secreted by cocultures of TB T cells and TB APC. The decreased cytokine profile in the presence of normal A-PC despite the presence of TB T cells suggests that A-PC contributes to the immune dysfunction, including Th skewing of tumor bearers, possibly through their influence on T-cell expansion and cytokine production. Finally, our assessment of the APC population contributing to the observed immune dysfunction-i.e., dendritic cells or macrophages-showed that the proliferation of TB T cells was decreased regardless of the APC population with which they were cocultured. However, normal T-cell proliferation was only reduced by the addition of TB macrophages and not by the addition of TB dendritic cells. In conclusion, our results demonstrate that LLC TB mice have a skewed immune response characterized by a decreased proliferative response with both T cells and A-PC affected by the presence of tumor. C1 Loyola Univ, Ctr Med, Dept Pathol, Maywood, IL 60153 USA. Loyola Univ, Ctr Med, Dept Pharmacol, Maywood, IL 60153 USA. Loyola Univ, Ctr Med, Dept Biochem, Maywood, IL 60153 USA. Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Rashid, RM (reprint author), Loyola Univ, Ctr Med, Dept Pathol, 2160 S 1st Ave,Bldg 102,Room 2638, Maywood, IL 60153 USA. EM Rrashid@lumc.edu FU NCI NIH HHS [CA85266, 1F31CA103768-01, CA79768, CA97813] NR 69 TC 6 Z9 7 U1 0 U2 1 PU BEGELL HOUSE INC PI NEW YORK PA 145 MADISON AVE, STE 601, NEW YORK, NY 10016-7892 USA SN 0731-8898 J9 J ENVIRON PATHOL TOX JI J. Environ. Pathol. Toxicol. Oncol. PY 2005 VL 24 IS 3 BP 175 EP 192 DI 10.1615/JEnvPathToxOncol.v24.i3.40 PG 18 WC Toxicology SC Toxicology GA 950LT UT WOS:000230859400004 PM 16050802 ER PT J AU Rodriguez, C Khachemoune, A AF Rodriguez, C Khachemoune, A TI A sore and sensitive tongue SO JOURNAL OF FAMILY PRACTICE LA English DT Editorial Material ID ORAL LICHEN-PLANUS; TOPICAL TACROLIMUS; MANAGEMENT C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA. Univ Illinois, Coll Med, Chicago, IL 60680 USA. RP Khachemoune, A (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, 40 Blossom St,BAR 314, Boston, MA 02114 USA. EM amorkh@pol.net NR 13 TC 0 Z9 0 U1 0 U2 0 PU DOWDEN PUBLISHING CORP PI MONTVALE PA 110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA SN 0094-3509 J9 J FAM PRACTICE JI J. Fam. Pract. PD JAN PY 2005 VL 54 IS 1 BP 33 EP 36 PG 4 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 891RV UT WOS:000226599300009 PM 15623405 ER PT J AU Huffman, JC Wulsin, LR Stern, TA AF Huffman, JC Wulsin, LR Stern, TA TI Newly diagnosed hypertension and depressive symptoms: How would you treat? SO JOURNAL OF FAMILY PRACTICE LA English DT Article; Proceedings Paper CT Annual Meetin of the Association-of-Medicine-and-Psychiatry CY NOV 19, 2003 CL San Diego, CA SP Assoc Med & Psychiat ID CORONARY-HEART-DISEASE; ARTERY-DISEASE; RISK-FACTOR C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45221 USA. Univ Cincinnati, Dept Family Med, Cincinnati, OH 45221 USA. Massachusetts Gen Hosp, Psychiat Consultat Serv, Boston, MA USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA USA. RP Huffman, JC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. NR 14 TC 0 Z9 0 U1 0 U2 0 PU DOWDEN PUBLISHING CORP PI MONTVALE PA 110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA SN 0094-3509 J9 J FAM PRACTICE JI J. Fam. Pract. PD JAN PY 2005 VL 54 IS 1 BP 39 EP 46 PG 8 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 891RV UT WOS:000226599300011 PM 15623406 ER PT J AU Russell, LB Suh, DC Safford, MM AF Russell, LB Suh, DC Safford, MM TI Time requirements for diabetes self-management: Too much for many? SO JOURNAL OF FAMILY PRACTICE LA English DT Article ID MEDICATION ADHERENCE; AFRICAN-AMERICAN; CARE; BARRIERS; OUTCOMES; WOMEN AB Background In Crossing the Quality Chasm, the Institute of Medicine laid out principles to improve quality of care and identified chronic diseases as a starting point. One of those principles was the wise use of patient time, but current recommendations for chronic conditions do not consider time spent on self-care or its impact on patients' lives. Objective To estimate the time, required for recommended diabetes self-care. Methods A convenience sample of 8 certified diabetes educators derived consensus-based estimates of the time required for all self-care tasks recommended by the American Diabetes Association. Results For experienced patients with type 2 diabetes controlled by oral agents, recommended self-care would require more than 2 extra hours daily. Elderly patients and those with newly diagnosed disease, or those with physical limitations, would need more time. Exercise and diet, required for self-care of many chronic conditions, are the most time-consuming tasks. Conclusion The time required by recommended self-care is substantial. Crossing the duality Chasm suggests how clinicians and guideline developers can help patients make the best use of their self-care time: elicit the patient's perspective; develop evidence on the health consequences of self-care tasks; and respect patients' time. C1 Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. Rutgers State Univ, Dept Pharm Practice & Adm, Piscataway, NJ USA. Univ Alabama, Sch Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. RP Safford, MM (reprint author), MT 643,1717 11th Ave S, Birmingham, AL 35294 USA. EM msafford@uab.edu NR 24 TC 53 Z9 53 U1 0 U2 4 PU DOWDEN PUBLISHING CORP PI MONTVALE PA 110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA SN 0094-3509 J9 J FAM PRACTICE JI J. Fam. Pract. PD JAN PY 2005 VL 54 IS 1 BP 52 EP 56 PG 5 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 891RV UT WOS:000226599300012 PM 15623407 ER PT J AU Mendoza, RJ AF Mendoza, RJ TI The need for involuntary medication in competency to stand trial proceedings: A necessary work in progress SO JOURNAL OF FORENSIC PSYCHOLOGY PRACTICE LA English DT Editorial Material DE competency restoration; involuntary medication; right to refuse treatment AB The recent United States Supreme Court decision in Sell v. United States has reignited the debate regarding involuntary medication of defendants for the purposes of restoration to competence to stand trial. While the Court did not provide any momentum for either side of this debate, its decision in essence continued to allow such a practice under specific conditions. The purpose of this commentary is to offer a reasoned approach to understanding the need to involuntarily medicate certain defendants in an effort to balance the rights of the individual against the rights of society. The commentary emphasizes the need for mental health professionals to focus on their duty to advise any client, including the court, of medically appropriate treatment including medication trials. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Chestnut Hill, MA 02467 USA. Cambridge Forens Consultants, Boston, MA USA. RP Mendoza, RJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, 675 VFW Pkwy 254, Chestnut Hill, MA 02467 USA. EM rjmdc2001@verizon.net NR 1 TC 0 Z9 0 U1 0 U2 0 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1522-8932 J9 J FORENSIC PSYCHOL P JI J. Forensic Psychol. Pract. PY 2005 VL 5 IS 3 BP 69 EP 78 DI 10.1300/J158v05n03_04 PG 10 WC Criminology & Penology; Psychology, Multidisciplinary SC Criminology & Penology; Psychology GA 986QF UT WOS:000233464100004 ER PT J AU Fernandez-del Castillo, C Gelrud, A Lauwers, GY Yeo, CJ AF Fernandez-del Castillo, C Gelrud, A Lauwers, GY Yeo, CJ TI "How I do it" session: Autoimmune sclerosing pancreatitis SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Cincinnati, Div Digest Dis, Cincinnati, OH 45221 USA. Vet Affairs Med Ctr, Cincinnati, OH 45267 USA. Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21287 USA. RP Fernandez-del Castillo, C (reprint author), Massachusetts Gen Hosp, 15 Parkman St,WAC 336, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD JAN PY 2005 VL 9 IS 1 BP 1 EP 1 DI 10.1016/j.gassur.2004.08.008 PG 1 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 896ZL UT WOS:000226973200001 ER PT J AU Mino-Kenudson, M Lauwers, GY AF Mino-Kenudson, M Lauwers, GY TI Histopathology of autoimmune pancreatitis: Recognized features and unsolved issues SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article; Proceedings Paper CT 38th Annual Meeting of the Pancreas-Club-Incorporated CY MAY 16, 2004 CL New Orleans, LA SP Pancreas Club Inc ID LYMPHOPLASMACYTIC SCLEROSING PANCREATITIS; DESTRUCTIVE CHRONIC-PANCREATITIS; IDIOPATHIC CHRONIC-PANCREATITIS; PRIMARY BILIARY-CIRRHOSIS; INFLAMMATORY PSEUDOTUMOR; STEROID-THERAPY; CHOLANGITIS; ASSOCIATION; DISEASE; PANCREATICODUODENECTOMY C1 Massachusetts Gen Hosp, Dept Pathol WRN2, Gastrointestinal Pathol Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Lauwers, GY (reprint author), Massachusetts Gen Hosp, Dept Pathol WRN2, Gastrointestinal Pathol Serv, 55 Fruit St, Boston, MA 02114 USA. EM glauwers@partners.org NR 43 TC 10 Z9 14 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD JAN PY 2005 VL 9 IS 1 BP 6 EP 10 DI 10.1016/j.gassur.2004.08.010 PG 5 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 896ZL UT WOS:000226973200003 PM 15773046 ER PT J AU Keating, NL Landrum, MB Ayanian, JZ Winer, EP Guadagnoli, E AF Keating, NL Landrum, MB Ayanian, JZ Winer, EP Guadagnoli, E TI The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 20th Annual Research Meeting of the Academy-of-Health CY JUN 29, 2003 CL Nashville, TN SP Acad Hlth DE breast cancer; outpatient care; Medicare; mammography ID OLDER WOMEN; MAMMOGRAPHY USE; WHITE WOMEN; OUTCOMES; SPECIALISTS; PHYSICIANS; INSURANCE; SERVICES; COVERAGE; UNDERUSE AB OBJECTIVE: Although nearly all elderly Americans are insured through Medicare, there is substantial variation in their use of services, which may influence detection of serious illnesses. We examined outpatient care in the 2 years before breast cancer diagnosis to identify women at high risk for limited care and assess the relationship of the physicians seen and number of visits with stage at diagnosis. DESIGN: Retrospective cohort study using cancer registry and Medicare claims data. PATIENTS: Population-based sample of 11,291 women aged greater than or equal to67 diagnosed with breast cancer during 1995 to 1996. MEASUREMENTS AND MAIN RESULTS: Ten percent of women had no visits or saw only physicians other than primary care physicians or medical specialists in the 2 years before diagnosis. Such women were more often unmarried, living in urban areas or areas with low median incomes (all Pgreater than or equal to.01). Overall, 11.2% were diagnosed with advanced (stage III/IV) cancer. The adjusted rate was highest among women with no visits (36.2%) or with visits to physicians other than primary care physicians or medical specialists (15.3%) compared to women with visits to either a primary care physician (8.6%) or medical specialist (9.4%) or both (7.8%) (P<.001). The rate of advanced cancer also decreased with increasing number of visits (P<.001). CONCLUSIONS: Even within this insured population, many elderly women had limited or no outpatient care in the 2 years before breast cancer diagnosis, and these women had a markedly increased risk of advanced-stage diagnosis. These women, many of whom were unmarried and living in poor and urban areas, may benefit from targeted outreach or coverage for preventive care visits. C1 Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA. RP Keating, NL (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM keating@hcp.med.harvard.edu NR 41 TC 21 Z9 22 U1 1 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2005 VL 20 IS 1 BP 38 EP 44 DI 10.1111/j.1525-1497.2004.40079.x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 895YF UT WOS:000226899900007 PM 15693926 ER PT J AU Allen, E Nicolaidis, C Helfand, M AF Allen, E Nicolaidis, C Helfand, M TI The evaluation of rectal bleeding in adults - A cost-effectiveness analysis comparing four diagnostic strategies SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE rectal bleeding; hematochezia; cost-effectiveness analysis; diagnosis; colorectal cancer ID DOUBLE-CONTRAST BARIUM; QUALITY-OF-LIFE; COLORECTAL-CANCER; ENEMA EXAMINATION; FLEXIBLE SIGMOIDOSCOPY; COLONIC POLYPS; COLONOSCOPIC PERFORATIONS; UNRESECTED POLYPS; GENERAL-PRACTICE; SINGLE-CONTRAST AB BACKGROUND: Though primary care patients commonly present with rectal bleeding, the optimal evaluation strategy remains unknown. OBJECTIVE: To compare the cost-effectiveness of four diagnostic strategies in the evaluation of rectal bleeding. DESIGN: Cost-effectiveness analysis using a Markov decision model. DATA SOURCES:Systematic review of the literature, Medicare reimbursement data, Surveillance, Epidemiology, and End Results (SEER) Cancer Registry. TARGET POPULATION: Patients over age 40 with otherwise asymptomatic rectal bleeding. TIME HORIZON: The patient's lifetime. PERSPECTIVE: Modified societal perspective. INTERVENTIONS: Watchful waiting, flexible sigmoidoscopy, flexible sigmoidoscopy followed by air contrast barium enema (FS+ACBE), and colonoscopy. OUTCOME MEASURES: Incremental cost-effectiveness ratio. RESULTS OF BASE-CASE ANALYSIS: The incremental cost-effectiveness ratio for colonoscopy compared with flexible sigmoidoscopy was $5,480 per quality-adjusted year of life saved (QALY). Watchful waiting and FS+ACBE were more expensive and less effective than colonoscopy. RESULTS OF SENSITIVITY ANALYSES: The cost of colonoscopy was reduced to $1,686 per QALY when age at entry was changed to 45. Watchful waiting became the least expensive strategy when community procedure charges replaced Medicare costs, when age at entry was maximized to 80, or when the prevalence of polyps was lowered to 7%, but the remaining strategies provided greater life expectancy at relatively low cost. The strategy of FS+ACBE remained more expensive and less effective in all analyses. In the remaining sensitivity analyses, the incremental cost-effectiveness of colonoscopy compared with flexible sigmoidoscopy never rose above $34,000. CONCLUSIONS: Colonoscopy is a cost-effective method to evaluate otherwise asymptomatic rectal bleeding, with a low cost per QALY compared to other strategies. C1 Portland Vet Affairs Med Ctr, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Allen, E (reprint author), Portland Vet Affairs Med Ctr, P3-Med,POB 1034, Portland, OR 97207 USA. EM allenel@ohsu.edu NR 107 TC 9 Z9 9 U1 1 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2005 VL 20 IS 1 BP 81 EP 90 DI 10.1111/j.1525-1497.2005.40077.x PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 895YF UT WOS:000226899900014 PM 15693933 ER PT J AU Gerrity, MS Tierney, W AF Gerrity, MS Tierney, W TI Online early and other changes in JGIM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 Portland VA Med Ctr, Portland, OR USA. Indiana Univ, Sch Med, Indianapolis, IN 46204 USA. RP Gerrity, MS (reprint author), Portland VA Med Ctr, Portland, OR USA. NR 5 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2005 VL 20 IS 1 BP 95 EP 95 DI 10.1111/j.1525-1497.2005.04003.x PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 895YF UT WOS:000226899900016 ER PT J AU Budoff, JE Lichtman, DM AF Budoff, JE Lichtman, DM TI Spontaneous wrist fusion: An unusual complication of Kienbock's disease SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE autofusion; avascular necrosis; carpus; radial; shortening; spontaneous fusion; ankylosis; lunate; Kienbock's disease ID INTRAOSSEOUS PRESSURE; LUNATE; RADIUS AB We report a case of spontaneous wrist fusion occurring in a magnetic resonance image (MRI)-proven stage I Kienbock's disease. The purpose of this case 'report' is to make hand surgeons aware of this potential finding and to alert hand surgeons and radiologists that diffuse MRI changes of the lunate may not necessarily be pathognomonic for Kienbock's disease. (Copyright (C) 2005 by the American Society for Surgery of the Hand.). C1 Baylor Coll Med, Dept Orthopaed Surg, Houston, TX 77030 USA. John Peter Smith Hosp, Dept Orthopaed Surg, Ft Worth, TX USA. Houston VAMC, Dept Orthopaed, Houston, TX USA. RP Budoff, JE (reprint author), Baylor Coll Med, Dept Orthopaed Surg, 6550 Fannin,2500, Houston, TX 77030 USA. NR 13 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD JAN PY 2005 VL 30A IS 1 BP 59 EP 64 DI 10.1016/j.jhsa.2004.09.003 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 896EK UT WOS:000226917200008 PM 15680556 ER PT J AU Budoff, JE Kraushaar, BS Ayala, G AF Budoff, JE Kraushaar, BS Ayala, G TI Flexor carpi unaris tendinopathy SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE flexor carpi ulnaris; tendinosis; tendinopathy; ulnar-sided wrist pain; flexor carpi ulnaris tendinopathy ID ACUTE CALCIFIC TENDINITIS; TENNIS ELBOW; PERITENDINITIS CALCAREA; SURGICAL-TREATMENT; WRIST; TENDINOSIS; TENDON; HAND AB Purpose: This study describes the pathology of flexor carpi ulnaris (FCU) tendinopathy and its treatment. Methods: Five patients (1 bilateral) who failed nonsurgical management of FCU tendinopathy had FCU tendon debridement. The excised tendon was examined histologically and 4 patients (1 bilateral) were followed-up for at least 12 months. Results: The pathology was degenerative tendinosis (angiofibroblastic hyperplasia) in all specimens, identical to that observed in tennis elbow and the rotator cuff. Surgical excision of the pathologic degeneration gave excellent pain relief in all cases. Conclusions: The pathology of FCU tendinopathy (ie, degenerative tendinosis) is similar to that of other extrasynovial tendons. Surgical debridement of the pathologic tendinosis tissue is effective treatment for patients who fail nonsurgical management. Copyright (C) 2005 by the American Society for Surgery of the Hand. C1 Baylor Coll Med, Dept Orthopaed Surg, Dept Pathol, Houston, TX 77030 USA. Houston VA Med Ctr, Spring Valley, NY USA. RP Budoff, JE (reprint author), 6550 Fannin,2525, Houston, TX 77030 USA. NR 37 TC 11 Z9 11 U1 1 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD JAN PY 2005 VL 30A IS 1 BP 125 EP 129 DI 10.1016/j.jhsa.2004.07.018 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 896EK UT WOS:000226917200019 PM 15680567 ER PT J AU Kuwaki, K Knosalla, C Dor, FJMF Gollackner, B Tseng, YL Houser, S Cooper, DKC AF Kuwaki, K Knosalla, C Dor, FJMF Gollackner, B Tseng, YL Houser, S Cooper, DKC TI Troponin T levels in baboons with pig heterotopic heart transplants SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Article ID REJECTION; ANTIBODY AB Troponin T levels have been monitored in baboons (n = 8) undergoing pig heterotopic heart transplantation, and correlated with a decrease in graft contractions and graft survival. Pig heart graft survival was from 12 to 139 days (mean 45, median 33), and graft failure was associated with predominant thrombotic microangiopathy and ischemia; with focal hemorrhage, and edema. An increase in troponin T levels 5 to 6 days before graft failure correlated closely with diminished graft contractions. An increase in troponin T was a reliable indicator that graft dysfunction was occurring. Copyright (C) 2005 by the International Society for Heart and Lung Transplantation. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02129 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02129 USA. RP Cooper, DKC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, MGH E,Bldg 149-9019,13th St, Boston, MA 02129 USA. EM david.cooper@tbrc.mgh.harvard.edu RI Dor, Frank/E-1032-2013 OI Dor, Frank/0000-0001-7845-3075 FU NIAID NIH HHS [1P01 AI45897] NR 7 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD JAN PY 2005 VL 24 IS 1 BP 92 EP 94 DI 10.1016/j.healun.2003.09.039 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA 889RZ UT WOS:000226461400014 PM 15653386 ER PT J AU Kunisaki, SM Hertl, M Bodner, BE Cosimi, AB AF Kunisaki, SM Hertl, M Bodner, BE Cosimi, AB TI Mirizzi syndrome secondary to an adenoma of the cystic duct SO JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY LA English DT Article DE Mirizzi syndrome; bile duct adenoma; cystic duct ID EXTRAHEPATIC BILE-DUCTS; PAPILLARY ADENOMA; VILLOUS ADENOMA; TUMORS AB Bile duct adenomas are uncommon lesions that can cause obstructive jaundice. We report the unusual case of a 54-year-old man who developed Mirizzi syndrome secondary to a bile duct papillary adenoma located in the cystic duct remnant. A case report is presented, together with a review of extrahepatic bile duct adenomas published in the English-language literature, with special attention directed toward the clinical manifestations, locations, and prognosis of these tumors. Bile duct adenomas are very rare tumors. Although cholangiography can detect many of these lesions, few cases were correctly diagnosed preoperatively. Most lesions were located in the distal common bile duct or at the ampulla of Vater. Pathologic examination often revealed foci of carcinoma in situ, dysplasia, or atypia. Local resection was performed in most cases. There were no previous case reports of extrinsic common bile duct obstruction caused by tumors within the cystic duct. We describe here a very rare, acalculous variant of Mirizzi syndrome secondary to a solitary papillary adenoma of the cystic duct. In general, bile duct adenomas are uncommon lesions that are difficult to diagnoses preoperatively. These tumors usually present with jaundice secondary to intraluminal biliary obstruction. These lesions are premalignant and should be managed by complete surgical resection. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. Morton Surg PC, Taunton, MA USA. RP Cosimi, AB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,WHT 515, Boston, MA 02114 USA. NR 28 TC 4 Z9 4 U1 0 U2 0 PU SPRINGER TOKYO PI TOKYO PA 3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN SN 0944-1166 J9 J HEPATO-BILIARY-PAN JI J. Hepato-Biliary-Pancreatic Surg. PY 2005 VL 12 IS 2 BP 159 EP 162 DI 10.1007/s00534-004-0970-z PG 4 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 922BV UT WOS:000228811700011 PM 15868083 ER PT J AU Gray, RGF Hutchin, T Preece, MA Chakrapani, A Hardy, J Olpin, S Brueton, L Shih, VE Zeng, WQ Gao, H AF Gray, R. G. F. Hutchin, T. Preece, M. A. Chakrapani, A. Hardy, J. Olpin, S. Brueton, L. Shih, V. E. Zeng, W-Q Gao, H. TI PARTIAL UNIPARENTAL DISOMY IN FUMARASE DEFICIENCY - A REASSESSMENT OF RECURRENCE RISK SO JOURNAL OF INHERITED METABOLIC DISEASE LA English DT Meeting Abstract C1 [Gray, R. G. F.; Hutchin, T.; Preece, M. A.; Chakrapani, A.; Hardy, J.] Birmingham Childrens Hosp, Birmingham, W Midlands, England. [Olpin, S.] Sheffield Childrens Hosp, Sheffield, S Yorkshire, England. [Brueton, L.] Birmingham Womens Hops, Birmingham, W Midlands, England. [Shih, V. E.] Massachusetts Gen Hosp, Amino Acid Disorders Lab, Boston, MA 02114 USA. [Zeng, W-Q; Gao, H.] Massachusetts Gen Hosp, Mol Neurogenet Unit, Boston, MA 02114 USA. NR 1 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0141-8955 J9 J INHERIT METAB DIS JI J. Inherit. Metab. Dis. PY 2005 VL 28 BP 84 EP 84 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 460TC UT WOS:000267210400169 ER PT J AU Cleary, MA Dorland, L de Koning, TJ Poll-The, BT Duran, M Mandell, R Shih, VE Berger, R Olpin, SE Besley, GTN AF Cleary, MA Dorland, L de Koning, TJ Poll-The, BT Duran, M Mandell, R Shih, VE Berger, R Olpin, SE Besley, GTN TI Ornithine aminotransferase deficiency: Diagnostic difficulties in neonatal presentation SO JOURNAL OF INHERITED METABOLIC DISEASE LA English DT Article ID GYRATE ATROPHY; HYPERORNITHINEMIA; SKIN AB We describe two unrelated cases of ornithine aminotransferase (OAT) deficiency with rare neonatal presentation of hyperammonaemia. The diagnosis in the neonatal presentation of OAT deficiency is hampered as hyperornithinaemia is absent. Enzyme and mutation studies confirmed the diagnosis. OAT deficiency should be included in differential diagnosis of neonatal hyperammonaemia. C1 Royal Manchester Childrens Hosp, Willink Biochem Genet Unit, Manchester M27 4HA, Lancs, England. Sheffield Childrens Hosp, Dept Neonatal Screening, Sheffield, S Yorkshire, England. Massachusetts Gen Hosp, Amino Acid Disorders Lab, Boston, MA 02114 USA. AMC Amsterdam, Lab Genet Metab Dis, Amsterdam, Netherlands. AMC Amsterdam, Dept Child Neurol, Amsterdam, Netherlands. UMC Utrecht, Dept Metab & Endocrine Dis, Utrecht, Netherlands. RP Besley, GTN (reprint author), Royal Manchester Childrens Hosp, Willink Biochem Genet Unit, Manchester M27 4HA, Lancs, England. EM guy.besley@cmmc.nhs.uk FU NINDS NIH HHS [NS05096] NR 12 TC 11 Z9 11 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0141-8955 J9 J INHERIT METAB DIS JI J. Inherit. Metab. Dis. PY 2005 VL 28 IS 5 BP 673 EP 679 DI 10.1007/s10545-005-0074-1 PG 7 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 962VA UT WOS:000231759900006 PM 16151897 ER PT J AU Rhatigan, DL Moore, TM Street, AE AF Rhatigan, DL Moore, TM Street, AE TI Reflections on partner violence - 20 years of research and beyond SO JOURNAL OF INTERPERSONAL VIOLENCE LA English DT Article DE partner violence; prevalence; measurement; intervention ID AGGRESSION; WOMEN AB The authors reflect on past research and technology as well as their hopes for future innovations within the field of intimate partner violence. They review work, that has contributed to current conceptual definitions of partner violence, particularly those that have shaped the field's broadened perspective. They discuss technological and measurement innovations that have contributed to more accurate assessments violence prevalence. The authors believe that via these technologies, the trite extent of violence within the home has been made known. In conclusion, the authors argue that to reduce violence between partners, there is an overwhelming need for future researchers to build on past data, develop unproved theories, and apply those ideas to prevention and intervention techniques and programs. Furthermore, they believe that it is imperative for current and future programs to be extensively evaluated and tested for their effectiveness. C1 VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA. Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. RP Rhatigan, DL (reprint author), VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA. NR 20 TC 9 Z9 9 U1 4 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0886-2605 J9 J INTERPERS VIOLENCE JI J. Interpers. Violence PD JAN PY 2005 VL 20 IS 1 BP 82 EP 88 DI 10.1177/0886260504268599 PG 7 WC Criminology & Penology; Family Studies; Psychology, Applied SC Criminology & Penology; Family Studies; Psychology GA 877GV UT WOS:000225556800012 PM 15618564 ER PT J AU Yamashita, T Kuwahara, T Gonzalez, S Takahashi, M AF Yamashita, T Kuwahara, T Gonzalez, S Takahashi, M TI Non-invasive visualization of melanin and melanocytes by reflectance-mode confocal microscopy SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article DE melanin; melanocyte; non-invasive method; reflectance-mode confocal microscopy; UVB ID SCANNING LASER MICROSCOPY; IN-VIVO; HUMAN SKIN; HUMAN EPIDERMIS; KERATINOCYTES; MELANOSOMES; UV AB In vivo visualization of epidermal melanin was performed by reflectance-mode confocal microscopy (RCM). Firstly, we examined the distribution of epidermal melanin in pigmented animals and compared with that of the human skin. Melanocytes in the skin of pigmented animals were found to accumulate a large amount of melanin that can be easily visualized because of its brightness. Their RCM images correlated well with the Fontana-Masson-stained sections for melanin. In contrast, in the human skin, typical dendritic melanocytes were hardly observed even in pigmented lesions, although supranuclear melanin caps were easily visible. These results suggested that human melanocytes rapidly transfer the produced melanin to keratinocytes and do not accumulate it. Secondly, to elucidate the production of melanin by human melanocytes, we evaluated the changes of melanin after a single ultraviolet (UV) exposure. The melanin-accumulating melanocytes were clearly visualized during the skin pigmentation process. The RCM images showed the brightness because of melanin gradually increased from day 4, then dendrite-elongated melanocytes appearing from day 8, and finally melanin caps formed from day 29. In conclusion, RCM successfully evidenced the difference in melanin distribution between the pigmented animals and humans, and the UV-induced pigmentation process invivo as well. C1 Shiseido Res Ctr Shin Yokohama, Tsuzuki Ku, Yokohama, Kanagawa 2248558, Japan. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Wellman Labs Photomed, Boston, MA USA. RP Yamashita, T (reprint author), Shiseido Res Ctr Shin Yokohama, Tsuzuki Ku, 2-2-1 Hayabuchi, Yokohama, Kanagawa 2248558, Japan. EM toyonobu.yamashita@to.shiseido.co.jp NR 22 TC 42 Z9 48 U1 0 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JAN PY 2005 VL 124 IS 1 BP 235 EP 240 DI 10.1111/j.0022-202X.2004.23562.x PG 6 WC Dermatology SC Dermatology GA 882PR UT WOS:000225951300037 PM 15654979 ER PT J AU Bogaert, Y Grippa, J Nemenoff, R Reusch, JEB AF Bogaert, Y Grippa, J Nemenoff, R Reusch, JEB TI cAMP response element binding protein and collagen 1 impact on vascular smooth muscle cell gene regulation and phenotype. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Denver VAMC, Denver, CO USA. Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 387 BP S146 EP S146 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700400 ER PT J AU Dahms, WJ Wagner, B Gorin, Y Abboud, HE AF Dahms, WJ Wagner, B Gorin, Y Abboud, HE TI NADPH oxidase-derived reactive oxygen species generation is increased in puromycin aminonucleoside nephropathy. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Div Nephrol, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 331 BP S312 EP S312 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700851 ER PT J AU Gensure, RC Makitie, O Barclay, C Chan, C DePalmer, S Bastepe, M Abuzahra, H Couper, R Seidman, J Cole, WG Juppner, H AF Gensure, RC Makitie, O Barclay, C Chan, C DePalmer, S Bastepe, M Abuzahra, H Couper, R Seidman, J Cole, WG Juppner, H TI A novel COLIA1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Tulane Univ, Sch Med, New Orleans, LA 70112 USA. Hosp Sick Children, Toronto, ON M5G 1X8, Canada. Univ Helsinki Hosp, Helsinki, Finland. Howard Hughes Med Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Adelaide, Adelaide, SA, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 108 BP S272 EP S272 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700628 ER PT J AU Goel, A Brooks-Worrell, B Chiu, H Palmer, JP AF Goel, A Brooks-Worrell, B Chiu, H Palmer, JP TI T cell proliferative and cytokine responses to islet proteins in autoantibody negative type 2 patients. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 431 BP S153 EP S154 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700444 ER PT J AU Kertesz, S Rose, S Palonen, K Kirk, K Halanych, J Safford, M Kiefe, C AF Kertesz, S Rose, S Palonen, K Kirk, K Halanych, J Safford, M Kiefe, C TI Access to outpatient diabetes care for homeless and housed veterans: More equal than not? SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. VA Qual Scholars, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 226 BP S292 EP S293 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700746 ER PT J AU Kulig, CC Beresford, TP Everson, GT AF Kulig, CC Beresford, TP Everson, GT TI Correlations between fatty acid ethyl ester levels, feeding status and serum lipids after acute alcohol ingestion. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 415 BP S151 EP S151 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700428 ER PT J AU Lee, MJ Feliers, D Choudhury, GG Kasinath, BS AF Lee, MJ Feliers, D Choudhury, GG Kasinath, BS TI Glucose-induced hypertrophy of glomerular epithelial cells: A role for AMP kinase. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 436 BP S331 EP S331 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700956 ER PT J AU Mariappan, MM Choudhury, GG Kasinath, BS AF Mariappan, MM Choudhury, GG Kasinath, BS TI High glucose, high insulin and their combination induce laminin BETA-1 synthesis in proximal tubular epithelial (MCT) cells: Involvement of translation mechanism. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 426 BP S329 EP S329 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700946 ER PT J AU Njoku, CJ Gilkeson, GS Patrick, KS Oates, JC AF Njoku, CJ Gilkeson, GS Patrick, KS Oates, JC TI Effect of inducible nitric oxide synthase inhibitors on isoprostane production in murine lupus nephritis. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 362 BP S317 EP S317 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700882 ER PT J AU Pereira, RI Draznin, B AF Pereira, RI Draznin, B TI Effect of insulin on adiponectin secretion from 3t3-L1 adipocytes is phosphatidylinositol 3-kinase dependent. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 UCHSC, Denver, CO USA. Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 459 BP S158 EP S158 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700472 ER PT J AU Rehman, SU Hutchison, FN Egan, BM AF Rehman, SU Hutchison, FN Egan, BM TI Comparison of racial/ethnic differences in blood pressure control rates among VA and non-VA hypertensive men. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 399 BP S324 EP S324 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700919 ER PT J AU Schauer, I Reusch, J AF Schauer, I Reusch, J TI Effects of free fatty acids on intracellular signaling through CREB protein in vascular smooth muscle cells: Implications for atherosclerosis. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Denver VAMC, Denver, CO USA. Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 456 BP S158 EP S158 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700469 ER PT J AU Scremin, M Leach, C Kunkel, C AF Scremin, M Leach, C Kunkel, C TI Thermal skin hyperemia as a diagnostic tool in peripheral vascular disease. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Western Univ Hlth Sci, Coll Osteopath Med Pacific, Pomona, CA 91766 USA. VA Greater Los Angeles Healthcare Syst, Pomona, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 1 BP S78 EP S78 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700015 ER PT J AU Tong, J McNeely, MJ Hull, RL Carr, DB Utzschneider, KM Shofer, JB Boyko, EJ Leonetti, DL Kahn, SE Fujimoto, WY AF Tong, J McNeely, MJ Hull, RL Carr, DB Utzschneider, KM Shofer, JB Boyko, EJ Leonetti, DL Kahn, SE Fujimoto, WY TI Intra-abdominal fat predicts future development of the metabolic syndrome in non-diabetic Japanese-Americans. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 318 BP S134 EP S134 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700331 ER PT J AU Utzschneider, KM Prigeon, RL Carr, DB Tong, J Hull, RL Knopp, RH Kahn, SE AF Utzschneider, KM Prigeon, RL Carr, DB Tong, J Hull, RL Knopp, RH Kahn, SE TI Evidence fora hyperbolic relationship between insulin sensitivity and the insulin response derived from an oral glucose tolerance test. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 167 BP S107 EP S107 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700181 ER PT J AU Vanek, C Kansagor, JN Munsey, T Olson, DA Belknap, JK Shea, M Orwoll, ES Klein, RF AF Vanek, C Kansagor, JN Munsey, T Olson, DA Belknap, JK Shea, M Orwoll, ES Klein, RF TI Genetic dissection of femoral bone strength in mice. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 400 BP S148 EP S148 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700413 ER PT J AU Wagner, B Gorin, Y Ricono, JM Abboud, HE AF Wagner, B Gorin, Y Ricono, JM Abboud, HE TI The phospholipase C-gamma domain of the platelet-derived growth factor receptor beta inhibits platelet-derived growth factor receptor dependent Akt/PKB and ERK1/2 pathways in metanephric mesenchymal cells. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, Div Nephrol, San Antonio, TX USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 434 BP S330 EP S330 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700954 ER PT J AU Wang, CCL Draznin, B AF Wang, CCL Draznin, B TI Insulin and oxidant stress effects on early growth response gene-1 expression are mediated differently in vascular smooth muscle cells. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Denver VA Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 159 BP S105 EP S105 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700173 ER PT J AU Weisbart, RH Chan, G Wakelin, R Nishimura, RN Hansen, JE Chang, SS Baresi, L Chamberlain, JS AF Weisbart, RH Chan, G Wakelin, R Nishimura, RN Hansen, JE Chang, SS Baresi, L Chamberlain, JS TI Development of a lupus anti-DNA antibody as an intracellular delivery vehicle for protein transduction of micro-dystrophin. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Vet Affairs Greater Los Angeles Hlth Care Syst, Dept Res, Sepulveda, CA USA. Olive View UCLA Med Ctr, Sylmar, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA. Calif State Univ Northridge, Dept Biol, Northridge, CA 91330 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2005 VL 53 IS 1 SU S MA 292 BP S129 EP S129 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 890VR UT WOS:000226539700305 ER PT J AU Monuteaux, MC Faraone, SV Herzig, K Navsaria, N Biederman, J AF Monuteaux, MC Faraone, SV Herzig, K Navsaria, N Biederman, J TI ADHD and dyscalculia: Evidence for independent familial transmission SO JOURNAL OF LEARNING DISABILITIES LA English DT Article ID ATTENTION-DEFICIT HYPERACTIVITY; LA-TOURETTES SYNDROME; READING-DISABILITY; LEARNING-DISABILITIES; DEFICIT/HYPERACTIVITY DISORDER; GENETIC-RELATIONSHIP; MULTIPLE THRESHOLDS; COMORBIDITY; ETIOLOGY; DEFINITIONS AB The familial relationship between dyscalculia and attention-deficit/hyperactivity disorder (ADHD) was assessed. We conducted a familial risk analysis using probands with and without ADHD of both genders and their first-degree relatives. Participants were assessed with structured diagnostic interviews and a cognitive test battery. We found elevated rates of ADHD in relatives of both ADHD proband groups, regardless of dyscalculia status, and elevated rates of dyscalculia in relatives of probands with dyscalculia, irrespective of ADHD status. There was no evidence for cosegregation or assortative mating. Our findings support the hypothesis that ADHD and dyscalculia are independently transmitted in families and are etiologically distinct. These results reinforce the current nosological approach to these disorders and underscore the need for separate identification and treatment strategies for children with both conditions. C1 Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. Massachusetts Gen Hosp, Pediat Psychopharmacol Program, Boston, MA 02114 USA. Massachusetts Gen Hosp, Adult ADHD Program, Boston, MA 02114 USA. RP Monuteaux, MC (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Program, Warren 705,15 Parkman St, Boston, MA 02114 USA. OI Faraone, Stephen/0000-0002-9217-3982 FU NIMH NIH HHS [R01MH-41314] NR 43 TC 21 Z9 22 U1 4 U2 11 PU PRO-ED INC PI AUSTIN PA 8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897 USA SN 0022-2194 J9 J LEARN DISABIL-US JI J. Learn. Disabil. PD JAN-FEB PY 2005 VL 38 IS 1 BP 86 EP 93 DI 10.1177/00222194050380010701 PG 8 WC Education, Special; Rehabilitation SC Education & Educational Research; Rehabilitation GA 890DY UT WOS:000226493100007 PM 15727331 ER PT J AU Takahashi, K Shi, L Gowda, L Ezekowitz, A AF Takahashi, K Shi, L Gowda, L Ezekowitz, A TI Relative roles of complement and mannose-binding lectin in host defense against infection SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Meeting Abstract CT 38th Annual Meeting of the Society-for-Leukocyte-Biology CY SEP 21-24, 2005 CL Sir William Dunn Sch Pathol, Oxford, ENGLAND SP Soc Leukocyte Biol HO Sir William Dunn Sch Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PY 2005 SU S MA 2 BP 19 EP 19 PG 1 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 962PB UT WOS:000231743600003 ER PT J AU Stuart, LM Boulais, J Hennessy, E Charriere, G Bader, J Desjardins, M Ezekowitz, A AF Stuart, LM Boulais, J Hennessy, E Charriere, G Bader, J Desjardins, M Ezekowitz, A TI Using systems biology to examine the Drosophila phagosome and define the basic template of phagocytosis. SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Meeting Abstract CT 38th Annual Meeting of the Society-for-Leukocyte-Biology CY SEP 21-24, 2005 CL Sir William Dunn Sch Pathol, Oxford, ENGLAND SP Soc Leukocyte Biol HO Sir William Dunn Sch Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. Univ Montreal, Montreal, PQ H3C 3J7, Canada. Johns Hopkins Univ, Baltimore, MD 21218 USA. RI Bader, Joel/A-1818-2009 OI Bader, Joel/0000-0002-6020-4625 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PY 2005 SU S MA 12 BP 22 EP 22 PG 1 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 962PB UT WOS:000231743600013 ER PT J AU Ip, WKE Stuart, LM Takahashi, K Ezekowitz, RAB AF Ip, WKE Stuart, LM Takahashi, K Ezekowitz, RAB TI Regulation of Toll-like receptor 2 signaling pathway by mannose-binding lectin-mediated phagocytosis SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Meeting Abstract CT 38th Annual Meeting of the Society-for-Leukocyte-Biology CY SEP 21-24, 2005 CL Sir William Dunn Sch Pathol, Oxford, ENGLAND SP Soc Leukocyte Biol HO Sir William Dunn Sch Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Dev Immunol,Dept Pediat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PY 2005 SU S MA 94 BP 47 EP 47 PG 1 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 962PB UT WOS:000231743600094 ER PT J AU Benarafa, C Priebe, GP Remold-O'Donnell, E AF Benarafa, C Priebe, GP Remold-O'Donnell, E TI Deffective innate immunity against lung bacterial infection in SERPINB1 (MNEI) knockout mice SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Meeting Abstract CT 38th Annual Meeting of the Society-for-Leukocyte-Biology CY SEP 21-24, 2005 CL Sir William Dunn Sch Pathol, Oxford, ENGLAND SP Soc Leukocyte Biol HO Sir William Dunn Sch Pathol C1 CBR Inst Biomed Res, Boston, MA USA. HMS, Boston, MA USA. Brigham & Womens Hosp, Childrens Hosp, Channing Lab, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PY 2005 SU S MA 150 BP 64 EP 64 PG 1 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 962PB UT WOS:000231743600150 ER PT J AU Fowler, CE Li, M Mann, S Margolis, HC AF Fowler, CE Li, M Mann, S Margolis, HC TI Influence of surfactant assembly on the formation of calcium phosphate materials - A model for dental enamel formation SO JOURNAL OF MATERIALS CHEMISTRY LA English DT Article ID REVERSE MICROEMULSIONS; AMELOGENESIS IMPERFECTA; OCTACALCIUM PHOSPHATE; CRYSTAL MORPHOLOGY; AQUEOUS-SOLUTION; GEL MATRIX; AEROSOL OT; HYDROXYAPATITE; PRECIPITATION; NANOPARTICLES AB Novel calcium phosphate materials were synthesized from solutions containing the surfactant bis(2-ethylhexyl)sulfosuccinate sodium salt (AOT), water and oil. A range of morphologies was obtained by varying the relative concentrations of the solution components. A material with structural features resembling tooth enamel was produced from a highly viscous reaction solution. This material consisted of bundles of co-aligned filaments, 750 nm(-1) mu m in length and 250-350 nm wide. Each bundle contained 10-20 filaments, identified as hydroxyapatite crystals. Electron diffraction of the bundles resulted in an arc pattern indicative of elongated aligned crystals, and similar to that known for dental enamel. Systems such as this may be used as models to gain insight into the mechanisms involved in the biomineralization of tooth enamel. Importantly, we have provided new evidence in support of the hypothesis that hierarchical structures in nature result from cooperative interactions between organic assembly and crystal growth. Amorphous calcium phosphate nanoparticles, hollow spheres, spherical octacalcium phosphate aggregates of plates and elongated plates of calcium hydrogen phosphate dihydrate were also obtained under different sets of conditions that altered AOT assembly and solution viscosity. These latter findings illustrate further the significant influence of organic assembly on the formation of calcium phosphate materials. C1 Forsyth Inst, Dept Biomineralizat, Boston, MA 02115 USA. Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England. GlaxoSmithKline Inc, Surrey KT13 0DE, England. RP Margolis, HC (reprint author), Forsyth Inst, Dept Biomineralizat, 140 Fenway, Boston, MA 02115 USA. EM hmargolis@forsyth.org RI Mann, Stephen/D-1332-2012 OI Mann, Stephen/0000-0003-3012-8964 NR 45 TC 74 Z9 75 U1 4 U2 38 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0959-9428 J9 J MATER CHEM JI J. Mater. Chem. PY 2005 VL 15 IS 32 BP 3317 EP 3325 DI 10.1039/b503312h PG 9 WC Chemistry, Physical; Materials Science, Multidisciplinary SC Chemistry; Materials Science GA 955SE UT WOS:000231247100010 ER PT J AU Wolfberg, AJ Lee-Parritz, A Peller, AJ Lieberman, ES AF Wolfberg, AJ Lee-Parritz, A Peller, AJ Lieberman, ES TI Obstetric and neonatal outcomes associated with maternal hypothyroid disease SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE LA English DT Article DE hypothyroid disease; pregnancy; neonatal outcome; pre-eclampsia ID BUTANOL-EXTRACTABLE IODINES; COMPLICATING PREGNANCY; THYROID FUNCTION; TBPA CAPACITIES; INFANTS; WOMEN; TBG AB Objective: We sought to determine whether women with treated hypothyroid disease were more likely than women without thyroid disease to suffer adverse obstetric or neonatal outcomes or to deliver a child with a congenital anomaly. Methods: Using an institutional database, we identified women with treated hypothyroid disease ( n = 482) who delivered a baby at our institution during a 33-month period. We compared the occurrence of adverse obstetric or neonatal outcomes among these women to the occurrence among women without thyroid disease ( n = 19,487). Results: Women with treated hypothyroid disease were not at increased risk for delivering a baby with low birth-weight, fetal demise, or congenital anomaly compared to the control group. Women with treated hypothyroid disease were more likely to have chronic hypertension (2.3% vs. 1.2%, p= 0.03) and had an increased risk of pre-eclampsia (4.3% vs. 2.6%, p= 0.03) compared to women without thyroid disease. Conclusion: Women with treated hypothyroid disease are not at higher risk than the general population for adverse neonatal outcomes, but may be at increased risk for pre-eclampsia. C1 Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA USA. Boston Univ, Boston Med Ctr, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA. Harvard Univ, Dept Massachusetts Gen Hosp, Sch Med, Genet & Teratol Unit, Boston, MA USA. Harvard Univ, Sch Med, Div Clin & Epidemiol Res Med, Dept Obstet & Gynecol,Brigham Womens Hosp, Boston, MA USA. RP Wolfberg, AJ (reprint author), Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA. EM awolfberg@partners.org OI Lee-Parritz, Aviva/0000-0003-4655-7720 NR 20 TC 13 Z9 13 U1 0 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1476-7058 J9 J MATERN-FETAL NEO M JI J. Matern.-Fetal Neonatal Med. PD JAN PY 2005 VL 17 IS 1 BP 35 EP 38 DI 10.1080/14767050400028642 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 933ZU UT WOS:000229672500005 PM 15804784 ER PT J AU Lin, JP O'Donnell, CJ Levy, D Cupples, LA AF Lin, JP O'Donnell, CJ Levy, D Cupples, LA TI Evidence for a gene influencing haematocrit on chromosome 6q23-24: genomewide scan in the Framingham Heart Study SO JOURNAL OF MEDICAL GENETICS LA English DT Article ID FETAL-HEMOGLOBIN PRODUCTION; SOMATIC-CELL HYBRIDS; INTERMITTENT CLAUDICATION; CEREBRAL INFARCTION; LINKAGE ANALYSIS; BLOOD-VISCOSITY; RISK; DISEASE; LOCALIZATION; CLONING C1 NHLBI, DECA, NIH, Bethesda, MD 20892 USA. NHLBI, Framingham Heart Study, Framingham, MA 01702 USA. Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. Boston Univ, Sch Med, Div Cardiol, Boston, MA 02115 USA. Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. RP Lin, JP (reprint author), NHLBI, DECA, NIH, 6701 Rockledge Dr,Suite 8110, Bethesda, MD 20892 USA. EM linj@nhlbi.nih.gov FU NHLBI NIH HHS [N01-HC-25195] NR 38 TC 15 Z9 15 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-2593 J9 J MED GENET JI J. Med. Genet. PD JAN PY 2005 VL 42 IS 1 BP 75 EP 79 DI 10.1136/jmg.2004.021097 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 890KL UT WOS:000226510000012 PM 15635079 ER PT J AU Wall, TC Mian, MAH Ray, MN Casebeer, L Collins, BC Kiefe, CI Weissman, N Allison, JJ AF Wall, TC Mian, MAH Ray, MN Casebeer, L Collins, BC Kiefe, CI Weissman, N Allison, JJ TI Improving physician performance through Internet-based interventions: Who will participate? SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE physician recruitment; chlamydia; chlamydiosis; Internet-based interventions; continuing medical education ID CONTINUING MEDICAL-EDUCATION; PRIMARY-CARE RESEARCH; RECRUITMENT AB Background: The availability of Internet-based continuing medical education is rapidly increasing, but little is known about recruitment of physicians to these interventions. Objective: The purpose of this study was to examine predictors of physician participation in an Internet intervention designed to increase screening of young women at risk for chlamydiosis. Methods: Eligibility was based on administrative claims data, and eligible physicians received recruitment letters via fax and/or courier. Recruited offices had at least one physician who agreed to participate in the study by providing an email address. After one physician from an office was recruited, intensive recruitment of that office ceased. Email messages reminded individual physicians to participate by logging on to the Internet site. Results: Of the eligible offices, 325 (33.2%) were recruited, from which 207 physicians (52.8%) participated. Recruited versus nonrecruited offices had more eligible patients (mean number of eligible patients per office: 44.1 vs 33.6; P < .001), more eligible physicians (mean number of eligible physicians per office: 6.2 vs 4.1; P < .001), and fewer doctors of osteopathy (mean percent of eligible physicians per office who were doctors of osteopathy: 20.5% vs 26.4%; P = .02). Multivariable analysis revealed that the odds of recruiting at least one physician from an office were greater if the office had more eligible patients and more eligible physicians. More participating versus nonparticipating physicians were female (mean percent of female recruited physicians: 39.1% vs 27.0%; P = .01); fewer participating physicians were doctors of osteopathy (mean percent of recruited physicians who were doctors of osteopathy: 15.5% vs 23.9%; P = .04) or international medical graduates (mean percent of recruited physicians who were international graduates: 12.3% vs 23.8%; P = .003). Multivariable analysis revealed that the odds of a physician participating were greater if the physician was older than 55 years (OR = 2.31; 95% CI = 1.09-4.93) and was from an office with a higher Chlamydia screening rate in the upper tertile (OR = 2.26; 95% CI = 1.23-4.16). Conclusions: Physician participation in an Internet continuing medical education intervention varied significantly by physician and office characteristics. C1 Univ Alabama, Dept Pediat, Birmingham, AL USA. Univ Alabama, Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL USA. Univ Alabama, Sch Hlth Related Profess, Birmingham, AL USA. Univ Alabama, Dept Hlth Serv Adm, Birmingham, AL USA. Univ Alabama, Div Continuing Med Educ, Birmingham, AL USA. Univ Alabama, Dept Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Wall, TC (reprint author), 1616 6th Ave S,Suite 201, Birmingham, AL 35233 USA. EM twall@peds.uab.edu FU AHRQ HHS [U18 HS011124, U18 HS11124] NR 14 TC 10 Z9 10 U1 0 U2 2 PU JOURNAL MEDICAL INTERNET RESEARCH PI TORONTO PA TORONTO GENERAL HOSPITAL, R FRASER ELLIOTT BLDG, 4TH FL, R 4S435, 190 ELIZABETH ST, TORONTO, ON M5G 2C4, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PY 2005 VL 7 IS 4 BP 25 EP 34 AR e48 DI 10.2196/jmir.7.4.e48 PG 10 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 010SK UT WOS:000235218000003 PM 16236700 ER PT J AU Kitsis, RN Mann, DL AF Kitsis, RN Mann, DL TI Apoptosis and the heart: a decade of progress SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Editorial Material DE apoptosis; heart; decade of progress ID CARDIAC MYOCYTE APOPTOSIS; FAILING HUMAN HEART; TRANSGENIC MICE; IN-VIVO; INJURY; FAILURE; DEATH; OVEREXPRESSION; CARDIOMYOPATHY AB In this Focused Issue we have attempted to highlight several important areas concerning the role of apoptosis in the heart. Seven articles written by leading investigators in the field should provide a timely review of our current understanding of the role of apoptosis in the adult mammalian heart. (C) 2004 Elsevier Ltd. All rights reserved. C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. Yeshiva Univ Albert Einstein Coll Med, Ctr Canc, Bronx, NY 10461 USA. Yeshiva Univ Albert Einstein Coll Med, Cardiovasc Res Ctr, Dept Med, Bronx, NY 10461 USA. Yeshiva Univ Albert Einstein Coll Med, Cardiovasc Res Ctr, Dept Cell Biol, Bronx, NY 10461 USA. RP Mann, DL (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Winters Ctr Heart Failure Res, MS 524,6565 Fannin, Houston, TX 77030 USA. EM dmann@bcm.tmc.edu OI Mann, Douglas /0000-0002-2516-0145 NR 14 TC 30 Z9 35 U1 0 U2 2 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD JAN PY 2005 VL 38 IS 1 BP 1 EP 2 DI 10.1016/j.yjmcc.2004.11.008 PG 2 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 889DL UT WOS:000226423600001 PM 15623416 ER PT J AU Matsui, T Rosenzweig, A AF Matsui, T Rosenzweig, A TI Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE apoptosis; signal transduction; cardiomyocyte; growth factors; cardioprotection; Akt; phosphoinositide 3-kinase ID PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE; NITRIC-OXIDE SYNTHASE; PHOSPHOINOSITIDE 3-KINASE PATHWAY; PRESSURE-OVERLOAD HYPERTROPHY; FORKHEAD TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR FUNCTION; ADENOVIRAL GENE-TRANSFER; INTEGRIN-LINKED KINASE; PROMOTES CELL-GROWTH AB Effective cardioprotection in clinical settings requires not only cardiomyocyte survival but also preservation of fonction. Multiple growth factors protect the heart from ischemic and other injury. While the downstream signaling pathways of these cardioprotective factors are complex, activation of phosphoinositide 3-kinase (PI 3-kinase) and its downstream effector. the serine-threonine kinase Akt (or Protein Kinase B), is a common feature in many cases. Genetic manipulations in cardiomyocytes both in vitro and in vivo suggest that acute activation of this pathway can promote both cardiomyocyte survival and function. Here. we review PI 3-kinase and Akt signaling. with a focus on their role in cardiomyocyte growth. survival. and function. Finally, the clinical implications of these studies will be considered. (C) 2004 Elsevier Ltd. All rights reserved. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Program Cardiovasc Gene Therapy,CVRC, Boston, MA 02114 USA. RP Rosenzweig, A (reprint author), Massachusetts Gen Hosp, Program Cardiovasc Gene Therapy, 114 16th St,Room 2600, Boston, MA 02129 USA. EM arosenzweig@partners.org FU NHLBI NIH HHS [HL04250, HL-073363, HL-61557, HL-59521] NR 95 TC 148 Z9 155 U1 0 U2 4 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD JAN PY 2005 VL 38 IS 1 BP 63 EP 71 DI 10.1016/j.yjmcc.2004.11.005 PG 9 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 889DL UT WOS:000226423600007 PM 15623422 ER PT J AU Wang, L Pooler, AM Albrecht, MA Wurtman, RJ AF Wang, L Pooler, AM Albrecht, MA Wurtman, RJ TI Dietary uridine-5'-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE microdialysis; dopamine; neurite outgrowth; nucleoside; CDP-choline ID CDP-CHOLINE; IN-VIVO; BIOSYNTHESIS; MEMBRANE; URIDINE; TRANSPORT; CELLS AB Membrane phospholipids like phosphatidylcholine (PC) are required for cellular growth and repair, and specifically for synaptic function. PC synthesis is controlled by cellular levels of its precursor, cytidine-5'-diphosphate choline (CDP-choline), which is produced from cytidine triphosphate (CTP) and phosphocholine. In rat PC12 cells exogenous uridine was shown to elevate intracellular CDP-choline levels, by promoting the synthesis of uridine triphosphate (UTP), which was partly converted to CTP. In such cells uridine also enhanced the neurite outgrowth produced by nerve growth factor (NGF). The present study assessed the effect of dietary supplementation with uridine-5'-monophosphate disodium (UMP-2Na(+), an additive in infant milk formulas) on striatal dopamine (DA) release in aged rats. Male Fischer 344 rats consumed either a control diet or one fortified with 2.5% UMP for 6 wk, ad libitum. In vivo microdialysis was then used to measure spontaneous and potassium (K+)-evoked DA release in the right striatum. Potassium (K+)-evoked DA release was significantly greater among UMP-treated rats, i.e., 341 +/- 21% of basal levels vs. 283 +/- 9% of basal levels in control rats (p < 0.05); basal DA release was unchanged. In general, each animal's K+-evoked DA release correlated with its striatal DA content, measured postmortem. The levels of neurofilament-70 and neurofilament-M proteins, biomarkers of neurite outgrowth, increased to 182 +/- 25% (p < 0.05) and 221 +/- 34% (p < 0.01) of control values, respectively, with UMP consumption. Hence, UMP treatment not only enhances membrane phosphatide production but also can modulate two membrane-dependent processes, neurotransmitter release and neurite outgrowth, in vivo. C1 MIT, Dept Brain & Cognit Sci, Cambridge, MA 02142 USA. Massachusetts Gen Hosp, Dept Anesthesia, Boston, MA 02114 USA. Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02142 USA. RP Wurtman, RJ (reprint author), MIT, Dept Brain & Cognit Sci, 77 Massachusetts Ave, Cambridge, MA 02142 USA. EM dick@mit.edu RI Pooler, Amy/C-5146-2008 FU NIMH NIH HHS [2 R01 MH028783-28] NR 25 TC 31 Z9 36 U1 1 U2 6 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PY 2005 VL 27 IS 1 BP 137 EP 145 DI 10.1385/JMN:27:01:137 PG 9 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 953SU UT WOS:000231101600011 PM 16055952 ER PT J AU Oh, DS Lieu, SN Yamaguchi, DJ Tachiki, K Lambrecht, N Ohning, GV Sachs, C Germano, PM Pisegna, JR AF Oh, DS Lieu, SN Yamaguchi, DJ Tachiki, K Lambrecht, N Ohning, GV Sachs, C Germano, PM Pisegna, JR TI PACAP regulation of secretionland proliferation of pure populations of gastric ECL cells SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE ECL cells; Fluor-PACAP; FACS; PAC1 ID ENTEROCHROMAFFIN-LIKE CELLS; ACID-SECRETION; RAT AB The gastric enterochromaffin-like (ECL) cell plays a major role in the regulation of gastric acid secretion. We have previously described that Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) is present on myenteric neurons in the rat and colocalizes with its high-affinity receptor, PAC1, expressed on the surface of gastric ECL cells. The study of ECL cell physiology has been hampered by the inability to isolate and purify ECL cells to homogeneity. Density gradient elutriation alone yields only 65-70% purity of ECL cells. In the present study, we used fluorescence-activated cell sorting (FACS) with a novel fluorescent ligand, Fluor-PACAP-38, for isolating pure ECL cells. FACS was used to isolate ECL cells based on their relatively small size, low density, and ability to bind the fluorescent ligand Fluor-PACAP-38. The sorted cells were unambiguously identified as ECL cells by immunohistochemical analysis using anti-PACAP type-I (PAC1), anti-histidine decarboxylase (HDC), and anti-somatostatin antibodies. Further confocal microscopy demonstrated that Fluor-PACAP-38, a ligand with a higher affinity for PAC1, bound to extracellular receptors of these FACS-purified cells. FACS yielded an average of 2 million ECL cells/4 rat stomachs, and > 99% of the sorted cells were positive for PAC1 receptor and HDC expression. The absence of immunohistochemical staining for somatostatin indicated lack of contamination by gastric D cells, which are similar in size and shape to the ECL cells. Internalization of PACAP receptors and a rapid Ca2+ response in purified ECL cells were observed upon PACAP activation, suggesting that these cells are viable and biologically active. These ECL cells demonstrated a dose-dependent stimulation of proliferation in response to PACAP, with a maximum of 30% proliferation at a concentration of 10(-7)M. Microarray studies were performed to confirm the expression of genes specific for ECL cells. These results demonstrate that rat gastric ECL cells can be isolated to homogeneity by using a combination of density gradient centrifugation, followed by cell sorting using Fluor-PACAP. These techniques now allow microarray studies to be performed in ECL cells to characterize their functional gene expression and will facilitate pharmacological, biochemical, and molecular studies on ECL cell function. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Res & Dev, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, CURE, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, VA Digest Dis Res Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, VA Digest Dis Res Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, VA Digest Dis Res Ctr, Dept Physiol, Los Angeles, CA 90073 USA. RP Pisegna, JR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu NR 8 TC 10 Z9 11 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PY 2005 VL 26 IS 1 BP 85 EP 97 DI 10.1385/JMN26:03:85 PG 13 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 944FT UT WOS:000230412700008 PM 15968088 ER PT J AU Luttrell, LM AF Luttrell, LM TI Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article; Proceedings Paper CT 2nd Wenner-Gren International Symposium CY SEP 08-11, 2004 CL Stockholm, SWEDEN SP Wenner-Gren Fdn DE G protein-coupled receptor; focal adhesion; epidermal growth factor; arrestin; mitogen-activated protein kinase; extracellular signal-regulated kinase ID EPIDERMAL-GROWTH-FACTOR; NUCLEAR EXPORT SIGNAL; SMOOTH-MUSCLE-CELLS; BETA-ARRESTIN; ANGIOTENSIN-II; EGF RECEPTOR; ERK ACTIVATION; BETA(2)-ADRENERGIC RECEPTOR; REGULATED KINASES; CLATHRIN ADAPTER AB Seven membrane-spanning G protein-coupled receptors (GPCRs) function as ligand-activated guanine nucleotide exchange factors for heterotrimeric guanine nucleotide-binding (G) proteins that relay extracellular stimuli by activating intracellular effector enzymes or ion channels. Recent work, however, has shown that GPCRs also participate in numerous other protein-protein interactions that generate intracellular signals in conjunction with, or even independent of, G-protein activation. Nowhere has the importance of protein complex assembly in GPCR signaling been demonstrated more clearly than in the control of the spatial and temporal activity of the extracellular signal-regulated kinase (ERK1/2) mitogen-activated protein (MAP) kinase cascade. ERK1/2 activation by GPCRs often involves cross talk with classical receptor tyrosine kinases or focal adhesion complexes, which scaffold the assembly of a Ras activation complex. Even more surprising is the phenomenon of G protein-independent signaling using beta-arrestins, proteins originally characterized for their role in homologous GPCR desensitization, as scaffolds for the assembly of a multiprotein signalsome directly upon the GPCR. Although both forms of signaling lead to MAP kinase activation, the pathways appear to be functionally, as well as mechanistically, distinct. Transactivated receptor tyrosine kinases mediate rapid and transient MAP kinase activation that favors nuclear translocation of the kinases and transcriptional activation. In contrast, beta-arrestin-dependent signaling produces a slower and more sustained increase in MAP kinase activity that is often restricted to the cytosol. Together, these highly organized signaling complexes dictate the location, duration, and ultimate function of GPCR-stimulated MAP kinase activity. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. EM luttrell@musc.edu FU NIDDK NIH HHS [DK 55524, DK 64353] NR 56 TC 78 Z9 82 U1 0 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PY 2005 VL 26 IS 2-3 SI SI BP 253 EP 263 DI 10.1385/JMN/06:02:253 PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 944FU UT WOS:000230412800017 PM 16012199 ER PT J AU Xie, ZC Romano, DM Tanzi, RE AF Xie, ZC Romano, DM Tanzi, RE TI Effects of RNAi-mediated silencing of PEN-2, APH-1a, and nicastrin on wild-type vs FAD mutant forms of presenilin 1 SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE Alzheimer's disease; gamma-secretase; presenilin 1; PEN-2; mutation; RNA interference ID GAMMA-SECRETASE COMPLEX; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; BETA-APP; NOTCH; STABILIZATION; ACCUMULATION; EXPRESSION; CASPASE-3; INTERACTS AB The γ-secretase complex consists of PS1/PS2, nicastrin, APH-1a, and PEN-2. PSI undergoes endoproteolytic processing to yield two fragments: PS1-NTF and PS1-CTF. Changes in PEN-2 levels have been shown previouslv to affect the endoproteolytic processing of wild-type (wt)-PS1. However, the effects of PEN-2 on the proteolytic processing of familial Alzheimer's disease (FAD) mutant forms of PSI have not yet been reported. To determine whether PEN-2 affects the proteolytic processing of mutant PSI in the same manner as that of wt-PS1, we established RNA interference (RNAi) for PEN-2 in H4 human neuroglioma cells stably transfected to express wt or FAD mutant forms of PSI including L286V, A246E, and that lacking exon 9 (&UDelta; 9). As expected, in H4 cells expressing wt-PS1, RNAi for PEN-2 increased levels of PS1-FL and attenuated PSI endoproteolysis. Likewise, in cells expressing PS1 with the FAD missense mutations, L286V and A246E, RNAi for PEN-2 increased PS1-FL and reduced PSI endoproteolysis. However, in H4 cells stably transfected to express the FAD-linked &UDelta; 9 mutation (PSI lacking exon 9), RNAi for PEN-2 did not increase but, instead, decreased PS1-FL. In contrast, RNAi for nicastrin and APH-1a decreased PS1-FL in H4 cells expressing either wt-PS1 or &UDelta; 9-PS1. In summary, the metabolism of wt-PS1 and FAD-linked &UDelta; 9-PS1 is specifically and differentially affected by loss of function of PEN-2. C1 Mass Gen Inst Neurodegenerat Dis, Genet & Aging Res Unit, Dept Neurol, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Tanzi, RE (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Genet & Aging Res Unit, 114 16th St C3009, Charlestown, MA 02129 USA. EM tanzi@helix.ragh.harvard.edu FU NIA NIH HHS [P50 AG05134, K12 AG00294-17, AG 014713-07]; NIGMS NIH HHS [T32 GM07592]; NIMH NIH HHS [MH 60009-03] NR 31 TC 19 Z9 20 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PY 2005 VL 25 IS 1 BP 67 EP 77 DI 10.1385/JMN:25:1:067 PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 924TV UT WOS:000229004200008 PM 15781968 ER PT J AU McNamara, P Benson, E McGeeney, B Brown, A Albert, ML AF McNamara, P Benson, E McGeeney, B Brown, A Albert, ML TI Modes of remembering in patients with chronic pain - Relation to current pain SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE chronic pain; memory; frontal lobes; observer memories; field memories ID POSITRON-EMISSION-TOMOGRAPHY; NEUROPATHIC PAIN; EPISODIC MEMORY; HANDEDNESS; FLUENCY; ACTIVATION; DISORDERS; INVENTORY; RESPONSES; POINT AB The objective of our study was to assess the relation of current pain ratings to observer versus field modes of memory retrieval in patients with chronic pain. Memories from an observer perspective involve seeing oneself in the original event as if from an external point of view; memories from a field perspective involve recalling the event as if viewing it through one's own eyes. Sixty-one patients with chronic pain were asked to (1) recall a painful memory, (2) indicate whether they saw themselves in the memory (observer mode) or re- experienced events of the memory from the first-person perspective (field mode), and (3) rate various phenomenologic properties of the memory. Twenty of these pain patients were also given two frontal lobe tests to examine potential neuropsychologic correlates of memory retrieval preferences. Memory retrieval in the field mode was associated with (a) significantly higher self-reported pain scores on the McGill Pain Questionnaire, (b) nonright-handedness, and (c) poorer performance on the tests of frontal function. Patients with chronic pain who adopt the field mode of memory retrieval when recalling painful memories experience greater current pain severity than chronic pain patients who adopt observer retrieval strategies. Those adopting field retrieval strategies may also evidence frontal system neuropsychologic anomalies. C1 Boston Univ, Dept Neurol 127, VA New England Healthcare Syst, Sch Med, Boston, MA 02130 USA. Boston Univ, Sch Med, Pain Management Grp, Dept Neurol, Boston, MA 02215 USA. Boston Univ, Sch Med, Harold Goodglass Aphasia Res Ctr, VA Boston Healthcare Syst, Boston, MA 02215 USA. RP McNamara, P (reprint author), Boston Univ, Dept Neurol 127, VA New England Healthcare Syst, Sch Med, 150 S Huntington Ave, Boston, MA 02130 USA. NR 39 TC 11 Z9 12 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD JAN PY 2005 VL 193 IS 1 BP 53 EP 57 DI 10.1097/01.nmd.00001492.04841.f5 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 887FU UT WOS:000226291800008 PM 15674135 ER PT J AU Sauvageot, C Dahia, PL Lipan, O Park, JK Chang, MS Alberta, JA Stiles, CD AF Sauvageot, C Dahia, PL Lipan, O Park, JK Chang, MS Alberta, JA Stiles, CD TI Distinct temporal genetic signatures of neurogenic and gliogenic cues in cortical stem cell cultures SO JOURNAL OF NEUROBIOLOGY LA English DT Article DE cortical stem cells; differentiation; expression analysis; growth factors ID RAT CEREBRAL-CORTEX; CILIARY NEUROTROPHIC FACTOR; CENTRAL-NERVOUS-SYSTEM; PRECURSOR CELL; GROWTH-FACTOR; RIBONUCLEIC-ACID; PROGENITOR CELLS; MAMMALIAN-CELLS; MAPPING DATA; DIFFERENTIATION AB Cortical progenitor cells from rat embryos give rise to neurons or glia following exposure to platelet derived growth factor (PDGF) or ciliary neurotrophic factor (CNTF), respectively. Both growth factors impart their developmental cues quickly through a transcription-dependent mechanism. Do the alternate developmental responses to PDGF and CNTF reflect induction of qualitatively distinct genes? Alternatively, do the same genes respond to each growth factor, but with quantitatively distinct kinetics? Using differential library screening and custom cDNA microarrays we show that a common set of genes responds to either growth factor. However, quantitative differences in the onset and duration of gene induction equate to the expression of factor-specific gene signatures. Multitissue cluster analysis also reveals tissue-specific gene signatures that may play important roles in the developing brain. (C) 2004 Wiley Periodicals, Inc. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Div Neurosci, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Computat Biol Lab, Boston, MA 02115 USA. RP Alberta, JA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA. EM John_Alberta@dfci.harvard.edu; Charles_Stiles@dfci.harvard.edu FU NHGRI NIH HHS [R01 HG02341]; NICHD NIH HHS [P01 HD24926-12] NR 33 TC 5 Z9 5 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0022-3034 J9 J NEUROBIOL JI J. Neurobiol. PD JAN PY 2005 VL 62 IS 1 BP 121 EP 133 DI 10.1002/neu.20072 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 879WC UT WOS:000225748800011 PM 15389679 ER PT J AU Ayasolla, KR Giri, S Singh, AK Singh, I AF Ayasolla, Kamesh R. Giri, Shailendra Singh, Avtar K. Singh, Inderjit TI 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and A beta peptide-induced inflammatory mediators in astroglia SO JOURNAL OF NEUROINFLAMMATION LA English DT Article AB Background: Alzheimer's disease (AD) pathology shows characteristic 'plaques' rich in amyloid beta (A beta) peptide deposits. Inflammatory process-related proteins such as pro-inflammatory cytokines have been detected in AD brain suggesting that an inflammatory immune reaction also plays a role in the pathogenesis of AD. Glial cells in culture respond to LPS and A beta stimuli by upregulating the expression of cytokines TNF-alpha, IL-1 beta, and IL-6, and also the expression of proinflammatory genes iNOS and COX-2. We have earlier reported that LPS/A beta stimulation-induced ceramide and ROS generation leads to iNOS expression and nitric oxide production in glial cells. The present study was undertaken to investigate the neuroprotective function of AICAR (a potent activator of AMP-activated protein kinase) in blocking the pro-oxidant/proinflammatory responses induced in primary glial cultures treated with LPS and A beta peptide. Methods: To test the anti-inflammatory/anti-oxidant functions of AICAR, we tested its inhibitory potential in blocking the expression of pro-inflammatory cytokines and iNOS, expression of COX-2, generation of ROS, and associated signaling following treatment of glial cells with LPS and A beta peptide. We also investigated the neuroprotective effects of AICAR against the effects of cytokines and inflammatory mediators (released by the glia), in blocking neurite outgrowth inhibition, and in nerve growth factor-(NGF) induced neurite extension by PC-12 cells. Results: AICAR blocked LPS/A beta-induced inflammatory processes by blocking the expression of proinflammatory cytokine, iNOS, COX-2 and MnSOD genes, and by inhibition of ROS generation and depletion of glutathione in astroglial cells. AICAR also inhibited down-stream signaling leading to the regulation of transcriptional factors such as NF kappa B and C/EBP which are critical for the expression of iNOS, COX-2, MnSOD and cytokines (TNF-alpha/IL-1 beta and IL-6). AICAR promoted NGF-induced neurite growth and reduced neurite outgrowth inhibition in PC-12 cells treated with astroglial conditioned medium. Conclusion: The observed anti-inflammatory/anti-oxidant and neuroprotective functions of AICAR suggest it as a viable candidate for use in treatment of Alzheimer's disease. C1 [Ayasolla, Kamesh R.; Giri, Shailendra; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Ayasolla, Kamesh R.] Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. [Ayasolla, Kamesh R.] Med Univ S Carolina, Dept Obstet & Gynaecol, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM ayasolkr@musc.edu; giris@musc.edu; Avtar.Singh@med.va.gov; singhi@musc.edu OI Ayasolla, kameshwar/0000-0002-4265-2168 FU National Institutes of Health [NS-22576, NS-34741, NS-40144, NS-40810, NS-37766] FX The authors wish to thank Dr. Shailendra Giri for his immense help during various stages of experimentation and in the process of preparation of the manuscript. We also thank Ramandeep Rattan for laboratory assistance, Dr. Manu Jatana for his assistance with microscopy and Ms. Joyce Bryan for secretarial help. This work was supported in parts by grants (NS-22576, NS-34741, NS-40144, NS-40810 and NS-37766) from National Institutes of Health. NR 67 TC 18 Z9 18 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PY 2005 VL 2 AR 21 DI 10.1186/1742-2094-2-21 PG 21 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA V29PC UT WOS:000208759300021 PM 16174294 ER PT J AU Harms, MP Guinan, JJ Sigalovsky, IS Melcher, JR AF Harms, MP Guinan, JJ Sigalovsky, IS Melcher, JR TI Short-term sound temporal envelope characteristics determine multisecond time patterns of activity in human auditory cortex as shown by fMRI SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID ACTIVITY-DEPENDENT INCREASES; RAT SOMATOSENSORY CORTEX; CEREBRAL-BLOOD-FLOW; SYNAPTIC ACTIVITY; NEURONAL-ACTIVITY; ACOUSTIC NOISE; HUMAN BRAIN; TELL US; ACTIVATION; FREQUENCY AB Functional magnetic resonance imaging (fMRI) of human auditory cortex has demonstrated a striking range of temporal waveshapes in responses to sound. Prolonged (30 s) low-rate (2/s) noise burst trains elicit "sustained" responses, whereas high-rate (35/s) trains elicit "phasic" responses with peaks just after train onset and offset. As a step toward understanding the significance of these responses for auditory processing, the present fMRI study sought to resolve exactly which features of sound determine cortical response waveshape. The results indicate that sound temporal envelope characteristics, but not sound level or bandwidth, strongly influence response waveshapes, and thus the underlying time patterns of neural activity. The results show that sensitivity to sound temporal envelope holds in both primary and nonprimary cortical areas, but nonprimary areas show more pronounced phasic responses for some types of stimuli (higher-rate trains, continuous noise), indicating more prominent neural activity at sound onset and offset. It has been hypothesized that the neural activity underlying the onset and offset peaks reflects the beginning and end of auditory perceptual events. The present data support this idea because sound temporal envelope, the sound characteristic that most strongly influences whether fMRI responses are phasic, also strongly influences whether successive stimuli (e.g., the bursts of a train) are perceptually grouped into a single auditory event. Thus fMRI waveshape may provide a window onto neural activity patterns that reflect the segmentation of our auditory environment into distinct, meaningful events. C1 Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. Harvard MIT Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol Program, Cambridge, MA USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA USA. RP Harms, MP (reprint author), Pfizer Inc, 700 Chesterfield Pkwy W, Chesterfield, MO 63017 USA. EM mharms@alam.mit.edu OI Harms, Michael/0000-0001-7945-036X FU NIDCD NIH HHS [P01 DC000119-260023, T32DC-00038, P01DC-00119] NR 47 TC 40 Z9 40 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD JAN PY 2005 VL 93 IS 1 BP 210 EP 222 DI 10.1152/jn.00712.2004 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 880GV UT WOS:000225777900021 PM 15306629 ER PT J AU Leger, JF Stern, EA Aertsen, A Heck, D AF Leger, JF Stern, EA Aertsen, A Heck, D TI Synaptic integration in rat frontal cortex shaped by network activity SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID NEURONS IN-VIVO; NEOCORTICAL PYRAMIDAL NEURONS; CAT VISUAL-CORTEX; MEMBRANE-POTENTIAL FLUCTUATIONS; CORTICAL-NEURONS; DENDRITIC INTEGRATION; COINCIDENCE DETECTOR; BACKGROUND ACTIVITY; SUMMATION; CELLS AB Neocortical neurons in vivo are embedded in networks with intensive ongoing activity. How this network activity affects the neurons' integrative properties and what function this may imply at the network level remain largely unknown. Most of our knowledge regarding synaptic communication and integration is based on recordings in vitro, where network activity is strongly diminished or even absent. Here, we present results from two complementary series of experiments based on intracellular in vivo recordings in anesthetized rat frontal cortex. Specifically, we measured 1) the relationship between the excursions of a neuron's membrane potential and the spiking activity in the surrounding network and 2) how the summation of several inputs to a single neuron changes with the different levels of its membrane potential excursions and the associated states of network activity. The combination of these measurements enables us to assess how the level of network activity influences synaptic integration. We present direct evidence that integration of synaptic inputs in frontal cortex is linear, independent of the level of network activity. However, during periods of high network activity, the neurons' response to synaptic input is markedly reduced in both amplitude and duration. This results in a drastic shortening of its window for temporal integration, requiring more precise coordination of presynaptic spike discharges to reliably drive the neuron to spike under conditions of high network activity. We conclude that ongoing activity, as present in the active brain, emphasizes the need for neuronal cooperation at the network level, and cannot be ignored in the exploration of cortical function. C1 Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA. Univ Freiburg, Dept Biol 3, Freiburg, Germany. Ecole Normale Super, CNRS, Unite Mixte Rech 8544, Neurobiol Cellulaire & Mol Lab, Paris, France. Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. RP Heck, D (reprint author), Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, 855 Monroe Ave,Room 405, Memphis, TN 38163 USA. EM dheck@utmem.edu NR 47 TC 76 Z9 77 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD JAN PY 2005 VL 93 IS 1 BP 281 EP 293 DI 10.1152/jm.00067.2003 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 880GV UT WOS:000225777900026 PM 15306631 ER PT J AU Taberner, AM Liberman, MC AF Taberner, AM Liberman, MC TI Response properties of single auditory nerve fibers in the mouse SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID VENTRAL COCHLEAR NUCLEUS; PRODUCT OTOACOUSTIC EMISSIONS; SPONTANEOUS DISCHARGE RATE; PROGRESSIVE HEARING-LOSS; INNER HAIR-CELLS; AGE-RELATED LOSS; GUINEA-PIG; CHARACTERISTIC FREQUENCY; INFERIOR COLLICULUS; CENTRAL PROJECTIONS AB The availability of transgenic and mutant lines makes the mouse a valuable model for study of the inner ear, and a powerful window into cochlear function can be obtained by recordings from single auditory nerve ( AN) fibers. This study provides the first systematic description of spontaneous and sound-evoked discharge properties of AN fibers in mouse, specifically in CBA/CaJ and C57BL/6 strains, both commonly used in auditory research. Response properties of 196 AN fibers from CBA/CaJ and 58 from C57BL/6 were analyzed, including spontaneous rates (SR), tuning curves, rate versus level functions, dynamic range, response adaptation, phase-locking, and the relation between SR and these response properties. The only significant interstrain difference was the elevation of high-frequency thresholds in C57BL/6. In general, mouse AN fibers showed similar responses to other mammals: sharpness of tuning increased with characteristic frequency, which ranged from 2.5 to 70 kHz; SRs ranged from 0 to 120 sp/s, and fibers with low SR (<1 sp/s) had higher thresholds, and wider dynamic ranges than fibers with high SR. Dynamic ranges for mouse high-SR fibers were smaller (<20 dB) than those seen in other mammals. Phase-locking was seen for tone frequencies <4 kHz. Maximum synchronization indices were lower than those in cat but similar to those found in guinea pig. C1 Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. Harvard Univ, MIT, Div Hlth Sci & Technol, Program Speech & Hearing Biosci & Technol, Cambridge, MA 02139 USA. RP Liberman, MC (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. EM mcl@epl.meei.harvard.edu FU NIDCD NIH HHS [R01 DC-00188, T32 DC-0038, P30 DC005209] NR 60 TC 195 Z9 200 U1 2 U2 9 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD JAN PY 2005 VL 93 IS 1 BP 557 EP 569 DI 10.1152/jn.00574.2004 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 880GV UT WOS:000225777900047 PM 15456804 ER PT J AU Wuthrich, C Kesari, S Kim, WK Williams, K Gelman, R Elmeric, D De Girolami, U Joseph, JT Hedley-Whyte, T Koralnik, IJ AF Wuethrich, Christian Kesari, Santosh Kim, Woong-Ki Williams, Kenneth Gelman, Rebecca Elmeric, Derek De Girolami, Umberto Joseph, Jeffrey T. Hedley-Whyte, Tessa Koralnik, Igor J. TI Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: Co-localization of CD8+ T cells with JCV-infected glial cells SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract C1 [Wuethrich, Christian; Kim, Woong-Ki; Williams, Kenneth; Koralnik, Igor J.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02115 USA. [Kesari, Santosh; De Girolami, Umberto] Harvard Univ, Sch Med, Children Hosp, Boston, MA USA. [Kesari, Santosh; De Girolami, Umberto] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA. [Kesari, Santosh; Gelman, Rebecca; Elmeric, Derek] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Kesari, Santosh; Gelman, Rebecca; Elmeric, Derek] Harvard Univ, Sch Med, Harvard Sch Publ Hlth, Boston, MA 02115 USA. [Joseph, Jeffrey T.; Koralnik, Igor J.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA. [Hedley-Whyte, Tessa] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Wuthrich, C (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02115 USA. RI Kesari, Santosh/E-8461-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2005 VL 14 SU 2 BP 21 EP 21 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA V80CU UT WOS:000205415200007 ER PT J AU Lima, MA Tompkins, T Jean-Jacques, J Kavanagh, DG Gandhi, RT Bhardwaj, N Koralnik, IJ AF Lima, Marco A. Tompkins, Troy Jean-Jacques, Jims Kavanagh, Daniel G. Gandhi, Rajesh T. Bhardwaj, Nina Koralnik, Igor J. TI Ex-vivo expansion of JCV specific cytotoxic T lymphocytes using autologous dendritic cells SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract C1 [Lima, Marco A.; Koralnik, Igor J.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. [Kavanagh, Daniel G.; Gandhi, Rajesh T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Partners AIDS Res Ctr, Cambridge, MA 02138 USA. [Lima, Marco A.; Tompkins, Troy; Jean-Jacques, Jims; Koralnik, Igor J.] Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA USA. [Lima, Marco A.] Univ Fed Rio de Janeiro, Sch Med, BR-21941 Rio De Janeiro, Brazil. [Bhardwaj, Nina] NYU, Sch Med, Canc Inst Tumor Vaccine Ctr, New York, NY 10003 USA. RP Lima, MA (reprint author), Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2005 VL 14 SU 2 BP 102 EP 103 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA V80CU UT WOS:000205415200079 ER PT J AU Liu, YC Woodin, MA Hauser, R Williams, PL Herrick, RF Christiani, DC Smith, TJ AF Liu, YC Woodin, MA Hauser, R Williams, PL Herrick, RF Christiani, DC Smith, TJ TI Estimation of personal exposures to particulate matter and metals in boiler overhaul work SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID FUEL-OIL ASH; VANADIUM COMPOUNDS; LUNG-FUNCTION; INDUSTRY; BENZENE; HEALTH AB Objective: We sought to develop an algorithm and estimate unmeasured exposures to particulate matter (PM) and metals in an epidemiologic study of boilermakers. Methods: The algorithm was based on limited measurements and workers' task and time activity Patterns. Half of the measurements were used to develop exposure estimates for unmeasured person days. The other half was used for method validation. Results: The validation demonstrated good approximations of actual exposures with differences less than 5% for PM and vanadium (V). Average estimated exposures to PM (mg/m(3)) and V (mug/m(3)) were significantly higher for workers doing boiler repair than utility work (0.36 vs. 0.09 for PM and 5.99 vs. 0.38 for V). Conclusions: This algorithm provided reasonably accurate exposure indices for our epidemiologic study in this population. It also is likely applicable to similar exposure scenarios in other studies. C1 Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Pulm & Crit Care Unit, Boston, MA USA. Tufts Univ, Sch Engn, Medford, MA 02155 USA. RP Liu, YC (reprint author), Yale Univ, Occupat & Environm Med Program, Sch Med, 135 Coll St, New Haven, CT 06510 USA. EM youcheng.liu@yale.edu FU NIEHS NIH HHS [ES07069, ES 00002, ES05947, ES09860]; ODCDC CDC HHS [CCU109979] NR 32 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD JAN PY 2005 VL 47 IS 1 BP 68 EP 78 DI 10.1097/01.jom.0000147212.93183.7e PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 887WV UT WOS:000226337100011 PM 15643161 ER PT J AU Sedagbatfar, M August, MA Dodson, TB AF Sedagbatfar, M August, MA Dodson, TB TI Panoramic radiographic findings as predictors of inferior alveolar nerve exposure following third molar extraction SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID SURGERY; DYSESTHESIA; REMOVAL; COMPLICATIONS; INJURY AB Objectives: The aim of this study was to estimate the sensitivity and specificity of panoramic radiographic findings in relation to inferior alveolar nerve (IAN) exposure after mandibular third molar M) extraction. Methods: The study used a retrospective cohort model. The primary predictor variable was the presence or absence of greater than or equal to 1 panoramic radiographic sign associated with an increased risk for IAN injury. The secondary predictor variable was the surgeon's assessment of IAN exposure risk. The outcome variable was IAN exposure, defined as direct visualization of the IAN at the time of M3 extraction. Appropriate univariate and bivariate statistics were computed and the level of statistical significance was set at P less than or equal to .05. Results: The sample was composed of 230 patients having 423 mandibular M3s evaluated and removed. Following M3 extraction, the IAN was visualized in 24 (5.7%) extraction sites. Four of the radiographic signs were statistically associated with IAN exposure (P less than or equal to .05). The sensitivities and specificities of the 4 radiographic findings ranged from 0.42 to 0.75 and 0.66 to 0.91. The clinician's preoperative estimate of the likelihood of IAN exposure was statistically associated with IAN exposure after M3 extraction (P <.001; sensitivity = 0.79; specificity = 0.86). Conclusion: Four radiographic findings (darkening of the tooth root, narrowing of the tooth root, interruption of the white lines, and diversion of the canal) were statistically associated with IAN exposure following M3 extraction. The surgeon's overall estimate of risk based on the panoramic radiograph was also statistically associated with an increased risk of IAN exposure. (C) 2005 American Association of Oral and Maxillofacial Surgeons. C1 Harvard Univ, Sch Dent Med, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. NYU, Dept Periodontol, Periodontol Training Program, New York, NY USA. RP Dodson, TB (reprint author), Harvard Univ, Sch Dent Med, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, 55 Fruit St,Warren 1201, Boston, MA 02114 USA. EM tbdodson@partners.org FU NIDCR NIH HHS [K24 DE 00448] NR 16 TC 67 Z9 69 U1 0 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD JAN PY 2005 VL 63 IS 1 BP 3 EP 7 DI 10.1016/j.jams.2004.05.217 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 889DT UT WOS:000226424400002 PM 15635549 ER PT J AU Behnam, K Phillips, ML Sliva, JDP Brochmann, EJ Duarte, MEL Murray, SS AF Behnam, K Phillips, ML Sliva, JDP Brochmann, EJ Duarte, MEL Murray, SS TI BMP binding peptide: a BMP-2 enhancing factor deduced from the sequence of native bovine bone morphogenetic protein/non-collagenous protein SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article AB Forty years ago, Marshall Urist described a partially purified extract of dermineralized bone matrix which induced the formation of ectopic bone. This substance, bone rnorphogenetic protein/non-collagenous protein (BMP\NCP), was never purified to homogeneity but other investigators used similar starting materials to clone a number of recombinant B-MPs. Urist recognized that his material probably contained the BMPs which had been cloned by others but always contended that it contained another, more potent, bone inducing material which differed significantly in its physical and chemical properties from the known BMPs. We have used Urist's protocol to isolate a protein that has the chemical and physical properties of Urist's "BMP". It is an 18.5 kD fragment of the bone matrix protein, SPP-24. This fragment contains the cystatin-like domain of SPP-24. We have located a 19 amino acid region which is similar to the TGF-beta/BMP-binding region of fetuin. a member of the cystatin family of protease inhibitors. A cyclic peptide, which we call BMP binding peptide (BBP) was generated rising this sequence. The peptide avidly bound rhBMP-2 with a K-D of 3 x 10(-5) M. When implanted alone in mouse muscle, the peptide frequently induced dystrophic calcification. When implanted with rhBMP-2. the peptide enhanced the osteogenic activity of the recombinant molecule. We hypothesize that Urist's "BMP" was a fragment of SPP-24 which influenced bone induction by binding to bone morphogenetic proteins. BBP may be clinically useful because of its effects on other bone-inducing Substances. Published by Elsevier Ltd. on behalf of Orthopaedic Research society. C1 Greater Los Angeles VA Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Sepulveda Ambulatory Care Ctr & Nursing Home, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, DOE Biochem, Dept Chem & Biochem, Instrumentat Facil, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Fed Rio de Janeiro, Dept Histol & Embryol, BR-21941590 Rio De Janeiro, Brazil. RP Murray, SS (reprint author), Greater Los Angeles VA Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Sepulveda Ambulatory Care Ctr & Nursing Home, 16111 Plummer St, Sepulveda, CA 91343 USA. EM murrayes@ulca.edu NR 8 TC 36 Z9 38 U1 1 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD JAN PY 2005 VL 23 IS 1 BP 175 EP 180 DI 10.1016/j.orthres.2004.05.001 PG 6 WC Orthopedics SC Orthopedics GA 888BJ UT WOS:000226348900023 PM 15607890 ER PT J AU Kong, J Fufa, DT Gerber, AJ Rosman, AS Vangel, MG Gracely, RH Gollub, RL AF Kong, J Fufa, DT Gerber, AJ Rosman, AS Vangel, MG Gracely, RH Gollub, RL TI Psychophysical outcomes from a randomized pilot study of manual, electro, and sham acupuncture treatment on experimentally induced thermal pain SO JOURNAL OF PAIN LA English DT Article DE acupuncture; acupuncture analgesia; acupuncture mode; deqi sensation; pain ID LOW-BACK-PAIN; CHRONIC NECK PAIN; PLACEBO NEEDLE; HEALTHY-SUBJECTS; CONTROLLED TRIAL; FOLLOW-UP; STIMULATION; MANAGEMENT; ELECTROACUPUNCTURE; SENSATION AB In this pilot study comparing the analgesic effects of three acupuncture modes-manual, electro, and placebo (with Streitberger placebo needles)-in a cohort of healthy subjects, we found that verum acupuncture treatment, but not placebo, lowered pain ratings in response to calibrated noxious thermal stimuli. This finding was mainly the result of highly significant analgesia in 5 of the 11 subjects who completed the 5-session study. Of the 5 responders, 2 responded only to electroacupuncture and 3 only to manual acupuncture, suggesting that acupuncture's analgesic effects on experimental pain may be dependent on both subject and mode. We developed a simple quantitative assessment tool, the Subjective Acupuncture. Sensation Scale (SASS), comprised of 9 descriptors and an anxiety measure to study the relationship between the deqi sensation induced by acupuncture and the putative therapeutic effects of acupuncture. The SASS results confirm that the deqi sensation is complex, with all subjects rating multiple descriptors during each mode. We found significant correlations of analgesia with SASS ratings of numbness and soreness, but not with ratings of stabbing, throbbing, tingling, burning, heaviness, fullness, or aching. This suggests that attributes of the deqi sensation may be useful clinical indicators of effective treatment. Perspective: The results of this study indicate the existence of both individual subject and acupuncture mode variability in the analgesic effects of acupuncture. This suggests that switching acupuncture mode may be a treatment option for unresponsive patients. (C) 2005 by the American Pain Society. C1 Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. Harvard Univ, Sch Med, Boston, MA 02138 USA. New York Presbyterian Hosp, Dept Psychiat, New York, NY USA. MGH MIT HMS, Charlestown, MA USA. MGH MIT GCRC Biomed Imaging Core, Charlestown, MA USA. Univ Michigan Hlth Syst, Chron Pain & Fatigue Res Ctr, Ann Arbor, MI USA. RP Kong, J (reprint author), 149 13th St,Room 2661, Charlestown, MA 02129 USA. EM kongj@nmr.mgh.harvard.edu RI Gerber, Andrew/B-1310-2008; OI Gollub, Randy L./0000-0002-9434-4044 FU NCCIH NIH HHS [R21 AT00949] NR 41 TC 94 Z9 107 U1 3 U2 9 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD JAN PY 2005 VL 6 IS 1 BP 55 EP 64 DI 10.1016/j.pain.2004.10.005 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 889SF UT WOS:000226462100009 PM 15629419 ER PT J AU Genton, L Kudsk, KA Reese, SR Ikeda, S AF Genton, L Kudsk, KA Reese, SR Ikeda, S TI Enteral feeding preserves gut Th-2 cytokines despite mucosal cellular adhesion molecule-1 blockade SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article ID LYMPHOID-TISSUE; EXPRESSION; MICE; NUTRITION; ADDRESSIN; MADCAM-1; IL-10; CELLS; LYMPHOCYTES AB Background: Parenteral nutrition (PN) decreases gut-associated lymphoid tissue (GALT), the intestinal IgA stimulating cytokines IL-4 and IL-10 in gut homogenates, intestinal IgA levels and the expression of Peyer patch (PP) mucosal cellular adhesion molecule-1 (MAdCAM-1), an adhesion molecule found on the high endothelial venules of PP and other tissues. IL-4 in PP stimulates MAdCAM expression in vitro. MAdCAM-1 blockade with MECA-367 reduces GALT cell populations to PN levels but maintains intestinal IgA levels if the animals are chow fed. This study compares IL-4 levels in PP of chow and PN fed mice and measures the effects of MAdCAM blockade on IL-4 and IL-10 levels in gut homogenates of chow fed mice. We hypothesized that in vivo IL-4 levels drop in PP of PN fed mice and IL-4 and IL-10 levels are maintained after MAdCAM-1 blockade in chow fed mice. Methods: Exp 1: 18 mice received chow or PN for 5 days to determine PP IL-4 levels. Exp 2: 44 mice were randomized to chow + control monoclonal antibody (mAb), chow + MECA-367 (anti-MAdCAM-1 mAb) or FIN for 4 days before measurement of IL-4 and IL-10 levels in gut homogenates. Results: Exp 1: IL-4 levels in vivo were lower in PP of PN-fed mice than chow fed mice (92.0 +/- 15.1 pg/mL vs 251.1 +/- 14.8, p = .0003). Exp 2: IL-4 levels were significantly higher in chow + control mAb (187.1 +/- 44.1 pg/mL) and chow + MECA-367 (110.9 +/- 19.1 pg/mL) groups than PN mice (21.8 +/- 30.6 pg/mL, p < .02 vs chow + control or chow + MECA-367). IL-10 levels were significantly lower with PN (23.1 +/- 40.9 pg/mL) with chow+control (174.0 +/- 22.2 pg/mL p < .01), or chow + MECA-367 (181.7 +/- 23.1 pg/mL, p < .02 vs PN). Conclusions: PN-feeding reduces in vivo IL-4 levels in PP (consistent with lowered MAdCAM-1 expression) and IL-4 and IL-10 levels in gut homogenates compared with chow. Despite MAdCAM-1 blockade, enteral feeding preserved gut IL-4 levels and increased IL-10 levels consistent with preserved IgA levels. C1 Univ Wisconsin, Sch Med, Dept Surg, Clin Sci Ctr H4 730, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Sch Med, Dept Surg, Clin Sci Ctr H4 730, 600 Highland Ave, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU NIGMS NIH HHS [R01 GM53439-06A1] NR 20 TC 9 Z9 9 U1 0 U2 1 PU AMER SOC PARENTERAL & ENTERAL NUTRITION PI SILVER SPRING PA 8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910 USA SN 0148-6071 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD JAN-FEB PY 2005 VL 29 IS 1 BP 44 EP 47 DI 10.1177/014860710502900144 PG 4 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 887MN UT WOS:000226310300007 PM 15715273 ER PT J AU Patenaude, AF Kupst, MJ AF Patenaude, AF Kupst, MJ TI Psychosocial functioning in pediatric cancer SO JOURNAL OF PEDIATRIC PSYCHOLOGY LA English DT Article; Proceedings Paper CT Pediatric Psycho-Oncology Research Summit CY OCT, 2001 CL San Antonio, TX SP Childhood Canc Grp, NCI ID QUALITY-OF-LIFE; ACUTE LYMPHOBLASTIC-LEUKEMIA; YOUNG-ADULT SURVIVORS; LONG-TERM SURVIVORS; BONE-MARROW-TRANSPLANTATION; PAINFUL MEDICAL PROCEDURES; CHILDHOOD-CANCER; ADOLESCENT CANCER; PSYCHOLOGICAL ADJUSTMENT; POSTTRAUMATIC STRESS AB Objective To describe the emergence of pediatric psycho-oncology and to summarize research on psychosocial aspects of childhood cancer and survivorship. Methods To review research into illness communication and informed consent, procedural pain, late effects, psychological distress, coping and adjustment, and special risk populations. Methodological challenges, appropriate methodology, and directions for future research are discussed. Results The past 30 years have seen change from avoidance of communication about cancer to an emphasis on straightforward discussion of diagnosis and prognosis. Behavioral research has led to interventions to reduce procedural distress. Late effects have been observed in social functioning. Although average levels of distress in survivors of pediatric cancer are typical, subsets of more vulnerable patients and family members exist. Factors predicting positive and negative coping have been identified. Conclusions As the numbers of pediatric cancer survivors increase, psychosocial researchers will be better able to conduct longitudinal studies not only of adjustment and its predictors but also of the impact of the emerging medical treatments and interventions to ameliorate late effects of treatment. Additional funding, improving methodology, and multi-institutional cooperation will aid future pediatric psycho-oncology investigators. C1 Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Med Coll Wisconsin, Milwaukee, WI USA. RP Patenaude, AF (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM andrea-patenaude@dfci.harvard.edu NR 137 TC 170 Z9 176 U1 4 U2 25 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0146-8693 J9 J PEDIATR PSYCHOL JI J. Pediatr. Psychol. PD JAN-FEB PY 2005 VL 30 IS 1 BP 9 EP 27 DI 10.1093/jpepsy/jsi012 PG 19 WC Psychology, Developmental SC Psychology GA 884OL UT WOS:000226094800003 PM 15610981 ER PT J AU Meyer, EA Fuemmeler, BF AF Meyer, EA Fuemmeler, BF TI Commentary: Psychosocial functioning of children and adolescents surviving cancer: The junior investigators' perspective SO JOURNAL OF PEDIATRIC PSYCHOLOGY LA English DT Editorial Material C1 Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02445 USA. Childrens Hosp, Boston, MA USA. NCI, Hlth Promot Res Branch, Bethesda, MD 20892 USA. RP Meyer, EA (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St,Room D312, Boston, MA 02445 USA. EM tony_meyer@dfci.harvard.edu NR 4 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0146-8693 J9 J PEDIATR PSYCHOL JI J. Pediatr. Psychol. PD JAN-FEB PY 2005 VL 30 IS 1 BP 47 EP 49 DI 10.1093/jpepsy.jsi015 PG 3 WC Psychology, Developmental SC Psychology GA 884OL UT WOS:000226094800006 PM 15610984 ER PT J AU Little, DC Yoder, SM Grikscheit, TC Jackson, CCA Fuchs, JR McCrudden, KW Holcomb, GW AF Little, DC Yoder, SM Grikscheit, TC Jackson, CCA Fuchs, JR McCrudden, KW Holcomb, GW TI Cost considerations and applicant characteristics for the Pediatric Surgery Match SO JOURNAL OF PEDIATRIC SURGERY LA English DT Article; Proceedings Paper CT 35th Annual Meeting of the American-Pediatric-Surgical-Association CY MAY 27-30, 2004 CL Ponte Vedra, FL SP Amer Pediatr Surg Assoc DE pediatric surgery match ID SURGICAL TRAINING-PROGRAMS; CANDIDATES; DIRECTORS AB Background/Purpose: Formal training in pediatric surgery is highly competitive. The limited number of accredited positions has historically favored applicants with basic science experience, numerous publications, national presentations, and exposure to well-known pediatric surgeons. This review analyzes characteristics of successful applicants and cost associated with the Match. Methods: A survey was e-mailed to 45 applicants after the 2003 Match. Geographic provenance, demographics, qualifications, costs, and valued program characteristics were assessed. Statistics were formulated by x(2) and Student's t test. Results: Thirty-six applicants (80%) responded. Successful characteristics for matched vs unmatched included number of publications, 11.2 vs 5.7 (P < .01); first-author designation, 6.4 vs 3.1 (P = .02); basic science papers, 5.7 vs 1.7 (P < .01); national presentations, 5.8 vs 2.4 (P = .02); and presentations at pediatric surgical meetings, 2.0 vs 0.6 (P = .04). Ninety percent of matched applicants took time off to perform basic science research (P < .01). Average candidate expense was $6974, which represented 14% of pretax salary. Forty-one percent of applicants noted that cost limited the number of interviews taken. Fifty percent preferred a regional interview process to limit expense. Candidates ranked case diversity, volume, and mentor's advice as the most valued program characteristics. Successful applicants matched at their fifth rank on average. Eighty-six percent of unsuccessfal applicants will reapply. Conclusions: Results of this study are important to those interested in the future of pediatric surgery. Successful applicants were shown to have several national presentations and multiple scientific publications, especially in basic sciences. Applicant costs are high, totaling more than $236,000 for survey respondents. (C) 2005 Elsevier Inc. All rights reserved. C1 Texas A&M Univ, Hlth Sci Syst, Dept Gen Surg, Temple, TX 76508 USA. Childrens Mercy Hosp, Dept Gen Surg, Kansas City, MO 64108 USA. Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. Univ Chicago Hosp, Dept Surg, Chicago, IL 60637 USA. Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA. New Yorks Presbyterian Hosp, Dept Gen Surg, New York, NY 10032 USA. RP Little, DC (reprint author), Texas A&M Univ, Hlth Sci Syst, Dept Gen Surg, Temple, TX 76508 USA. EM dlittle@cmh.edu NR 10 TC 13 Z9 14 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0022-3468 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD JAN PY 2005 VL 40 IS 1 BP 69 EP 73 DI 10.1016/j.jpedsurg.2004.09.013 PG 5 WC Pediatrics; Surgery SC Pediatrics; Surgery GA 896IE UT WOS:000226927000015 PM 15868561 ER PT J AU Kawaguchi, AL Donahoe, PK Ryan, DP AF Kawaguchi, AL Donahoe, PK Ryan, DP TI Management and long-term follow-up of patients with types III and IV laryngotracheoesophageal clefts SO JOURNAL OF PEDIATRIC SURGERY LA English DT Article; Proceedings Paper CT 35th Annual Meeting of the American-Pediatric-Surgical-Association CY MAY 27-30, 2004 CL Ponte Vedra, FL SP Amer Pediatr Surg Assoc DE laryngotracheo-esophageal cleft; postoperative tracheoesophageal fistulas; microgastria ID REPAIR; LARYNGEAL AB Background: Laryngotracheoesophageal cleft (LTEC) is a rare congenital anomaly that occurs when the trachea and esophagus fail to separate during fetal development. The 2 most severe forms of LTEC are type III, with extension of the cleft from the larynx to the carina, and type IV, with extension of the cleft into one or both mainstem bronchi. Methods: Over the past 25 years, we have accumulated an experience caring for 9 patients with severe LTEC, including 4 with type III and 5 with type IV. Results: Morbidity and mortality from severe LTEC often result from aspiration and chronic lung disease. Patients with types III (1/4) and IV (5/5) LTEC have an extremely high incidence of microgastria with a shortened esophagus for which fundoplication is ineffective. Because gastric feeding often does not initially increase stomach volume and may cause severe aspiration, we suggest early gastric division with later reconstruction of intestinal continuity in patients with microgastria. Postoperative tracheoesophageal fistulas have occurred in 6 of 9 patients. Conclusions: Generous interposition of vascularized tissue with a multiple-layer closure has helped to prevent further recurrences. Postoperative tracheomalacia may be managed with continuous positive airway pressure and may require customized endotracheal tubes. Evaluation of respiratory and digestive function, school performance, and quality of life for the surviving patients is described. (C) 2005 Elsevier Inc. All rights reserved. C1 Massachusetts Gen Hosp, Massachusetts Gen Hosp Children, Dept Pediat Surg, Boston, MA 02114 USA. RP Ryan, DP (reprint author), Massachusetts Gen Hosp, Massachusetts Gen Hosp Children, Dept Pediat Surg, Boston, MA 02114 USA. EM dryan@partners.org NR 14 TC 21 Z9 21 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0022-3468 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD JAN PY 2005 VL 40 IS 1 BP 158 EP 164 DI 10.1016/j.jpedsurg.2004.09.041 PG 7 WC Pediatrics; Surgery SC Pediatrics; Surgery GA 896IE UT WOS:000226927000043 PM 15868578 ER PT J AU Heyman, MB Kirschner, BS Gold, BD Ferry, G Baldassano, R Cohen, SA Winter, HS Fain, P King, C Smith, T El-Serag, HB AF Heyman, MB Kirschner, BS Gold, BD Ferry, G Baldassano, R Cohen, SA Winter, HS Fain, P King, C Smith, T El-Serag, HB TI Children with early-onset inflammatory bowel disease (IBD): Analysis of a pediatric IBD Consortium Registry SO JOURNAL OF PEDIATRICS LA English DT Article ID 10 YEARS OLD; CROHNS-DISEASE; ULCERATIVE-COLITIS; POSTOPERATIVE RECURRENCE; POPULATION; CHILDHOOD; YOUNGER; AGE; EPIDEMIOLOGY; ADOLESCENCE AB Objective To determine the characteristics of inflammatory bowel disease (IBD) in young patients. Study design Uniform data were collected from a cohort of patients with IBD who were enrolled from January 2000 to November 2002 at six pediatric centers (Pediatric IBD Consortium). Results Of 1370 children in the registry, the mean age at IBD diagnosis was 10.3 +/- 4.4 years; 54% were male, and 86% were white. Diagnosis was confirmed in 87 (6.1%) under 3 years of age, 211 (15.4%) before 6 years, 654 (47.7%) at 6 to 12 years, and 505 (36.9%) at 13 to 17 years. More than 63% of children younger than 8 years of age had isolated colonic disease, whether Crohn disease, ulcerative colitis I or indeterminate colitis. Conversely, only 35% of those 8 years of age or older had isolated colonic disease (P <.0001). Overall, 29% had one or more family members with IBD. The subgroup of children younger than 3 years of age with UC had the highest prevalence of first-degree relatives with IBD (44%). Conclusions This demographically diverse pediatric IBD cohort revealed age-related variation in the distribution of IBD phenotype, with a high prevalence of isolated colonic disease in voting children. Positive family history was especially common in voting patients with UC. C1 Univ Calif San Francisco, Childrens Hosp, San Francisco, CA 94143 USA. Emory Univ, Sch Med, Atlanta, GA 30322 USA. Baylor Coll Med, Texas Childrens Hosp, Houston, TX 77030 USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Childrens Ctr Digest Healthcare, Atlanta, GA USA. MassGen Hosp Children, Boston, MA USA. Houston VA Med Ctr, Gastroenterol & Hlth Serv Res, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Heyman, MB (reprint author), Univ Calif San Francisco, 500 Parnassus Ave,MU 4 E,Room 406, San Francisco, CA 94143 USA. EM mheyman@peds.ucsf.edu FU NIDDK NIH HHS [DK053708, DK060617, DK062149] NR 38 TC 241 Z9 251 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD JAN PY 2005 VL 146 IS 1 BP 35 EP 40 DI 10.1016/j.jpeds.2004.08.043 PG 6 WC Pediatrics SC Pediatrics GA 887XB UT WOS:000226337700012 PM 15644819 ER PT J AU Holmes, LB Coull, BA Dorfman, J Rosenberger, PB AF Holmes, LB Coull, BA Dorfman, J Rosenberger, PB TI The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs SO JOURNAL OF PEDIATRICS LA English DT Article ID FETAL-HYDANTOIN SYNDROME; LIP AND/OR PALATE; ANTIEPILEPTIC DRUGS; PRENATAL EXPOSURE; ADULT MALES; CARBAMAZEPINE; PREGNANCY; CLEFTS; BRAIN; TERATOGENICITY AB Objective Children exposed during pregnancy to the anticonvulsant drugs phenytoin, phenobarbital, and carbamazepine as monotherapy and polytherapy have an increased frequency of midface and digit hypoplasia. Some children also have cognitive dysfunction. The hypothesis tested is that the anticonvulsant drug-exposed child with midface and digit hypoplasia is more likely to have cognitive dysfunction. Methods Children exposed to anticonvulsant drugs (n = 80) were recruited for a follow-up evaluation, which included testing cognitive function and a physical examination for head size, height, and the presence of midface and digit hypoplasia, and major malformations were correlated with full scale (FSI), performance (PIQ) Microcephaly, midface and digit hypoplasia, and verbal (VIQ) intelligence. Results The presence of the 3 anticonvulsant-exposed children with microcephaly had a deficit of 23.7 IQ points in FSI in comparison with the other children with a normal head size. Either midface or digit hypoplasia, after excluding the persons with microcephaly and with the Bonferroni correction, correlated significantly with deficits in VIQ (-12.7), PIQ (-1.0) and FSI (-12.8) IQ points (P =.0061). There was no decrease in IQ in association with major malformations. Conclusion The presence of midface and digit hypoplasia in a child exposed to anticonvulsant drugs in pregnancy is an indication for a systematic developmental evaluation. C1 Massachusetts Gen Hosp, Genet & Teratol Unit, Serv Pediat, Boston, MA 02115 USA. Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Cambridge, MA 02138 USA. RP Holmes, LB (reprint author), Massachusetts Gen Hosp, Genet & Teratol Unit, Serv Pediat, Warren 801,Fruit St, Boston, MA 02115 USA. EM holmes.lewis@mgh.harvard.edu NR 37 TC 20 Z9 22 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD JAN PY 2005 VL 146 IS 1 BP 118 EP 122 DI 10.1016/j.jpeds.2004.08.048 PG 5 WC Pediatrics SC Pediatrics GA 887XB UT WOS:000226337700028 PM 15644835 ER PT J AU Johnson, CE Handberg, E Dobalian, A Gurol, N Pearson, V AF Johnson, CE Handberg, E Dobalian, A Gurol, N Pearson, V TI Improving perinatal and neonatal patient safety - The AHRQ patient safety indicators SO JOURNAL OF PERINATAL & NEONATAL NURSING LA English DT Article DE administrative data; patient safety; quality indicators ID HOSPITALS; MORTALITY; RATES AB This study reviews the development and implementation of the Agency for Healthcare Research and Quality (AHRQ) patient safety indicators (PSIs). The genesis of the use of administrative data as a tool to combat safety problems is presented, and how indicators were constructed using various administrative codes. Examples of how the PSIs are being used to identify potential safety problems within the general population are presented, with a special emphasis on how these are being used within the perinatal and neonatal arena to understand current issues within that subpopulation. Results from studies within the general population and targeted at perinatal and neonatal patients are presented. Finally, suggestions are discussed for clinicians to use the AHRQ PSIs as one of their early warning tools for potential safety-related problems. C1 N Florida S Georgia Vet Hlth Syst, Rehabil Outcomes Res Ctr Excellence, Gainesville, FL 32608 USA. Univ Florida, Dept Hlth Serv Res Management & Policy, Coll Publ Hlth & Hlth Profess, Gainesville, FL USA. Univ Florida, Div Cardiovasc Med, Gainesville, FL USA. VA Greater Los Angeles Healthcare Syst, Ctr Excellence Study Healthcare Provider Behav, Sepulveda Ambulatroy Care Ctr & Nursing Home, Sepulveda, CA USA. Shands AGH, Maternal Child Serv, Gainesville, FL USA. RP Johnson, CE (reprint author), N Florida S Georgia Vet Hlth Syst, Rehabil Outcomes Res Ctr Excellence, 1601 SW Archer Rd, Gainesville, FL 32608 USA. EM christopher.Johnson4@med.va.gov NR 16 TC 9 Z9 9 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-2190 J9 J PERINAT NEONAT NUR JI J. Perinat. Neonatal Nurs. PD JAN-MAR PY 2005 VL 19 IS 1 BP 15 EP 23 PG 9 WC Nursing; Obstetrics & Gynecology; Pediatrics SC Nursing; Obstetrics & Gynecology; Pediatrics GA 899MR UT WOS:000227149000007 PM 15796421 ER PT J AU Crosby, MB Svenson, JL Zhang, J Nicol, CJ Gonzalez, FJ Gilkeson, GS AF Crosby, MB Svenson, JL Zhang, J Nicol, CJ Gonzalez, FJ Gilkeson, GS TI Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPAR gamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID NF-KAPPA-B; RECEPTOR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); MACROPHAGE ACTIVATION; IN-VITRO; INFLAMMATORY CYTOKINES; INDUCED ARTHRITIS; IFN-GAMMA; LIGANDS; GENE AB Peroxisome proliferation-activated receptor (PPAR)gamma agonists inhibit inducible nitric-oxide synthase (iNOS), tumor necrosis factor-alpha, and interleukin-6. Because of these effects, synthetic PPARgamma agonists, including thiazolidinediones, are being studied for their impact on inflammatory disease. The anti-inflammatory concentrations of synthetic PPARgamma agonists range from 10 to 50 muM, whereas their binding affinity for PPARgamma is in the nanomolar range. The specificity of synthetic PPARgamma agonists for PPARgamma at the concentrations necessary for anti-inflammatory effects is thus in question. We report that PPARgamma is not necessary for the inhibition of iNOS by synthetic PPARgamma agonists. RAW 264.7 macrophages possess little PPARgamma, yet lipopolysaccharide (LPS)/interferon (IFN) gamma-induced iNOS was inhibited by synthetic PPARgamma agonists at 20 muM. Endogenous PPARgamma was inhibited by the transfection of a dominant-negative PPARgamma construct into murine mesangial cells. In the transfected cells, synthetic PPARgamma agonists inhibited iNOS production at 10 muM, similar to nontransfected cells. Using cells from PPARgamma Cre/lox conditional knockout mice, baseline and LPS/IFN gamma-induced nitric oxide levels were higher in macrophages lacking PPARgamma versus controls. However, synthetic PPARgamma agonists inhibited iNOS at 10 muM in the PPARgamma-deficient cells, similar to macrophages from wild-type mice. These results indicate that PPARgamma is not necessary for inhibition of iNOS expression by synthetic PPARgamma agonists at concentrations over 10 muM. Intrinsic PPARgamma function, in the absence of synthetic agonists, however, may play a role in inflammatory modulation. C1 Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. NCI, Met Lab, NIH, Bethesda, MD USA. Ralph H Johnson VA Med Ctr, Med Res Serv, Charleston, SC USA. RP Gilkeson, GS (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, 96 Jonathon Lucas St,Suite 912,POB 25063, Charleston, SC 29425 USA. EM gilkeson@musc.edu FU NIAMS NIH HHS [AR45476, AR47451] NR 40 TC 38 Z9 39 U1 0 U2 0 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD JAN PY 2005 VL 312 IS 1 BP 69 EP 76 DI 10.1124/jpet.104.074005 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 880CM UT WOS:000225766400009 PM 15356214 ER PT J AU Cook, KF Roddey, TS O'Malley, KJ Gartsman, GM AF Cook, KF Roddey, TS O'Malley, KJ Gartsman, GM TI Development of a Flexilevel Scale for use with computer-adaptive testing for assessing shoulder function SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article; Proceedings Paper CT Closed Meeting of the American-Shoulder-and-Elbow-Surgeons CY OCT, 2003 CL Dana Point, CA ID ITEM RESPONSE THEORY; HEADACHE IMPACT; HEALTH-STATUS; RELIABILITY; OUTCOMES; RECOMMENDATIONS; 21ST-CENTURY; VALIDITY AB In a 5-year study, a self-report measure of shoulder function-the Flexilevel Scale of Shoulder Function (FLEX-SF)-was developed by use of item response theory. A large pool of candidate items (N = 68) was developed. A questionnaire that included the 68 items, another scale of shoulder function, and clinical and demographic questions were administered to 400 persons with shoulder complaints. Patients' responses to the 68 items were calibrated by use of Andrich's rating scale model. Thirty-three items were selected from the pool and subdivided into three overlapping testlets targeting low, medium, and high shoulder function. A table translates raw scores on testlets to a common mathematical metric. The validity and reliability of the FLEX-SF was evaluated in a longitudinal study of 199 patients. The FLEX-SF scores were highly reliable and exhibited excellent validity (including responsiveness). We report on a simulation of a computer-adaptive test of shoulder function. This simulation is based on the developmental items we tested for use in the FLEX-SF. The results indicate that greater measurement efficiency can be achieved with a computer-adaptive test format. C1 Houston VAMC, Houston, TX 77030 USA. Texas Womans Univ, Measurement Excellence & Training Resource Inform, Vet Affairs Hlth Serv Res & Dev Resource Ctr, Denton, TX 76204 USA. Univ Texas, Sch Med, Houston, TX USA. Pearson Educ Measurement, Austin, TX USA. RP Cook, KF (reprint author), Houston VAMC, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM karonc@bcm.tmc.edu NR 24 TC 12 Z9 12 U1 1 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD JAN-FEB PY 2005 VL 14 IS 1 SU S BP 90S EP 94S DI 10.1016/j.jse.2004.09.024 PG 5 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 902CH UT WOS:000227328400014 PM 15726093 ER PT J AU Souza, AL Boninger, ML Fitzgerald, SG Shimada, SD Cooper, RA Ambrosio, F AF Souza, AL Boninger, ML Fitzgerald, SG Shimada, SD Cooper, RA Ambrosio, F TI Upper limb strength in individuals with spinal cord injury who use manual wheelchairs SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE wheelchair; isokinetic; strength; torque; spinal cord injuries; shoulder; rotator cuff impingement ID SHOULDER PAIN; IMPINGEMENT SYNDROME; ISOKINETIC SHOULDER; ROTATOR CUFF; PARAPLEGIA; PROPULSION; TORQUE; MEN; ABNORMALITIES; IMBALANCE AB Introduction: Manual wheelchair users have been found to be at risk for secondary upper extremity injuries. Purpose: The primary goal of this study was to compare shoulder strength and muSCIe imbalance of individuals with paraplegia to case-wise matched unimpaired controls (UC). A secondary goal was to evaluate the impact of age and neurologic level of injury (NLI) on weight-normalized strength (WNS). Methods: The SCI group (n = 28) and the UC group (n = 28) completed bilateral shoulder isokinetic strength testing in the sagittal, frontal, and horizontal plane at 60 degrees/second using the BioDex system. Strength ratios, an indicator of muSCIe imbalance, were also calculated. Results: No significant difference was seen in shoulder strength or strength ratios between the SCI group and the UC group. However, NLI was significantly related to WNS on several planes in the SCI group. Therefore, we dichotomized the SCI group into equal groups based on an NLI. The Low-SCI group was significantly stronger than the High-SCI group in most planes (P < 0.05). The High-SCI group was significantly weaker than the UC in extension (P < 0.01) and a trend (P < 0.01) was seen in flexion, abduction, and external rotation. The Low-SCI group was significantly stronger in abduction than the UC. Conclusion: WNS at the shoulder correlated with NLI. It is likely that this is related to contributions of the trunk and abdominal muscles during testing, since proximal trunk strength aids in generating forces distally. This study and others of strength in individuals with paraplegia may overestimate shoulder strength. C1 Univ Pittsburgh, Human Engn Res Lab, VA Ctr Excellence, Highland Dr VA Med Ctr, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. Biomech Consultants Calif, Davis, CA USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15206 USA. RP Boninger, ML (reprint author), Univ Pittsburgh, Human Engn Res Lab, VA Pittsburgh Healthcare Syst, 151R-1,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu OI Boninger, Michael/0000-0001-6966-919X NR 31 TC 7 Z9 7 U1 3 U2 7 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2005 VL 28 IS 1 BP 26 EP 32 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 005PF UT WOS:000234835600009 PM 15832901 ER PT J AU Burns, SP Nelson, AL Bosshart, HT Goetz, LL Harrow, JJ Gerhart, KD Bowers, H Krasnicka, B Guihan, M AF Burns, SP Nelson, AL Bosshart, HT Goetz, LL Harrow, JJ Gerhart, KD Bowers, H Krasnicka, B Guihan, M TI Implementation of clinical practice guidelines for prevention of thromboembolism in spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE spinal cord injuries; venous thrombosis; thromboembolism; practice guidelines; anticoagulants; patient education; prophylaxis; low-molecular-weight heparin ID DEEP-VEIN THROMBOSIS; VENOUS THROMBOSIS; DUPLEX ULTRASOUND; DOSE HEPARIN; PROPHYLAXIS; REHABILITATION; SURVEILLANCE; PERFORMANCE; ENOXAPARIN; ADMISSION AB Background/Objectives: The purpose of this study was to determine whether publication of the "Prevention of Thromboembolism in Spinal Cord Injury" clinical practice guideline (CPG) changed patient management and whether adherence to CPG recommendations improved after a targeted implementation strategy. Methods: Data were abstracted from medical records of 134 and 520 patients with acute and chronic spinal cord injury (SCI), respectively, from 6 Veterans Affairs medical centers over 3 time periods: prepublication (T1), preimplementation (T2), and postimplementation (T3) of the CPG. Targeted interventions were developed to address provider-perceived barriers to guideline adherence, based on findings from focus groups conducted at each site. The interventions incorporated two implementation strategies: standardized documentation templates/standing orders and social marketing /outreach visits. Results: Use of the specified duration for pharmacologic prophylaxis increased from 60% to 65% to 75% of patients with acute SCI in T1, T2, and T3, respectively (P = 0.060 and 0.041 for T1 vs T2 and T2 vs T3, respectively). Rates of use for individual pharmacologic prophylaxis agents changed significantly over the course of the study, with use of low-molecular-weight heparin increasing from 7% in T1 to 42% in T3. Physical assessments for thrombosis on hospitalization days I and 30 improved between T2 and T3. Use of prophylaxis in chronically injured patients with new risk factors for thromboembolism increased from 16% to 31% to 34% during T1, T2, and T3 (P = 0.001 and 0.87, respectively). Conclusions: The CPG publication had only a modest effect on practice. Use of structured implementation further increased the adherence to some CPG recommendations for thromboembolism prophylaxis. Similar implementation strategies should be considered for CPG recommendations with low adherence and high potential for morbidity and mortality. C1 VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv 128, Seattle, WA 98108 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. James A Haley Vet Adm Med Ctr, Patient Safety Ctr Inquiry, Tampa, FL 33612 USA. James A Haley Vet Adm Med Ctr, SCI Serv, Tampa, FL 33612 USA. VA Med Ctr, SCI Serv, Augusta, GA USA. VA N Texas Hlth Care Syst, SCI Serv, Dallas, TX USA. Univ Texas, SW Med Ctr, Dallas, TX 75230 USA. VA San Diego Hlth Care Syst, SCI Serv, San Diego, CA USA. VA Med Ctr, SCI Serv, Miami, FL USA. Vet Affairs Edward Hines Jr Hosp, Midw Ctr Hlth Serv & Policy Res, Hines, IL USA. Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program, Hines, IL USA. RP Burns, SP (reprint author), VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv 128, 1660 S Columbian Way, Seattle, WA 98108 USA. EM spburns@u.washington.edu NR 36 TC 15 Z9 15 U1 0 U2 0 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2005 VL 28 IS 1 BP 33 EP 42 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 005PF UT WOS:000234835600010 PM 15832902 ER PT J AU Zeitzer, JM Ayas, NT Wu, AD Czeisler, CA Brown, R AF Zeitzer, JM Ayas, NT Wu, AD Czeisler, CA Brown, R TI Bilateral oculosympathetic paresis associated with loss of nocturnal melatonin secretion in patients with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Horner's syndrome; bilateral oculosympathetic paresis; spinal cord injuries; melatonin; sleep disorders; tetraplegia ID BROWN-SEQUARD-SYNDROME; HORNERS-SYNDROME; COCAINE TEST; DIAGNOSIS; RAT AB Background: Lesions along the sympathetic pathway to the eye produce oculosympathetic paresis (OSP, Horner's syndrome). The oculosympathetic pathway descends from the hypothalamus through the cervical spinal cord and ascends to the superior cervical ganglion (SCG), which innervates sympathetic targets in the ipsilateral face and eye. This pathway appears to closely co-localize with a similar retino-pineal neural pathway from the hypothalamus through the cervical spinal cord and SCG to the pineal gland. As such, lesions along this shared pathway, such as occur in neurologically complete injury to the cervical spinal cord (tetraplegia), would be predicted to result in simultaneous OSP and loss of pineal melatonin production. Loss of melatonin production may contribute to the pervasive sleep disruption observed in patients with tetraplegia. Methods: We assessed the presence of OSP by photographic documentation of ptosis and pupillary dilation response to cocaine eye drops in 5 individuals with neurologically complete damage to their upper thoracic or lower cervical spinal cord. We correlated these results with an analysis of the pattern of melatonin production in these same individuals. Results: Bilateral OSP was present in individuals with cervical spinal cord injury; each also lacked significant production of melatonin. No evidence of OSP was observed in the 2 individuals with thoracic spinal cord injury below the level of the oculosympathetic pathway. Both had normal circadian rhythms of melatonin production, with timing and amplitude of the rhythm within normal parameters. Conclusion: The presence of bilateral oculosympathetic paresis can be predictive of the complete loss of the nocturnal production of melatonin. C1 Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Div Sleep Med, Boston, MA 02115 USA. Brockton W Roxbury Vet Adm Med Ctr, Spinal Cord Injury Serv, Pulm & Crit Care Sect, Brockton, MA USA. RP Brown, R (reprint author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, Bullfinch 148,55 Fruit St, Boston, MA 02114 USA. EM rbrown5@partners.org NR 22 TC 10 Z9 10 U1 0 U2 0 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2005 VL 28 IS 1 BP 55 EP 59 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 005PF UT WOS:000234835600012 PM 15832904 ER PT J AU Kendall, RW Jacquemin, G Frost, R Burns, SP AF Kendall, RW Jacquemin, G Frost, R Burns, SP TI Creatine supplementation for weak muscles in persons with chronic tetraplegia: A randomized double-blind placebo-controlled crossover trial SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE creatine; spinal cord injuries; tetraplegia; muscle strength; fatigue ID SPINAL-CORD INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; EXERCISE PERFORMANCE; MUSCULAR STRENGTH; RELEASE TEST; MONOHYDRATE; QUADRIPLEGIA; RECRUITMENT; INGESTION; CAPACITY AB Background and Objectives: Creatine supplementation improves muscle strength in some patient populations with neurologic disorders. The purpose of this study was to determine whether creatine supplementation improves muscle strength and endurance in weak upper limb muscles in persons with tetraplegia, and whether it improves function. Methods: Outpatients with tetraplegia and mild wrist extensor weakness were randomized to receive either creatine or placebo in a double-blind crossover design. During creatine supplementation, participants were loaded with 10 g orally twice per day for 6 days, then maintained on 5 g daily until undergoing testing. Main outcome measures, performed at baseline, after placebo, and after creatine supplementation, included maximal voluntary wrist extensor isometric contraction strength (MVC), endurance times for 5 submaximal wrist extensor contractions, and the Grasp and Release Test for hand function. Results: Eight individuals (7 men, 1 woman) with tetraplegia met inclusion criteria and completed all study phases. The mean age of participants was 48 years, and 7 of 8 had C6 motor level injuries. There were no significant differences in MVC, endurance times, or hand function for creatine vs placebo. Conclusion: Creatine does not improve MVC and endurance of weak wrist extensors and does not improve hand function in individuals with tetraplegia. C1 Univ Utah, Div Phys Med & Rehabil, Salt Lake City, UT USA. Univ Montreal, Inst Readaptat Montreal, Montreal, PQ, Canada. VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA. Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Burns, SP (reprint author), VA Puget Sound Hlth Care Syst, SCI 128, Spinal Cord Injury Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. EM spburns@u.washington.edu NR 32 TC 6 Z9 7 U1 0 U2 2 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2005 VL 28 IS 3 BP 208 EP 213 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 005PJ UT WOS:000234836000003 PM 16048138 ER PT J AU Goldstein, B Weaver, FM Hammond, MC AF Goldstein, B Weaver, FM Hammond, MC TI New CDC recommendations: Annual influenza vaccination recommended for individuals with spinal cord injuries SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Editorial Material ID DEATH C1 Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. Hines VA Med Ctr, Dept Vet Affairs, Midw Ctr Hlth Serv & Policy Res, Hines, IL USA. RP Goldstein, B (reprint author), VAPSHCS, Spinal Cord Injury & Disorders Strateg Healthcare, 128NAT,1660 S Columbian Way, Seattle, WA 98108 USA. EM barry.goldstein@med.va.gov NR 12 TC 4 Z9 4 U1 0 U2 0 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2005 VL 28 IS 5 BP 383 EP 384 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 005PN UT WOS:000234836400003 PM 16869084 ER PT J AU Goetz, LL Nelson, AL Guihan, M Bosshart, HT Harrow, JJ Gerhart, KD Krasnicka, B Burns, SP AF Goetz, LL Nelson, AL Guihan, M Bosshart, HT Harrow, JJ Gerhart, KD Krasnicka, B Burns, SP TI Provider adherence to implementation of clinical practice guidelines for neurogenic bowel in adults with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE spinal cord injuries; neurogenic bowel; practice guidelines; consensus guidelines; patient education AB Background/Objectives: Clinical Practice Guidelines (CPGs) have been published on a number of topics in spinal cord injury (SCI) medicine. Research in the general medical literature shows that the distribution of CPGS has a minimal effect on physician practice without targeted implementation strategies. The purpose of this study was to determine (a) whether dissemination of an SCI CPG improved the likelihood that patients would receive CPG recommended care and (b) whether adherence to CPG recommendations could be improved through a targeted implementation strategy. Specifically, this study addressed the "Neurogenic Bowel Management in Adults with Spinal Cord Injury" Clinical Practice Guideline published in March 1998 by the Consortium for Spinal Cord Medicine Methods: CPG adherence was determined from medical record review at 6 Veterans Affairs SCI centers for 3 time periods: before guideline publication (T1), after guideline publication but before CPG implementation (T2), and after targeted CPG implementation (T3). Specific implementation strategies to enhance guideline adherence were chosen to address the barriers identified by SCI providers in focus groups before the intervention. Results: Overall adherence to recommendations related to neurogenic bowel did not change between T1 and T2 (P = not significant) but increased significantly between T2 and T3 (P < 0.001) for 3 of 6 guideline recommendations. For the other 3 guideline recommendations, adherence rates were noted to be high at T1. Conclusions: While publication of the CPG alone did not alter rates of provider adherence, the use of a targeted implementation plan resulted in increases in adherence rates with some (3 of 6) CPG recommendations for neurogenic bowel management. C1 VA N Texas Hlth Care Syst, Spinal Cord Injury Serv 128, Dallas, TX 75216 USA. Univ Texas, SW Med Ctr, Dallas, TX USA. James A Haley VA Med Ctr, SCI Serv, Tampa, FL USA. James A Haley VA Med Ctr, Patient Safety Ctr Inquiry, Tampa, FL USA. Vet Affairs Edward Hines Jr Hosp, Midw Ctr Hlth Serv & Policy Res, Hines, IL USA. VA Med Ctr, Sci Serv, Augusta, GA USA. VA San Diego Hlth Care Syst, SCI Serv, San Diego, CA USA. Edward Hines Jr VA Hosp, Cooperat Studies Program, Hines, IL USA. VA Puget Sound Hlth Care Syst, SCI Serv, Seattle, WA USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Goetz, LL (reprint author), VA N Texas Hlth Care Syst, Spinal Cord Injury Serv 128, 4500 S Lancaster Rd, Dallas, TX 75216 USA. EM lance.goetz@med.va.gov NR 25 TC 13 Z9 14 U1 1 U2 1 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2005 VL 28 IS 5 BP 394 EP 406 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA 005PN UT WOS:000234836400005 PM 16869086 ER PT J AU Ambrosio, F Boninger, ML Souza, AL Fitzgerald, SG Koontz, AM Cooper, RA AF Ambrosio, F Boninger, ML Souza, AL Fitzgerald, SG Koontz, AM Cooper, RA TI Biomechanics and strength of manual wheelchair users SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE force; shoulder pain; wheelchair propulsion; pushrim biomechanics; spinal cord injuries; muscle strength; strength training; paraplegia ID UPPER-EXTREMITY; IMPINGEMENT SYNDROME; SHOULDER PAIN; PUSHRIM BIOMECHANICS; GLENOHUMERAL JOINT; PROPULSION; PARAPLEGIA; PATTERNS; KINETICS; MUSCLES AB Background/Objective: Previous investigations have identified muscular imbalance in the shoulder as a source of pain and injury in manual wheelchair users. Our aim was to determine whether a correlation exists between strength and pushrim biomechanical variables including: tangential (motive) force (Ft), radial force (Fr), axial force (Fz), total (resultant) force (FR), fraction of effective force (FEF), and cadence. Methods: Peak isokinetic shoulder strength (flexion [FLX], extension [EXT], abduction [ABD], adduction [ADD], internal rotation [IR], and external rotation [ER]) was tested in 22 manual wheelchair users with a BioDex system for 5 repetitions at 60 degrees/s. Subjects then propelled their own manual wheelchair at 2 speeds, 0.9 m/s (2 mph) and 1.8 m/s (4 mph), for 20 seconds, during which kinematic (OPTOTRAK) and kinetic (SMAR(WHEEL)) data were collected. Peak isokinetic forces in the cardinal planes were correlated with pushrim biomechanical variables. Results: All peak torque strength variables correlated significantly (P <= 0.05) with Ft, Fir, and FIR, but were not significantly correlated with Fz, FEF, or cadence. Finally, there were no relationships found between muscle strength ratios (for example, FLX/EXT) and Ft, Fr, FIR, Fz, or FEF. Conclusion: There was a correlation between strength and force imparted to the pushrim among wheelchair users; however, there was no correlation found in wheelchair propulsion or muscle imbalance. Clinicians should be aware of this, and approach strength training and training in wheelchair propulsion techniques separately. C1 Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. VA Med Ctr, AVA Ctr Excellence, Human Engn Res Labs, Pittsburgh, PA USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. RP Boninger, ML (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 151R-1,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU PHS HHS [H133A011107] NR 36 TC 25 Z9 25 U1 3 U2 8 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2005 VL 28 IS 5 BP 407 EP 414 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 005PN UT WOS:000234836400006 PM 16869087 ER PT J AU Cluver, JS Schuyler, D Frueh, BC Brescia, F Arana, GW AF Cluver, JS Schuyler, D Frueh, BC Brescia, F Arana, GW TI Remote psychotherapy for terminally ill cancer patients SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID TELEPSYCHIATRY; SATISFACTION; SERVICE AB We conducted a feasibility study of remote psychotherapy in 10 terminally ill cancer patients with diagnoses of adjustment disorder or major depression. Subjects received six sessions of individual cognitive therapy with the same therapist. Sessions alternated between face-to-face sessions and remote sessions delivered by analogue videophone. After each therapy session, a brief questionnaire was used to evaluate the subjects' level of satisfaction with the session, sense of connectedness to the therapist and overall progress being made in the therapy. Nine patients completed the study. Of 53 completed therapy sessions, 21 were by videophone and 32 were conducted face to face. Participants reported strong positive perceptions and acceptance after almost all therapy sessions, regardless of service delivery mode. The study suggests that there may be a role for the delivery of psychotherapy using low-bandwidth videophones. C1 Ralph H Johnson VAMC, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA. RP Cluver, JS (reprint author), Ralph H Johnson VAMC, 109 Bee St, Charleston, SC 29401 USA. EM cluverj@musc.edu NR 13 TC 21 Z9 22 U1 0 U2 3 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2005 VL 11 IS 3 BP 157 EP 159 DI 10.1258/1357633053688741 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 923QT UT WOS:000228925100008 PM 15901444 ER PT J AU Cavallerano, J Aiello, LM AF Cavallerano, J Aiello, LM TI Emerging trends in ocular telemedicine: the diabetic retinopathy model SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID EYE CARE; CURRENT GUIDELINES; MELLITUS AB Diabetes mellitus is a leading cause of vision loss in industrialized countries. Diabetic retinopathy has features which make it ideal for disease management by telemedicine. The American Telemedicine Association (ATA) has recently established consensus recommendations for ocular telemedicine for diabetic retinopathy, in cooperation with the US National Institute of Standards and Technology. The guiding principle is that it would be inappropriate to use telemedicine to provide anything less than the accepted standard of clinical care. The ATA practice recommendations delineate performance standards for the clinical, technical and administrative elements of ocular telemedicine for diabetic retinopathy. Four clinical categories of assessment were identified. Category 4 validation, for example, indicates that a system matches or exceeds the ability of current photographs to identify lesions of diabetic retinopathy. To create the practice recommendations, workshops were held to address each of the three components: (1) clinical, (2) technical, and (3) operational and business. Ocular telemedicine programmes will need to demonstrate sustainability and cost-effectiveness, and respect a patient's right to privacy. Nevertheless, ocular telemedicine seems poised to become an integral part of eye health care, as long as programmes meet or exceed present clinical standards of care, and patient and provider expectations are clearly defined. C1 Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. New England Coll Optometry, Boston, MA USA. Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Cavallerano, J (reprint author), Joslin Diabet Ctr, Beetham Eye Inst, 1 Joslin Pl, Boston, MA 02215 USA. EM jerry.covallerano@joslin.harvard.edu NR 12 TC 7 Z9 7 U1 0 U2 2 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2005 VL 11 IS 4 BP 163 EP 166 DI 10.1258/1357633054068874 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 937FL UT WOS:000229909900001 PM 15969790 ER PT J AU Frueh, BC Henderson, S Myrick, H AF Frueh, BC Henderson, S Myrick, H TI Telehealth service delivery for persons with alcoholism SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID TELECOMMUNICATION; TELEPSYCHIATRY; CARE AB Videoconferencing at a bandwidth of 384 kbit/s was used in open sessions for subjects with alcohol use disorders (AUD). Study participants received eight sessions of group therapy over a four-week period from an accredited addictions counsellor. Outcome assessment included self-report measures, a qualitative interview and a chart review. Of the 18 subjects who started the study, 14 attended at least four sessions of therapy, completed self-report assessments and the thematic interview. The participants reported high levels of satisfaction with telepsychiatry, found the intervention to be highly credible, had good session attendance and attrition comparable to that expected with conventional same-room treatment. In all, 82% of subjects reported that they would recommend the service to a friend or family member. The results demonstrate the feasibility of using videoconferencing for service delivery to adults with AUD, and encourage the future performance of randomized controlled trials. C1 Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. Med Univ S Carolina, Charleston, SC 29425 USA. RP Frueh, BC (reprint author), VAMC, MHS, 109 Bee St, Charleston, SC 29401 USA. EM fruehbc@musc.edu FU AHRQ HHS [HS11642]; NIAAA NIH HHS [AA00314]; NIMH NIH HHS [MH01660] NR 10 TC 30 Z9 30 U1 0 U2 0 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2005 VL 11 IS 7 BP 372 EP 375 DI 10.1258/135763305774472060 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 980RT UT WOS:000233036600009 PM 16238840 ER PT J AU Heinzelmann, PJ Lugn, NE Kvedar, JC AF Heinzelmann, PJ Lugn, NE Kvedar, JC TI Telemedicine in the future SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID HEALTH-CARE; QUALITY; SERVICE; COMMUNICATION; INFORMATION; TECHNOLOGY AB Telemedicine can provide a compelling alternative to conventional acute, chronic and preventive care, and can improve clinical outcomes. In the industrialized world, it is likely that telemedicine will continue to move healthcare delivery from the hospital or clinic into the home. In the developing world or in regions with limited infrastructure, telemedicine will mainly be used in applications that link providers based at health centres, referral hospitals and tertiary centres. The future of telemedicine will depend on: (1) human factors, (2) economics and (3) technology. Behaviours related to technology affect change at the individual, organizational and societal level. Personnel shortages and decreasing third-party reimbursement are significant drivers of technology-enabled health care in the industrialized world, particularly in the areas of home care and self-care. We can safely assume that developments in mobile communications, sensor devices and nanotechnology will alter the way that health care is delivered in the future. The growth and integration of information and communication technologies into health-care delivery holds great potential for patients, providers and payers in health systems of the future. Perhaps the most difficult question to answer, however, is 'When will telemedicine become part of the standard of care?' C1 Partners Telemed, Partners Healthcare Syst, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA USA. RP Kvedar, JC (reprint author), Partners Telemed, Partners Healthcare Syst, 2 Longfellow Pl,Suite 216, Boston, MA 02114 USA. EM jkvedar@partners.org NR 35 TC 19 Z9 19 U1 2 U2 7 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2005 VL 11 IS 8 BP 384 EP 390 DI 10.1258/135763305775013554 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 002GB UT WOS:000234598400002 PM 16356311 ER PT J AU Weinberger, LE Sreenivasan, S Garrick, T Osran, H AF Weinberger, LE Sreenivasan, S Garrick, T Osran, H TI The impact of surgical castration on sexual recidivism risk among sexually violent predatory offenders SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID TESTICULAR CANCER; SERUM TESTOSTERONE; MEN; BEHAVIOR; MEDROXYPROGESTERONE; NEUROBIOLOGY; PARAPHILIAS; ASSESSMENTS; ANDROGEN; ISSUES AB The relationship of surgical castration to sexual recidivism in a sexually violent predator/sexually dangerous person (SVP/SDP) population is reviewed. A review of the literature on castrated sex offenders reveals a very low incidence of sexual recidivism. The low sexual recidivism rates reported are critiqued in light of the methodologic limitations of the studies. Better designed testicular/prostate cancer studies have demonstrated that, while sexual desire is reduced by orchiectomy, the capacity to develop an erection in response to sexually stimulating material is not eliminated. The relevance of this literature to SVP/SDP commitment decisions and ethics is discussed. Two vignettes of castrated, high-risk sex offenders illustrate how to address risk reduction. Two tables are presented: the first outlines individual case data from a difficult-to-obtain report, and the second summarizes the most frequently cited castration studies on sexual recidivism. Orchiectomy may have a role in risk assessments; however, other variables should be considered, particularly as the effects can be reversed by replacement C1 Univ S Carolina, Keck Sch Med, Inst Psychiat Law & Behav Sci, Los Angeles, CA 90086 USA. Greater Los Angeles VA Med Ctr, Forens Outreach Serv, Los Angeles, CA USA. Greater Los Angeles VA Med Ctr, Gen Hosp Psychiat, Los Angeles, CA USA. Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA. Atascadero State Hosp, Atascadero, CA USA. RP Weinberger, LE (reprint author), Univ S Carolina, Inst Psychiat & Law, POB 86125, Los Angeles, CA 90086 USA. NR 58 TC 27 Z9 27 U1 0 U2 11 PU AMER ACAD PSYCHIATRY LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2005 VL 33 IS 1 BP 16 EP 36 PG 21 WC Law; Psychiatry SC Government & Law; Psychiatry GA 907WL UT WOS:000227748700004 PM 15809235 ER PT J AU Edersheim, JG Beck, JC AF Edersheim, JG Beck, JC TI Commentary: Expert testimony as a potential asset in Defense of capital sentencing cases SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Editorial Material ID DEATH-PENALTY; EFFECTIVE ASSISTANCE; COUNSEL; LIFE AB Montgomery et al. have documented the extent to which jurors apparently do and do not rely on expert testimony regarding dangerousness and mental illness. This article reviews some of the methodological issues raised by their findings and argues that their results have potential value for appellate defense counsel in appealing death sentences in which trial counsel failed to introduce expert testimony on mental illness. C1 Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. Massachusetts Gen Hosp, Law & Psychiat Serv, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. RP Beck, JC (reprint author), Harvard Univ, Sch Med, Dept Psychiat, 25 Shattuck St, Boston, MA 02115 USA. EM jbeck1@bidmc.harvard.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PSYCHIATRY LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2005 VL 33 IS 4 BP 519 EP 522 PG 4 WC Law; Psychiatry SC Government & Law; Psychiatry GA 997FW UT WOS:000234231600013 PM 16394229 ER PT J AU Raisch, DW Fudala, PJ Saxon, AJ Walsh, R Casadonte, P Ling, W Johnson, BA Malkerneker, U Ordorica, P Williford, WO Sather, MR AF Raisch, DW Fudala, PJ Saxon, AJ Walsh, R Casadonte, P Ling, W Johnson, BA Malkerneker, U Ordorica, P Williford, WO Sather, MR TI Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Pharmacists-Association CY MAR 28-APR 01, 2003 CL New Orleans, LA SP Amer Pharmacists Assoc DE opioid dependence; buprenorphine; naloxone; community and ambulatory pharmacy; pharmaceutical care; prescription forgery; drug diversion; attitudes; perceptions ID OPIATE ADDICTION; PAIN; NALOXONE AB Objective: To assess the perceptions and attitudes of pharmacists and pharmacy technicians involved in an office-based opioid dependence treatment program using buprenorphine/naloxone. Design: Cross-sectional attitudinal assessment. Setting: Community, outpatient hospital, and clinic pharmacies. Participants: Pharmacists and technicians participating in a clinical trial of opioid dependence treatment using buprenorphine/naloxone. Intervention: Written and telephone surveys followed by interviews with open-ended items. Main Outcome Measures: Attitudes and perceptions regarding opioid dependent patients and use of buprenorphine/naloxone for treatment of opioid dependence. Results: Pharmacies in seven states (New York, Virginia, Illinois, Florida, Texas, California, and Washington) participated in the clinical trial. A total of 40 pharmacists and pharmacy technicians responded to the initial written survey, representing 27 of the 32 pharmacies (84%). Follow-up interviews were obtained from one individual at 30 of those pharmacies (93.8%). Most pharmacy personnel (77.5%) involved with this study were not more concerned about theft or break-ins and would be willing to participate in opioid dependence treatment as the medication became available commercially (70%). The majority of respondents (85%) indicated that patients did not cause problems at their pharmacies. Compared with their experiences in administering other narcotic medications, most respondents did not express increased concern regarding prescription forgery (75%) or diversion (80%) of buprenorphine/naloxone. Conclusion: The majority of respondents expressed positive attitudes and perceptions regarding patients treated for opioid dependence with buprenorphine/naloxone. C1 Clin Res Pharm Coordinating Ctr, Vet Affairs Cooperat Studies Program, Albuquerque, NM 87106 USA. Vet Affairs Med Ctr, Albuquerque, NM 87106 USA. Vet Affairs Puget Sound Hlth Care Syst, Addict Patient Care Line, Albuquerque, NM USA. NIDA, Div Treatment Res & Dev, Regulatory Affairs Branch, NIH, Bethesda, MD USA. Univ Calif Los Angeles, David Geffen Sch Med, Integrated Substance Abuse Programs, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. Univ Virginia, Dept Psychiat Med, Charlottesville, VA USA. Hines Vet Affairs Med Ctr, Chicago, IL USA. James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL USA. RP Raisch, DW (reprint author), Clin Res Pharm Coordinating Ctr, Vet Affairs Cooperat Studies Program, 2401 Ctr, Albuquerque, NM 87106 USA. EM dennis.raisch@csp.research.med.va.gov FU NIDA NIH HHS [3Y01-DA030011-04] NR 20 TC 10 Z9 11 U1 4 U2 4 PU AMER PHARMACEUTICAL ASSN PI WASHINGTON PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037 USA SN 1544-3191 J9 J AM PHARM ASSN JI J. Am. Pharm. Assoc. PD JAN-FEB PY 2005 VL 45 IS 1 BP 23 EP 32 DI 10.1331/1544345052843200 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 915TK UT WOS:000228333900009 PM 15730114 ER PT J AU Humphreys, BD Soiffer, RJ Magee, CC AF Humphreys, BD Soiffer, RJ Magee, CC TI Renal failure associated with cancer and its treatment: An update SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID BONE-MARROW-TRANSPLANTATION; HEMOLYTIC-UREMIC SYNDROME; TUMOR LYSIS SYNDROME; HEPATIC VENOOCCLUSIVE DISEASE; STEM-CELL TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VERSUS-HOST-DISEASE; RECOMBINANT URATE OXIDASE; ACUTE TUBULAR-NECROSIS; HIGH-DOSE PAMIDRONATE C1 Brigham & Womens Hosp, Div Renal, Dept Med, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Magee, CC (reprint author), Brigham & Womens Hosp, Div Renal, Dept Med, MRB-4,75 Francis St, Boston, MA 02115 USA. EM cmagee@partners.org FU NIDDK NIH HHS [F32 DK069037-01] NR 122 TC 57 Z9 60 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2005 VL 16 IS 1 BP 151 EP 161 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 883JZ UT WOS:000226008700021 PM 15574506 ER PT J AU Young, BA Katon, WJ Von Korff, N Simon, GE Lin, EHB Ciechanowski, PS Bush, T Oliver, M Ludman, EJ Boyko, EJ AF Young, BA Katon, WJ Von Korff, N Simon, GE Lin, EHB Ciechanowski, PS Bush, T Oliver, M Ludman, EJ Boyko, EJ TI Racial and ethnic differences in microalbuminuria prevalence in a diabetes population: The pathways study SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article; Proceedings Paper CT 64th Annual Meeting of the American-Diabetes-Association CY JUN 04-08, 2004 CL Orlando, FL SP Amer Diabetes Assoc ID STAGE RENAL-DISEASE; NUTRITION EXAMINATION SURVEY; EPITHELIAL SODIUM-CHANNEL; URINARY ALBUMIN EXCRETION; RENIN-ANGIOTENSIN SYSTEM; 3RD NATIONAL-HEALTH; AFRICAN-AMERICANS; BLOOD-PRESSURE; MEXICAN-AMERICANS; KIDNEY-DISEASE AB The objective of this study was to determine whether racial or ethnic differences in prevalence of diabetic microalbuminuria were observed in a large primary care population in which comparable access to health care exists. A cross-sectional analysis of survey and automated laboratory data 2969 primary care diabetic patients of a large regional health maintenance organization was conducted. Study data were analyzed for racial/ethnic differences in microalbuminuria (30 to 300 mg albumin/g creatinine) and macroalbuminuria (>300 mg albumin/g creatinine) prevalence among diabetes registry-identified patients who completed a survey that assessed demographics, diabetes care, and depression. Computerized pharmacy, hospital, and laboratory data were linked to survey data for analysis. Racial/ethnic differences in the odds of microalbuminuria and macroalbuminuria were assessed by unconditional logistic regression, stratified by the presence of hypertension. Among those tested, the unadjusted prevalence of micro- or macroalbuminuria was 30.9%, which was similar among the various racial/ethnic groups. Among those without hypertension, microalbuminuria was twofold greater (odds ratio [OR] 2.01; 95% confidence interval [CI] 1.14 to 3.53) and macroalbuminuria was threefold greater (OR 3.17; 95% CI 1.09 to 9.26) for Asians as compared with whites. Among those with hypertension, adjusted odds of microalbuminuria were greater for Hispanics (OR 182; 95% CI 1.16 to 12.57) than whites, whereas adjusted odds of macroalbuminuria were threefold greater for blacks (OR 3.32; 95% CI 1.26 to 8.76) than for whites. For most racial/ethnic minorities, hypertriglyceridemia was significantly associated with greater odds of micro- and macroalbuminuria. Among a large primary care population, racial/ethnic differences exist in the adjusted prevalence of microalbuminuria and macroalbuminuria depending on hypertension status. In this setting, racial/ ethnic differences in early diabetic nephropathy were observed despite comparable access to diabetes care. C1 Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. VA Puget Sound Hlth Care Syst E 152, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. NW Kidney Ctrs, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Ctr Hlth Studies, Grp Hlth Cooperat, Seattle, WA USA. RP Young, BA (reprint author), VA Puget Sound Hlth Care Syst E 152, Epidemiol Res & Informat Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM youngb@u.washington.edu FU NIMH NIH HHS [MH 01643, MH 4-1739] NR 81 TC 44 Z9 45 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2005 VL 16 IS 1 BP 219 EP 228 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 883JZ UT WOS:000226008700030 PM 15563572 ER PT J AU Fjell, AM Walhovd, KB Reinvang, I Lundervold, A Dale, AM Quinn, BT Makris, N Fischl, B AF Fjell, AM Walhovd, KB Reinvang, I Lundervold, A Dale, AM Quinn, BT Makris, N Fischl, B TI Age does not increase rate of forgetting over weeks - Neuro anatomical volumes and visual memory across the adult life-span SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE visual memory; hippocampus; cortex; MRI ID MEDIAL TEMPORAL-LOBE; ALZHEIMERS-DISEASE; HIPPOCAMPAL-FORMATION; RECOGNITION MEMORY; IN-VIVO; HEMISPHERIC-ASYMMETRY; CEREBRAL-CORTEX; FUNCTIONAL MRI; VERBAL MEMORY; OLDER-ADULTS AB The aim of the study was to investigate whether age affects visual memory retention across extended time intervals. In addition, we wanted to study how memory capabilities across different time intervals are related to the volume of different neuroanatomical structures (right hippocampus, right cortex, right white matter). One test of recognition (CVMT) and one test of recall (Rey-Osterrieth Complex Figure Test) were administered, giving measures of immediate recognition /recall, 20-30 min recognition/recall, and recognition /recall at a mean of 75 days. Volumetric measures of right hemisphere hippocampus, cortex, and white matter were obtained through an automated labelling procedure of MRI recordings. Results did not demonstrate a steeper rate of forgetting for older participants when the retention intervals were increased, indicating that older people have spared ability to retain information in the long-term store. Differences in neuroanatomical volumes could explain up to 36% of the variance in memory performance, but were not significantly related to rates of forgetting. Cortical volume and hippocampal volume were in some cases independent as predictors of memory function. Generally, cortical volume was a better predictor of recognition memory than hippocampal volume, while the 2 structures did not differ in their predictive power of recall abilities. While neuroanatomical volumetric differences can explain some of the differences in memory functioning between younger and older persons, the hippocampus does not seem to be unique in this respect. C1 Univ Oslo, Inst Psychol, N-0317 Oslo, Norway. Univ Hosp, Rikshosp, Dept Psychosomat Med, Oslo, Norway. Univ Bergen, Dept Physiol & Locus Neurosci, Bergen, Norway. Harvard Univ, Massachusetts Gen Hosp, MGH NMR Ctr, Cambridge, MA 02138 USA. Norwegian Univ Sci & Technol, MR Ctr, N-7034 Trondheim, Norway. Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Morphometr Anal, Cambridge, MA 02138 USA. RP Fjell, AM (reprint author), Univ Oslo, Inst Psychol, PB 1094, N-0317 Oslo, Norway. EM andersmf@psykologi.uio.no RI Dale, Anders/A-5180-2010 FU NCRR NIH HHS [P01-RR13609, P41-RR14075, R01-RR16594]; NINDS NIH HHS [R01-NS39581] NR 88 TC 21 Z9 21 U1 2 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD JAN PY 2005 VL 11 IS 1 BP 2 EP 15 PG 14 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 906CA UT WOS:000227616900001 PM 15686603 ER PT J AU Hilsabeck, RC Hassanein, TI Ziegler, EA Carlson, MD Perry, W AF Hilsabeck, RC Hassanein, TI Ziegler, EA Carlson, MD Perry, W TI Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE neuropsychological impairment; HCV; chronic liver disease ID HEALTH SURVEY SF-36; QUALITY-OF-LIFE; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; ALFA THERAPY; NEUROTOXICITY; BRAIN; DISORDERS; INFECTION; FATIGUE AB Treatment with inter feron- alpha (IFN-alpha) has been shown to adversely affect cognitive functioning in patients with a variety of medical disorders, but information about the effects of IFN-alpha on cognitive functioning in patients with chronic hepatitis C (CHC) is limited. The purpose of this study was to examine the effects of IFN-alpha on neuropsychological test performance in CHC patients. Participants were 30 patients with CHC, 11 who underwent IFN-a therapy and 19 who did not. All participants were tested at baseline (i.e., pretreatment) and approximately 6 months later with the Symbol Digit Modalities Test and Trail Making Test. Results revealed that the treatment group performed significantly worse than untreated CHC patients on Part B of the Trail Making Test after approximately 6 months of treatment. No significant group differences were found on Part A of the Trail Making Test or Symbol Digit Modalities Test. Findings suggest that CHC patients undergoing treatment with IFN-a may experience reduced abilities to benefit from practice but suffer no decrements in performance after 6 months of treatment. Additional research is needed to replicate these findings and to explore risk factors for susceptibility to IFN-alpha-induced effects. C1 Texas Tech Univ, Ctr Hlth Sci, Dept Neuropsychiat & Behav Sci, Lubbock, TX 79409 USA. Univ Calif San Diego, Dept Med, Div Hepatol, San Diego, CA 92103 USA. Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Hilsabeck, RC (reprint author), S Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM Robin.Hilsabeck@med.va.gov NR 56 TC 26 Z9 27 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD JAN PY 2005 VL 11 IS 1 BP 16 EP 22 PG 7 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 906CA UT WOS:000227616900002 PM 15686604 ER PT J AU Harris, MR AF Harris, MR TI The librarian's roles in the systematic review process: a case study SO JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION LA English DT Article AB Question/Setting: Although the systematic review has become a research standard, little information addresses the actions of the librarian on a systematic review team. Method: This article is an observational case study that chronicles a librarian's required involvement, skills, and responsibilities in each stage of a real-life systematic review. Main Results: Examining the review process reveals that the librarian's multiple roles as an expert searcher, organizer, and analyzer form an integral part of the Cochrane Collaboratior's criteria for conducting systematic reviews. Moreover, the responsibilities of the expert searcher directly reflect the key skills and knowledge depicted in the "Definition of Expert Searching" section of the Medical Library Association's policy statement, "Role of Expert Searching in Health Sciences Libraries." Conclusion: Although the librarian's multiple roles are important in all forms of medical research, they are crucial in a systematic review. As an expert searcher, the librarian must interact with the investigators to develop the terms required for a comprehensive search strategy in multiple appropriate sources. As an organizer and analyzer, the librarian must effectively manage the articles and document the search, retrieval, and archival processes. C1 S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX 78229 USA. RP Harris, MR (reprint author), S Texas Vet Hlth Care Syst, VERDICT, 7400 Merton Minter Blvd,11C6, San Antonio, TX 78229 USA. EM mharris@verdict.uthscsa.edu NR 22 TC 23 Z9 27 U1 0 U2 8 PU MEDICAL LIBRARY ASSOC PI CHICAGO PA 65 EAST WACKER PLACE, STE 1900, CHICAGO, IL 60601-7298 USA SN 1536-5050 J9 J MED LIBR ASSOC JI J. Med. Libr. Assoc. PD JAN PY 2005 VL 93 IS 1 BP 81 EP 87 PG 7 WC Information Science & Library Science SC Information Science & Library Science GA 893OL UT WOS:000226729000015 PM 15685279 ER PT J AU Trimarchi, S Nienaber, CA Rampoldi, V Myrmel, T Suzuki, T Mehta, RH Bossone, E Cooper, JV Smith, DE Menicanti, L Frigiola, A Oh, JK Deeb, MG Isselbacher, EM Eagle, KA AF Trimarchi, S Nienaber, CA Rampoldi, V Myrmel, T Suzuki, T Mehta, RH Bossone, E Cooper, JV Smith, DE Menicanti, L Frigiola, A Oh, JK Deeb, MG Isselbacher, EM Eagle, KA CA International Registry of Acute Ao TI Contemporary results of surgery in acute type A aortic dissection: The International Registry of Acute Aortic Dissection experience SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 84th Annual Meeting of the American-Association-for-Thoracic-Surgery CY APR 25-MAY 28, 2004 CL Toronto, CANADA SP Amer Assoc Throac Surg ID PREVIOUS CARDIAC-SURGERY; ASCENDING AORTA; COMPLETE REPLACEMENT; RISK-FACTORS; MANAGEMENT; MORTALITY; ANEURYSMS; DEFICIT; DEATH; ARCH AB Background: Surgical mortality for acute type A aortic dissection reported in different experiences from single centers or surgeons varies from 7% to 30%. The International Registry of Acute Aortic Dissection, collecting patients from 18 referral centers worldwide, identifies a preoperative risk stratification scheme and a real average surgical mortality for acute type A aortic dissection in the current era. Methods: A comprehensive analysis was completed of 290 clinical variables and their relationship to surgical outcomes in 526 of 1032 patients enrolled in the International Registry of Acute Aortic Dissection from 1996 through 2001. Extracted cases, categorized according to risk profile, were defined as unstable (group I) in the presence of cardiac tamponade; shock; congestive heart failure; cerebrovascular accident; stroke; coma; myocardial ischemia, infarction, or both; electrocardiograms with new Q waves or ST elevation; acute renal failure; or mesenteric ischemia-infarction at the time of the operation. Outside of an unstable condition, patients were categorized as stable (group II). Results: The overall in-hospital mortality was 25.1%. Mortality in group I was 31.4% compared with 16.7% in group II (P < .001). Independent preoperative predictors of operative mortality were history of aortic valve replacement (odds ratio = 3.12), migrating chest pain (odds ratio = 2.77), hypotension as sign of acute type A aortic dissection (odds ratio = 1.95), shock or tamponade (odds ratio = 2.69), preoperative cardiac tamponade (odds ratio = 2.22), and preoperative limb ischemia (odds ratio 2.10). Conclusions: The International Registry of Acute Aortic Dissection experience confirms that patient selection plays an important role in determining surgical outcomes in patients with acute type A aortic dissection. Knowledge of significant risk factors for operative mortality can contribute to better management and a more defined risk assessment in patients affected by acute type A aortic dissection. C1 Ist Policlin S Donato, I-20097 San Donato Milanese, Italy. CNR, Lecce, Italy. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Tromso Hosp, N-9012 Tromso, Norway. Mayo Clin, Rochester, MN USA. Univ Tokyo, Tokyo, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Rostock, D-2500 Rostock 1, Germany. RP Trimarchi, S (reprint author), Ist Policlin S Donato, Via Morandi 30, I-20097 San Donato Milanese, Italy. EM satrimarchi@yahoo.it RI Trimarchi, Santi/J-7361-2016 OI Trimarchi, Santi/0000-0001-5996-3264 NR 31 TC 195 Z9 211 U1 0 U2 5 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JAN PY 2005 VL 129 IS 1 BP 112 EP 122 DI 10.1016/j.jtcvs.2004.09.005 PG 11 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 886HD UT WOS:000226216600016 PM 15632832 ER PT J AU Mempel, TR Pittet, MJ Khazaie, K von Boehmer, H von Andrian, UH AF Mempel, TR Pittet, MJ Khazaie, K von Boehmer, H von Andrian, UH TI Intravital immunology: imaging T cell activation and effector function in vivo SO JOURNAL OF VASCULAR RESEARCH LA English DT Meeting Abstract CT 3rd European Meeting on Vascular Biology and Medicine CY SEP 28-30, 2005 CL Hamburg, GERMANY C1 Harvard Univ, Sch Med, CBR, Inst Biomed Res, Boston, MA 02115 USA. Harvard Univ, Sch Med, CBR, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Faber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2005 VL 42 SU 2 BP 79 EP 79 PG 1 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 974PO UT WOS:000232604100218 ER PT J AU Nicosia, RF Zhu, WH Fogel, E Howson, KM Aplin, AC AF Nicosia, RF Zhu, WH Fogel, E Howson, KM Aplin, AC TI A new ex vivo model to study venous angiogenesis and arterio-venous anastomosis formation SO JOURNAL OF VASCULAR RESEARCH LA English DT Article DE anastomosis; angiogenesis; aorta; collagen; endothelium; pericyte; vein; vena cava ID ENDOTHELIAL GROWTH-FACTOR; RAT AORTA; ASSAY AB Explants of rat inferior vena cava embedded in collagen gel and cultured under serum-free conditions produced microvascular outgrowths composed of endothelial cells and pericytes. Exogenous vascular endothelial growth factor ( VEGF) and basic fibroblast growth factor ( bFGF) dose-dependently stimulated angiogenesis and induced the formation of complex networks of highly branched microvessels. VEGF and the VEGF/bFGF combination also promoted pericyte recruitment. Medium conditioned by untreated vena cava cultures contained endogenous VEGF, and a blocking antibody against VEGF significantly reduced the spontaneous angiogenic response of the explants. Vena cava explants exhibited a greater capacity to form neovessels than aortic rings when tested in parallel cultures from the same animal. When compared with aorta-derived microvessels, neovessels of vena cava origin were longer and had fewer pericytes. Vena cava-aorta cocultures produced extensive anastomosing networks of microvessels, which were primarily contributed by the venous explants. Because of its florid angiogenesis and exquisite sensitivity to angiogenic factor stimulation, the vena cava model may provide novel insights into the regulation of the angiogenic process, which typically initiates from the venous side of the vascular bed. Combined with the aortic ring model, this new assay may also enhance our understanding of the mechanisms of anastomosis formation between the arterial and the venous circulations. Copyright (C) 2005 S. Karger AG, Basel. C1 VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Seattle, WA 98108 USA. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med S113 Lab, 1660 S Columbian Way, Seattle, WA 98108 USA. EM roberto.nicosia@med.va.gov FU NHLBI NIH HHS [HL52585] NR 18 TC 23 Z9 26 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2005 VL 42 IS 2 BP 111 EP 119 DI 10.1159/000083457 PG 9 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 917CV UT WOS:000228434500003 PM 15665546 ER PT J AU Dominguez, H Storgaard, H Rask-Madsen, C Hermann, TS Ihlemann, N Nielsen, DB Spohr, C Kober, L Vaag, A Torp-Pedersen, C AF Dominguez, H Storgaard, H Rask-Madsen, C Hermann, TS Ihlemann, N Nielsen, DB Spohr, C Kober, L Vaag, A Torp-Pedersen, C TI Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes SO JOURNAL OF VASCULAR RESEARCH LA English DT Article DE etanercept; tumor necrosis factor-alpha; type 2 diabetes ID IMPROVES ENDOTHELIAL FUNCTION; INCREASED INSULIN SENSITIVITY; A REDUCTASE INHIBITOR; TNF-ALPHA; ADIPOSE-TISSUE; RHEUMATOID-ARTHRITIS; FACTOR RECEPTOR; FUSION PROTEIN; GLUCOSE-UPTAKE; WEIGHT-LOSS AB Objective: The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) impairs insulin action in insulin-sensitive tissues, such as fat, muscle and endothelium, and causes endothelial dysfunction. We hypothesized that TNF-alpha blockade with etanercept could reverse vascular and metabolic insulin resistance. Method and Results: Twenty obese patients with type 2 diabetes were randomized to etanercept treatment ( 25 mg subcutaneously twice weekly for 4 weeks) or used as controls in an open parallel study. Forearm blood flow and glucose uptake were measured during intra-arterial infusions of serotonin, sodium nitroprusside and insulin co-infused with serotonin. beta-Cell function was assessed with oral and intra-venous glucose tolerance tests and whole-body insulin sensitivity by hyperinsulinemic euglycemic clamps. Plasma levels of C-reactive protein and interleukin-6 decreased significantly with etanercept (C-reactive protein from 9.9 +/- 3.1 to 4.8 +/- 1.4 mg l(-1), p = 0.04; interleukin-6 from 3.1 +/- 0.4 to 1.9 +/- 0.2 ng l(-1), p = 0.03). Vasodilatory responses to serotonin and sodium nitroprusside infusions remained unchanged. Insulin effect on vasodilatation and on whole-body and forearm glucose uptake remained unchanged as well. beta-Cell function tended to improve. Conclusion: Although short-term etanercept treatment had a significant beneficial effect on systemic inflammatory markers, no improvement of vascular or metabolic insulin sensitivity was observed. Copyright (C) 2005 S. Karger AG, Basel. C1 Bispebjerg Univ Hosp, Dept Cardiol, Res Unit, DK-2400 Copenhagen, Denmark. Univ Hosp, Rigshosp, Ctr Heart, Copenhagen, Denmark. Steno Diabet Ctr, DK-2820 Gentofte, Denmark. Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Dominguez, H (reprint author), Bispebjerg Univ Hosp, Dept Cardiol, Res Unit, Bldg 40,Bispebjerg Bakke 234, DK-2400 Copenhagen, Denmark. EM hd@heart.dk RI Torp-Pedersen, Christian/E-5931-2013; OI DOMINGUEZ, HELENA/0000-0002-7089-2636 NR 48 TC 145 Z9 150 U1 1 U2 14 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2005 VL 42 IS 6 BP 517 EP 525 DI 10.1159/000088261 PG 9 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 975MU UT WOS:000232667400008 PM 16155368 ER PT J AU Makaroun, MS Dillavou, ED Kee, ST Sicard, G Chaikof, E Bavaria, J Williams, D Cambria, RP Mitchell, RS AF Makaroun, MS Dillavou, ED Kee, ST Sicard, G Chaikof, E Bavaria, J Williams, D Cambria, RP Mitchell, RS CA GORE TAG Investigators TI Endovascular treatment of thoracic aortic aneurysms: Results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 58th Annual Meeting of the Society-for-Vascular-Surgery CY JUN 03-06, 2004 CL Anaheim, CA SP Soc Vasc Surg ID STENT-GRAFT REPAIR; INITIAL EXPERIENCE; FOLLOW-UP; PLACEMENT; EXCLUDER; SURGERY; DEVICES AB Objective: A decade after the first report of descending thoracic aortic aneurysm (DTA) repair with endografts, a commercial device is yet to be approved in the United States. The GORE TAG endoprosthesis, an investigational nitinol-supported expanded polytetrafluoroethylene tube graft with diameters of 26 to 40 mm, is the first DTA device to enter phase 11 trials in the United States and has been used worldwide for a host of thoracic pathologies. Methods. A multicenter prospective nonrandomized phase 11 study of the GORE TAG endoprosthesis was conducted at 17 sites. Enrollment was from September 1999 to May 2001. Preoperative workup included arteriography and spiral computed tomography scans of the chest, abdomen, and pelvis. Follow-up radiographs and computed tomography scans were obtained at 1, 6, and 12 months and yearly thereafter. Results. A total of 139 (98%) of 142 patients had a successful implantation of the device. Inadequate arterial access was responsible for the 3 failures. The mean DTA size was 64.1 +/- 15.4 mm. Men slightly outnumbered women (57.7%), with an average age of 71 years, and 88% of the patients were white. Ninety percent were American Society of Anesthesiologists category III or IV. One device was used in 44% of patients, and 56% required two or more devices to bridge the thoracic aorta. The left subclavian artery was covered in 28 patients, with planned carotid-subclavian transposition. The procedure time averaged 150 minutes, estimated blood loss averaged 506 mL, intensive care unit stay averaged 2.6 days, and hospital stay averaged 7.6 days. Within 30 days, 45 (32%) patients had at least 1 major adverse event: 5 (4%) experienced a stroke, 4 (3%) demonstrated temporary or permanent paraplegia, 20 (14%) experienced vascular trauma or thrombosis, and 2 (1.5%) died. Mean follow-up was 24.0 months. Four patients had aneurysm-related deaths. Three patients underwent endovascular revisions for endoleak. No ruptures have been reported. Twenty wire fractures have been identified in 19 patients; 18 (90%) of these occurred in the longitudinal spine, and only 1 patient required treatment. At 2 years, aneurysm-related and overall survival rates are 97% and 75%, respectively. Conclusions. The GORE TAG thoracic endoprosthesis provides a safe alternative for the treatment of DTAs, with low mortality, relatively low morbidity, and excellent 2-year freedom from aneurysm-related death. Longitudinal spine fractures have so far been associated with rare clinical events. C1 Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA. Stanford Univ, Stanford, CA 94305 USA. Washington Univ, St Louis, MO 63130 USA. Emory Univ, Atlanta, GA 30322 USA. Univ Penn, Philadelphia, PA 19104 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Makaroun, MS (reprint author), Univ Pittsburgh, Med Ctr, 200 Lothrop,Ste A-1011, Pittsburgh, PA 15213 USA. EM makarounms@upmc.edu NR 22 TC 365 Z9 381 U1 1 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2005 VL 41 IS 1 BP 1 EP 8 DI 10.1016/j.jvs.2004.10.046 PG 8 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 902XH UT WOS:000227389500001 PM 15696036 ER PT J AU Casey, PJ Black, JH Szabo, C Frosch, M Albadawi, H Chen, M Cambria, RP Watkins, MT AF Casey, PJ Black, JH Szabo, C Frosch, M Albadawi, H Chen, M Cambria, RP Watkins, MT TI Poly(adenosine diphosphate ribose) polymerase inhibition modulates spinal cord dysfunction after thoracoabdominal aortic ischemia-reperfasion SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 89th Annual Clinical Congress of the American-College-of-Surgeons CY OCT 19-23, 2003 CL CHICAGO, IL SP Amer Coll Surg ID CENTRAL-NERVOUS-SYSTEM; POTENT INHIBITOR; INFLAMMATORY CYTOKINE; DEFICIENT MICE; SYNTHETASE; INJURY; MODEL; REPERFUSION; CONTRIBUTES; DISRUPTION AB Objective: Spinal cord injury (SCI) remains a source of morbidity after thoracoabdominal aortic reconstruction. These studies were designed to determine whether PJ34, a novel ultrapotent inhibitor of the nuclear enzyme poly(adenosine diphosphate ribose) polymerase (PAR-P) could modulate neurologic injury after thoracic aortic ischemia reperfusion (TAR) in a murine model of SCI. Methods. Forty-one anesthetized male mice were subject to thoracic aortic occlusion (11 minutes) through a cervical mediastinotomy followed by 48 hours of reperfusion (TAR) under normothermic conditions. PJ34-treated mice (PJ, n = 12) were given 10 mg/kg PJ34 intraperitoneally I hour before ischemia and I hour after unclamping. The control group (UN, n = 21) received normal saline intraperitoneally I hour before ischemia and I hour after unclamping. Sham animals (n = 10) were subject to thoracic aortic exposure with no aortic clamping and similar intraperitoneal normal saline injections. PARP-1-/- (KO, n = 8) mice were subjected to the same conditions as the UN mice. Blinded observers rated murine neurologic status after TAR.by using an established rodent paralysis scoring system. Murine spinal cords were subjected to cytokine (GRO-1) protein analysis as a marker of inflammation and immunohistochemical analysis (hematoxylin-eosin and PAR staining). Paralysis scores (PS) and GRO-1 levels were compared with analysis of variance, and survival data were compared with x(2). Results: Immediately after TAR, UN and PJ mice had severe neurologic dysfunction (PS = 5.8 +/- 0.1 and 4.6 +/- 0.6, respectively; P >.05), which was significantly worse than the KO mice (PS = 1.0 +/- 0.7, P <.001). After 6, 24, and 48 hours KO mice had no discernable neurologic injury (PS = 0). Six hours after TAR, PJ mice significantly improved (PS = 1.1 +/- 0.73, P <.001) and remained improved at 24 (PS = 0.7 +/- 0.6) and 48 hours (PS = 0.6 +/- 0.6). UN mice did not improve their PS, and Sham mice showed no neurologic abnormality at any time during these experiments. The mortality at 48 hours was 0% for PJ and KO mice, 43% for UN (P =.012), and 0% for Sham. GRO-1 levels were significantly decreased in PJ and KO versus UN mice (UN, 583 +/- 119 vs PJ, 5.8 +/- 0 vs KO, 5.3 +/- 1.4 mg/pg; P <.0001). Immunohistochemistry showed evidence of decreased PAR staining and ventral motor neuron injury in PJ mice. Conclusions. Genetic deletion of PAR-P or inhibition of its activity (PJ34) rescued neurologic function in mice subjected to TAR. PARP inhibition might represent a novel therapeutic approach for prevention of SCI after TAR. (J Vasc Surg 2005;41:99-107.) Clinical relevance: Because paralysis caused by spinal cord ischemia remains a serious complication of thoracic aortic aneurysm repair, effective therapeutic strategies to prevent or decrease its incidence are desirable. Although there is hope that the systemic complications associated with open thoracic aortic aneurysm repair will be avoided by managing these lesions with catheter-based endovascular approaches, the initial experiences suggest that spinal cord ischemia might continue to be an unresolved clinical problem. C1 Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Neuropathol, Boston, MA 02114 USA. Inotek Pharmaceut Corp, Beverly, MA USA. VA Boston Healthcare Syst, Dept Surg, Boston, MA USA. RP Watkins, MT (reprint author), Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, 15 Parkman St,Suite 458, Boston, MA 02114 USA. EM mtwatkins@partners.org NR 32 TC 18 Z9 18 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2005 VL 41 IS 1 BP 99 EP 107 DI 10.1016/j.jvs.2004.10.040 PG 9 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 902XH UT WOS:000227389500020 PM 15696051 ER PT J AU Rosenfield, KM AF Rosenfield, KM CA SCAI SVMB SVS Writing Comm TI Clinical competence statement on carotid stenting: Training, and credentialing for carotid stenting - Multispecialty consensus recommendations SO JOURNAL OF VASCULAR SURGERY LA English DT Editorial Material ID ARTERIES; DISEASE C1 Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Rosenfield, KM (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,Bullfinch 105, Boston, MA 02114 USA. EM krosenfield@fastmail.us NR 7 TC 27 Z9 28 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2005 VL 41 IS 1 BP 160 EP 168 DI 10.1016/j.jvs.2004.12.009 PG 9 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 902XH UT WOS:000227389500031 PM 15696063 ER PT J AU Zupan, LH Merfeld, DA AF Zupan, LH Merfeld, DA TI Human ocular torsion and perceived roll responses to linear acceleration SO JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION LA English DT Article DE human; graviceptors; ocular torsion; tilt perception; spatial orientation ID SQUIRREL-MONKEY; VESTIBULOOCULAR REFLEX; SPATIAL ORIENTATION; ECCENTRIC ROTATION; HEAD ORIENTATION; INERTIAL MOTION; OTOLITH ORGANS; EYE-MOVEMENTS; TILT; PERCEPTION AB We investigated if human ocular torsion (OT) and perceived roll (PR) are elicited in response to either dynamic interaural linear acceleration or dynamic roll tilt of the gravito-inertial force (GEF). We expanded a previous study [26] that measured only OT across a limited frequency-range (from 0.35 Hz to 1 Hz) by simultaneously measuring OT and PR at three very low (0.01, 0.02 and 0.05 Hz) and one high (1 Hz) frequencies. Three experimental conditions were investigated: (1) Y-Upright with acceleration along the interaural (Y) axis while upright, (2) Y-Supine with acceleration along the Y-axis while supine, and (3) Z-RED with acceleration along the rostro-caudal (Z) axis with right-ear-down (RED). OT was measured by video-oculography, while PR was measured by use of a somatosensory bar. OT and PR were qualitatively different. Large OT responses were measured for Y-Upright and Y-Supine, while large perceived roll responses were observed for Y-Upright and Z-RED. OT for Z-RED was small, and PR for Y-Supine was absent. In conclusion, OT and PR appear governed by qualitatively different neural mechanisms. OT appears mostly influenced by central low-pass filtering of interaural graviceptor cues, while PR appears mostly influenced by roll tilt of the GIF. C1 Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Zupan, LH (reprint author), Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, Suite 421, Boston, MA 02114 USA. EM lionel_zupan@meei.harvard.edu FU NIDCD NIH HHS [DC000205, DC004158, F32 DC000205, R01 DC000205, R01 DC004158] NR 43 TC 14 Z9 14 U1 0 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0957-4271 J9 J VESTIBUL RES-EQUIL JI J. Vestib. Res.-Equilib. Orientat. PY 2005 VL 15 IS 4 BP 173 EP 183 PG 11 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 003SC UT WOS:000234700900001 PM 16286699 ER PT J AU Wall, C Kentala, E AF Wall, C Kentala, E TI Control of sway using vibrotactile feedback of body tilt in patients with moderate and severe postural control deficits SO JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION LA English DT Article DE balance rehabilitation; postural control; balance prosthesis ID VESTIBULAR DEFICITS AB We evaluated the effect of the vibrotactile display of body tilt upon the postural stability of vestibulopathic subjects during standing. Two groups were studied: those with moderate and with severe deficits as defined by postural stability test scores. They were studied under conditions of distorted sensory input, and during anterior-posterior perturbations. Seventeen subjects, with uni- or bilateral vestibular deficits, as determined by electronystagrnography and vertical axis rotation, were tested using Equitest(R) computerized dynamic posturography (CDP). Based on their performance on the CDP they were divided into two groups having either moderate (nine subjects) or severe (eight subjects) postural control deficits. Their anterior-posterior (A/P) body motion at the waist was measured with a micromechanical rate gyroscope and a linear accelerometer. The resulting tilt estimate was displayed by a vibrotactile array attached to the torso. The vibration served as a tilt feedback to the subject. The subject's performance was evaluated using the root-mean-square (RMS) of both the A/P body motion and center-of-pressure (CoP) estimates. Sensory distortions were introduced using the Equitest(R) Sensory Organization Tests (SOT). These tests are designed to distort A/P sensory inputs while standing. The SOT 5 distorts proprioceptive information about ankle joint movement, while the subject stands eyes-closed on a moving support platform that measures foot pressure. The SOT 6 adds distorted visual information about body movement instead of testing with eyes closed. Perturbations were introduced using the Equitest(R) Motor Control Tests (MCT). These move the support platform forward or backward with small, medium and large displacements in the horizontal plane while measuring subjects' foot pressure responses. We used the medium and large backward tests. Vibrotactile display of body tilt reduced the subjects' A/P sway and improved their balance. The finding was more evident for those subjects with severe deficits than those moderate ones. This trend was found for both SOT 5 and 6, as well as the medium and large MCT. Additionally, during the MCT, the peak deflection and mean recovery time also decreased significantly. C1 Massachusetts Eye & Ear Infirm, Jenks Vestibular Diagnost Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. Univ Helsinki Hosp, Dept Otolaryngol, Helsinki, Finland. RP Wall, C (reprint author), Massachusetts Eye & Ear Infirm, Jenks Vestibular Diagnost Lab, 243 Charles St, Boston, MA 02114 USA. EM cwall@mit.edu FU NIDCD NIH HHS [R01 DC6201] NR 13 TC 59 Z9 61 U1 7 U2 12 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0957-4271 J9 J VESTIBUL RES-EQUIL JI J. Vestib. Res.-Equilib. Orientat. PY 2005 VL 15 IS 5-6 BP 313 EP 325 PG 13 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 044RB UT WOS:000237688900007 PM 16614476 ER PT J AU Butt, AA Wagener, M Shakil, AO Ahmad, J AF Butt, AA Wagener, M Shakil, AO Ahmad, J TI Reasons for non-treatment of hepatitis C in veterans in care SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE hepatitis C; treatment; veterans; adherence; viral hepatitis ID INJECTION-DRUG USERS; VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; PEGINTERFERON ALPHA-2A; PLUS RIBAVIRIN; PREVALENCE; INTERFERON; THERAPY; RISK AB We prospectively studied 354 patients with hepatitis C virus (HCV) infection who were referred to a hepatology specialty clinic to find the reasons for non-treatment of HCV. The median age was 48 years (range 27-77 years), 98.5% were male and 71% were white. Seventy per cent of the patients were not treated. The most common reasons for non-treatment were non-adherence to follow-up visit (24%), normal liver enzymes (14%), concurrent medical problems (11%), alcohol and drug use (9%), psychiatric problems (7%), advanced liver disease (7%), referral for transplant evaluation (6.4%) and patient refusal, transfer of care to another facility and non-detectable HCV RNA levels (5% each). The reason was not recorded for 5% of the patients and was treatment deferred in 2.4% while waiting for pegylated interferon approval. Non-treatment was more likely in patients with less than 12 years of education and a history of incarceration. Patients who were lost to follow-up and refused treatment were more likely to have current alcohol and drug use and a history of incarceration. C1 Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. RP Butt, AA (reprint author), 36014 5th Ave,Suite 3A,Falk Med Bldg, Pittsburgh, PA 15213 USA. EM butta@msx.dept-med.pitt.edu NR 16 TC 64 Z9 64 U1 0 U2 1 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD JAN PY 2005 VL 12 IS 1 BP 81 EP 85 DI 10.1111/j.1365-2893.2005.00547.x PG 5 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 889QR UT WOS:000226458000012 PM 15655052 ER PT J AU Saab, S Lee, C Shpaner, A Ibrahim, AB AF Saab, S Lee, C Shpaner, A Ibrahim, AB TI Seroepidemiology of hepatitis A in patients with chronic liver disease SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE hepatitis A seroprevalence; chronic liver disease ID DRUG-USERS; VACCINATION; VIRUSES AB Hepatitis A virus (HAV) rarely causes fulminant hepatic failure in the general population. Yet it is a cause of significant morbidity and mortality in patients with chronic liver disease (CLD), in whom routine HAV vaccination is recommended. However, studies of HAV seroprevalence and exposure predictors in populations with CLD are scarce. We have studied a cohort of 473 patients with various causes of CLD between July 2000 and June 2002. Patients were stratified on the basis of age, gender, ethnicity and aetiology of liver disease. The HAV seroprevalence in patients with CLD was compared with that in the general population. We used a logistic regression analysis to identify independent predictors of HAV exposure. Of the 473 patients studied, HAV seroprevalence was available for 454 individuals. HCV, HBV, alcohol, and HCV and alcohol were the causes of CLD in 337, 72, 37 and eight patients, respectively. The overall HAV seroprevalence was 55% in the studied cohort. The age-stratified HAV prevalence for ages 21-30, 31-40, 41-50, 51-60, 61-70 and greater than 70 years was 44, 51, 44, 63, 65 and 64%, respectively. Hispanic ethnicity, Asian ethnicity, alcohol use and ages of 51-70 years were found to be independent predictive variables of prior exposure to HAV. HAV infection in patients with CLD causes considerable morbidity and mortality. We demonstrated that age-stratified seroprevalence of HAV in patients with CLD of various aetiologies is significantly higher than that of the general population, and identified several independent predictors of HAV prior exposure. C1 Univ Calif Los Angeles, Med Ctr, Div Digest Dis, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dumont UCLA Liver Transplant Ctr, Dept Surg, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Epidemiol Sch Publ Hlth, Los Angeles, CA 90095 USA. W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. RP Saab, S (reprint author), Univ Calif Los Angeles, Med Ctr, Div Digest Dis, Dept Med, 44-138 CHS MC 168417,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM ssaab@mednet.ucla.edu NR 19 TC 16 Z9 16 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD JAN PY 2005 VL 12 IS 1 BP 101 EP 105 DI 10.1111/j.1365-2893.2005.00551.x PG 5 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 889QR UT WOS:000226458000016 PM 15655056 ER PT J AU Muller, L Saydam, O Saeki, Y Heid, I Fraefel, C AF Muller, L Saydam, O Saeki, Y Heid, I Fraefel, C TI Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Baff virus hybrid amplicons SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE HSV-1 hybrid vectors; liver; gene therapy; amplicon; SEAP ID SITE-SPECIFIC INTEGRATION; BARR-VIRUS; TRANSGENE EXPRESSION; CAG PROMOTER; HUMAN-CELLS; HIGH-LEVEL; VECTORS; SYSTEM; THERAPY; MICE AB Gene transfer into hepatocytes is highly desirable for the long-term goal of replacing deficient proteins and correcting metabolic disorders. Vectors based on herpes simplex virus type-1 (HSV-1) have been demonstrated to mediate efficient gene transfer into hepatocytes both in vitro and in vivo. Large transgene capacity and extrachromosomall persistence make HSV-1/EBV hybrid amplicon vectors an attractive candidate for hepatic gene replacement therapy. To assess liver-directed gene transfer, we constructed (i) a conventional HSV-1 amplicon vector encoding a secreted reporter protein (secreted alkaline phosphatase, SEAP) under the control of the HSV-1 immediate-early 4/5 promoter; (ii) a HSV-1 amplicon encoding SEAP under the control of the artificial CAG promoter (the chicken P-actin promoter and cytomegalovirus (CMV) immediate-early enhancer); and (iii) a HSV-1/EBV hybrid amplicon, also encoding SEAP under the control of the CAG promoter. While all three vector constructs yielded high SEAP concentrations in vitro and in vivo, use of HSV-1/EBV hybrid amplicon vectors significantly prolonged the duration of gene expression. Using conventional amplicon vectors in cultured hepatocytes, SEAP was detected for two weeks, whereas SEAP was detected for at least six weeks when HSV-1/EBV amplicons were used. Intraparenchymal injection into the liver of SICD mice yielded high (up to 77 ng of SEAP per milliliter serum) and sustained (greater than three weeks) expression of SEAR Serum transaminases (ALT/AST) were measured at different time points to monitor for hepatocellular damage. While initially elevated four times above baseline, the transaminase levels returned to normal after three to seven days. These results demonstrate the usefulness of HSV-1-based amplicons and SEAP for the evaluation of gene replacement strategies in the liver. (C) 2004 Elsevier B.V. All rights reserved. C1 Univ Dusseldorf, Ctr Pediat & Adolescent Med, D-4000 Dusseldorf, Germany. Univ Zurich, Inst Virol, Zurich, Switzerland. Massachusetts Gen Hosp, Mol Neurooncol Labs, Neurosurg Serv, Charlestown, MA USA. RP Muller, L (reprint author), Childrens Hosp, Med Ctr, 3333 Burnett Ave, Cincinnati, OH 45229 USA. EM lars.muller@cchmc.org NR 31 TC 20 Z9 21 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD JAN PY 2005 VL 123 IS 1 BP 65 EP 72 DI 10.1016/j.jviromet.2004.09.007 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 885WS UT WOS:000226188600009 PM 15582700 ER PT J AU Popov, S Chenine, AL Gruber, A Li, PL Ruprecht, RM AF Popov, S Chenine, AL Gruber, A Li, PL Ruprecht, RM TI Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells SO JOURNAL OF VIROLOGY LA English DT Article ID LANGERHANS CELLS; T-CELLS; CHEMOKINE-CORECEPTORS; VIRAL REPLICATION; MOLECULAR CLONE; IN-VIVO; HIV-1; TYPE-1; ACTIVATION; BLOOD AB Myeloid, CD1a-sorted dendritic cells (MDC) productively replicated human immunodeficiency virus strains encoding envelope genes of either primary X4R5 or R5 strains for up to 45 days. Cell-free supernatant collected from long-term infected MDC, which had been exposed to an X4R5 virus 45 days earlier, was still infectious when placed over activated T cells. These data imply that DC can act as a persistent reservoir of infectious virus. C1 Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Ruprecht, RM (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St,JFB 809, Boston, MA 02115 USA. EM ruth_ruprecht@dfci.harvard.edu FU NIAID NIH HHS [R01 AI43839]; NIDCR NIH HHS [R01 DE016013, R01 DE012937, R01 DE12937] NR 34 TC 22 Z9 23 U1 2 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2005 VL 79 IS 1 BP 602 EP 608 DI 10.1128/JVI.79.1.602-608.2005 PG 7 WC Virology SC Virology GA 881YF UT WOS:000225904700057 PM 15596853 ER PT J AU Chenine, AL Ferrantelli, F Hofmann-Lehmann, R Vangel, MG McClure, HM Ruprecht, RM AF Chenine, AL Ferrantelli, F Hofmann-Lehmann, R Vangel, MG McClure, HM Ruprecht, RM TI Older rhesus macaque infants are more susceptible to oral infection with simian-human immunodeficiency virus 89.6P than neonates SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN MONOCLONAL-ANTIBODIES; PASSIVE-IMMUNIZATION; MUCOSAL INFECTION; LYMPHOID-TISSUE; HIV-1; TRANSMISSION; TYPE-1; MONKEYS; VIVO; SIV AB Earlier primate studies revealed that oral transmission of immunodeficiency viruses can occur at all ages [R. M. Ruprecht et al., J. Infect. Dis. 179(Suppl. 3):S408-S412, 1999]. Using a stock of pathogenic simian-human immunodeficiency virus, SHIV89.6P, we compared the 50% animal infectious dose needed to achieve systemic infection after oral challenge in newborn and older infant or juvenile rhesus macaques. Unexpectedly, the older monkeys required a 150-fold-lower virus challenge dose than the neonates (P = 3.3 x 10(-5)). In addition, at least 60,000 times more virus was needed to achieve systemic infection in neonates by the oral route than by the intravenous route (P < 1 x 10(-5)). Thus, route of inoculation and age are important determinants of SHIV89.6P infectivity in rhesus macaques. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. RP Ruprecht, RM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, 44 Binney St,JFB809, Boston, MA 02115 USA. EM ruth_ruprecht@dfci.harvard.edu RI Hofmann-Lehmann, Regina/C-6528-2009; Ferrantelli, Flavia/J-7794-2016 OI Ferrantelli, Flavia/0000-0002-0768-1078 FU NCIRD CDC HHS [IP30 28691]; NCRR NIH HHS [RR-00165, P51 RR000165]; NIAID NIH HHS [P01 AI048240, R37 AI034266, AI34266, P01AI48240, R01 AI034266]; NIDCR NIH HHS [DE016013, R01 DE012937, R01 DE016013, R01DE12937] NR 27 TC 5 Z9 5 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2005 VL 79 IS 2 BP 1333 EP 1336 DI 10.1128/JVI.79.2.1333-1336.2005 PG 4 WC Virology SC Virology GA 885IG UT WOS:000226149700068 PM 15613361 ER PT J AU Martin, JL Mory, AK Alessi, CA AF Martin, JL Mory, AK Alessi, CA TI Nighttime oxygen desaturation and symptoms of sleep-disordered breathing in long-stay nursing home residents SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 14-18, 2003 CL BALTIMORE, MD SP Amer Geriatr Soc ID APNEA; MORTALITY; DEMENTIA; OXIMETRY; ADULTS; RISK AB Background. Sleep-disordered breathing (SDB) is common in older adults and has been implicated as a cause of decreased quality of life and even death. Sparse data exist on SDB in the nursing home setting. The authors evaluated SDB (using attended nocturnal pulse oximetry) in nursing home residents with daytime sleepiness and nighttime sleep disturbance. Methods. Pulse oximetry was used to estimate the prevalence of nighttime oxygen desaturation in 109 long-stay nursing home residents (mean [standard deviation] age = 86.2 [9.2] years: 74% women). Pulse oximetry findings were compared to a structured observational measurement of symptoms of SDB, the Observational Sleep Assessment Instrument. Seventy-one participants had concurrent wrist actigraphy to estimate total sleep time during oximetry recording. Results. Using the oxygen desaturation index (ODI: average number of oxygen desaturations 4% or more below the baseline level per hour), the authors found that 40% of the residents had abnormal ODI (ODI more than 5, which is suggestive of SDB). Of all observational variables assessed, only loud breathing during sleep was significantly correlated with ODI (r = .284; p = .003). When ODI was adjusted for estimated total sleep time, higher adjusted ODI was associated with higher body mass index (kg/m(2)). Conclusions. Abnormal ODI is common in nursing home residents. Observed loud breathing at night and high body mass index may suggest that further assessment of SDB is indicated. Future research should determine the importance of SDB and abnormal nocturnal oxygen desaturation on functioning and quality of life in nursing home residents. C1 Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. Jefferson Med Coll, Philadelphia, PA USA. RP Martin, JL (reprint author), Vet Adm Med Ctr, GRECC 11E,16111 Plummer St, Sepulveda, CA 91343 USA. FU NIA NIH HHS [AG13885] NR 23 TC 16 Z9 16 U1 1 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2005 VL 60 IS 1 BP 104 EP 108 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 902MF UT WOS:000227360500016 PM 15741291 ER PT J AU Fox, CS Yang, Q Guo, CY Cupples, LA Wilson, PWF Levy, D Meigs, JB AF Fox, CS Yang, Q Guo, CY Cupples, LA Wilson, PWF Levy, D Meigs, JB TI Genome-wide linkage analysis to urinary microalbuminuria in a community-based sample: The Framingham Heart Study SO KIDNEY INTERNATIONAL LA English DT Article DE microalbuminuria; kidney; genetics; linkage ID ALBUMIN EXCRETION; DIABETIC-NEPHROPATHY; CARDIOVASCULAR MORTALITY; VARIANCE-COMPONENTS; RENAL-INSUFFICIENCY; CHROMOSOME 19Q13; BLOOD-PRESSURE; DISEASE; PREDICTOR; PEDIGREES AB Introduction. Microalbuminuria is a powerful risk factor for cardiovascular disease. It is not known whether genetic factors play a role in the expression of microalbuminuria in population-based samples. Methods. Genome-wide variance components linkage-analysis using 401 markers spaced at similar to10 cM was performed on subjects from 330 extended families of the Framingham Heart Study; a subanalysis was performed on families enriched for hypertension. Urinary microalbumin was indexed to urinary creatinine [urine albumin/creatinine ratio (UACR)] and was log-transformed for analysis. Residuals of log-transformed UACR adjusted for age, gender, body mass index, diabetes, systolic blood pressure, hypertension treatment, smoking, and serum creatinine were used in the linkage analysis. Results. Among 1055 subjects (52% women), mean age 56 years, median UACR was 5.8 mg/g (11%>30 mg/g). The unadjusted heritability for UACR was 0.20; after multivariable adjustment, heritability was 0.16. The peak multivariable-adjusted multipoint logarithm of odds (LOD) score was 2.22 on chromosome 8 at 135 cM (marker D8S1179); one LOD support interval=129-145 cM. In the subanalysis in families enriched for hypertension (N=676), the peak multivariable-adjusted LOD score of 2.11 was observed at the same location. Conclusion. We found suggestive linkage to urinary microalbumin on chromosome 8. At least one potential candidate gene implicated in the pathogenesis of nephropathy (HAS2) lies in this region. Further research is warranted to understand the genetic basis of microalbuminuria. C1 NHLBI, Framingham Heart Study, Framingham, MA USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. Boston Univ, Sch Med, Boston, MA 02118 USA. NHLBI, NIH, Bethesda, MD 20892 USA. Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA. RP Fox, CS (reprint author), 73 Mt Wayte Ave Suite 2, Framingham, MA 01702 USA. EM foxca@nhlbi.nih.gov RI Yang, Qiong/G-5438-2014 FU NHLBI NIH HHS [N01-HC-25195] NR 36 TC 37 Z9 38 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2005 VL 67 IS 1 BP 70 EP 74 DI 10.1111/j.1523-1755.2005.00056.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 878GO UT WOS:000225635000007 PM 15610229 ER PT J AU Revzin, A Sekine, K Sin, A Tompkins, RG Toner, M AF Revzin, A Sekine, K Sin, A Tompkins, RG Toner, M TI Development of a microfabricated cytometry platform for characterization and sorting of individual leukocytes SO LAB ON A CHIP LA English DT Article ID LASER-SCANNING CYTOMETRY; POLY(ETHYLENE GLYCOL) PHOTOLITHOGRAPHY; CAPTURE MICRODISSECTION; GENE-EXPRESSION; FLOW-CYTOMETRY; CELL BEHAVIOR; CANCER; MICROENVIRONMENT; LYMPHOCYTES; DIAGNOSIS AB Organizing leukocytes into high-density arrays makes these cells amenable to rapid optical characterization and subsequent sorting, pointing to clinical and basic science applications. The present paper describes development of a cytometry platform for creating high-density leukocyte arrays and demonstrates retrieval of single cells from the array. Poly( ethylene glycol) (PEG) photolithography was employed to fabricate arrays of microwells composed of PEG hydrogel walls and glass attachment pads 20 mum x 20 mum and 15 mum x 15 mum in size. PEG micropatterned glass surfaces were further modified with cell-adhesive ligands, poly-L-lysine, anti-CD5 and anti-CD19 antibodies, in order to engineer specific cell-surface interactions within the individual wells. Localization of the fluorescently-labeled proteins in the glass attachment pads of PEG microwells was visualized by fluorescence microscopy. Glass slides micropatterned with PEG and cell-adhesive ligands were exposed to T-lymphocytes for 30 min. These anchorage-independent cells became selectively captured in the ligand-modified microwells forming high-density cell arrays. Cell occupancy in the microwells was found to be antibody-dependent, reaching 94.6 +/- 2.3% for microwells decorated with T-cell specific anti-CD5 antibodies. Laser capture microdissection (LCM) was investigated as a method for sorting cells from the array and retrieval of single selected cells was demonstrated. C1 Shriners Hosp Children, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA. RP Toner, M (reprint author), Shriners Hosp Children, 51 Blossom St, Boston, MA 02114 USA. EM mtoner@hms.harvard.edu RI Sekine, Kazuhiko/I-5835-2012 FU NIBIB NIH HHS [P41 EB002503]; NIGMS NIH HHS [T32GM07035] NR 44 TC 115 Z9 119 U1 1 U2 24 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0189 J9 LAB CHIP JI Lab Chip PY 2005 VL 5 IS 1 BP 30 EP 37 DI 10.1039/b405557h PG 8 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 881SF UT WOS:000225889000005 PM 15616737 ER PT J AU Azabdaftari, G Shah, R Bismar, TA Kim, R Zerkowski, MP Rimm, D Pienta, KJ AF Azabdaftari, G Shah, R Bismar, TA Kim, R Zerkowski, MP Rimm, D Pienta, KJ TI Androgen receptor expression in hormone refractory prostate cancer from a rapid autopsy series: Quantitative subcellular localization using AQUA SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Yale Univ, Sch Med, New Haven, CT USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 5 BP 5A EP 5A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600006 ER PT J AU Oliveira, AM Perez-Atayde, AR Dal Cin, P Gebhardt, MC Rosenberg, AE Bridge, JA Fletcher, JA AF Oliveira, AM Perez-Atayde, AR Dal Cin, P Gebhardt, MC Rosenberg, AE Bridge, JA Fletcher, JA TI Novel USP6 fusion oncogenes with TRAP150, ZNF9, osteomodulin, and COL1A1 in aneurysmal bone cyst variant translocations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Mayo Clin, Rochester, MN USA. Childrens Hosp, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Nebraska, Med Ctr, Omaha, NE USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 73 BP 19A EP 19A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600074 ER PT J AU Brachtel, EF Kawakubo, H Maheswaran, S AF Brachtel, EF Kawakubo, H Maheswaran, S TI BTG2 expression in human breast cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 111 BP 27A EP 28A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600112 ER PT J AU Rabban, JT Koerner, FC Lerwill, MF AF Rabban, JT Koerner, FC Lerwill, MF TI Cytokeratin 5/6 distinguishes solid papillary ductal carcinoma in-situ from florid usual ductal hyperplasia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 203 BP 47A EP 47A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600204 ER PT J AU Witkiewicz, AK Pliss, N Kamma, M Schnitt, S Burstein, HJ Harris, L AF Witkiewicz, AK Pliss, N Kamma, M Schnitt, S Burstein, HJ Harris, L TI The effect of trastuzumab (Herceptin (R)) treatment on estrogen receptor status in patients with early stage HER2 positive breast cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 NYU, Sch Med, New York, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 242 BP 55A EP 55A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600243 ER PT J AU Stone, JR Talusan, P Kattapuram, T AF Stone, JR Talusan, P Kattapuram, T TI Proteomic profiling of human vascular intimal proteoglycans SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 260 BP 59A EP 59A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600261 ER PT J AU Chen, AA McKee, GT Deshpande, V AF Chen, AA McKee, GT Deshpande, V TI Fine-needle aspiration cytology of schwannoma and its distinction from other spindle cell lesions SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 271 BP 61A EP 62A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600272 ER PT J AU Garcia, CF Pilch, BZ Tannous, Z Mihm, ZC Koerner, F Zembowicz, A AF Garcia, CF Pilch, BZ Tannous, Z Mihm, ZC Koerner, F Zembowicz, A TI Endocrine-mucin producing sweat gland carcinoma of the eyelid: Analysis of 12 cases suggests that it is a precursor of mucinous carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. IRCCS, Bambino Gesu Hosp, Rome, Italy. Belcolle Hosp, Viterbo, Italy. Univ Roma La Sapienza, Rome, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 375 BP 84A EP 84A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600376 ER PT J AU Dahia, PL Powers, JF Ehsani, SA Tischler, AS AF Dahia, PL Powers, JF Ehsani, SA Tischler, AS TI Expression of NOTCH3 protein identifies a distinctive subset of pheochromocytomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Tufts Univ, New England Med Ctr, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 404 BP 89A EP 89A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600405 ER PT J AU Koutsogiannis, D Young, RH Meier, CA Bongiovanni, M Pache, JC Faquin, WC AF Koutsogiannis, D Young, RH Meier, CA Bongiovanni, M Pache, JC Faquin, WC TI Bilateral adrenal myelolipomas: Association with adrenal cortical hyperplasia and congenital syndromes SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Western Ontario, London, ON, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hosp Geneva, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 418 BP 92A EP 92A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600419 ER PT J AU Hull, MJ Mino, M Sepehr, A Ban, S Shimizu, M Lauwers, GY AF Hull, MJ Mino, M Sepehr, A Ban, S Shimizu, M Lauwers, GY TI Endoscopic mucosal resection (EMR): An improved diagnostic procedure for early esophago-gastric epithelial neoplasms SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 484 BP 106A EP 107A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600485 ER PT J AU Mino, M Kirley, SD Lauwers, GY Zukerberg, LR AF Mino, M Kirley, SD Lauwers, GY Zukerberg, LR TI Loss of cables, a cyclin-dependent kinase (CDK) interacting protein, is frequent in intestinal type gastric dysplasia and early gastric cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 512 BP 112A EP 113A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600513 ER PT J AU Mino, M Zukerberg, L Misdraji, J Lauwers, GY AF Mino, M Zukerberg, L Misdraji, J Lauwers, GY TI Management of superficial Barrett's epithelium (BE) related neoplasms by endoscopic mucosal resection (EMR): Evaluation of 27 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 511 BP 112A EP 112A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600512 ER PT J AU Ogino, S Kirkner, G Cantor, M Brahnandam, M Kawasaki, T Namgyal, C Giovannucci, EL Loda, M Fuchs, CS AF Ogino, S Kirkner, G Cantor, M Brahnandam, M Kawasaki, T Namgyal, C Giovannucci, EL Loda, M Fuchs, CS TI Family history of sporadic colorectal cancer modifies risks for specific molecular pathology in tumors: data from prospective cohort of 86,220 women SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 519 BP 114A EP 114A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600520 ER PT J AU Ogino, S Brahmandam, M Cantor, M Namgyal, C Kawasaki, T Loda, M Fuchs, CS AF Ogino, S Brahmandam, M Cantor, M Namgyal, C Kawasaki, T Loda, M Fuchs, CS TI Activating mutation of the EGFR gene is rare and not responsible for gefitinib sensitivity in colorectal cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 520 BP 114A EP 114A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600521 ER PT J AU Rossi, S Chinellato, S Bhouacharya, N Dei Tos, AP Loda, M AF Rossi, S Chinellato, S Bhouacharya, N Dei Tos, AP Loda, M TI Immunohistochemical expression of fatty acyd synthase (FAS) in GIST SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 HOsp Treviso, Treviso, Italy. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 533 BP 116A EP 117A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600534 ER PT J AU Bennett, AK Ulbright, TM Ramnani, D Young, RH Mills, SE AF Bennett, AK Ulbright, TM Ramnani, D Young, RH Mills, SE TI Immunohistochemical expression of calretinin, CD99, and inhibin in sertoli and Leydig cells and their lesions, emphasizing large cell calcifying sertoli cell tumor SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Virginia, Charlottesville, VA USA. Indiana Univ, Indianapolis, IN 46204 USA. Virginia Urol Grp, Richmond, VA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 588 BP 128A EP 128A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600589 ER PT J AU Bismar, TA Demichelis, F Riva, A Kim, R Lim, S Kutok, J Aster, JC Tang, J Kuefer, R Hofer, MD Febbo, PG Chinnaiyan, AM Rubin, MA AF Bismar, TA Demichelis, F Riva, A Kim, R Lim, S Kutok, J Aster, JC Tang, J Kuefer, R Hofer, MD Febbo, PG Chinnaiyan, AM Rubin, MA TI Defining prostate cancer progression using a multiplex panel of 13 tissue biomarkers SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. Ist Ric Sci & Tecnol, I-38050 Trento, Italy. Childrens Hosp, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Hosp Ulm, Ulm, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 596 BP 130A EP 130A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600597 ER PT J AU Choi, WWL Amin, MB Tamboli, P Eble, JN Young, RH AF Choi, WWL Amin, MB Tamboli, P Eble, JN Young, RH TI Glandular neoplasms of the urachus: Clinicopathologic and immunohistochemical analysis of 43 cases with special emphasis on SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Emory Univ, Sch Med, Atlanta, GA 30322 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Indiana Univ, Indianapolis, IN 46204 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 613 BP 134A EP 134A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600614 ER PT J AU De Marzo, AM Platz, EA Epstein, JI Billis, A Chan, TY Cheng, L Datta, M Ertoy-Baydar, D Farre, X Fine, S Iczkowski, KA Ittmann, M Knudsen, BS Loda, M Lopez-Beltran, A Magi-Galluzzi, C Mikuz, G Montironi, R Rubin, MA Sebo, T Sesterhenn, IA Shah, R Signoretti, S Simko, J Troncoso, P Tsuzuki, T van Leenders, GJLH Yang, X Zhou, M Figg, WD Hoque, A Lucia, MS AF De Marzo, AM Platz, EA Epstein, JI Billis, A Chan, TY Cheng, L Datta, M Ertoy-Baydar, D Farre, X Fine, S Iczkowski, KA Ittmann, M Knudsen, BS Loda, M Lopez-Beltran, A Magi-Galluzzi, C Mikuz, G Montironi, R Rubin, MA Sebo, T Sesterhenn, IA Shah, R Signoretti, S Simko, J Troncoso, P Tsuzuki, T van Leenders, GJLH Yang, X Zhou, M Figg, WD Hoque, A Lucia, MS TI Interobserver reproducibility of a proposed classification of focal prostate atrophy lesions SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Colorado, Boulder, CO 80309 USA. Univ Campinas, Campinas, SP, Brazil. Emory Univ, Atlanta, GA 30322 USA. VA Med Ctr, Gainesville, FL USA. Fred Hutchinson Canc Res Ctr, Seattle, WA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Cordoba, E-14071 Cordoba, Spain. Cleveland Clin, Cleveland, OH USA. Innsbruck Med Univ, Innsbruck, Austria. Poltech U Som, Ancona, Italy. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Northwestern Univ, Evanston, IL 60208 USA. NIH, Bethesda, MD 20892 USA. Indiana Univ, Bloomington, IN 47405 USA. RI Billis, Athanase/D-7365-2012; BAYDAR, DILEK/I-9610-2013; Figg Sr, William/M-2411-2016 NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 622 BP 135A EP 135A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600623 ER PT J AU Descazeaud, A Laxman, B Creighton, C Setlur, S Hofer, M Beroukhim, R De La Taille, A Chinnaiyan, A Rubin, MA AF Descazeaud, A Laxman, B Creighton, C Setlur, S Hofer, M Beroukhim, R De La Taille, A Chinnaiyan, A Rubin, MA TI Benign prostatic hyperplasia: Towards the development of a clinically relevant molecular signature SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. CHU Henri Mondor, F-94010 Creteil, France. Assistance Publ Hop Paris, Creteil, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 625 BP 136A EP 136A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600626 ER PT J AU Elvin, JA Bismar, TA Chimaiyan, AM Loda, M Rubin, MA AF Elvin, JA Bismar, TA Chimaiyan, AM Loda, M Rubin, MA TI Quantitative analysis of alpha-methylacyl CoA racemase (AMACR) and fatty acid synthase (FAS) co-expression in localized prostate cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 638 BP 139A EP 139A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600639 ER PT J AU Faith, DA Ertoy-Baydar, D Spotler, YS Platz, EA Rubin, MA Ayala, G De Marzo, AM AF Faith, DA Ertoy-Baydar, D Spotler, YS Platz, EA Rubin, MA Ayala, G De Marzo, AM TI Multi-institution automated image analysis of PTEN protein in prostatic adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Johns Hopkins Sch Med, Baltimore, MD USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Baylor Coll Med, Houston, TX 77030 USA. Bloomberg Sch Publ Hlth, Baltimore, MD USA. RI BAYDAR, DILEK/I-9610-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 643 BP 140A EP 140A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600644 ER PT J AU Hofer, MD Mucci, L Andren, O Kim, R Kantoff, PW Johansson, JE Rubin, MA AF Hofer, MD Mucci, L Andren, O Kim, R Kantoff, PW Johansson, JE Rubin, MA TI Metastasis-associated gene 1 (MTA1) is associated with prostate cancer specific death SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Orebro Univ Hosp, Orebro, Sweden. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 671 BP 146A EP 146A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600672 ER PT J AU Hofer, MD Kuefer, R Setlur, S Wu, H Rubin, MA AF Hofer, MD Kuefer, R Setlur, S Wu, H Rubin, MA TI High-throughput analysis of chromosomal aberrations in formalin-fixed paraffin embedded tissue: A novel approach to define prostate cancer biomarkers from archival material SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Hosp Ulm, Ulm, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 672 BP 146A EP 146A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600673 ER PT J AU Li, C Jiang, Z Zhang, Y Banner, B Wu, CL AF Li, C Jiang, Z Zhang, Y Banner, B Wu, CL TI Expression of alpha-methylacyl-CoA racemase (AMACR)/P504S in renal neoplasms SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Massachusetts, Med Ctr, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 703 BP 152A EP 152A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600704 ER PT J AU Roma, AA Montironi, R Loda, M Magi-Galluzzi, C AF Roma, AA Montironi, R Loda, M Magi-Galluzzi, C TI Increased expression of fatty acid synthase in prostate adenocarcinoma following total androgen ablation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Cleveland Clin Fdn, Cleveland, OH 44195 USA. Univ Ancona, I-60128 Ancona, Italy. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 746 BP 161A EP 161A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600747 ER PT J AU Rubin, MA Bismar, TA Andren, O Mucci, L Kim, R Shen, R Ghosh, D Wei, JT Chinnaiyan, AM Adami, HO Kantoff, PW Johansson, JE AF Rubin, MA Bismar, TA Andren, O Mucci, L Kim, R Shen, R Ghosh, D Wei, JT Chinnaiyan, AM Adami, HO Kantoff, PW Johansson, JE TI Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer specific death SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Orebro Univ Hosp, Orebro, Sweden. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Karolinska Inst, Stockholm, Sweden. Dana Farber Canc Inst, Boston, MA 02115 USA. RI Wei, John/E-8967-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 748 BP 162A EP 162A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600749 ER PT J AU Turbiner, J Amin, MB Radhakrishnan, A Humphrey, PA Srigley, JR De Leval, L Oliva, E AF Turbiner, J Amin, MB Radhakrishnan, A Humphrey, PA Srigley, JR De Leval, L Oliva, E TI Cystic nephroma (CN) and mixed epithelial and stromal tumor (MEST) of the kidney: Are they one and the same entity? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Emory Univ, Atlanta, GA 30322 USA. Washington Univ, St Louis, MO USA. McMaster Univ, Hamilton, ON L8S 4L8, Canada. CHU Sart Tilman, B-4000 Liege, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 782 BP 169A EP 169A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600783 ER PT J AU Ulbright, TM Young, RH AF Ulbright, TM Young, RH TI Seminoma with microcystic and tubular patterns: A study of 28 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Indiana Univ, Sch Med, Indianapolis, IN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 784 BP 169A EP 170A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600785 ER PT J AU Alvarez, T Bhan, AK Miller, E Oliva, E AF Alvarez, T Bhan, AK Miller, E Oliva, E TI Molecular profile of grade 3 endometrial endometrioid carcinoma (EEC): Is it a type I or type II endometrial carcinoma (EC)? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 820 BP 177A EP 177A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600816 ER PT J AU Bissonnette, JP Bilbur, DC AF Bissonnette, JP Bilbur, DC TI Low grade dysplasia pap smears and negative cervical biopsies: Are they really non-correlating specimens? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 827 BP 178A EP 178A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238600823 ER PT J AU de Leval, L Waltregny, D Glenisson, W Boniver, J Young, RH Castronovo, V Oliva, E AF de Leval, L Waltregny, D Glenisson, W Boniver, J Young, RH Castronovo, V Oliva, E TI Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the subclassification of mesenchymal tumors of the uterus, particularly epithelioid smooth muscle tumors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 CHU Sart Tilman, B-4000 Liege, Belgium. Ctr Expt Canc Res, Liege, Belgium. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 837 BP 180A EP 181A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601010 ER PT J AU Irving, JA Young, RH AF Irving, JA Young, RH TI Lung carcinoma metastatic to the ovary - A clinicopathologic study of 33 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 869 BP 187A EP 187A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601042 ER PT J AU Lerwill, MF Irving, JA Young, RH AF Lerwill, MF Irving, JA Young, RH TI Gastrointestinal stromal tumors metastatic to the ovary SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 887 BP 191A EP 191A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601060 ER PT J AU Logani, S Soslow, RA Oliva, E Nolen, JD Aleodor, AA Saunders, NA Polydorides, A Ellenson, LH AF Logani, S Soslow, RA Oliva, E Nolen, JD Aleodor, AA Saunders, NA Polydorides, A Ellenson, LH TI Is pure uterine clear cell carcinoma clinically distinct from endometrioid/serous carcinoma with a clear cell component? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Emory Univ, Atlanta, GA 30322 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Cornell Univ, Weill Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 896 BP 193A EP 193A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601069 ER PT J AU Turbiner, J Sanchez, C Dahiya, S Moreno, G Hardisson, D Palacios, J Oliva, E AF Turbiner, J Sanchez, C Dahiya, S Moreno, G Hardisson, D Palacios, J Oliva, E TI Beta-catenin expression in endometrial carcinoma (EC) in patients with estrogen stimulation secondary to ovarian hyperthecosis or tamoxifen therapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Ctr Nacl Invest Oncol, Madrid, Spain. Hosp Univ La Paz, Madrid, Spain. RI Hardisson, David/E-2832-2010 OI Hardisson, David/0000-0002-2183-3699 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 959 BP 206A EP 206A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601132 ER PT J AU Rahemtullah, A Preffer, FI Harris, NL Hasserjian, RP AF Rahemtullah, A Preffer, FI Harris, NL Hasserjian, RP TI Atypical T-cell populations in nodular lymphocyte predominant Hodgkin lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 1149 BP 248A EP 248A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601322 ER PT J AU Soupir, CP Preffer, FI Hasserjian, RP AF Soupir, CP Preffer, FI Hasserjian, RP TI Effects of rituximab therapy on immune system recovery following chemotherapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 1166 BP 251A EP 252A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601339 ER PT J AU Cornell, LD Selig, MK Collins, AB Colvin, RB AF Cornell, LD Selig, MK Collins, AB Colvin, RB TI Evaluation of "penetrating" electron-dense deposits to distinguish lupus and idiopathic membranous glomerulonephritis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 1232 BP 266A EP 266A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601405 ER PT J AU Ly, A Ligon, K Bush, C Tihan, T AF Ly, A Ligon, K Bush, C Tihan, T TI Use of tissue microarrays in the immunohistochemical analysis of olig-2 and Ki-67 in gliomas. A quality control study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 1351 BP 292A EP 293A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601524 ER PT J AU Swain, RS Horvai, AE Loda, M Burger, PC Scheithauer, BW Tihan, T Kim, GE AF Swain, RS Horvai, AE Loda, M Burger, PC Scheithauer, BW Tihan, T Kim, GE TI Inflammatory myofibroblastic tumors in the CNS and respiratory tract: A comparative analysis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Johns Hopkins, Baltimore, MD USA. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 1364 BP 295A EP 295A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601537 ER PT J AU Di Vizio, D O'Connell, FP Bhattacharya, N Shapiro, GI Loda, M AF Di Vizio, D O'Connell, FP Bhattacharya, N Shapiro, GI Loda, M TI Pharmacodynamic assessment of the cyclin-depenclent kinase inhibitor flavopiridol: Modulation of cdk targets in clinical samples SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 1375 BP 297A EP 297A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601548 ER PT J AU Hofer, MD Tapia, C Browne, TJ Mirlacher, MC Sauter, G Rubin, MA AF Hofer, MD Tapia, C Browne, TJ Mirlacher, MC Sauter, G Rubin, MA TI Comprehensive analysis of the expression of the metastasis-associated gene 1 (MTA1) in neoplastic tissue SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Basel, Basel, Switzerland. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 1379 BP 298A EP 298A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601552 ER PT J AU Matsubara, O Imazeki, N Nakatani, Y Mark, EJ AF Matsubara, O Imazeki, N Nakatani, Y Mark, EJ TI Roles of Wnt/beta-catenin pathway signaling and TGF-beta 1 in repair and remodeling of the lung after acute lung injury SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 1463 BP 315A EP 315A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601635 ER PT J AU Kim, R Tang, J Lnu, S Shen, R Gibbs, D Mahavishnu, V Wei, J Kleer, CG Chinnaiyan, AM Rubin, MA AF Kim, R Tang, J Lnu, S Shen, R Gibbs, D Mahavishnu, V Wei, J Kleer, CG Chinnaiyan, AM Rubin, MA TI Profiler: A powerful web-based Tissue Microarray analysis system and relational database for collaborative translational research SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 1535 BP 331A EP 331A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601707 ER PT J AU Ogino, S Kawasaki, T Brahmandam, M Yan, L Cantor, M Namgyal, C Giovannucci, E Mino, M Lauwers, G Loda, M Fuchs, CS AF Ogino, S Kawasaki, T Brahmandam, M Yan, L Cantor, M Namgyal, C Giovannucci, E Mino, M Lauwers, G Loda, M Fuchs, CS TI Sensitive method for KRAS mutation detection by Pyrosequencing(TM) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Biotage, Westborough, MA USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2005 VL 85 SU 1 MA 1543 BP 332A EP 332A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 886OQ UT WOS:000226238601715 ER PT J AU Kelley, P Reilly, J Eavey, RD AF Kelley, P Reilly, J Eavey, RD TI Sylvan Stool SO LARYNGOSCOPE LA English DT Biographical-Item C1 Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol,Pediat Otolaryngol Serv, Boston, MA 02114 USA. Univ Colorado, Hlth Sci Ctr, Pediat Otolaryngol Serv, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver Childrens Hosp, Denver, CO USA. Alfred L Dupont Hosp Children, Div Pediat Otolaryngol, Wilmington, DE USA. RP Eavey, RD (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol,Pediat Otolaryngol Serv, 243 Charles St, Boston, MA 02114 USA. EM roland_eavey@meei.harvard.edu NR 1 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2005 VL 115 IS 1 BP 2 EP 3 DI 10.1097/01.mig.0000152158.25710.4d PG 2 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 887YF UT WOS:000226340700001 PM 15630356 ER PT J AU Stern, RE Yueh, B Lewis, C Norton, S Sie, KCY AF Stern, RE Yueh, B Lewis, C Norton, S Sie, KCY TI Recent epidemiology of pediatric cochlear implantation in the United States: Disparity among children of different ethnicity and socioeconomic status SO LARYNGOSCOPE LA English DT Article DE cochlear implant; epidemiology; pediatrics ID NEONATAL HEARING IMPAIRMENT; SPEECH-PERCEPTION; IDENTIFICATION; INFANTS; CARE AB Objectives/Hypothesis. Congenital severe to profound sensorineural hearing loss (SNHL) is found in higher proportions of children with minority and/or lower socioeconomic status (SES). Cochlear implants were approved by the U.S. Food and Drug Administration for use in children with bilateral severe to profound SNHL in 1990. The objectives of the study were as follows: 1) to study the epidemiology of pediatric cochlear implantation, assessing whether cochlear implant technology is provided to children with severe to profound SNHL in proportion to their racial/ethnic or SES, and 2) to compare data provided by a national health care database with data provided by cochlear implant manufacturers. Study Design: Patients aged 0 to 18 years who underwent cochlear implantation in 1997 using a cross-sectional study design. Methods. Analyses were made of pediatric cochlear implant patients, using data from the 1997 Health Care and Utilization Project/Kids' Inpatient Database. Relative rates of implantation compared with rates of severe to profound SNHL were calculated using national estimates generated from census and Galludet Research Institution data. Logistic regression analysis was carried out to compare implanted children of different racial/ethnic backgrounds. A surrogate measure of socioeconomic status was used based on the median household income of the patient's home ZIP code. Information was also obtained from the two companies producing U.S. Food and Drug Administration-approved cochlear implants in 1997 and used to determine whether the data obtained from the Health Care and Utilization Project/Kids' Inpatient Database were representative of the national cohort of implanted children. Results. The Health Care and Utilization Project/Kids' Inpatient Database identified 124 children who underwent cochlear implant surgery in 1997. White and Asian children were implanted at higher rates than Hispanic and black children. Furthermore, white and Asian children received implants at greater rates than would be expected based on prevalence of severe to profound SNHL. The relative rate (RR) of implantation, defined as the proportion of children who received cochlear implants divided by the proportion of children with severe to profound SNHL (in each race/ethnicity group compared with the same ratio in white children), was similar in white (RR = 1.00) and Asian (RR = 0.93) children but markedly different in Hispanic (RR = 0.28) and black (RR = 0.10) children. Comparison of SES information from the Health Care and Utilization Project/Kids' Inpatient Database population with the manufacturers' database suggested that the Health Care and Utilization Project/Kids' Inpatient Database is representative of all implanted children in the United States. Both sources of information suggested that children receiving cochlear implants in the United States in 1997 resided in above-average SES areas. Conclusion: White and Asian children with severe to profound SNHL had higher proportionate rates of cochlear implantation than black and Hispanic children in 1997. Implanted children were more likely to live in areas (represented by ZIP codes) with higher median incomes. Although there was a disparity in rate of cochlear implantation based on race/ethnicity and surrogate measures of SES, these data did not allow the authors to determine the causes for these differences. C1 Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Hlth Serv, Seattle, WA 98195 USA. Childrens Hosp & Reg Med Ctr, Dept Otolaryngol Head & Neck Surg, Seattle, WA USA. RP Stern, RE (reprint author), 1959 NE Pacific,BB 1165 HSC,Box 356515, Seattle, WA 98195 USA. EM restern@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053 NR 14 TC 33 Z9 35 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2005 VL 115 IS 1 BP 125 EP 131 DI 10.1097/01.mlg.0000150698.61624.3c PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 887YF UT WOS:000226340700025 PM 15630380 ER PT J AU Nakajima, HH Ravicz, ME Rosowski, JJ Peake, WT Merchant, SN AF Nakajima, HH Ravicz, ME Rosowski, JJ Peake, WT Merchant, SN TI Experimental and clinical studies of malleus fixation SO LARYNGOSCOPE LA English DT Article DE ossicular fixation; malleus fixation; stapes fixation; anterior malleal ligament; otosclerosis ID CONDUCTIVE HEARING-LOSS; DOPPLER VIBROMETER LDV; TYMPANIC MEMBRANE; ANTERIOR; SURGERY; TOOL; EAR AB Objectives/Hypothesis: Preoperative clinical diagnosis of malleus fixation can be difficult. "Fixation" of the malleus can be caused by various disorders or diseases: fibrous tissue, bony spurs, and neo-osteogenesis around the malleus head or stiffening of the anterior malleal ligament. The conductive hearing loss produced by these disorders or diseases has not been well characterized. The study goals were 1) to determine the effects of various types of malleus fixation using a cadaveric temporal bone preparation and 2) to assess the clinical utility of umbo velocity measurements in preoperative differential diagnosis of malleus fixation and stapes fixation. Methods: Umbo and stapes velocity were measured in 18 fresh cadaveric human temporal bones with laser vibrometry before and after controlled application of adhesives to the malleus, stapes, or both ossicles. Results: Each simulated pathological condition produced a specific degree of loss in stapes velocity: stiffening of anterior malleal ligament, 0 to 8 dB; fibrous tissue around malleus head, less than 10 dB; bony bar to malleus head, 10 to 30 dB; and extensive neo-osteogenesis around malleus head, greater than 35 dB. Simulated malleus fixations generally produced similar reductions in both umbo and stapes velocity. Stapes fixation reduced stapes velocity with little change in umbo velocity. Because the change in stapes velocity would be similar to conductive hearing loss, experimental results were directly compared with clinical measurements of umbo velocity in surgically confirmed cases of malleus or stapes fixation. The effects of malleus and stapes fixations between the clinical and experimental data were similar. Conclusion: The study showed that measurements of umbo velocity and air-bone gap can enable one to diagnose malleus fixation and specifies how to differentiate malleus from stapes fixation. C1 Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Eaton Peabody Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. MIT, Elect Res Lab, Cambridge, MA 02139 USA. RP Merchant, SN (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. EM saumil_merchant@meei.harvard.edu FU NIDCD NIH HHS [R01 DC004798, T32 DC00020-13, R01 DC 04798] NR 15 TC 38 Z9 38 U1 3 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2005 VL 115 IS 1 BP 147 EP 154 DI 10.1097/01.mlg.0000150692.23506.b7 PG 8 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 887YF UT WOS:000226340700029 PM 15630384 ER PT J AU Zehnder, AF Kristiansen, AG Adams, JC Merchant, SN McKenna, MJ AF Zehnder, AF Kristiansen, AG Adams, JC Merchant, SN McKenna, MJ TI Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule SO LARYNGOSCOPE LA English DT Article DE bone remodeling; osteoprotegerin (OPG); otic capsule; RANK liganf (RANKL); receptor activator of nuclear factor Kappa B (RANK) ID KAPPA-B LIGAND; RECEPTOR ACTIVATOR; OSTEOCLAST DIFFERENTIATION; MATURE OSTEOCLASTS; CELLS; TURNOVER; COCHLEA; SURFACE AB Objectives: To elucidate factors that may be responsible for the inhibition of remodeling of bone within the otic capsule. Methods: Expression of osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (RANK), and RANK ligand (RANKL) were assayed in samples of bone obtained from the otic capsule, calvarium, and femur, and from the soft tissue within the cochlea using semiqantitative reverse transcriptase polymerase chain reaction (RTPCR) in mice. Immunostaining was used for histologic localization of the gene products. An enzyme-linked immunosorbent assay (ELISA) was used to quantify the amount of OPG within perilymph, serum, and cerebrospinal fluid. The microanatomy of the interface between the otic capsule and the fluid spaces of the cochlea was investigated by brightfield and phase-contrast microscopy and by three-dimensional reconstruction in the mouse and human. Results: OPG, a powerful inhibitor of bone remodeling, was expressed at extremely high levels within the soft tissue of the cochlea and was present in the perilymph at very high concentrations. The OPG produced within the inner ear may diffuse into the surrounding otic capsule, where it may be responsible for inhibition of bone turnover. Our anatomic studies revealed an extensive system of interconnected canaliculi within the otic capsule that had direct openings into the fluid spaces of the inner ear, thus providing a possible anatomic route for the diffusion of OPG from the inner ear into the surrounding bone. Conclusion: OPG, a potent inhibitor of osteoclast formation and function, is expressed at high levels within the inner ear and is secreted into the perilymph and the surrounding bone and may serve to inhibit active bone remodeling within the otic capsule, especially immediately adjacent to the cochlea. By this means, the cochlear soft tissue may control the nature of the surrounding petrous bone. C1 Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP McKenna, MJ (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. FU NIDCD NIH HHS [5R01 DC03401-06] NR 27 TC 53 Z9 55 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2005 VL 115 IS 1 BP 172 EP 177 DI 10.1097/01.mlg.0000150702.28451.35 PG 6 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 887YF UT WOS:000226340700034 PM 15630389 ER PT J AU Levine, RL Wadleigh, M Sternberg, DW Wlodarska, I Galinsky, I Stone, RM DeAngelo, DJ Gilliland, DG Cools, J AF Levine, RL Wadleigh, M Sternberg, DW Wlodarska, I Galinsky, I Stone, RM DeAngelo, DJ Gilliland, DG Cools, J TI KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32) SO LEUKEMIA LA English DT Article DE translocation; imatinib; myeloproliferative disorder ID FACTOR RECEPTOR-BETA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; GENE; PROTEIN; REARRANGEMENTS; TRANSLOCATION; DROSOPHILA; DISORDERS AB We report the cloning of a novel PDGFRB fusion gene partner in a patient with a chronic myeloproliferative disorder characterized by t(5;14)(q33;q32), who responded to treatment with imatinib mesylate. Fluorescence in situ hybridization demonstrated that PDGFRB was involved in the translocation. Long distance inversion PCR identified KIAA1509 as the PDGFRB fusion partner. KIAA1509 is an uncharacterized gene with a predicted coiled-coil oligomerization domain with homology to the HOOK family of proteins. The predicted KIAA1509-PDGFRbeta fusion protein contains the KIAA1509 coiled-coil domain fused to the cytoplasmic domain of PDGFRbeta that includes the tyrosine kinase domain. Imatinib therapy resulted in rapid normalization of the patient's blood counts, and subsequent bone marrow biopsies and karyotypic analysis were consistent with sustained complete remission. C1 Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA. CUNY Mt Sinai Sch Med, Div Hematol Oncol, New York, NY 10029 USA. Univ Louvain VIB, Dept Human Genet, Louvain, Belgium. RP Gilliland, DG (reprint author), Brigham & Womens Hosp, Div Hematol, 75 Francis St, Boston, MA 02115 USA. EM ggilliland@rics.bwh.harvard.edu OI Cools, Jan/0000-0001-6626-5843 FU NCI NIH HHS [CA 66996, CA 82261]; NIDDK NIH HHS [DK 50654] NR 25 TC 48 Z9 52 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD JAN PY 2005 VL 19 IS 1 BP 27 EP 30 DI 10.1038/sj.leu.2403548 PG 4 WC Oncology; Hematology SC Oncology; Hematology GA 879IR UT WOS:000225710700005 PM 15496975 ER PT J AU Cassileth, PA Lee, SJ Litzow, MR Miller, KB Stadtmauer, EA Tallman, MS Lazarus, HM Bennett, JM Paietta, E Dewald, GW Rowe, JM AF Cassileth, PA Lee, SJ Litzow, MR Miller, KB Stadtmauer, EA Tallman, MS Lazarus, HM Bennett, JM Paietta, E Dewald, GW Rowe, JM TI Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995) SO LEUKEMIA & LYMPHOMA LA English DT Article DE AML; intensive therapy; high-dose cytarabine; autologous stem cell transplantation ID ACUTE MYELOGENOUS LEUKEMIA; BONE-MARROW-TRANSPLANTATION; POSTREMISSION CHEMOTHERAPY; 1ST REMISSION; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; SURVIVAL AB The feasibility of intensified therapy in adults 561-years-old with de novo acute myeloid leukemia (AML) was evaluated by adding high-dose cytarabine ( HDAC) to conventional induction therapy and in post-remission therapy prior to peripheral blood stem cell transplantation (PBSCT). Patients were treated with conventional induction therapy ( daunorubicin days 1-3 and cytarabine days 1-7), followed by HDAC (2 gm/M-2) every 12 h ( x 6) on days 8-10. Patients in complete remission (CR) with HLA-matched siblings were assigned to allogeneic PBSCT; the others received two courses of HDAC (3 gm/M-2 every 12 h on days 1, 3, and 5) given 1 month apart. Peripheral blood stem cells were then harvested and infused after high-dose chemotherapy. Of 62 eligible, evaluable patients, 47 (76%) achieved CR. The mortality rate was 10% (6 patients); no deaths occurred during the two post-remission courses of HDAC. Fifteen patients were assigned to allogeneic PBSCT and 32 to autologous PBSCT. All surviving patients have been followed for more than 4 years. Including all patients scheduled to receive autoPBSCT in an intent-to-treat analysis, after a median 5-year follow-up the current, non-actuarial, four-year event-free and overall survival was 47% and 47%, respectively. Intensified induction therapy was associated with more toxicity than conventional induction therapy, and the CR rate did not improve. Nevertheless, intensive post-remission therapy was well tolerated, no treatment-related mortality occurred with autologous PBSCT, and disease-free survival and overall survival were lengthy. C1 Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mayo Clin, Rochester, MN USA. Tufts New England Med Ctr, Boston, MA USA. Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA. Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Miami, FL USA. Univ Hosp Cleveland, Cleveland, OH 44106 USA. Univ Rochester, Ctr Canc, Rochester, NY USA. Our Lady Mercy Med Ctr, Bronx, NY USA. Technion Israel Inst Technol, Rambam Med Ctr, Haifa, Israel. RP Cassileth, PA (reprint author), Univ Miami, Sylvester Comprehens Canc Ctr, 1475 NW 12th Ave, Miami, FL 33136 USA. EM pcassile@med.miami.edu FU NCI NIH HHS [CA21115, CA11083, CA15488, CA23318, CA66636, CA13650, CA07190, CA17145] NR 21 TC 13 Z9 17 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD JAN PY 2005 VL 46 IS 1 BP 55 EP 61 DI 10.1080/10428190412331283288 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 881OV UT WOS:000225877700007 PM 15621781 ER PT J AU Stone, ME AF Stone, ME TI The American Heritage((R)) - Stedman's medical dictionary. SO LIBRARY JOURNAL LA English DT Book Review C1 Massachusetts Gen Hosp, Treadwell Lib, Boston, MA 02114 USA. RP Stone, ME (reprint author), Massachusetts Gen Hosp, Treadwell Lib, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 1 U2 2 PU BOWKER MAGAZINE GROUP CAHNERS MAGAZINE DIVISION PI NEW YORK PA 249 W 17TH ST, NEW YORK, NY 10011 USA SN 0363-0277 J9 LIBR J JI Libr. J. PD JAN PY 2005 VL 130 IS 1 BP 150 EP 150 PG 1 WC Information Science & Library Science SC Information Science & Library Science GA 887YA UT WOS:000226340200306 ER PT S AU Kirchhausen, T Boll, W van Oijen, A Ehrlich, M AF Kirchhausen, T Boll, W van Oijen, A Ehrlich, M BE McIlhinney, RAJ Hooper, NM TI Single-molecule live-cell imaging of clathrin-based endocytosis SO LIPIDS, RAFTS AND TRAFFIC SE BIOCHEMICAL SOCIETY SYMPOSIUM LA English DT Article; Proceedings Paper CT Annual Symposium of the Biochemical-Society on Lipids, Rafts and Traffic held at the BioScience 2004 Conference CY JUL, 2004 CL Glasgow, SCOTLAND SP Biochem Soc ID COATED VESICLES; MEDIATED ENDOCYTOSIS; BETA-PROPELLER; COMPLEX; ADAPTER; ORGANIZATION; RECRUITMENT; MEMBRANE; PROTEINS; RECEPTOR AB Clathrin-coated vesicles carry traffic from the plasma membrane to endosomes. We report here the first real-time visualization of cargo sorting and endocytosis by clathrin-coated pits in living cells. We have visualized the formation of coats by monitoring the incorporation of fluorescently tagged clathrin or its adaptor AP-2 (adaptor protein 2), and have followed clathrin-mediated uptake of transferrin, single LDL (low-density lipoprotein) and single reovirus particles. The intensity of a cargo-loaded clathrin cluster grows steadily during its lifetime, and the time required to complete assembly is proportional to the size of the cargo particle. These results are consistent with a nucleation-growth mechanism and an approximately constant growth rate. There are no preferred nucleation sites. A proportion of the nucleation events appear to be abortive. Cargo incorporation occurs primarily or exclusively in a newly formed coated pit, and loading appears to commit that pit to finish assembly. Our data led to a model in which coated pits initiate randomly, but collapse with high likelihood unless stabilized, presumably by cargo capture. C1 Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. Ctr Blood Res, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. RP Kirchhausen, T (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA. EM Kirchhausen@crystal.harvard.edu OI van Oijen, Antoine/0000-0002-1794-5161 NR 28 TC 10 Z9 10 U1 1 U2 2 PU PORTLAND PRESS LTD PI LONDON PA 59 PORTLAND PL, LONDON W1N 3AJ, ENGLAND SN 0067-8694 BN 1-85578-162-X J9 BIOCHEM SOC SYMP PY 2005 VL 72 BP 71 EP 76 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BBY32 UT WOS:000228315000007 ER PT S AU Vijg, J Busuttil, RA Bahar, R Dolle, MET AF Vijg, J Busuttil, RA Bahar, R Dolle, MET BE Cutler, RG Harman, SM Heward, C Gibbons, M TI Aging and genome maintenance SO LONGEVITY HEALTH SCIENCES: THE PHOENIX CONFERENCE SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Phoenix Conference on Longevity Health Sciences CY DEC 11-14, 2003 CL Scottsdale, AZ SP AURORA Fdn, Exeter Life Sci, Int Soc Hlth Aging Res, Kronos Lab Res Inst, Oxidat Stress & Aging Assoc DE genome instability; somatic mutations; gene regulation; aging ID TRANSGENIC MOUSE MODEL; IN-VIVO MUTATIONS; SOMATIC MUTATION; GENE-EXPRESSION; AGE; MICE; ACCUMULATION; CHROMOSOME; REARRANGEMENTS; TRANSCRIPTOME AB Genomic instability in somatic cells has been implicated as a major stochastic mechanism of aging. Using a transgenic mouse model with chromosomally integrated lacZ mutational target genes, we found mutations to accumulate with age at an organ- and tissue-specific rate. Also the spectrum of age-accumulated mutations was found to differ greatly from organ to organ; while initially similar, mutation spectra of different tissues diverged significantly over the lifetime. To explain how genomic instability, which is inherently stochastic, can be a causal factor in aging, it is proposed that randomly induced mutations may adversely affect normal patterns of gene regulation, resulting in a mosaic of cells at various stages on a trajectory of degeneration, eventually resulting in cell death or neoplastic transformation. To directly address this question we demonstrate that it is now possible to analyze single cells, isolated from old and young tissues, for specific alterations in gene expression. C1 Univ Texas, Hlth Sci Ctr, STCBM, San Antonio, TX 78245 USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Vijg, J (reprint author), Univ Texas, Hlth Sci Ctr, STCBM, 15355 Lambda Dr,Suite 2-200, San Antonio, TX 78245 USA. EM vijg@uthscsa.edu FU NIA NIH HHS [AG17242] NR 34 TC 38 Z9 41 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-561-3 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1055 BP 35 EP 47 DI 10.1196/annals.1323.007 PG 13 WC Biochemistry & Molecular Biology; Genetics & Heredity; Geriatrics & Gerontology; Multidisciplinary Sciences SC Biochemistry & Molecular Biology; Genetics & Heredity; Geriatrics & Gerontology; Science & Technology - Other Topics GA BDY44 UT WOS:000236116400004 PM 16387716 ER PT J AU Karlson, EW Costenbader, KH McAlindon, TE Massarotti, EM Fitzgerald, LM Jajoo, R Husni, E Wright, EA Pankey, H Fraser, PA AF Karlson, EW Costenbader, KH McAlindon, TE Massarotti, EM Fitzgerald, LM Jajoo, R Husni, E Wright, EA Pankey, H Fraser, PA TI High sensitivity, specificity and predictive value of the connective tissue disease screening questionnaire among urban African-American women SO LUPUS LA English DT Article DE African-American; connective tissue disease; lupus; screening; sensitivity ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; REVISED CRITERIA; COHORT; RACE; CLASSIFICATION; POPULATION; PREVALENCE; COMMUNITY; SYMPTOMS; FEATURES AB The Connective Tissue Disease Screening Questionnaire (CSQ), developed to screen populations for SLE and other CTDs, has been validated in a predominantly Caucasian population with hospital-based controls. We aimed to test the performance characteristics of the CSQ in an urban, predominantly African-American population. The CSQ was administered by interview to women recruited for a study of environmental risk factors and SLE, including 99 cases with SLE validated by medical record review and 202 healthy controls recruited from the community. Overall, 88% of subjects had African heritage, 6% were Hispanic and 4% were non-Hispanic Caucasian. Controls were more likely to report African heritage than cases (91% versus 82%, P = 0.001). Sensitivity for detecting SLE was 88% and specificity was 91%. In this study, where the prevalence of SLE was 33%, predictive value of a positive CSQ was 82% and predictive value of a negative CSQ was 94%. The CSQ has slightly lower sensitivity but greater specificity for SLE in an urban, predominantly African-American population with community-based controls compared with a Caucasian population with hospital-based controls. These results suggest that the CSQ has adequate sensitivity and specificity and could be used in population studies to screen African-American women for SLE. Lupus(2005)14, 832-836. C1 Robert B Brigham Arthritis & Musculoskeletal Dis, Sect Clin Sci, Div Rheumatol Immunol & Allergy, Boston, MA USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Tufts Univ New England Med Ctr, Boston, MA 02111 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Karlson, EW (reprint author), 75 Francis St, Boston, MA 02115 USA. EM ekarlson@partners.org FU NIAMS NIH HHS [AR36308, AR42630, K08 AR 02074-1]; NIEHS NIH HHS [R25ES10457-01] NR 22 TC 11 Z9 11 U1 0 U2 2 PU HODDER ARNOLD, HODDER HEADLINE PLC PI LONDON PA 338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PY 2005 VL 14 IS 10 BP 832 EP 836 DI 10.1191/0961203305lu2227oa PG 5 WC Rheumatology SC Rheumatology GA 984AK UT WOS:000233274600007 PM 16304727 ER PT J AU Farrar, CT Wedeen, VJ Ackerman, JL AF Farrar, CT Wedeen, VJ Ackerman, JL TI Cylindrical meanderline radiofrequency coil for intravascular magnetic resonance studies of atherosclerotic plaque SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE intravascular MRI; atherosclerotic plaque; meanderline coil; zigzag coil ID MRI; PROBE; FLAT AB In order to improve the performance of magnetic resonance imaging and spectroscopy of atherosclerotic plaque the potential use of novel radiofrequency coil structures with sensitive detection volumes tailored to the geometry of the arterial wall was investigated. It was found that a cylindrical meanderline (zig-zag) coil design provides a sensitive volume that is restricted to a cylindrical shell, thereby maximizing the filling factor and signal-to-noise ratio for plaques while reducing the intense blood signal. The cylindrical meanderline coil has the added advantages of an open interior, which allows for unimpeded blood flow during scanning, and the potential to be expanded against the walls of the artery, thereby stabilizing the coil against the pulsatile blood flow and minimizing motion artifacts. The performance of cylindrical meanderline coils with theoretical simulations of the electromagnetic fields as well as with experimental images of test objects (phantoms) and human endarterectomy surgical specimens is demonstrated. This radically new RF coil geometry offers the potential to improve the efficiency of MR data acquisition in medical applications in which curved surfaces or slabs contain the material of interest. (C) 2004 WileyLiss, Inc. C1 Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Ackerman, JL (reprint author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Dept Radiol, 149 13th St,Room 2320, Charlestown, MA 02129 USA. EM jerry@nmr.mgh.harvard.edu RI Ackerman, Jerome/E-2646-2015 OI Ackerman, Jerome/0000-0001-5176-7496 FU NCRR NIH HHS [S10RR16811, P41RR14075]; NIMH NIH HHS [R01MH64004] NR 20 TC 14 Z9 14 U1 1 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0740-3194 J9 MAGNET RESON MED JI Magn. Reson. Med. PD JAN PY 2005 VL 53 IS 1 BP 226 EP 230 DI 10.1002/mrm.20330 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 888NE UT WOS:000226380700031 PM 15690524 ER PT S AU Lopes-Virella, MF Thorpe, SR Derrick, MB Chassereau, C Virella, G AF Lopes-Virella, MF Thorpe, SR Derrick, MB Chassereau, C Virella, G BE Baynes, JW Monnier, VM Ames, JM Thorpe, SR TI The immunogenicity of modified lipoproteins SO MAILLARD REACTION: CHEMISTRY AT THE INTERFACE OF NUTRITION, AGING, AND DISEASE SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 8th International Symposium on the Maillard Reaction CY AUG 29-SEP 01, 2004 CL Charleston, SC SP Asahi Kasei Pharma, Avents, BASF, Biostratum, Univ S Carolina, Coll Sci & Math, Danisco, Danone Vitapole, Ctr Rech Daniel Carasso, DSM, Estee Lauder Co, Inlight Solut, IUBMB, Juvenile Diabet Res Fdn, KOWA, Oregon State Univ, Linus Pauling Inst, LOreal, Med Univ S Carolina, Merck, NIA, Nestle, Renascience, Univ S Carolina, Res & Hlth Sci, Taisho Pharmaceut Co Ltd, UNILEVER DE atherosclerosis; inflammation; autoimmunity; anti-lipoprotein antibodies; modified lipoproteins; diabetes; diabetic complications; Maillard reaction; AGE-LDL ID LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; CONTAINING IMMUNE-COMPLEXES; OXIDIZED LDL; DIABETES-MELLITUS; ATHEROSCLEROTIC LESIONS; LYSINE RESIDUES; ANTIBODIES; AUTOANTIBODIES; MALONDIALDEHYDE AB The immunogenicity of modified low-density lipoprotein (mLDL) has been demonstrated both in laboratory animals and humans. Circulating human mLDL antibodies, purified by affinity chromatography, are predominantly of the IgG isotype, subclasses I and 3. The purified antibodies react with malondialdehyde-lysine and carboxymethyl-lysine epitopes, but also recognize minimally modified forms of LDL that do not contain significant amounts of those two epitopes. The quantitative assays of mLDL and mLDL antibodies in serum samples by enzymoinummoassay (EIA) are unreliable owing to the interference of preformed circulating immune complexes (CICs). Isolation of CICs by precipitation with low concentrations of polyethylene glycol followed by analysis of antigens and antibodies contained in the precipitates is a technically complex approach, but one that yields valuable data. With this approach we have confirmed that the IgG antibodies involved in IC formation belong to the proinflammatory IgG1 and IgG3 isotypes, have a higher avidity than those that remain unbound in the supernatant after CIC precipitation, and are of higher avidity in diabetic patients with macroalbuminuria than in those with normal albuminuria. We have also developed capture assays for different forms of mLDL. These assays have shown a significant enrichment in mLDL of the precipitated ICs. The enrichment is also more pronounced in the CICs obtained from diabetic patients with macroalbuminuria. In conclusion, isolation and characterization of LDL-ICs appears to yield information of significant value that is not derived from other approaches to measure LDL modifications and their corresponding antibodies in humans. C1 Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Nutr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29403 USA. Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA. RP Virella, G (reprint author), Strom Thurmond Res Bldg,114 Doughty St,Room 529, Charleston, SC 29425 USA. EM virellam@musc.edu.edu FU NHLBI NIH HHS [HL-55782] NR 36 TC 3 Z9 3 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-531-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1043 BP 367 EP 378 DI 10.1196/annals.1333.043 PG 12 WC Biochemistry & Molecular Biology; Chemistry, Applied; Multidisciplinary Sciences; Physiology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics; Physiology GA BCY08 UT WOS:000231834100043 PM 16037258 ER PT S AU Klein, RL Semler, AJ Baynes, JW Thorpe, SR Lyons, TJ Jenkins, AJ AF Klein, RL Semler, AJ Baynes, JW Thorpe, SR Lyons, TJ Jenkins, AJ BE Baynes, JW Monnier, VM Ames, JM Thorpe, SR TI Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells SO MAILLARD REACTION: CHEMISTRY AT THE INTERFACE OF NUTRITION, AGING, AND DISEASE SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 8th International Symposium on the Maillard Reaction CY AUG 29-SEP 01, 2004 CL Charleston, SC SP Asahi Kasei Pharma, Avents, BASF, Biostratum, Univ S Carolina, Coll Sci & Math, Danisco, Danone Vitapole, Ctr Rech Daniel Carasso, DSM, Estee Lauder Co, Inlight Solut, IUBMB, Juvenile Diabet Res Fdn, KOWA, Oregon State Univ, Linus Pauling Inst, LOreal, Med Univ S Carolina, Merck, NIA, Nestle, Renascience, Univ S Carolina, Res & Hlth Sci, Taisho Pharmaceut Co Ltd, UNILEVER DE fibrinolysis; lipoproteins; LDL; glycation; endothelial cells; tissue plasminogen activator; plasminogen activator inhibitor-1 ID LOW-DENSITY-LIPOPROTEIN; FIBRINOLYTIC REGULATORS; GENERATION AB Diabetes may induce both quantitative and qualitative changes in lipoproteins, especially low-density lipoprotein (LDL). Effects of LDL glycation on endothelial cell secretion of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) have not been fully elucidated. Human aortic endothelial cell (HAEC) tPA and PAI-1 production were determined after incubation with LDL (50 to 500 mu g/mL protein, 24 h) from three sources: (1) nondiabetic LDL (N-LDL) modified in vitro to form six preparations: native, nonmodified (N); glycated (G); minimally oxidized (MO); minimally oxidized and glycated (MOG); heavily oxidized (HO); and heavily oxidized and glycated (HOG); (2) in vivo glycated and relatively nonglycated LDL subfractions from type 1 diabetic patients; (3) LDL from type I diabetic patients and matched controls, which was subfractionated using density gradient ultracentrifugation. In experiments using LDL modified in vitro, the rate of tPA release by HAECs incubated with N-LDL (83 +/- 4 ng/mg cell protein/24 h) did not differ significantly from those incubated with G-LDL (73 7), MO-LDL (74 +/- 13), or MOG-LDL (66 +/- 15) and was not influenced by LDL concentration. The rate of PAI-1 release was similar in HAECs incubated with N-LDL (5.7 +/- 0.6 mu g/mg cell protein/24 h), G-LDL (5.7 +/- 0.7), MO-LDL (5.5 +/- 0.8), or MOG-LDL (5.7 +/- 0.9) and was not influenced by LDL concentration. In contrast, tPA release was significantly decreased in cells incubated with LDL (10 mu g/mL) modified extensively by oxidation, and averaged 45.2 +/- 5.0 and 43.7 +/- 9.9 ng/mg/24 h for HO-LDL and HOG-LDL, respectively, and was further decreased with increasing concentrations of the heavily oxidized LDL preparations. PAI-1 release was not significantly decreased relative to N-LDL in cells incubated with low concentrations (5 to 50 mu g/mL) of HO-LDL and HOG-LDL, but was decreased to 3.2 +/- 0.5 and 3.1 +/- 0.7 mu g/mg/24 h for HO-LDL and HOG-LDL at 200 mu g/mL, respectively. Results using in vivo glycated versus nonglycated LDL showed that tPA and PAI-1 release did not differ between subfractions. Release of tPA averaged 5.11 +/- 0.6 and 5.12 +/- 0.7 ng/mg/ 24 h, whereas release of PAI-1 averaged 666 +/- 27 ng/mg/24 h and 705 30 ng/ mg/24 h for nonglycated and glycated LDL subfractions, respectively. Using LDL of different density subclasses, tPA and PAI-1 release in response to LDL from diabetic patients compared with control subjects did not differ when HAECs were incubated with LDLs of increasing density isolated from each subject pair. We conclude that oxidation of LDL, but not glycation, may contribute to the altered fibrinolysis observed in diabetes. C1 Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA. Univ Oklahoma, Hlth Sci Ctr, Endocrinol Sect, Oklahoma City, OK 73104 USA. Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia. RP Klein, RL (reprint author), Med Univ S Carolina, Strom Thurmond Biomed Res Facil, Room 501,114 Doughty St, Charleston, SC 29403 USA. EM kleinrl@musc.edu RI Jenkins, Alicia/N-2482-2015 NR 12 TC 5 Z9 6 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-531-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1043 BP 379 EP 389 DI 10.1196/annals.1333.044 PG 11 WC Biochemistry & Molecular Biology; Chemistry, Applied; Multidisciplinary Sciences; Physiology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics; Physiology GA BCY08 UT WOS:000231834100044 PM 16037259 ER PT J AU Collins, TC Petersen, NJ Suarez-Almazor, M Ashton, CM AF Collins, TC Petersen, NJ Suarez-Almazor, M Ashton, CM TI Ethnicity and peripheral arterial disease SO MAYO CLINIC PROCEEDINGS LA English DT Article ID ANKLE-ARM INDEX; VASCULAR-DISEASE; INTERMITTENT CLAUDICATION; DIABETES-MELLITUS; OCCLUSIVE DISEASE; INCOME INEQUALITY; LOWER-EXTREMITIES; UNITED-STATES; SOCIAL-CLASS; MORTALITY AB OBJECTIVE: To determine whether race/ethnicity is an independent risk factor for peripheral arterial disease (PAD). PATIENTS AND METHODS: From September 2000 through August 2001, we screened patients (age greater than or equal to55 years) for PAD within 4 primary care clinics located in the Houston, Tex, area. Variables that were bivariately associated with PAD (P less than or equal to .05) were selected for entry into a multivariate logistic regression model to determine the independent risk factors for PAD. RESULTS: Among 403 patients (136 white, 136 African American, and 131 Latino patients, 81 of whom were Spanish speaking), the prevalence of PAD was 22.8% among African American patients, 13.7% among Latino patients, and 13.2% among white patients (P = .06). Within the multivariate model, adjusting for age, smoking status (odds ratio [OR], 2.58; 95% confidence interval [CI] 1.27-5.25), diabetes mellitus (OR, 2.98; 95% CI, 1.58-5.63): hypertension (OR, 2.58; 95% CI, 1.12-5.95), and education, African American and Latino patients were not more likely than white patients to have a diagnosis of PAD (OR 1.89, 95% CI 0.89-3.99 and OR 1.54, 95% CI 0.59-4.06, respectively). CONCLUSION: After adjusting for atherosclerotic risk factors and level of education, ethnicity was not an independent risk factor for PAD. When determining ethnic variation in outcomes among patients with PAD, efforts are needed to better understand the role of the primary care setting to reduce the burden of social inequality on health. C1 Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Collins, TC (reprint author), Dept Vet Affairs, 2002 Holcombe Blvd,152, Houston, TX 77030 USA. EM tcollins@bcm.tmc.edu NR 35 TC 16 Z9 16 U1 0 U2 1 PU MAYO CLINIC PROCEEDINGS PI ROCHESTER PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD JAN PY 2005 VL 80 IS 1 BP 48 EP 54 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 884AM UT WOS:000226057000009 PM 15667029 ER PT B AU Gutkin, DW Metes, D Shurin, MR AF Gutkin, Dmitriy W. Metes, Diana Shurin, Michael R. BE Lotze, MT Thomson, AW TI Handling Sera and Obtaining Fluid from Different Compartments: Practical Considerations SO MEASURING IMMUNITY: BASIC BIOLOGY AND CLINICAL ASSESSMENT LA English DT Article; Book Chapter ID SYSTEMIC LUPUS-ERYTHEMATOSUS; IMMUNOGLOBULIN LIGHT-CHAINS; AMNIOTIC-FLUID; MULTIPLE-SCLEROSIS; CEREBROSPINAL-FLUID; RHEUMATOID-ARTHRITIS; PRETERM DELIVERY; SYNOVIAL-FLUID; PLEURAL FLUID; CLINICAL-FEATURES C1 [Gutkin, Dmitriy W.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Metes, Diana] Univ Pittsburgh, Med Ctr, Div Clin Immunopathol, Dept Surg, Pittsburgh, PA USA. [Shurin, Michael R.] Univ Pittsburgh, Med Ctr, Div Clin Immunopathol, Dept Pathol, Pittsburgh, PA USA. RP Gutkin, DW (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 59 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-047933-0; 978-0-12-455900-4 PY 2005 BP 121 EP 130 DI 10.1016/B978-012455900-4/50271-3 PG 10 WC Immunology; Medical Laboratory Technology SC Immunology; Medical Laboratory Technology GA BCN55 UT WOS:000310783900011 ER PT J AU Austad, SN AF Austad, SN TI Diverse aging rates in metazoans: targets for functional genomics SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article; Proceedings Paper CT 2nd International Conference on Functional Genomics of Ageing CY APR 28-MAY 01, 2004 CL Hersonissos, GREECE DE longevity; age-specific mortality; accelerated aging; slow-aging ID AGE-RELATED-CHANGES; DIETARY RESTRICTION; ANTECHINUS-STUARTII; BODY-COMPOSITION; LIFE-SPAN; LONGEVITY; DOG; METABOLISM; BREEDS; SIZE AB Aging, or senescence. has typically been measured by demographic analysis, which has its merits but is blind to key aspects of functional development and deterioration. If one uses demographic analyses, however, the approach providing most insight is the analysis of age-specific mortality. The continuing increase in DNA sequencing power combined with emerging computational techniques will allow in the near future detailed investigation of mechanisms of aging in diverse species beyond the typical laboratory bestiary. A comparative approach of this son needs to consider, in addition to simple longevity, the effects of phylogeny and body size on the species in question. Insight may be gained from the study of species exhibiting accelerated aging relative to more "typical" species. These naturally short-lived species. such as several small shrews and marsupials, avoid the worry inherent in "accelerated aging" genotypes of common models, which is that they are only short-lived because of some idiosyncratic pathology unrelated to general aging. A case of special interest that has yet to be seriously investigated is the domestic dog in which selective breeding has produced phenotypes within the same species that age at two-fold different rates. Exceptionally long-lived species offer exceptional opportunities to discover whether there are few or many ways to create long-lived organisms. Slow-aging species with the most to offer include bats and naked mole-rats. Perhaps no fundamental question in biology is more intriguing that why and how nature has produced such a dazzling array of aging rates. The development of functional genetics over the next several decades promises to lead us toward an answer. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RP Austad, SN (reprint author), Univ Texas, Hlth Sci Ctr, Barshop Inst Longev & Aging Studies, SCTBM Bldg,Room 3-100,15355 Lambda Dr, San Antonio, TX 78245 USA. EM austad@uthscsa.edu NR 32 TC 43 Z9 46 U1 0 U2 9 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD JAN PY 2005 VL 126 IS 1 SI SI BP 43 EP 49 DI 10.1016/j.mad.2004.09.022 PG 7 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 891EL UT WOS:000226564000007 PM 15610761 ER PT J AU Levin, M AF Levin, M TI Left-right asymmetry in embryonic development: a comprehensive review SO MECHANISMS OF DEVELOPMENT LA English DT Review DE embryogenesis.; left-fight asymmetry; chirality ID LEFT-RIGHT AXIS; LEFT-RIGHT SPECIFICATION; GAP JUNCTIONAL COMMUNICATION; NODAL-RELATED GENE; HOLT-ORAM-SYNDROME; RIGHT DETERMINANT INVERSIN; PRIMARY CILIARY DYSKINESIA; EARLY AMPHIBIAN EMBRYO; CENTRAL-NERVOUS-SYSTEM; LEFT-RIGHT PATTERN AB Embryonic morphogenesis occurs along three orthogonal axes. While the patterning of the anterior-posterior and dorsal-ventral axes has been increasingly well characterized, the left-right (LR) axis has only recently begun to be understood at the molecular level. The mechanisms which ensure invariant LR asymmetry of the heart, viscera, and brain represent a thread connecting biomolecular chirality to human cognition, along the way involving fundamental aspects of cell biology, biophysics, and evolutionary biology. An understanding of LR asymmetry is important not only for basic science, but also for the biomedicine of a wide range of birth defects and human genetic syndromes. This review summarizes the current knowledge regarding LR patterning in a number of vertebrate and invertebrate species. discusses several poorly understood but important phenomena, and highlights some important open questions about the evolutionary origin and conservation of mechanisms underlying embryonic asymmetry. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Harvard Univ, Sch Dent Med, Cytokine Biol Dept, Forsyth Inst, Boston, MA 02115 USA. Harvard Univ, Sch Dent Med, Dept Oral & Dev Biol, Boston, MA 02115 USA. RP Levin, M (reprint author), Harvard Univ, Sch Dent Med, Cytokine Biol Dept, Forsyth Inst, 140 Fenway, Boston, MA 02115 USA. EM mlevin@forsyth.org FU NIGMS NIH HHS [1-R01-GM-06227] NR 345 TC 254 Z9 259 U1 7 U2 37 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-4773 J9 MECH DEVELOP JI Mech. Dev. PD JAN PY 2005 VL 122 IS 1 BP 3 EP 25 DI 10.1016/j.mod.2004.08.006 PG 23 WC Developmental Biology SC Developmental Biology GA 888EG UT WOS:000226356400001 PM 15582774 ER PT S AU Ezekowitz, RA Shi, L Fraser, I Takahashi, K AF Ezekowitz, RA Shi, L Fraser, I Takahashi, K BE Gupta, S Paul, WE Steinman, R TI The mannose-binding lectin: An infection susceptibility gene SO MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION X: INNATE IMMUNITY SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Article; Proceedings Paper CT 10th International Conference on Mechanisms of Lymphocyte Activation and Immune Regulation CY FEB 06-08, 2004 CL Newport Beach, CA ID PATTERN-RECOGNITION MOLECULES; INNATE IMMUNE DEFENSE; SERINE-PROTEASE; MANNAN; SERUM; ASSOCIATION; COMPLEMENT; COLLECTINS; ACTIVATION; SALMONELLA C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat,Lab Dev Immunol, Boston, MA 02114 USA. RP Ezekowitz, RA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat,Lab Dev Immunol, 55 Fruit St,GRJ1402, Boston, MA 02114 USA. NR 39 TC 10 Z9 10 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 0065-2598 BN 0-387-24188-4 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2005 VL 560 BP 99 EP 103 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA BDB52 UT WOS:000232367600013 PM 15932025 ER PT J AU Ashton, CM Pietz, K AF Ashton, CM Pietz, K TI Setting a new standard for studies of geographic variation in hospital utilization rates SO MEDICAL CARE LA English DT Editorial Material ID PREVENTABLE HOSPITALIZATIONS; PRIMARY-CARE; HEALTH-CARE; CLINICS; ACCESS C1 VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Ashton, CM (reprint author), VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM carol.ashton@med.va.gov NR 20 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2005 VL 43 IS 1 BP 1 EP 3 PG 3 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 883MQ UT WOS:000226017000001 PM 15626927 ER PT J AU Kim, M Zaslavsky, AM Cleary, PD AF Kim, M Zaslavsky, AM Cleary, PD TI Adjusting pediatric Consumer Assessment of Health Plans Study (CAHPS) scores to ensure fair comparison of health plan performances SO MEDICAL CARE LA English DT Article DE patient satisfaction; casemix adjustment; children; parents ID BENCHMARKING DATA 1.0; MEDICAL-CARE; CASE-MIX; MANAGED CARE; QUALITY; SATISFACTION; IMPACT; MODEL AB Objectives: When comparing the scores from Consumer Assessment of Health Plans Study (CAHPS) surveys across health plans, it is important to adjust for patient characteristics (casemix) that are not under the control of the plan but that affect plan ratings. Our goal was to develop casemix models for pediatric CAHPS surveys. Methods: We analyzed responses to the pediatric CAHPS 2.0 surveys from 50,583 Medicaid beneficiaries and 43,579 persons with private health insurance. We identified patient characteristics with the most substantial impact on scores and assessed casemix models that include different combinations of adjusters. In addition, we tested whether casemix coefficients differed between the Medicaid and commercial samples and across health plans. Results: Parent age and education and child health status and race were important casemix adjustment variables for pediatric CAHPS surveys. Child age and gender had smaller effects. The relationship between patient characteristics and CAHPS scores was different in the Medicaid and commercial samples for some variables. The effects of a patient's characteristics on ratings and report scores were not consistent across Medicaid plans but more consistent for commercial plans. Conclusions: Our analyses indicate that plan scores on the pediatric CAHPS survey should be adjusted for plan differences in casemix. Users should consider estimating separate models for Medicaid and commercially insured respondents. Such models should adjust for child health status, parent age, and parent education. C1 Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA USA. RP Cleary, PD (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM cleary@hcp.med.harvard.edu FU AHRQ HHS [U18 HS09 205] NR 27 TC 17 Z9 17 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2005 VL 43 IS 1 BP 44 EP 52 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 883MQ UT WOS:000226017000007 PM 15626933 ER PT J AU Petersen, LA Pietz, K Woodard, LD Byrne, M AF Petersen, LA Pietz, K Woodard, LD Byrne, M TI Comparison of the predictive validity of diagnosis-based risk adjusters for clinical outcomes SO MEDICAL CARE LA English DT Article DE risk adjustment; Diagnostic Cost Groups; Adjusted Clinical Groups; capitation; predictive validity; mortality; long-term care; age ID LAST YEAR; MEDICARE; ADJUSTMENT; LIFE; CARE; PAYMENTS; SERVICES AB Objectives: Many possible methods of risk adjustment exist, but there is a dearth of comparative data on their performance. We compared the predictive validity of 2 widely used methods (Diagnostic Cost Groups [DCGs] and Adjusted Clinical Groups [ACGs]) for 2 clinical outcomes using a large national sample of patients. Methods: We studied all patients who used Veterans Health Administration (VA) medical services in fiscal year (FY) 2001 (n = 3,069,168) and assigned both a DCG and an ACG to each. We used logistic regression analyses to compare predictive ability for death or long-term care (LTC) hospitalization for age/gender models, DCG models, and ACG models. We also assessed the effect of adding age to the DCG and ACG models. Results: Patients in the highest DCG categories, indicating higher severity of illness, were more likely to die or to require LTC hospitalization. Surprisingly, the age/gender model predicted death slightly more accurately than the ACG model (c-statistic of 0.710 versus 0.700, respectively). The addition of age to the ACG model improved the c-statistic to 0.768. The highest c-statistic for prediction of death was obtained with a DCG/age model (0.830). The lowest c-statistics were obtained for age/gender models for LTC hospitalization (c-statistic 0.593). The c-statistic for use of ACGs to predict LTC hospitalization was 0.783, and improved to 0.792 with the addition of age. The c-statistics for use of DCGs and DCG/age to predict LTC hospitalization were 0.885 and 0.890, respectively, indicating the best prediction. Conclusions: We found that-risk adjusters based upon diagnoses predicted an increased likelihood of death or LTC hospitalization, exhibiting good predictive validity. In this comparative analysis using VA data, DCG models were generally superior to ACG models in predicting clinical outcomes, although ACG model performance was enhanced by the addition of age. C1 Houston Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence 152, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Houston, TX USA. Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL USA. RP Petersen, LA (reprint author), Houston Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 24 TC 77 Z9 77 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2005 VL 43 IS 1 BP 61 EP 67 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 883MQ UT WOS:000226017000009 PM 15626935 ER PT J AU Syngal, S Bandipalliam, P Boland, R AF Syngal, S Bandipalliam, P Boland, R TI Surveillance of patients at high risk for colorectal cancer SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article ID PEUTZ-JEGHERS-SYNDROME; FAMILIAL ADENOMATOUS POLYPOSIS; RILEY-RUVALCABA-SYNDROME; FECAL-OCCULT-BLOOD; MISMATCH-REPAIR GENES; GERM-LINE MUTATIONS; JUVENILE POLYPOSIS; ULCERATIVE-COLITIS; COWDEN-DISEASE; MICROSATELLITE INSTABILITY AB Colorectal cancer (CRC) is a common disease, and its incidence increases dramatically with advancing age. There will be an estimated 140,000 new cases of CRC in 2004, and 57,000 deaths attributable to this disease, making it a major public health concern [1]. CRC mortality may be greatly reduced by clinically feasible screening programs (Table 1). The reduction in mortality may be as great as 80% when colonoscopy and colonoscopic polypectomy programs are implemented, because this technique not only screens for cancer, but prevents cancer from developing by ablating premalignant (adenomatous) lesions [2]. Two programs can reduce morbidity and mortality from CRC: screening programs for healthy, asymptomatic individuals greater than 50 years of age, and surveillance programs for groups at increased risk of developing CRC, including a personal history of CRC or colorectal adenomas, a family history of CRC or gastrointestinal cancer syndromes, and inflammatory bowel disease. The benefits of surveillance of high-risk groups are evident. Cancer mortality can be dramatically reduced by eradication of precursor lesions and by detection of cancer at an early and highly curable stage. Few rigorous studies of CRC surveillance in high-risk groups, however, have been performed. The main uncertainty and challenge is to determine the appropriate intervals between surveillance by randomized clinical trials. C1 Baylor Univ, Med Ctr, Div Gastroenterol, Dallas, TX 75246 USA. Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA. Dana Farber Canc Inst, Populat Sci Div, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Boland, R (reprint author), Baylor Univ, Med Ctr, Div Gastroenterol, H-250,3500 Gaston Ave, Dallas, TX 75246 USA. EM Rickbo@baylorhealth.edu NR 82 TC 8 Z9 8 U1 0 U2 3 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD JAN PY 2005 VL 89 IS 1 BP 61 EP + DI 10.1016/j.mcna.2004.08.013 PG 26 WC Medicine, General & Internal SC General & Internal Medicine GA 874RX UT WOS:000225368600004 PM 15527809 ER PT J AU Stahl, JE Kong, N Shechter, SM Schaefer, AJ Roberts, MS AF Stahl, JE Kong, N Shechter, SM Schaefer, AJ Roberts, MS TI A methodological framework for optimally reorganizing liver transplant regions SO MEDICAL DECISION MAKING LA English DT Article DE transplant regions; organ procurement organizations; liver transplants ID COLD ISCHEMIA TIME; UNIVERSITY-OF-WISCONSIN; EURO-COLLINS SOLUTIONS; UW-SOLUTION; PRESERVATION INJURY; GRAFT FUNCTION; MEGX TEST; DONOR; COSTS; EUROCOLLINS AB Background. The United States is divided currently into 11 transplant regions, which vary in area and number of organ procurement organizations (OPOs). Region size affects organ travel time and organ viability at transplant. Purpose. To develop a methodologic framework for determining optimal configurations of regions maximizing transplant allocation efficiency and geographic parity. Methods. An integer program was designed to maximize a weighted combination of 2 objectives: 1) intraregional transplants, 2) geographic Parity-maximizing the lowest intraregional transplant rate across all OPOs. Two classes of functions relating liver travel time to liver viability were also examined as part of the sensitivity analyses. Results. Preliminary results indicate that reorganizing regions, while constraining their number to 11, resulted in up to 17 additional transplants/year depending on the travel-viability function; when not constrained, it resulted in up to 18/year of increase. Conclusion. Our analysis indicates that liver transplantation may benefit through region reorganization. The analytic method developed here should be applicable to other organs and sets of organs. C1 Univ Pittsburgh, Dept Ind Engn, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15260 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment,Dept Radiol, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA. RP Stahl, JE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment,Dept Radiol, 101 Merimac St,10th Floor, Boston, MA 02114 USA. EM James@mgh-ita.org FU AHRQ HHS [1K08HS011637-01A1, R01HS-09694] NR 53 TC 19 Z9 19 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD JAN-FEB PY 2005 VL 25 IS 1 BP 35 EP 46 DI 10.1177/0272989X04273137 PG 12 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 889SV UT WOS:000226463800004 PM 15673580 ER PT J AU Turner, EH Blackwell, AD AF Turner, EH Blackwell, AD TI 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: Synergistic mechanisms for normalizing synaptic serotonin SO MEDICAL HYPOTHESES LA English DT Article ID SEASONAL AFFECTIVE-DISORDER; HEPATITIS-C; ANTIDEPRESSANT ACTION; TRYPTOPHAN DEPLETION; LIGHT THERAPY; ALPHA; L-5-HYDROXYTRYPTOPHAN; METABOLISM; REMISSION; 5-HYDROXY-L-TRYPTOPHAN AB Interferon-α (IFN) is widely used in the treatment of certain cancers and viral infections, including hepatitis C (HCV). Unfortunately, depression is a common side effect of IFN therapy, affecting approximately a third of HCV patients receiving IFN therapy. Studies have shown that selective serotonin reuptake inhibitors (SSRIs) can effectively treat IFN-induced depression in only 63-75% of cases. For the remaining percentage, depression often necessitates dose reduction of or discontinuation from IFN therapy. Emerging evidence indicates that IFN may cause depression by affecting brain serotonin. IFN has been shown to increase serotonin reuptake and to decrease serotonin synthesis. We hypothesize that SSRIs are not fully effective because they affect only serotonin reuptake, not serotonin synthesis, and that effective treatment must address both uptake and synthesis. 5-Hydroxytryptophan (5-HTP) effectively increases central nervous system synthesis of serotonin. It is the immediate precursor of serotonin and is widely available as a dietary supplement, which is well absorbed after an oral dose. Several double-blind studies have shown 5-HTP to be effective in the treatment of nondrug-induced depression. We hypothesize that patients who become depressed on IFN will respond to the synergistic combination of SSRIs plus 5-HTP. © 2005 Elsevier Ltd. All rights reserved. C1 Portland VA Med Ctr, Mood Disorders Res Ctr, Mental Hlth Div, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Pharmacol & Physiol, Portland, OR 97239 USA. Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR 97239 USA. RP Turner, EH (reprint author), Portland VA Med Ctr, Mood Disorders Res Ctr, Mental Hlth Div, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Erick.turner@med.va.gov RI Blackwell, Aaron/B-5258-2008; Turner, Erick/A-4848-2008 OI Blackwell, Aaron/0000-0002-5871-9865; Turner, Erick/0000-0002-3522-3357 NR 55 TC 23 Z9 26 U1 0 U2 2 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2005 VL 65 IS 1 BP 138 EP 144 DI 10.1016/j.mehy.2005.01.026 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 932DW UT WOS:000229535400023 PM 15893130 ER PT J AU Sonnenberg, A AF Sonnenberg, A TI The inevitable rise of mediocrity in academic medicine SO MEDICAL HYPOTHESES LA English DT Article ID CREATIVITY; REQUIREMENTS; DEPARTMENTS; GUIDELINES; JOURNALS; FACULTY AB The present analysis addresses the question of how it has been possible for academic medicine to grow and lose its creative productivity at the same time. A mathematical model is developed to simulate the mechanisms that govern growth of medical systems over time. Time-dependent growth of system size increases the occurrence of statistical deviations of all system parameters. Deviations are correlated with costs and creative output. As deviation-induced costs start to strain the system's tolerance, means become implemented to restrict deviation, which ultimately also reduces its creative output. To maintain growth combined with high levels of creative output, an academic medical system would need to continuously branch off and nurture smaller subsystems, which pursue their own set of goals relatively independently of the overall academic structure. Published by Elsevier Ltd. C1 Portland VA Med Ctr, Gastroenterol Sect, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Gastroenterol Sect, P3-G1,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 22 TC 1 Z9 1 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2005 VL 65 IS 2 BP 400 EP 404 DI 10.1016/j.mehy.2005.02.028 PG 5 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 935YI UT WOS:000229818900034 PM 15894430 ER PT J AU Awdeh, ZL Alper, CA AF Awdeh, ZL Alper, CA TI Mendelian inheritance of polygenic diseases: a hypothetical basis for increasing incidence SO MEDICAL HYPOTHESES LA English DT Article ID GENE AB The incidence of common polygenic diseases, such as type 1 diabetes, bronchial asthma, and gluten-sensitive enteropathy, is increasing. Although this is usually attributed to environmental factors, it is possible that this rising incidence also has a genetic basis. The hypothesis is put forth that, in the past, these diseases, with their increased morbidity and mortality, were selected against. In contrast to monogenic diseases, the incidence of polygenic diseases can be reduced by selection against susceptibility alleles of any of the genetic loci necessary for disease to occur. In different isolated populations, different disease susceptibility loci may have been selected against. Parents who derive from different isolated populations in which there are inversely different susceptibility allele frequencies because of selection or genetic drift, would be expected to have offspring with an increased risk for that polygenic disease. It is shown mathematically that the incidence of a hypothetical polygenic disease increases under these circumstances. The increased risk in these offspring results from a kind of genetic complementation in which they have inherited a more complete set of susceptibility alleles at all susceptibility loci than is carried by either of their parents. Hallmarks of this hypothesized phenomenon would be increased heterozygosity for specific population markers (whether susceptibility alleles or not) among the disease-affected offspring and a paucity of such heterozygotes among their parents. The parents and patients would also be expected to give more evidence of ethnic or subethnic disparity than that observed in controls. (C) 2004 Elsevier Ltd. All rights reserved. C1 CBR Inst Biomed Res, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Alper, CA (reprint author), CBR Inst Biomed Res, 800 Huntington Ave, Boston, MA 02115 USA. EM alper@cbr.med.harvard.edu FU NHLBI NIH HHS [P01 HL29583] NR 8 TC 5 Z9 5 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2005 VL 64 IS 3 BP 495 EP 498 DI 10.1016/j.mehy.2004.08.025 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 899IX UT WOS:000227139200012 PM 15617855 ER PT J AU Bhidayasiri, R Bronstein, JM AF Bhidayasiri, R Bronstein, JM TI Improvement of cervical dystonia: possible role of transcranial magnetic stimulation simulating sensory tricks effect SO MEDICAL HYPOTHESES LA English DT Article ID SUBTHALAMIC NUCLEUS RESULT; EXCITOTOXIC ACID LESIONS; SENSORIMOTOR INTEGRATION; NEURONAL-ACTIVITY; FOCAL DYSTONIA; WRITERS CRAMP; MOTOR CORTEX; DEPRESSION; RESPONSES; HAND AB Idiopathic cervical dystonia (ICD) is the most common form of focal dystonia. A characteristic and unique diagnostic feature is the presence of "sensory tricks", for example, a finger placed on the chin to neutralize the spasm. Although approximately 70% of patients with ICD experience effective sensory tricks, the exact mechanism of these tricks is still unknown. However, recent evidence suggests that higher sensorimotor integration processes are involved. A study using H(2)(15)O positron emission tomography demonstrated that the application of sensory trick stimulus, resulting in a near-neutral head position, led to an increased activation mainly of the superior and inferior parietal lobules (ipsilateral to head turn) and bilateral occipital cortex and to a decreased activity of the supplementary motor area and the primary sensorimotor cortex (contralateral to head turn). Since transcranial magnetic stimulation (TMS) is an experimental device with the ability to excite or depress the neural circuits, we hypothesize that the use of TMS of specific parameters to specific brain areas (as above) may produce an effect similar to sensory tricks resulting in the relief of spasms and the improvement of cervical dystonia. (c) 2004 Elsevier Ltd. All rights reserved. C1 Univ Calif Los Angeles, Med Ctr, Dept Neurol, Geffen Sch Med, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Dept Neurol, PADRECC, Los Angeles, CA 90095 USA. RP Bhidayasiri, R (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Neurol, Geffen Sch Med, Los Angeles, CA 90095 USA. EM rbh@ucla.edu OI Bhidayasiri, Roongroj/0000-0002-6901-2064 NR 30 TC 7 Z9 8 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2005 VL 64 IS 5 BP 941 EP 945 DI 10.1016/j.mehy.2004.11.022 PG 5 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 912VH UT WOS:000228107500009 PM 15780489 ER PT S AU Martin-Fernandez, M Bouix, S Ungar, L McCarley, RW Shenton, ME AF Martin-Fernandez, M Bouix, S Ungar, L McCarley, RW Shenton, ME BE Duncan, JS Gerig, G TI Two methods for validating brain tissue classifiers SO MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2005, PT 1 SE LECTURE NOTES IN COMPUTER SCIENCE LA English DT Article; Proceedings Paper CT 8th International Conference on Medical Image Computing and Computer-Assisted Intervention CY OCT 26-29, 2005 CL Palm Springs, CA SP No Digital Inc Waterloo, Springer Lecture Notes Comp Sci, GE Healthcare, Medtron Navigat, Siemens Corp Res, NIBIB ID MRI DATA; IMAGE SEGMENTATION; ALGORITHM AB In this paper, we present an evaluation of seven automatic brain tissue classifiers based on level of agreements. A number of agreement measures are explained, and we show how they can be used to compare different segmentation techniques. We use the Simultaneous Truth and Performance Level Estimation (STAPLE) of Warfield et al. but also introduce a novel evaluation technique based on the Williams' index. The methods are evaluated using these two techniques on a population of forty subjects, each having an SPGR scan and a co-registered T2 weighted scan. We provide an interpretation of the results and show how similar the output of the STAPLE analysis and Williams' index are. When no ground truth is required, we recommend the use of Williams' index as it is easy and fast to compute. C1 Brigham & Womens Hosp, Lab Math & Imaging, Boston, MA 02115 USA. Univ Valladolid, Lab Procesado Imagen, Valladolid, Spain. Harvard Univ, Sch Med, VA Boston Healthcare Syst, Dept Psychiat, Brockton, MA 02401 USA. RP Martin-Fernandez, M (reprint author), Brigham & Womens Hosp, Lab Math & Imaging, 75 Francis St, Boston, MA 02115 USA. RI Martin-Fernandez, Marcos/L-8366-2014; OI Martin-Fernandez, Marcos/0000-0001-9342-9989; McCarley, Robert/0000-0001-5705-7495 NR 17 TC 8 Z9 8 U1 0 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 3-540-29327-2 J9 LECT NOTES COMPUT SC PY 2005 VL 3749 BP 515 EP 522 PG 8 WC Computer Science, Information Systems; Computer Science, Theory & Methods; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Radiology, Nuclear Medicine & Medical Imaging GA BDG20 UT WOS:000233337000064 ER PT S AU Diamond, SG Huppert, TJ Kolehmainen, V Franceschini, MA Kaipio, JP Arridge, SR Boas, DA AF Diamond, SG Huppert, TJ Kolehmainen, V Franceschini, MA Kaipio, JP Arridge, SR Boas, DA BE Duncan, JS Gerig, G TI Physiological system identification with the Kalman filter in diffuse optical tomography SO MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2005, PT 2 SE Lecture Notes in Computer Science LA English DT Article; Proceedings Paper CT 8th International Conference on Medical Image Computing and Computer-Assisted Intervention CY OCT 26-29, 2005 CL Palm Springs, CA SP No Digital Inc Waterloo, Springer Lecture Notes Comp Sci, GE Healthcare, Medtron Navigat, Siemens Corp Res, NIBIB ID TIME-SERIES; FMRI AB Diffuse optical tomography (DOT) is a noninvasive imaging technology that is sensitive to local concentration changes in oxy and deoxyhemoglobin. When applied to functional neuroirnaging, DOT measures hemodynamics in the scalp and brain that reflect competing metabolic demands and cardiovascular dynamics. Separating the effects of systemic cardiovascular regulation from the local dynamics is vitally important in DOT analysis. In this paper, we use auxiliary physiological measurements such as blood pressure and heart rate within a Kalman filter framework to model physiological components in DOT. We validate the method on data from a human subject with simulated local hemodynamic responses added to the baseline physiology. The proposed method significantly improved estimates of the local hemodynamics in this test case. Cardiovascular dynamics also affect the blood oxygen dependent (BOLD) signal in functional magnetic resonance imaging (fMRI). This Kalman filter framework for DOT may be adapted for BOLD fMRI analysis and multimodal studies. C1 Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. UCL, Dept Comp Sci, London, England. Univ Kuopio, Dept Appl Phys, FIN-70211 Kuopio, Finland. RP Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM sdiamond@nmr.mgh.harvard.edu RI Kolehmainen, Ville/K-1963-2012; OI Kolehmainen, Ville/0000-0002-5621-795X; Diamond, Solomon/0000-0002-7589-2942; Kaipio, Jari/0000-0002-7392-5149 NR 11 TC 6 Z9 6 U1 0 U2 3 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 3-540-29326-4 J9 LECT NOTES COMPUT SC PY 2005 VL 3750 BP 649 EP 656 PG 8 WC Computer Science, Information Systems; Computer Science, Theory & Methods; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Radiology, Nuclear Medicine & Medical Imaging GA BDG25 UT WOS:000233356900080 ER PT S AU Cai, WL Dachille, F Meissner, M AF Cai, WL Dachille, F Meissner, M BE Amini, AA Manduca, A TI Centerline optimization using vessel quantification model SO Medical Imaging 2005: Physiology, Function, and Structure From Medical Images, Pts 1 and 2 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2005 Conference CY FEB 15-17, 2005 CL San Diego, CA SP SPIE DE computed tomography angiography; vessel analysis; medial axis transformation; centerline refinement ID ANGIOGRAPHIC IMAGES; 3 DIMENSIONS; VISUALIZATION; EXTRACTION; SKELETONS; ALGORITHM; TRANSFORM AB An accurate and reproducible centerline is needed in many vascular applications, such as virtual angioscopy, vessel quantification, and surgery planning. This paper presents a progressive optimization algorithm to refine a centerline after it is extracted. A new centerline model definition is proposed that allows quantifiable minimum cross-sectional area. A centerline is divided into a number of segments. Each segment corresponds to a local generalized cylinder. A reference frame (cross-section) is set up at the center point of each cylinder. The position and the orientation of the cross-section are optimized within each cylinder by finding the minimum cross-sectional area. All local-optimized center points are approximated by a NURBS curve globally, and the curve is re-sampled to the refined set of center points. This refinement iteration, local optimization plus global approximation, converges to the optimal centerline, yielding a smooth and accurate central axis curve. The application discussed in this paper is vessel quantification and virtual angioscopy. However, the algorithm is a general centerline refinement method that can be applied to other applications that need accurate and reproducible centerlines. C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02125 USA. RP Cai, WL (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02125 USA. NR 20 TC 0 Z9 0 U1 0 U2 3 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-5720-5 J9 P SOC PHOTO-OPT INS PY 2005 VL 5746 BP 796 EP 803 DI 10.1117/12.594801 PN 1-2 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA BCH30 UT WOS:000229312100084 ER PT S AU Vosburgh, KG AF Vosburgh, Kirby G. BE Westwood, JD Haluck, RS Hoffman, HM Mogel, GT Phillips, R Robb, RA Vosburgh, KG TI Beyond VR: Creating the Augmented Physician SO MEDICINE MEETS VIRTUAL REALITY 13: THE MAGICAL NEXT BECOMES THE MEDICAL NOW SE Studies in Health Technology and Informatics LA English DT Proceedings Paper CT 13th Conference on Medicine Meets Virtual Reality CY JAN 26-29, 2005 CL Long Beach, CA ID PHYSIOME PROJECT; CANCER PATIENTS; SURVIVAL; THERAPY AB The ongoing shift of high tech capability from the specialist to the primary physician and the merging of medical and surgical therapies will demand more sophisticated measurement and control, but more positively, it will be possible to differentiate each individual situation and tailor treatment to provide an optimum result for each person, for each condition, in each environment, if these could all be measured, understood, and effected. The effective augmentation of the care-giver's physical, sensory, and cognitive capabilities will require more transparent, nuanced, and adaptive interfaces to information and to its therapeutic application. While the enhancement and classification of digitized findings is a beginning, the key may be better tracking and presentation of the chronological course, particularly the prior events which set the physiologic or morphologic data in context. Systems engineering approaches will define paths toward optimized, autonomous treatment, where the most rapid progress may be made through functional partitioning using scale-independent models, and the delineation of intermediate stages between today's macroscopic presentation of disease and molecular-scale treatment. These stages will comprise the steps toward useful patient avatars; our task is to fill in, with successively more powerful models, the convergence of large scale and small scale information, as it is used to support diagnostic and therapeutic decisions. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, CIMIT, Cambridge, MA 02465 USA. RP Vosburgh, KG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, CIMIT, 65 Landsdowne St, Cambridge, MA 02465 USA. EM kirby@bwh.harvard.edu; kirby@bwh.harvard.edu NR 14 TC 0 Z9 0 U1 0 U2 0 PU I O S PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0926-9630 BN 978-1-58603-498-6 J9 ST HEAL T PY 2005 VL 111 BP 574 EP 578 PG 5 WC Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Computer Science; Engineering; Research & Experimental Medicine GA BMX46 UT WOS:000273828700113 PM 15718800 ER PT J AU August, M AF August, M TI Oral health implications of menopause SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Editorial Material ID PERIODONTAL-DISEASE; INCREASED RISK; BONE LOSS; OSTEOPOROSIS C1 Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. RP August, M (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. NR 12 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PY 2005 VL 12 IS 2 BP 123 EP 124 DI 10.1097/01.GME.000155298.35944.4B PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 909AB UT WOS:000227830200003 PM 15772556 ER PT J AU McFall, M Tackett, J Maciejewski, ML Richardson, RD Hunt, SC Roberts, L AF McFall, M Tackett, J Maciejewski, ML Richardson, RD Hunt, SC Roberts, L TI Predicting costs of Veterans Affairs health care in Gulf War veterans with medically unexplained physical symptoms SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; POPULATION-BASED SURVEY; SELF-REPORTED SYMPTOMS; PSYCHIATRIC-DISORDERS; VIETNAM VETERANS; SOMATIZATION; EXPOSURES; SEVERITY; SERVICES; OUTCOMES AB Measures of post-traumatic stress disorder (PTSD) and depression were used to predict Veterans Affairs outpatient treatment costs among Persian Gulf War veterans with medically unexplained physical symptoms. Patients (N=206) enrolled in a Veterans Affairs primary care clinic for Persian Gulf War veterans completed study assessments at the initial appointment or at a proximal follow-up visit. Costs of care for mental health, medical, and pharmacy services for these veterans were computed for the subsequent 6-month period. Depression and PTSD symptoms explained a significant share of variance in costs of mental health care and pharmacy services, after adjustment for covariates. None of the mental status measures was significantly related to costs of medical care. Models using global measures of mental health status were as robust as models using disorder-specific measures of PTSD and depression in predicting mental health care and pharmacy costs. The implications of these findings for anticipating costs of care for Persian Gulf War veterans are discussed. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Hlth Serv, Seattle, WA 98108 USA. Univ Washington, Dept Occupat & Environm Med, Seattle, WA 98108 USA. RP McFall, M (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 40 TC 5 Z9 5 U1 0 U2 0 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD JAN PY 2005 VL 170 IS 1 BP 70 EP 75 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 019JG UT WOS:000235830800013 PM 15724858 ER PT J AU Azabdaftari, G Shah, R Bismar, TA Kim, R Zerkowski, MP Rimm, S Pienta, KJ Rubin, MA AF Azabdaftari, G Shah, R Bismar, TA Kim, R Zerkowski, MP Rimm, S Pienta, KJ Rubin, MA TI Androgen receptor expression in hormone refractory prostate cancer from a rapid autopsy series: Quantitative subcellular localization using AQUA SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Harvard Univ, Sch Med, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Yale Univ, Sch Med, New Haven, CT USA. Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 5 BP 5A EP 5A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900006 ER PT J AU Logani, S Oliva, E Arnell, PM Amin, MB Young, RH AF Logani, S Oliva, E Arnell, PM Amin, MB Young, RH TI Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma SO MODERN PATHOLOGY LA English DT Article DE ovarian cancer; mucinous; adenocarcinoma; endometrioid adenocarcinoma; metastatic; colorectal carcinoma; CDX2; beta-catenin; P504S ID METHYLACYL-COA RACEMASE; BETA-CATENIN EXPRESSION; MUCINOUS CARCINOMAS; INTESTINAL ORIGIN; HOMEOBOX GENE; CDX2; DIFFERENTIATION; CYTOKERATIN-20; DISTINCTION; MUTATIONS AB Distinguishing primary ovarian carcinoma, particularly endometrioid and mucinous subtypes, from metastatic colorectal carcinoma to the ovary is often difficult on histologic examination alone. Recently, three immunohistochemical markers CDX2, a homeobox gene encoding an intestine-specific transcription factor; alpha-methylacyl-CoA racemase (AMACR/P504S), a mitochondrial and peroxisomal enzyme with fairly restricted expression in selective tumors and beta-catenin, an adenomatous polyposis coli (APC) mutation product resulting in activation of the Wnt pathway, have been reported to have specific and sensitive expression in colorectal carcinomas. We evaluated a panel consisting of antibodies to CDX2, beta-catenin and P504S in 23 primary ovarian adenocarcinomas ( 13 mucinous and 10 endometrioid) and compared the findings to 22 metastatic colorectal adenocarcinomas ( seven mucinous and 15 nonmucinous tumors with endometrioid-like morphology hereafter referred to as pseudo-endometrioid) to the ovary stained with the same panel. Twenty (91%) metastatic tumors expressed at least two markers and seven (32%) expressed all three. In contrast, only three (13%) primary ovarian tumors expressed at least two markers and none expressed all three. Strong (2+, 3+) and diffuse (>40%) expression for CDX2 was noted in 21 (95%) metastatic tumors and five (22%) primary ovarian tumors ( three mucinous, two endometrioid). P504S was similarly expressed in seven ( 32%) metastatic and none of the primary ovarian carcinomas. Nuclear expression of beta-catenin was noted in 13 (59%) metastatic tumors and in eight cases (36%), it was diffuse and strong. In contrast, four (19%) primary tumors showed nuclear expression of this protein with only one (5%) case expressing it in a diffuse pattern. Immunohistochemical expression of gene products and enzymes of colorectal carcinogenesis in some primary ovarian carcinomas suggest that the morphologic similarities between colorectal and mucinous/endometrioid carcinoma of the ovary extends to the genetic level, although differences in the level of expression exist between these tumors. Diffuse expression of all three markers ( CDX2, beta-catenin and P504S) in a tumor in the ovary was found to be virtually diagnostic of metastasis from a colorectal primary in this study. C1 Emory Univ, Sch Med, Atlanta, GA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA USA. RP Logani, S (reprint author), Emory Univ Hosp, Dept Pathol, Suite H187,1364 Clifton Rd NE, Atlanta, GA 30322 USA. EM slogani@emory.edu NR 37 TC 64 Z9 67 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 IS 1 BP 19 EP 25 DI 10.1038/modpathol.3800260 PG 7 WC Pathology SC Pathology GA 884TS UT WOS:000226109900003 PM 15389251 ER PT J AU Oliveira, AM Perez-Atayde, AR Dal Cin, P Gebhardt, MC Rosenberg, AE Bridge, JA Fletcher, JA AF Oliveira, AM Perez-Atayde, AR Dal Cin, P Gebhardt, MC Rosenberg, AE Bridge, JA Fletcher, JA TI Novel USP6 fusion oncogenes with TRAP150, ZNF9, osteomodulin, and COL1A1 in aneurysmal bone cyst variant translocations SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Mayo Clin, Rochester, MN USA. Childrens Hosp, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Nebraska, Med Ctr, Omaha, NE 68182 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 73 BP 19A EP 19A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900074 ER PT J AU Brachtel, EF Kawakubo, H Maheswaran, S AF Brachtel, EF Kawakubo, H Maheswaran, S TI BTG2 expression in human breast cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 111 BP 27A EP 28A PG 2 WC Pathology SC Pathology GA 884WR UT WOS:000226117900112 ER PT J AU Rabban, JT Koerner, FC Lerwill, MF AF Rabban, JT Koerner, FC Lerwill, MF TI Cytokeratin 5/6 distinguishes solid papillary ductal carcinoma in-situ from florid usual ductal hyperplasia SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 203 BP 47A EP 47A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900204 ER PT J AU Witkiewicz, AK Pliss, N Kamma, M Schnitt, S Burstein, HJ Harris, L AF Witkiewicz, AK Pliss, N Kamma, M Schnitt, S Burstein, HJ Harris, L TI The effect of trastuzumab (Herceptin (R)) treatment on estrogen receptor status in patients with early stage HER2 positive breast cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 NYU, Sch Med, New York, NY USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 242 BP 55A EP 55A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900243 ER PT J AU Stone, JR Talusan, P Kattapuram, T AF Stone, JR Talusan, P Kattapuram, T TI Proteomic profiling of human vascular intimal proteoglycans SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 260 BP 59A EP 59A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900261 ER PT J AU Chen, AA McKee, GT Deshpande, V AF Chen, AA McKee, GT Deshpande, V TI Fine-needle aspiration cytology of schwannoma and its distinction from other spindle cell lesions SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 271 BP 61A EP 62A PG 2 WC Pathology SC Pathology GA 884WR UT WOS:000226117900272 ER PT J AU Garcia, CF Pilch, BZ Tannous, Z Mihm, ZC Koerner, F Zembowicz, A AF Garcia, CF Pilch, BZ Tannous, Z Mihm, ZC Koerner, F Zembowicz, A TI Endocrine-mucin producing sweat gland carcinoma of the eyelid: Analysis of 12 cases suggests that it is a precursor of mucinous carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA USA. Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 375 BP 84A EP 84A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900376 ER PT J AU Dahia, PL Powers, JF Ehsani, SA Tischler, AS AF Dahia, PL Powers, JF Ehsani, SA Tischler, AS TI Expression of NOTCH3 protein identifies a distinctive subset of pheochromocytomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Tufts Univ, New England Med Ctr, Boston, MA 02111 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 BP 89A EP 89A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900405 ER PT J AU Koutsogiannis, D Young, RH Meier, CA Bongiovanni, M Pache, JC Faquin, WC AF Koutsogiannis, D Young, RH Meier, CA Bongiovanni, M Pache, JC Faquin, WC TI Bilateral adrenal myelolipomas: Association with adrenal cortical hyperplasia and congenital syndromes SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Western Ontario, London, ON, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hosp Geneva, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 418 BP 92A EP 92A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900419 ER PT J AU Hull, MJ Mino, M Sepehr, A Ban, S Shimizu, M Lauwers, GY AF Hull, MJ Mino, M Sepehr, A Ban, S Shimizu, M Lauwers, GY TI Endoscopic Nucosal Resection (EMR): An improved diagnostic procedure for early esophago-gastric epithelial neoplasms SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 484 BP 106A EP 107A PG 2 WC Pathology SC Pathology GA 884WR UT WOS:000226117900485 ER PT J AU Mino, M Kirley, S Lauwers, G Zukerberg, LR AF Mino, M Kirley, S Lauwers, G Zukerberg, LR TI Loss of cables, a cyclin-dependent kinase (CDK) interacting protein, is frequent in intestinal type gastric dysplasia and early gastric cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 512 BP 112A EP 113A PG 2 WC Pathology SC Pathology GA 884WR UT WOS:000226117900513 ER PT J AU Mino, M Zukerberg, L Misdraji, J Lauwers, GY AF Mino, M Zukerberg, L Misdraji, J Lauwers, GY TI Management of superficial Barrett's epithelium (BE) related neoplasms by endoscopic mucosal resection (EMR): Evaluation of 27 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 511 BP 112A EP 112A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900512 ER PT J AU Ogino, S Brahmandam, M Cantor, M Namgyal, C Kawasaki, T Loda, M Fuchs, CS AF Ogino, S Brahmandam, M Cantor, M Namgyal, C Kawasaki, T Loda, M Fuchs, CS TI Activating mutation of the EGFR gene is rare and not responsible for gefitinib sensitivity in colorectal cancer expression SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 520 BP 114A EP 114A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900521 ER PT J AU Ogino, S Kirkner, G Cantor, M Brahmandam, M Kawasaki, T Namgyal, C Giovannucci, EL Loda, M Fuchs, CS AF Ogino, S Kirkner, G Cantor, M Brahmandam, M Kawasaki, T Namgyal, C Giovannucci, EL Loda, M Fuchs, CS TI Family history of sporadic colorectal cancer modifies risks for specific molecular pathology in tumors: Data from prospective cohort of 86,220 women SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 519 BP 114A EP 114A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900520 ER PT J AU Rossi, S Chinellato, S Bhattacharya, N Dei Tos, AP Loda, M AF Rossi, S Chinellato, S Bhattacharya, N Dei Tos, AP Loda, M TI Immunohistochemical expression of fatty acyd synthase (FAS) in GIST SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Hosp Treviso, Treviso, Italy. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 533 BP 116A EP 117A PG 2 WC Pathology SC Pathology GA 884WR UT WOS:000226117900534 ER PT J AU Bennett, AK Ulbright, TM Ramnani, DM Young, RH Mills, SE AF Bennett, AK Ulbright, TM Ramnani, DM Young, RH Mills, SE TI Immunohistochemical expression of calretinin, CD99, and alpha-inhibin in sertoli and Leydig cells and their lesions, emphasizing large cell calcifying sertoli cell tumor SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Virginia, Charlottesville, VA USA. Indiana Univ, Indianapolis, IN 46204 USA. Virginia Urol Grp, Richmond, VA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 588 BP 128A EP 128A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900589 ER PT J AU Bismar, TA Demichelis, F Riva, A Kim, R Lnu, S Kutok, J Aster, JC Tang, J Kuefer, R Hofer, MD Febbo, PG Chinnaiyan, AM Rubin, MA AF Bismar, TA Demichelis, F Riva, A Kim, R Lnu, S Kutok, J Aster, JC Tang, J Kuefer, R Hofer, MD Febbo, PG Chinnaiyan, AM Rubin, MA TI Defining prostate cancer progression using a multiplex panel of 13 tissue biomarkers SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Ist Ric Sci & Tecnol, Trento, Italy. Childrens Hosp, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Hosp Ulm, Ulm, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 596 BP 130A EP 130A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900597 ER PT J AU Choi, WWL Amin, MB Tamboli, P Eble, JN Young, RH AF Choi, WWL Amin, MB Tamboli, P Eble, JN Young, RH TI Glandular neoplasms of the urachus: Clinicopathologic and immunohistochemical analysis of 43 cases with special emphasis on low-grade mucinous cystic tumors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Emory Univ, Sch Med, Atlanta, GA 30322 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Indiana Univ, Indianapolis, IN 46204 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 613 BP 134A EP 134A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900614 ER PT J AU De Marzo, A Platz, EA Epstein, JI Billis, A Chan, TY Cheng, L Datta, M Ertoy-Baydar, D Farre, X Fine, S Iczkowski, KA Ittmann, M Knudsen, BS Loda, M Lopez-Beltran, A Magi-Galluzzi, C Mikuz, G Montironi, R Rabin, MA Sebo, T Sesterhenn, IA Shah, R Signoretti, S Simko, J Troncoso, P Tsuzuki, T van Leenders, GJLH Yang, X Zhou, M Figg, WD Hoque, A Lucia, MS AF De Marzo, A Platz, EA Epstein, JI Billis, A Chan, TY Cheng, L Datta, M Ertoy-Baydar, D Farre, X Fine, S Iczkowski, KA Ittmann, M Knudsen, BS Loda, M Lopez-Beltran, A Magi-Galluzzi, C Mikuz, G Montironi, R Rabin, MA Sebo, T Sesterhenn, IA Shah, R Signoretti, S Simko, J Troncoso, P Tsuzuki, T van Leenders, GJLH Yang, X Zhou, M Figg, WD Hoque, A Lucia, MS TI Interobserver reproducibility of a proposed classification of focal prostate atrophy lesions SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Johns Hopkins, Baltimore, MD USA. Univ Colorado, Boulder, CO 80309 USA. Univ Campinas, Campinas, SP, Brazil. Emory Univ, Atlanta, GA 30322 USA. VA Med Ctr, Gainesville, FL USA. Univ Cordoba, E-14071 Cordoba, Spain. Cleveland Clin, Cleveland, OH 44106 USA. Innsbruck Med Univ, Innsbruck, Austria. Polytech U Som, Ancona, Italy. Mayo Clin, Rochester, MN USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Nagoya DRC Hosp, Nagoya, Aichi, Japan. Northwestern Univ, Evanston, IL 60208 USA. NIH, Bethesda, MD 20892 USA. Indiana Univ, Bloomington, IN 47405 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Dana Farber, Boston, MA USA. RI Billis, Athanase/D-7365-2012; BAYDAR, DILEK/I-9610-2013; Figg Sr, William/M-2411-2016 NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 622 BP 135A EP 135A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900623 ER PT J AU Descazeaud, A Laxman, B Creighton, C Setlur, S Hofer, MD Beroukhim, R De La Taille, A Chinnaiyan, AM Rubin, MA AF Descazeaud, A Laxman, B Creighton, C Setlur, S Hofer, MD Beroukhim, R De La Taille, A Chinnaiyan, AM Rubin, MA TI Benign prostatic hyperplasia: Towards the development of a clinically relevant molecular signature SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. CHU Henri Mondor, Assistance Publ Hop Paris, F-94010 Creteil, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 625 BP 136A EP 136A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900626 ER PT J AU Elvin, JA Bismar, TA Wei, JT Chinnaiyan, AM Loda, M Rubin, MA AF Elvin, JA Bismar, TA Wei, JT Chinnaiyan, AM Loda, M Rubin, MA TI Quantitative analysis of alpha-methylacyl CoA racemase (AMACR) and fatty acid synthase (FAS) co-expression in localized prostate cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RI Wei, John/E-8967-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 638 BP 139A EP 139A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900639 ER PT J AU Faith, DA Ertoy-Baydar, D Spolter, YS Platz, EA Rubin, MA Ayala, G De Marzo, AM AF Faith, DA Ertoy-Baydar, D Spolter, YS Platz, EA Rubin, MA Ayala, G De Marzo, AM TI Multi-institution automated image analysis of PTEN protein in prostatic adenocarcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Baylor Coll Med, Houston, TX 77030 USA. Bloomberg Sch Publ Hlth, Baltimore, MD USA. RI BAYDAR, DILEK/I-9610-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 643 BP 140A EP 140A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900644 ER PT J AU Hofer, MD Kuefer, R Setlur, S Wu, H Rubin, MA AF Hofer, MD Kuefer, R Setlur, S Wu, H Rubin, MA TI High-throughput analysis of chromosomal aberrations in formalin-fixed paraffin embedded tissue: A novel approach to define prostate cancer biomarkers from archival material SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Hosp Ulm, Ulm, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 672 BP 146A EP 146A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900673 ER PT J AU Hofer, MD Mucci, L Andren, O Kim, R Kantoff, PW Johansson, JW Rubin, MA AF Hofer, MD Mucci, L Andren, O Kim, R Kantoff, PW Johansson, JW Rubin, MA TI Metastasis-associated gene 1 (MTA1) is associated with prostate cancer specific death SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Orebro Univ Hosp, Orebro, Sweden. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 671 BP 146A EP 146A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900672 ER PT J AU Li, C Jiang, Z Zhang, Y Banner, B Wu, CL AF Li, C Jiang, Z Zhang, Y Banner, B Wu, CL TI Expression of alpha-methylacyl-CoA racemase (AMACR)/P504S in renal neoplasms SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Massachusetts, Sch Med, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 703 BP 152A EP 152A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900704 ER PT J AU Roma, AA Montironi, R Loda, M Magi-Galluzzi, C AF Roma, AA Montironi, R Loda, M Magi-Galluzzi, C TI Increased expression of fatty acid synthase in prostate adenocarcinoma following total androgen ablation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Cleveland Clin Fdn, Cleveland, OH 44195 USA. Univ Ancona, I-60128 Ancona, Italy. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 746 BP 161A EP 161A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900747 ER PT J AU Rubin, MA Bismar, TA Andren, O Mucci, L Kim, R Shen, R Ghosh, D Wei, JT Chinnaiyan, AM Adami, HO Kantoff, PW Johansson, JE AF Rubin, MA Bismar, TA Andren, O Mucci, L Kim, R Shen, R Ghosh, D Wei, JT Chinnaiyan, AM Adami, HO Kantoff, PW Johansson, JE TI Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer specific death SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Orebro Univ Hosp, Orebro, Sweden. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Karolinska Inst, Stockholm, Sweden. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 748 BP 162A EP 162A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900749 ER PT J AU Turbiner, J Amin, MB Radhakrishnan, A Humphrey, PA Srigley, JR De Leval, L Oliva, E AF Turbiner, J Amin, MB Radhakrishnan, A Humphrey, PA Srigley, JR De Leval, L Oliva, E TI Cystic nephroma (CN) and mixed epithelial and stromal tumor (MEST) of the kidney: Are they one and the same entity? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Emory Univ, Atlanta, GA 30322 USA. Washington Univ, St Louis, MO USA. McMaster Univ, Hamilton, ON L8S 4L8, Canada. CHU Sart Tilman, B-4000 Liege, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 782 BP 169A EP 169A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900783 ER PT J AU Ulbright, TM Young, RH AF Ulbright, TM Young, RH TI Seminoma with microcystic and tubular patterns: A study of 28 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Indiana Univ, Sch Med, Indianapolis, IN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 784 BP 169A EP 170A PG 2 WC Pathology SC Pathology GA 884WR UT WOS:000226117900785 ER PT J AU Alvarez, T Bhan, AK Miller, E Oliva, E AF Alvarez, T Bhan, AK Miller, E Oliva, E TI Molecular profile of grade 3 endometrial endometrioid carcinoma (EEC): Is it a Type I or Type II endometrial carcinoma (EC)? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 820 BP 177A EP 177A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900821 ER PT J AU Bissonnette, JP Wilbur, DC AF Bissonnette, JP Wilbur, DC TI Low grade dysplasia pap smears and negative cervical biopsies: Are they really non-correlating specimens? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 827 BP 178A EP 178A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117900828 ER PT J AU de Leval, L Waltregny, D Glenisson, W Boniver, J Young, RH Castronovo, V Oliva, E AF de Leval, L Waltregny, D Glenisson, W Boniver, J Young, RH Castronovo, V Oliva, E TI Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the subclassification of mesenchymal tumors of the uterus, particularly epithelioid smooth muscle tumors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 CHU Sart Tilman, B-4000 Liege, Belgium. HH Humphrey Ctr Expt Med & Canc Res, Liege, Belgium. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 837 BP 180A EP 181A PG 2 WC Pathology SC Pathology GA 884WR UT WOS:000226117900838 ER PT J AU Irving, JA Young, RH AF Irving, JA Young, RH TI Lung carcinoma metastatic to the ovary - A clinicopathologic study of 33 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 869 BP 187A EP 187A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901022 ER PT J AU Lerwill, MF Irving, JA Young, RH AF Lerwill, MF Irving, JA Young, RH TI Gastrointestinal stromal tumors metastatic to the ovary SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 887 BP 191A EP 191A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901040 ER PT J AU Logani, S Saslow, RA Oliva, E Nolen, JF Aleodar, AA Saunders, NA Polydorides, A Ellenson, LH AF Logani, S Saslow, RA Oliva, E Nolen, JF Aleodar, AA Saunders, NA Polydorides, A Ellenson, LH TI Is pure uterine clear cell carcinoma clinically distinct from endometrioid/serous carcinoma with a clear cell component? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Emory Univ, Atlanta, GA 30322 USA. Mem Sloan Kettering, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Cornell Univ, Weill Med Coll, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 896 BP 193A EP 193A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901049 ER PT J AU Turbiner, J Sanchez, C Dahiya, S Moreno, G Hardisson, D Palacios, J Oliva, E AF Turbiner, J Sanchez, C Dahiya, S Moreno, G Hardisson, D Palacios, J Oliva, E TI Beta-catenin expression in endometrial carcinoma (EC) in patients with estrogen stimulation secondary to ovarian hyperthecosis or tamoxifen therapy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Ctr Nacl Invest Oncol, Madrid, Spain. Hosp Univ La Paz, Madrid, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 959 BP 206A EP 206A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901112 ER PT J AU Rahemtullah, A Preffer, FI Harris, NL Hasserjian, RP AF Rahemtullah, A Preffer, FI Harris, NL Hasserjian, RP TI Atypical T-cell populations in nodular lymphocyte predominant Hodgkin lymphoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 1149 BP 248A EP 248A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901302 ER PT J AU Soupir, CP Preffer, FI Hasserjian, RP AF Soupir, CP Preffer, FI Hasserjian, RP TI Effects of rituximab therapy on immune system recovery following chemotherapy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 1166 BP 251A EP 252A PG 2 WC Pathology SC Pathology GA 884WR UT WOS:000226117901319 ER PT J AU Cornell, LD Selig, MK Collins, AB Colvin, RB AF Cornell, LD Selig, MK Collins, AB Colvin, RB TI Evaluation of "penetrating" electron-dense deposits to distinguish lupus and idiopathic membranous glomerulonephritis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 1232 BP 266A EP 266A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901385 ER PT J AU Ly, A Ligon, K Bush, C Tihan, T AF Ly, A Ligon, K Bush, C Tihan, T TI Use of tissue microarrays in the immunohistochemical analysis of Olig-2 and Ki-67 in gliomas. A quality control study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 1351 BP 292A EP 293A PG 2 WC Pathology SC Pathology GA 884WR UT WOS:000226117901504 ER PT J AU Swain, R Horvai, AE Loda, M Burger, PC Scheithauer, BW Tihan, T Kim, GE AF Swain, R Horvai, AE Loda, M Burger, PC Scheithauer, BW Tihan, T Kim, GE TI Inflammatory myofibroblastic tumors in the CNS and respiratory tract: A comparative analysis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Johns Hopkins, Baltimore, MD USA. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 1364 BP 295A EP 295A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901517 ER PT J AU Di Vizio, D O'Connell, FP Bhattacharya, N Shapiro, GI Loda, M AF Di Vizio, D O'Connell, FP Bhattacharya, N Shapiro, GI Loda, M TI Pharmacodynamic assessment of the cyclin-dependent kinase inhibitor flavopiridol: Modulation of cdk targets in clinical samples SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 1375 BP 297A EP 297A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901528 ER PT J AU Hofer, MD Tapia, C Browne, TJ Mirlacher, M Sauter, G Rubin, MA AF Hofer, MD Tapia, C Browne, TJ Mirlacher, M Sauter, G Rubin, MA TI Comprehensive analysis of the expression of the metastasis-associated gene 1 (MTA1) in neoplastic tissue SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Basel, Basel, Switzerland. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 1379 BP 298A EP 298A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901532 ER PT J AU Matsubara, O Imazeki, N Nakatani, Y Mark, EJ AF Matsubara, O Imazeki, N Nakatani, Y Mark, EJ TI Roles of Wnt/beta-catenin pathway signaling and TGF-beta 1 in repair and remodeling of the lung after acute lung injury SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 1463 BP 315A EP 315A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901615 ER PT J AU Kim, R Tang, J Lnu, S Shen, R Gibbs, D Mahavishnu, V Wei, J Kleer, CG Chinnaiyan, AM Rubin, MA AF Kim, R Tang, J Lnu, S Shen, R Gibbs, D Mahavishnu, V Wei, J Kleer, CG Chinnaiyan, AM Rubin, MA TI Profiler: A powerful web-based tissue microarray analysis system and relational database for collaborative translational research SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 1535 BP 331A EP 331A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901687 ER PT J AU Ogino, S Kawasaki, T Brahmandam, M Yan, L Cantor, M Namgyal, C Giovannucci, E Mino, M Lauwers, G Loda, M Fuchs, CS AF Ogino, S Kawasaki, T Brahmandam, M Yan, L Cantor, M Namgyal, C Giovannucci, E Mino, M Lauwers, G Loda, M Fuchs, CS TI Sensitive method for KRAS mutation detection by Pyrosequencing(TM) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 94th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2005 CL San Antonio, TX SP US Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Biotage, Westborough, MA USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2005 VL 18 SU 1 MA 1543 BP 332A EP 332A PG 1 WC Pathology SC Pathology GA 884WR UT WOS:000226117901695 ER PT S AU Bogdanov, AA Chen, JW Kang, HW Weissleder, R AF Bogdanov, AA Chen, JW Kang, HW Weissleder, R BE Bogdanov, AA Licha, K TI Magnetic resonance signal amplification probes SO MOLECUALR IMAGING: AN ESSENTIAL TOOL IN PRECLINICAL RESEARCH, DIAGNOSTIC IMAGING, AND THERAPY SE ERNST SCHERING RESEARCH FOUNDATION WORKSHOP LA English DT Proceedings Paper CT 49th International Workshop of the Ernst-Schering-Research-Foundation CY 2002 CL Berlin, GERMANY SP Ernst Schering Res Fdn ID LEUKOCYTE ADHESION; E-SELECTIN; GENE-EXPRESSION; IN-VIVO; ENDOCYTOSIS; CELLS C1 Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. RP Bogdanov, AA (reprint author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Bldg 149,13th St, Charlestown, MA 02129 USA. EM abogdanov@helix.mgh.harvard.edu; weissleder@helix.mgh.havard.edu; abogdanov@helix.mgh.harvard.edu NR 15 TC 1 Z9 1 U1 1 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0947-6075 BN 3-540-21021-0 J9 E SCHERING RES FDN W PY 2005 VL 49 BP 147 EP 157 PG 11 WC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical Imaging GA BBL57 UT WOS:000226024400008 ER PT S AU Solban, N Ortel, B Pogue, B Hasan, T AF Solban, N Ortel, B Pogue, B Hasan, T BE Bogdanov, AA Licha, K TI Targeted optical imaging and photodynamic therapy SO MOLECUALR IMAGING: AN ESSENTIAL TOOL IN PRECLINICAL RESEARCH, DIAGNOSTIC IMAGING, AND THERAPY SE ERNST SCHERING RESEARCH FOUNDATION WORKSHOP LA English DT Proceedings Paper CT 49th International Workshop of the Ernst-Schering-Research-Foundation CY 2002 CL Berlin, GERMANY SP Ernst Schering Res Fdn ID LOW-DENSITY-LIPOPROTEIN; INTERNALIZING MONOCLONAL-ANTIBODIES; FLUORESCENT CONTRAST AGENTS; GROWTH-FACTOR RECEPTOR; IN-VIVO; 5-AMINOLEVULINIC ACID; FLUENCE RATE; SELECTIVE PHOTOSENSITIZATION; ZN(II) PHTHALOCYANINES; CATIONIC PORPHYRIN C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Labs Photomed,Dept Dermatol, Boston, MA 02114 USA. RP Solban, N (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Labs Photomed,Dept Dermatol, Boston, MA 02114 USA. EM ortel@helix.mgh.havard.edu; edqvist@partners.org NR 84 TC 11 Z9 12 U1 0 U2 3 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0947-6075 BN 3-540-21021-0 J9 E SCHERING RES FDN W PY 2005 VL 49 BP 229 EP 258 PG 30 WC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical Imaging GA BBL57 UT WOS:000226024400012 ER PT J AU Rozenblatt-Rosen, O Hughes, CM Nannepaga, SJ Shanmugam, KS Copeland, TD Guszczynski, T Resau, JH Meyerson, M AF Rozenblatt-Rosen, O Hughes, CM Nannepaga, SJ Shanmugam, KS Copeland, TD Guszczynski, T Resau, JH Meyerson, M TI The parafibromin tumor suppressor protein is part of a human Paf1 complex SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID RNA-POLYMERASE-II; HISTONE METHYLTRANSFERASE COMPLEX; TRANSCRIPTION ELONGATION-FACTORS; SACCHAROMYCES-CEREVISIAE; HEREDITARY HYPERPARATHYROIDISM; GENE-EXPRESSION; BINDING-PROTEIN; IN-VIVO; METHYLATION; HRPT2 AB Parafibromin, the product of the HRPT2 (hyperparathyroidism-jaw tumor syndrome 2) tumor suppressor gene, is the human homologue of yeast Cdc73, part of the yeast RNA polymerase II/Paf1 complex known to be important for histone modification and connections to posttranscriptional events. By purifying cellular parafibromin and characterizing its associated proteins, we have identified a human counterpart to the yeast Paf1 complex including homologs of Leo1, Paf1, and Ctr9. Like the yeast complex, the parafibromin complex associates with the nonphosphorylated and Ser2 and Ser5 phosphorylated forms of the RNA polymerase II large subunit. Immunofluorescence experiments show that parafibromin is a nuclear protein. In addition, cotransfection data suggest that parafibromin can interact with a histone methyltransferase complex that methylates histone H3 on lysine 4. Some mutant forms of parafibromin lack association with hPaf1 complex members and with the histone methyltransferase complex, suggesting that disruption of these complexes may correlate with the oncogenic process. C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Dept Pathol, Boston, MA USA. NCI, Canc Res Ctr, Lab Prot Dynam & Signaling, Frederick, MD USA. Van Andel Inst, Mol Microbiol Lab, Grand Rapids, MI USA. RP Meyerson, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM matthew_meyerson@dfci.harvard.edu RI Meyerson, Matthew/E-7123-2012 NR 36 TC 152 Z9 159 U1 2 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 2005 VL 25 IS 2 BP 612 EP 620 DI 10.1128/MCB.25.2.612-620.2005 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 887EJ UT WOS:000226287800009 PM 15632063 ER PT J AU Kang, J Ferguson, D Song, H Bassing, C Eckersdorff, M Alt, FW Xu, Y AF Kang, J Ferguson, D Song, H Bassing, C Eckersdorff, M Alt, FW Xu, Y TI Functional interaction of H2AX, NBS1, and p53 in ATM-dependent DNA damage responses and tumor suppression SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID NIJMEGEN BREAKAGE SYNDROME; ATAXIA-TELANGIECTASIA; HISTONE H2AX; TARGETED DISRUPTION; GENOMIC INSTABILITY; CHECKPOINT PATHWAY; IONIZING-RADIATION; PROTEIN-KINASE; DEFICIENT MICE; MURINE MODEL AB Ataxia-telangiectasia (A-T) mutated (ATM) kinase signals all three cell cycle checkpoints after DNA double-stranded break (DSB) damage. H2AX, NBS1, and p53 are substrates of ATM kinase and are involved in ATM-dependent DNA damage responses. We show here that H2AX is dispensable for the activation of ATM and p53 responses after DNA DSB damage. Therefore, H2AX functions primarily as a downstream mediator of ATM functions in the parallel pathway of p53. NBS1 appears to function both as an activator of ATM and as an adapter to mediate ATM activities after DNA DSB damage. Phosphorylation of ATM and H2AX induced by DNA DSB damage is normal in NBS1 mutant/mutant (NBS1(m/m)) mice that express an N-terminally truncated NBS1 at lower levels. Therefore, the pleiotropic A-T-related systemic and cellular defects observed in NBS1(m/m) mice are due to the disruption of the adapter function of NBS1 in mediating ATM activities. While H2AX is required for the irradiation-induced focus formation of NBS1. our findings indicate that NBS1 and H2AX have distinct roles in DNA damage responses. ATM-dependent phosphorylation of p53 and p43 responses are largely normal in NBS1(m/m) mice after DNA DSB damage, and p53 deficiency greatly facilitates tumorigenesis in NBS1(m/m) mice. Therefore, NBS1, H2AX, and p53 play. synergistic roles in ATM-dependent DNA damage responses and tumor suppression. C1 Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA. Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Ctr Blood Res, Boston, MA USA. RP Xu, Y (reprint author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA. EM yangxu@ucsd.edu FU NCI NIH HHS [R01 CA077563, CA77563] NR 55 TC 75 Z9 78 U1 0 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 2005 VL 25 IS 2 BP 661 EP 670 DI 10.1128/MCB.25.2.661-670.2005 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 887EJ UT WOS:000226287800013 PM 15632067 ER PT S AU Tonon, G Brennan, C Protopopov, A Maulik, G Feng, B Zhang, Y Khatry, DB You, MJ Aguirre, AJ Martin, ES Yang, Z Ji, H Chin, L Wong, KK DePinho, RA AF Tonon, G. Brennan, C. Protopopov, A. Maulik, G. Feng, B. Zhang, Y. Khatry, D. B. You, M. J. Aguirre, A. J. Martin, E. S. Yang, Z. Ji, H. Chin, L. Wong, K. -K. DePinho, R. A. GP Cold Spring Harbor Lab Press TI Common and contrasting genomic profiles among the major human lung cancer subtypes SO Molecular Approaches to Controlling Cancer SE COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY SERIES LA English DT Proceedings Paper CT 70th Cold Spring Harbor Symposium on Quantitative Biology CY 2005 CL Cold Spring Harbor, NY SP Amgen Inc, Bristol-Myers Squibb Co, GlaxoSmithKline, Appl Biosyst, AstraZeneca, Bio Ventures Inc, Diagnost Prod Corp, Forest Labs Inc, Genentech Inc, Hoffmann-La Roche Inc, Johnson & Johnson Pharmaceut Res & Dev L L C, Kyowa Hakko Kogyo Co Ltd, Lexicon Genet Inc, Merck Res Labs, New England BioLabs Inc, OSI Pharmaceut Inc, Pall Corp, Schering Plough Res Inst, Wyeth Genet Inst, ArborGen, Monsanto Co, Affymetrix Inc, Agencourt Biosci, Aviva Syst Biol, EMD Biosci, Illumina, IRx Therapeut Inc, Qiagen, Albert B Sabin Vaccine Inst Inc, Hudson Alpha Inst Biotechnol, Novartis Inst BioMed Res, Biogen ID SQUAMOUS-CELL CARCINOMAS; COPY-NUMBER CHANGES; MESSENGER-RNA EXPRESSION; TUMOR-SUPPRESSOR GENES; ACUTE MYELOID-LEUKEMIA; DOMAIN-CONTAINING GENE; EPITHELIAL MALIGNANCIES; CHROMOSOMAL IMBALANCES; MICROARRAY ANALYSIS; PROSTATE-CANCER AB Lung cancer is the leading cause of cancer mortality worldwide. With the recent success of molecularly targeted therapies in this disease, a detailed knowledge of the spectrum of genetic lesions in lung cancer represents a critical step in the development of additional effective agents. An integrated high-resolution survey of regional amplifications and deletions and gene expression profiling of non-small-cell lung cancers (NSCLC) identified 93 focal high-confidence copy number alterations (CNAs), with 21 spanning less than 0.5 Mb with a median of five genes. Most CNAs were novel and included high-amplitude amplification and homozygous deletion events. Pathogenic relevance of these genomic alterations was further reinforced by their recurrence and overlap with focal alterations of other tumor types. Additionally, the comparison of the genomic profiles of the two major subtypes of NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SCC), showed an almost complete overlap with the exception of one amplified region on chromosome 3, specific for SCC. Among the few genes over-expressed within this amplicon was p63, a known regulator of squamous cell differentiation. These findings suggest that the AC and SCC subtypes may arise from a common cell of origin and they are driven to their distinct phenotypic end points by altered expression of a limited number of key genes such as p63. C1 Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA. RP Tonon, G (reprint author), Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA. OI Khatry, Deepak/0000-0002-2388-9434; Brennan, Cameron/0000-0003-4064-8891 FU NCI NIH HHS [R01 CA084628-12, U01-CA084313-07, R01 CA099041, U01 U01-CA084313-07]; NIA NIH HHS [K08AG 2400401] NR 72 TC 12 Z9 14 U1 0 U2 0 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 USA SN 0091-7451 BN 0-87969-773-3 J9 COLD SH Q B PY 2005 VL 70 BP 11 EP 24 DI 10.1101/sqb.2005.70.021 PG 14 WC Oncology SC Oncology GA BEW93 UT WOS:000239915900002 PM 16869734 ER PT S AU Garraway, LA Weir, BA Zhao, X Widlund, H Beroukhim, R Berger, A Rimm, D Rubin, MA Fisher, DE Meyerson, ML Sellers, WR AF Garraway, L. A. Weir, B. A. Zhao, X. Widlund, H. Beroukhim, R. Berger, A. Rimm, D. Rubin, M. A. Fisher, D. E. Meyerson, M. L. Sellers, W. R. GP Cold Spring Harbor Lab Press TI "Lineage Addiction" in human cancer: Lessons from integrated genomics SO Molecular Approaches to Controlling Cancer SE COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY SERIES LA English DT Proceedings Paper CT 70th Cold Spring Harbor Symposium on Quantitative Biology CY 2005 CL Cold Spring Harbor, NY SP Amgen Inc, Bristol-Myers Squibb Co, GlaxoSmithKline, Appl Biosyst, AstraZeneca, Bio Ventures Inc, Diagnost Prod Corp, Forest Labs Inc, Genentech Inc, Hoffmann-La Roche Inc, Johnson & Johnson Pharmaceut Res & Dev L L C, Kyowa Hakko Kogyo Co Ltd, Lexicon Genet Inc, Merck Res Labs, New England BioLabs Inc, OSI Pharmaceut Inc, Pall Corp, Schering Plough Res Inst, Wyeth Genet Inst, ArborGen, Monsanto Co, Affymetrix Inc, Agencourt Biosci, Aviva Syst Biol, EMD Biosci, Illumina, IRx Therapeut Inc, Qiagen, Albert B Sabin Vaccine Inst Inc, Hudson Alpha Inst Biotechnol, Novartis Inst BioMed Res, Biogen ID CELL LUNG-CANCER; DNA COPY NUMBER; TRANSCRIPTION FACTOR; EXPRESSION PATTERNS; IMATINIB MESYLATE; TUMOR PROGRESSION; MICROARRAYS; GENE; MELANOMA; KINASE AB Genome-era advances in the field of oncology endorse the notion that many tumors may prove vulnerable to targeted therapeutic avenues once their salient molecular alterations are elucidated. Accomplishing this requires both detailed genomic characterization and the ability to identify in situ the critical dependencies operant within individual tumors. To this end, DNA microarray platforms such as high-density single-nucleotide polymorphism (SNP) arrays enable large-scale cancer genome characterization, including copy number and loss-of-heterozygosity analyses at high resolution. Clustering analyses of SNP array data from a large collection of tumor samples and cell lines suggest that certain copy number alterations correlate strongly with the tissue of origin. Such lineage-restricted alterations may harbor novel cancer genes directing genesis or progression of tumors from distinct tissue types. We have explored this notion through combined analysis of genome-scale data sets from the NCI60 cancer cell line collection. Here, several melanoma cell lines clustered on the basis of increased dosage at a region of chromosome 3p containing the master melanocyte regulator MITF. Combined analysis of gene expression data and additional functional studies established MITF as an amplified oncogene in melanoma. MITF may therefore represent a nodal point within a critical lineage survival pathway operant in a subset of melanomas. These findings suggest that, like oncogene addiction, "lineage addiction" may represent a fundamental tumor survival mechanism with important therapeutic implications. C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Garraway, LA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. OI Rubin, Mark/0000-0002-8321-9950 NR 58 TC 14 Z9 15 U1 0 U2 0 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 USA SN 0091-7451 BN 0-87969-773-3 J9 COLD SH Q B PY 2005 VL 70 BP 25 EP 34 DI 10.1101/sqb.2005.70.016 PG 10 WC Oncology SC Oncology GA BEW93 UT WOS:000239915900003 PM 16869735 ER PT S AU Thomas, RK Greulich, H Yuza, Y Lee, JC Tengs, T Feng, W Chen, TH Nickerson, E Simons, J Echolm, M Rothberg, JM Sellers, WR Meyerson, ML AF Thomas, R. K. Greulich, H. Yuza, Y. Lee, J. C. Tengs, T. Feng, W. Chen, T. -H. Nickerson, E. Simons, J. Echolm, M. Rothberg, J. M. Sellers, W. R. Meyerson, M. L. GP Cold Spring Harbor Lab Press TI Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors SO MOLECULAR APPROACHES TO CONTROLLING CANCER SE COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY SERIES LA English DT Proceedings Paper CT 70th Cold Spring Harbor Symposium on Quantitative Biology CY 2005 CL Cold Spring Harbor, NY SP Amgen Inc, Bristol-Myers Squibb Co, GlaxoSmithKline, Appl Biosyst, AstraZeneca, Bio Ventures Inc, Diagnost Prod Corp, Forest Labs Inc, Genentech Inc, Hoffmann-La Roche Inc, Johnson & Johnson Pharmaceut Res & Dev L L C, Kyowa Hakko Kogyo Co Ltd, Lexicon Genet Inc, Merck Res Labs, New England BioLabs Inc, OSI Pharmaceut Inc, Pall Corp, Schering Plough Res Inst, Wyeth Genet Inst, ArborGen, Monsanto Co, Affymetrix Inc, Agencourt Biosci, Aviva Syst Biol, EMD Biosci, Illumina, IRx Therapeut Inc, Qiagen, Albert B Sabin Vaccine Inst Inc, Hudson Alpha Inst Biotechnol, Novartis Inst BioMed Res, Biogen ID GROWTH-FACTOR-RECEPTOR; NONSMALL CELL LUNG; GASTROINTESTINAL STROMAL TUMORS; CHRONIC MYELOID-LEUKEMIA; OF-FUNCTION MUTATIONS; ACTIVATING MUTATIONS; ACQUIRED-RESISTANCE; THERAPEUTIC TARGET; CANCER-THERAPY; HIGH-FREQUENCY AB The complete sequencing of the human genome and the development of molecularly targeted cancer therapy have promoted efforts to identify systematically the genetic alterations in human cancer. By high-throughput sequencing of tyrosine kinase genes in human non-small-cell lung cancer, we identified somatic mutations in the kinase domain of the epidermal growth factor receptor tyrosine kinase gene (EGFR) that are correlated with clinical response to EGFR tyrosine kinase inhibitors (TKIs). We have shown that these mutant forms of EGFR induce oncogenic transformation in different cellular systems. Cells whose growth depends on EGFR with mutations in exons 19 and 21 are sensitive to EGFR-TKIs, whereas cells expressing insertion mutations in exon 20 or the T790M point mutant, found in tumor biopsies from patients that relapsed after an initial response to EGFR-TKIs, are resistant. Furthermore, by applying a novel, massively parallel sequencing technology, we have shown that clinically relevant oncogene mutations can be detected in clinical specimens with very low tumor content, thereby enabling optimal patient selection for mutation-directed therapy. In summary, by applying high-throughput genomic resequencing, we have identified a novel therapeutic target, mutant EGFR, in lung cancer and evaluated its role in predicting response to targeted therapy. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Thomas, RK (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. NR 55 TC 30 Z9 32 U1 0 U2 1 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 USA SN 0091-7451 BN 0-87969-774-1 J9 COLD SH Q B PY 2005 VL 70 BP 73 EP 81 DI 10.1101/sqb.2005.70.056 PG 9 WC Oncology SC Oncology GA BEW93 UT WOS:000239915900008 PM 16869740 ER PT S AU Kaelin, WG AF Kaelin, W. G., Jr. GP Cold Spring Harbor Lab Press TI The von Hippel-Lindau tumor suppressor protein: Roles in cancer and oxygen sensing SO Molecular Approaches to Controlling Cancer SE COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY SERIES LA English DT Proceedings Paper CT 70th Cold Spring Harbor Symposium on Quantitative Biology CY 2005 CL Cold Spring Harbor, NY SP Amgen Inc, Bristol-Myers Squibb Co, GlaxoSmithKline, Appl Biosyst, AstraZeneca, Bio Ventures Inc, Diagnost Prod Corp, Forest Labs Inc, Genentech Inc, Hoffmann-La Roche Inc, Johnson & Johnson Pharmaceut Res & Dev L L C, Kyowa Hakko Kogyo Co Ltd, Lexicon Genet Inc, Merck Res Labs, New England BioLabs Inc, OSI Pharmaceut Inc, Pall Corp, Schering Plough Res Inst, Wyeth Genet Inst, ArborGen, Monsanto Co, Affymetrix Inc, Agencourt Biosci, Aviva Syst Biol, EMD Biosci, Illumina, IRx Therapeut Inc, Qiagen, Albert B Sabin Vaccine Inst Inc, Hudson Alpha Inst Biotechnol, Novartis Inst BioMed Res, Biogen ID HYPOXIA-INDUCIBLE FACTOR; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; NUCLEAR-CYTOPLASMIC TRAFFICKING; BIOLOGICALLY-ACTIVE PRODUCT; RECEPTOR INHIBITOR SU5416; HIF PROLYL HYDROXYLASES; CENTRAL-NERVOUS-SYSTEM; DISEASE GENE-PRODUCT; SYMPATHETIC NEURONS AB Biallelic inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is a common event in hereditary (von Hippel-Lindau disease) and sporadic hemangioblastomas and clear-cell renal carcinomas. Germ-line VHL mutations are also linked to some hereditary pheochromocytoma families. The VHL gene product, pVHL, interacts with a number of cellular proteins and is implicated in the control of angiogenesis, extracellular matrix formation, cell metabolism, and mitogenesis. The best understood function of pVHL relates to its role as the substrate recognition unit of an E3 ligase that targets the heterodimeric transcription factor HIF (hypoxia-inducible factor) for destruction in the presence of oxygen. Down-regulation of HIF appears to be both necessary and sufficient for renal tumor suppression by pVHL, and HIF is strongly suspected of contributing to hemangioblastoma development as well. Recent work suggests that pVHL's role in pheochromocytoma is not related to HIF but rather to the ability of pVHL to regulate neuronal apoptosis, which is mediated by c-Jun, when growth factors such as NGF become limiting. Loss of pVHL leads to up-regulation of JunB, which antagonizes c-Jun and blunts apoptosis. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA. RP Kaelin, WG (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, 44 Binney St, Boston, MA 02115 USA. NR 116 TC 42 Z9 43 U1 0 U2 2 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 USA SN 0091-7451 BN 0-87969-773-3 J9 COLD SH Q B PY 2005 VL 70 BP 159 EP 166 DI 10.1101/sqb.2005.70.001 PG 8 WC Oncology SC Oncology GA BEW93 UT WOS:000239915900017 PM 16869749 ER PT S AU Haber, DA Bell, DW Sordella, R Kwak, EL Godin-Heymann, N Sharma, SV Lynch, TJ Settleman, J AF Haber, D. A. Bell, D. W. Sordella, R. Kwak, E. L. Godin-Heymann, N. Sharma, S. V. Lynch, T. J. Settleman, J. GP Cold Spring Harbor Lab Press TI Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors SO Molecular Approaches to Controlling Cancer SE COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY SERIES LA English DT Proceedings Paper CT 70th Cold Spring Harbor Symposium on Quantitative Biology CY 2005 CL Cold Spring Harbor, NY SP Amgen Inc, Bristol-Myers Squibb Co, GlaxoSmithKline, Appl Biosyst, AstraZeneca, Bio Ventures Inc, Diagnost Prod Corp, Forest Labs Inc, Genentech Inc, Hoffmann-La Roche Inc, Johnson & Johnson Pharmaceut Res & Dev L L C, Kyowa Hakko Kogyo Co Ltd, Lexicon Genet Inc, Merck Res Labs, New England BioLabs Inc, OSI Pharmaceut Inc, Pall Corp, Schering Plough Res Inst, Wyeth Genet Inst, ArborGen, Monsanto Co, Affymetrix Inc, Agencourt Biosci, Aviva Syst Biol, EMD Biosci, Illumina, IRx Therapeut Inc, Qiagen, Albert B Sabin Vaccine Inst Inc, Hudson Alpha Inst Biotechnol, Novartis Inst BioMed Res, Biogen ID ACQUIRED-RESISTANCE; TYROSINE KINASE; GEFITINIB; RECEPTOR; ERLOTINIB; ADENOCARCINOMAS; SENSITIVITY AB Somatic mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are present in approximately 10% of non-small-cell lung cancer (NSCLC), with an increased frequency in adenocarcinomas arising in nonsmokers, women, and individuals of Asian ethnicity. These mutations lead to altered downstream signaling by the receptor and appear to define a subset of NSCLC characterized by "oncogene addiction" to the EGFR pathway, which displays dramatic responses to the reversible tyrosine kinase inhibitors gefitinib and erlotinib. The rapid acquisition of drug resistance in most cases, either through mutation of the "gateway" residue in the EGFR kinase domain or by alternative mechanisms, appears to limit the impact on patient survival. Irreversible inhibitors of EGFR display continued effectiveness in vitro against cells with acquired resistance and are now undergoing genotype-directed clinical trials. The molecular and clinical insights derived from targeting EGFR in NSCLC offer important lessons for the broader application of targeted therapeutic agents in solid tumors. C1 Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. RP Haber, DA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. NR 21 TC 68 Z9 70 U1 0 U2 3 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 USA SN 0091-7451 BN 0-87969-773-3 J9 COLD SH Q B PY 2005 VL 70 BP 419 EP 426 DI 10.1101/sqb.2005.70.043 PG 8 WC Oncology SC Oncology GA BEW93 UT WOS:000239915900047 PM 16869779 ER PT J AU Huang, SC Liu, ES Chan, SH Munagala, ID Cho, HT Jagadeeswaran, R Benz, EJ AF Huang, SC Liu, ES Chan, SH Munagala, ID Cho, HT Jagadeeswaran, R Benz, EJ TI Mitotic regulation of protein 4.1R involves phosphorylation by cdc2 kinase SO MOLECULAR BIOLOGY OF THE CELL LA English DT Article ID PRE-MESSENGER-RNA; IN-VITRO; CYTOPLASMIC DYNEIN; APPARATUS PROTEIN; MAMMALIAN-CELLS; ERYTHROID-CELLS; SPINDLE POLES; NUMA PROTEIN; GENE FAMILY; EXPRESSION AB The nonerythrocyte isoform of the cytoskeletal protein 4.1R (4.1R) is associated with morphologically dynamic structures during cell division and has been implicated in mitotic spindle function. In this study, we define important 4.1R isoforms expressed in interphase and mitotic cells by RT-PCR and mini-cDNA library construction. Moreover, we show that 4.1R is phosphorylated by p34(cdc2) kinase on residues Thr60 and Ser679 in a mitosis-specific manner. Phosphorylated 4.1R(135) isoform(s) associate with tubulin and Nuclear Mitotic Apparatus protein (NuMA) in intact HeLa cells in vivo as well as with the microtubule-associated proteins in mitotic asters assembled in vitro. Recombinant 4.1R(135) is readily phosphorylated in mitotic extracts and reconstitutes mitotic aster assemblies in 4.1R-immunodepleted extracts in vitro. Furthermore, phosphorylation of these residues appears to be essential for the targeting of 4.1R to the spindle poles and for mitotic microtubule aster assembly in vitro. Phosphorylation of 4.1R also enhances its association with NuMA and tubulin. Finally, we used siRNA inhibition to deplete 4.1R from HeLa cells and provide the first direct genetic evidence that 4.1R is required to efficiently focus mitotic spindle poles. Thus, we suggest that 4.1R is a member of the suite of direct cdc2 substrates that are required for the establishment of a bipolar spindle. C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. Childrens Hosp, Dept Pediat, Boston, MA 02115 USA. RP Huang, SC (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM shu-ching_huang@dfci.harvard.edu RI Jagadeeswaran, Ramasamy/C-9987-2013; OI Chan, Siu-Hong/0000-0002-9554-7273 FU NHLBI NIH HHS [R01 HL044985, HL61295, R01 HL061295, HL44985, R29 HL061295] NR 50 TC 9 Z9 12 U1 0 U2 1 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PD JAN PY 2005 VL 16 IS 1 BP 117 EP 127 DI 10.1091/mbc.E04-05-0426 PG 11 WC Cell Biology SC Cell Biology GA 882QW UT WOS:000225954400014 PM 15525677 ER PT J AU Sun, CP Liao, JC Zhang, YH Gau, V Mastali, M Babbitt, JT Grundfest, WS Churchill, BM McCabe, ERB Haake, DA AF Sun, CP Liao, JC Zhang, YH Gau, V Mastali, M Babbitt, JT Grundfest, WS Churchill, BM McCabe, ERB Haake, DA TI Rapid, species-specific detection of uropathogen 16S rDNA and rRNA at ambient temperature by dot-blot hybridization and an electrochemical sensor array SO MOLECULAR GENETICS AND METABOLISM LA English DT Article DE diagnosis; molecular; DNA probes; microbiology; molecular microbiology; nucleic acid hybridization/methods; oligonucleotide probes; RNA; ribosomal; 16S; urinary tract infections; molecular diagnosis ID BACTERIAL; PROBES; IDENTIFICATION; AMPLIFICATION; INFECTIONS; BIOSENSORS; SEQUENCES; GENE AB Development of rapid molecular approaches for pathogen detection is key to improving treatment of infectious diseases. For this study, the kinetics and temperature-dependence of DNA probe hybridization to uropathogen species-specific sequences were examined. A set of oligonucleotide probes were designed based on variable regions of the 16S gene of the Escherichia coli, Proteus mirabilis, Klebsiella oxytoca, and Pseudomonas aeruginosa. A universal bacterial probe and probes-specific for gram-positive and gram-negative organisms were also included. The oligonucleotide probes discriminated among 16S genes derived from I I different species of uropathogenic bacteria applied to nylon membranes in a dot-blot format. Significant binding of oligonucleotide probes to target DNA and removal of nonspecific binding by membrane washing could both be achieved rapidly, requiring as little as 10 min. An oligonucleotide probe from the same species-specific region of the E coli 16S gene was used as a capture probe in a novel electro-chemical 16-sensor array based on micro fabrication technology. Sequence-specific hybridization of target uropathogen 16S rDNA was detected through horseradish peroxidase acting as an electrochemical transducer via a second, detector probe. The sensor array demonstrated rapid, species-specific hybridization in a time course consistent with the rapid kinetics of the dot-blot hybridization studies. As in the dot-blot hybridization studies, species-specific detection of bacterial nucleic acids using the sensor array approach was demonstrated both at 65 degreesC and at room temperature. These results demonstrate that molecular hybridization approaches can be adapted to rapid, room temperature conditions ideal for an electrochemical sensor array platform. Published by Elsevier Inc. C1 Univ Calif Los Angeles, Dept Human Genet, David Geffen Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Biomed Engn, Henry Samueli Sch Engn & Appl Sci, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Pediat, David Geffen Sch Med, Los Angeles, CA 90024 USA. GenFluid Inc, Monterey, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Haake, DA (reprint author), Univ Calif Los Angeles, Dept Human Genet, David Geffen Sch Med, Los Angeles, CA USA. EM dhaake@ucla.edu RI Liao, Joseph/J-5874-2015 FU NIBIB NIH HHS [R01 EB000127-03, R01 EB000127-04, R01 EB000127-01, R01 EB000127-05, EB00127, R01 EB000127-02] NR 23 TC 30 Z9 32 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD JAN PY 2005 VL 84 IS 1 BP 90 EP 99 DI 10.1016/j.ymgme.2004.11.006 PG 10 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 899VL UT WOS:000227173700012 PM 15639199 ER PT J AU Thurman, JM Kraus, DM Girardi, G Hourcade, D Kang, HJ Royer, PA Mitchell, LM Giclas, PC Salmon, J Gilkeson, G Holers, VM AF Thurman, JM Kraus, DM Girardi, G Hourcade, D Kang, HJ Royer, PA Mitchell, LM Giclas, PC Salmon, J Gilkeson, G Holers, VM TI A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice SO MOLECULAR IMMUNOLOGY LA English DT Article DE complement; antigens/peptides/epitopes; antibodies; autoantibodies; rodent ID FACTOR-B; RENAL-DISEASE; COMPONENT C3; MRL/LPR MICE; DEFICIENT; GLOMERULONEPHRITIS; THERAPY; INNATE; SYSTEM; INJURY AB Studies in gene-targeted mice have demonstrated that factor B of the alternative complement pathway plays an important role in several disease models, but an exogenous inhibitor of factor B has not previously been available. We have developed an inhibitory monoclonal antibody directed against a critical epitope on mouse factor B and have tested it in a model of antiphospholipid (aPL) antibody (Ab)-induced fetal loss. Gene-targeted factor B-deficient mice (fB(-/-)) were injected with a fusion protein comprised of the second and third short consensus repeat (SCR) domains of mouse factor B linked to a mouse IgG(1) Fc domain. Hybridomas were made from splenocytes of the immunized mouse. One mAb, designated 1379, produced an IgG, antibody that inhibited alternative pathway activation in vitro and in vivo by preventing formation of the C3bBb complex. Strikingly, this mAb inhibited alternative pathway activation in serum from mice, rats, humans, monkeys, pigs and horses. Fab fragments made from this mAb also inhibited alternative pathway activation. Epitope mapping demonstrated that this antibody binds to factor B within the third SCR domain. When mAb 1379 was administered to mice that also received human IgG containing antiphospholipid antibodies, it provided significant protection from antiphospholipid antibody-induced complement activation and fetal loss. Thus, this mAb to factor B has broad species reactivity and effectively inhibits alternative pathway activation. The mAb protects mice in an in vivo model of antiphospholipid antibody syndrome, demonstrating the therapeutic potential for the inhibition of factor B in this disease. (C) 2004 Elsevier Ltd. All rights reserved. C1 Univ Colorado, Hlth Sci Ctr, Div Nephrol & Hypertens, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Div Rheumatol, Denver, CO 80262 USA. Weill Med Coll, Hosp Special Surg, Dept Med, New York, NY 10021 USA. Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA. Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy & Immunol, Denver, CO 80262 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Med Res Serv, Charleston, SC 29425 USA. RP Thurman, JM (reprint author), Univ Colorado, Hlth Sci Ctr, Div Nephrol & Hypertens, 4200 E 9th Ave,B-115, Denver, CO 80262 USA. EM joshua.thurman@uchsc.edu FU NIAID NIH HHS [R0-1 AI051436-01A1, R0-1 AI31105, R0-1 AI47469]; NIDDK NIH HHS [K08 DK064790-01] NR 26 TC 89 Z9 90 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD JAN PY 2005 VL 42 IS 1 BP 87 EP 97 DI 10.1016/j.molimm.2004.07.043 PG 11 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 875NR UT WOS:000225427800010 PM 15488947 ER PT J AU Wucherpfennig, KW AF Wucherpfennig, KW TI The structural interactions between T cell receptors and MHC-peptide complexes place physical limits on self-nonself discrimination SO MOLECULAR MIMICRY: INFECTION-INDUCING AUTOIMMUNE DISEASE SE CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY LA English DT Review ID MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CLASS-II MOLECULES; CROSS-REACTIVITY; ANTIGENIC PEPTIDE; CRYSTAL-STRUCTURE; VIRAL PEPTIDE; RECOGNITION; MIMICRY; VIRUS AB The activation and expansion of T cells in an antimicrobial immune response is based on the ability of T cell receptors (TCR) to discriminate between MHC-bound peptides derived from different microbial agents as well as self-proteins. However, the specificity of T cells is constrained by the limited number of peptide side chains that are available for TCR binding. By considering the structural requirements for peptide binding to MHC molecules and TCR recognition of MHC-peptide complexes, we demonstrated that human T cell clones could recognize a number of peptides from different organisms that were remarkably distinct in their primary sequence. These peptides were particularly diverse at those sequence positions buried in pockets of the MHC binding site, whereas a higher degree of similarity was present at a limited number of peptide residues that created the interface with the TCR. These T cell clones had been isolated from multiple sclerosis patients with human myelin basic protein, demonstrating that activation of such autoreactive T cells by microbial peptides with sufficient structural similarity may contribute to the disease process. Similar findings have now been made for a variety of human and murine T cell clones, indicating that specificity and cross-reactivity are inherent properties of TCR recognition. The observations that particular TCR are highly sensitive to changes at particular peptide positions but insensitive to many other changes in peptide sequence are not contradictory, but rather the result of structural interactions in which a relatively flat TCR surface contacts a limited number of side chains from a peptide that is deeply embedded in the MHC binding site. C1 Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RP Wucherpfennig, KW (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM wucherpf@mbcrr.harvard.edu FU NIAID NIH HHS [R01 AI064177, P01 AI45757] NR 47 TC 12 Z9 13 U1 1 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0070-217X J9 CURR TOP MICROBIOL JI Curr.Top.Microbiol.Immunol. PY 2005 VL 296 BP 19 EP 37 PG 19 WC Immunology; Microbiology SC Immunology; Microbiology GA BDT52 UT WOS:000235217000002 PM 16329190 ER PT J AU Yao, JK Reddy, RD AF Yao, JK Reddy, RD TI Metabolic investigation in psychiatric disorders SO MOLECULAR NEUROBIOLOGY LA English DT Article; Proceedings Paper CT Satellite Symposium on Oxidative Mechanisms in Neurodegenerative Disorder CY FEB 07-11, 2004 CL Guilin, PEOPLES R CHINA DE high-pressure liquid chromatography; coulometric multielectrode array system; metabolomics; psychiatric disorders; oxidative stress ID REDOX-ACTIVE COMPOUNDS; THERAPEUTIC IMPLICATIONS; SCHIZOPHRENIA; SEROTYPES; ARRAY; RATS; FEMALE; ACID AB A multiplicity of theories have been proposed over the years that aim to conceptualize the pathophysiology of neuropsychiatric disorders, including impaired neurotransmission, viral infections, genetic mutation, energy metabolism deficiency, excitotoxicity, oxidative stress, and others. It is likely that complex disorders such as schizophrenia, bipolar disorder, and major depression are associated with multiple etiologies and pathogenetic mechanisms. In light of the interwoven biochemistry of human organs, identifying a network of multiple interacting biochemical pathways that account for the constellation of clinical and biological features would advance our understanding of these disorders. One such approach is to evaluate simultaneously the multiple metabolites in order to uncover the dynamic relations in the relevant biochemical systems. These metabolites are a group of low-molecular-weight, redox-active compounds, such as antioxidants, amino acids, catecholamines vitamins, lipids, and nucleotides, which reflect the metabolic processes, including anabolism and catabolism as well as other related cellular processes (e.g., signal transduction, regulation, detoxification, etc.). Such an analytic approach has the potential to yield valuable insights into the likely complex pathophysiological mechanisms that affect multiple metabolic pathways and thereby offer multiple windows of therapeutic opportunities. C1 VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, WPIC, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. EM jkyao@pitt.edu FU NIMH NIH HHS [MH58141, MH64118] NR 27 TC 17 Z9 18 U1 1 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0893-7648 J9 MOL NEUROBIOL JI Mol. Neurobiol. PY 2005 VL 31 IS 1-3 BP 193 EP 203 DI 10.1385/MN:31:1-3:193 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 940BY UT WOS:000230119900015 PM 15953821 ER PT J AU Papisov, MI Yurkovetskiy, A Syed, S Koshkina, N Yin, M Hiller, A Fischman, AJ AF Papisov, M. I. Yurkovetskiy, A. Syed, S. Koshkina, N. Yin, M. Hiller, A. Fischman, A. J. TI A systemic route for drug loading to lymphatic phagocytes SO MOLECULAR PHARMACEUTICS LA English DT Article DE lymph node; phagocyte; drug delivery; biodefense; anthrax; cancer AB Lymph nodes are primary germination and proliferation sites for many types of pathogens. Maintaining therapeutic levels of appropriate chemotherapeutic agents in the lymph node tissue is critical for the treatment of both infection and cancer. This study was intended to develop a systemic route for loading lymph node phagocytes with drugs, using a lymph node specific nanocarrier. The latter is assembled as a 10-15 nm particle with a drug-carrying core and a phagocyte-homing poly(1 -> 6)-alpha-D-glucose based interface. Biokinetics and microdistribution of the model carrier were investigated in vivo. Nanocarrier accumulation in lymph nodes reached 30-35% dose/g in central lymph nodes, with deposition in various phagocytic cell populations. The latter included cells harboring inhaled microparticles translocated to lymph nodes from the lungs. In view of the nanocarrier ability to transport and release significant amounts of various drug substances, the data suggests feasibility of systemic drug loading to lymphatic phagocytes and, through drug release, to the neighboring cells. C1 [Papisov, M. I.; Yurkovetskiy, A.; Syed, S.; Hiller, A.; Fischman, A. J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Papisov, M. I.; Yurkovetskiy, A.; Syed, S.; Hiller, A.; Fischman, A. J.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Koshkina, N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Yin, M.] Nanopharma Corp, Boston, MA 02116 USA. RP Papisov, MI (reprint author), Massachusetts Gen Hosp, Dept Radiol, Bartlett Hall 500R, Boston, MA 02114 USA. EM papisov@helix.mgh.harvard.edu OI Papisov, Mikhail/0000-0003-4716-2122 FU NIH [R41 AI052921, T32 GM07035]; Massachusetts General Hospital FX This research was supported by NIH grants R41 AI052921 and T32 GM07035 and by internal funds of Massachusetts General Hospital. Authors take this opportunity to thank Drs. T. Brady and R. Weissleder for many valuable discussions and Vera Papisov for assistance in editing the manuscript. NR 24 TC 3 Z9 3 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1543-8384 J9 MOL PHARMACEUT JI Mol. Pharm. PD JAN-FEB PY 2005 VL 2 IS 1 BP 47 EP 56 DI 10.1021/mp0499149 PG 10 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA V52JA UT WOS:000203538600007 PM 15804177 ER PT J AU Tung, CH Quinti, L Jaffer, FA Weissleder, R AF Tung, Ching-Hsuan Quinti, Luisa Jaffer, Farouc A. Weissleder, Ralph TI A branched fluorescent peptide probe for imaging of activated platelets SO MOLECULAR PHARMACEUTICS LA English DT Article DE activated platelets; thrombi detection; fluorescence; IIb/IIIa; receptor imaging AB Novel fluorescent probes for thrombi and activated-platelet detection were developed that were based on the glycoprotein IIb/IIIa (GP-IIb/IIIa) binding sequence, Pro-Ser-Pro-Gly-Asp-Trp. Linear, Pro-Ser-Pro-Gly-Asp-Trp-Aha-Gly-Cys(Cy5.5)-NH2 (1PF), and branched, (Pro-Ser-Pro-Gly-Asp-Trp-Aha)(2)-Lys-Gly-Cys(Cy5.5)-NH2 (2PF), fluorescent-labeled peptide probes were synthesized. A third probe, also branched, (Pro-Ser-Pro-Gly-Glu-Trp-Aha)(2)-Lys-Gly-Cys(Cy5.5)-NH2 (2CF), was synthesized as control. The platelet-binding activity of the probes was tested in clots generated from human platelet-rich plasma, Fluorescence reflectance imaging results showed that 2PF has a 16-fold increase in fluorescence intensity compared to the autofluorescence of clots. The linear conjugate, 1PF, and free dye did not show appreciable fluorescence enhancement. 2PF fluorescence was also found 5.5-fold higher than that of the control probe, 2CF. Overall, our results suggest that 2PF binds tightly to GP-IIb/IIIa and potentially can be used for in vivo imaging of thrombosis. C1 [Tung, Ching-Hsuan; Quinti, Luisa; Jaffer, Farouc A.; Weissleder, Ralph] Harvard Univ, Sch Med, Ctr Mol Imaging Res, Massachusetts Gen Hosp, Charlestown, MA 02129 USA. RP Tung, CH (reprint author), Harvard Univ, Sch Med, Ctr Mol Imaging Res, Massachusetts Gen Hosp, Charlestown, MA 02129 USA. EM tung@helix.mgh.harvard.edu OI Jaffer, Farouc/0000-0001-7980-384X; Tung, Ching-Hsuan/0000-0001-6648-6195 FU NIH [P50-CA86355, RO1 CA99385]; Donald W. Reynolds Foundation FX The authors thank Dr. Guy Reed for valuable discussions. This research was supported in part by NIH P50-CA86355, RO1 CA99385, and the Donald W. Reynolds Foundation. NR 18 TC 12 Z9 12 U1 0 U2 4 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1543-8384 J9 MOL PHARMACEUT JI Mol. Pharm. PD JAN-FEB PY 2005 VL 2 IS 1 BP 92 EP 95 DI 10.1021/mp0499048 PG 4 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA V52JA UT WOS:000203538600012 PM 15804182 ER PT J AU Mayer, L Walker, WA AF Mayer, Lloyd Walker, W. Allan BE Mestecky, J Lamm, ME Strober, W Bienenstock, J McGhee, JR Mayer, L TI Development and Physiology of Mucosal Defense: An Introduction SO MUCOSAL IMMUNOLOGY, 3RD EDITION LA English DT Editorial Material; Book Chapter ID INFLAMMATORY-BOWEL-DISEASE; RAT SMALL-INTESTINE; NEONATAL FC-RECEPTOR; HELICOBACTER-PYLORI INFECTION; CIRCULATING IMMUNE-COMPLEXES; MICROVILLUS MEMBRANES MVM; GASTRIC EPITHELIAL-CELLS; EPIDERMAL-GROWTH-FACTOR; CATHEPSIN-D ACTIVITIES; COWS MILK-PROTEINS C1 [Mayer, Lloyd] Mt Sinai Med Ctr, Ctr Immunol, New York, NY 10029 USA. [Walker, W. Allan] Massachusetts Gen Hosp, Mucosal Immunol Lab, Boston, MA 02114 USA. RP Mayer, L (reprint author), Mt Sinai Med Ctr, Ctr Immunol, New York, NY 10029 USA. NR 166 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-045426-9 PY 2005 BP 5 EP 18 DI 10.1016/B978-012491543-5/50005-X PG 14 WC Immunology SC Immunology GA BCR49 UT WOS:000311099400005 ER PT J AU Taubman, MA Genco, RJ Page, RC AF Taubman, Martin A. Genco, Robert J. Page, Roy C. BE Mestecky, J Lamm, ME Strober, W Bienenstock, J McGhee, JR Mayer, L TI Mucosal Vaccines for Dental Diseases SO MUCOSAL IMMUNOLOGY, 3RD EDITION LA English DT Article; Book Chapter ID SURFACE PROTEIN ANTIGEN; GLUCAN-BINDING-PROTEIN; PERIODONTAL BONE LOSS; RAPIDLY PROGRESSIVE PERIODONTITIS; LOCALIZED JUVENILE PERIODONTITIS; SALIVARY-IGA ANTIBODY; STREPTOCOCCUS-SOBRINUS GLUCOSYLTRANSFERASE; SECRETORY IMMUNOGLOBULIN-A; GINGIVAL CREVICULAR FLUID; GENERALIZED SEVERE PERIODONTITIS C1 [Taubman, Martin A.] Forsyth Inst, Dept Immunol, Boston, MA USA. [Genco, Robert J.] SUNY Buffalo, Buffalo, NY 14260 USA. [Page, Roy C.] Univ Washington, Reg Clin Dent Res Ctr, Seattle, WA 98195 USA. RP Taubman, MA (reprint author), Forsyth Inst, Dept Immunol, Boston, MA USA. NR 290 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-045426-9 PY 2005 BP 1109 EP 1137 DI 10.1016/B978-012491543-5/50066-8 PG 29 WC Immunology SC Immunology GA BCR49 UT WOS:000311099400066 ER PT B AU Jaramillo, D Sebag, G AF Jaramillo, D Sebag, G BE VonSchulthess, GK Zollikofer, CL TI Special aspects of musculoskeletal imaging in children SO Musculoskeletal Diseases: DIAGNOSTIC IMAGING AND INTERVENTIONAL TECHNIQUES LA English DT Proceedings Paper CT 37th International Diagnostic Course in Davos on Musculoskeletal Diseases CY APR 02-08, 2005 CL Davos, SWITZERLAND SP Fdn Advancement Educ Med Radiol ID MAGNETIC-RESONANCE IMAGE; CALVE-PERTHES DISEASE; DEVELOPMENTAL DYSPLASIA; BONE-SCINTIGRAPHY; FEMORAL-HEAD; 3-DIMENSIONAL EVALUATION; CARTILAGINOUS EPIPHYSIS; NEONATAL OSTEOMYELITIS; TARSAL COALITION; PHYSEAL INJURIES C1 Massachusetts Gen Hosp, Div Pediat Radiol, Boston, MA 02114 USA. RP Jaramillo, D (reprint author), Massachusetts Gen Hosp, Div Pediat Radiol, Boston, MA 02114 USA. NR 75 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG ITALIA PI MILAN PA MILAN, ITALY BN 88-470-0318-0 PY 2005 BP 148 EP 155 DI 10.1007/88-470-0339-3_22 PG 8 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA BCP49 UT WOS:000230551000022 ER PT J AU Re, D Thomas, RK Zander, T Diehl, V AF Re, D Thomas, RK Zander, T Diehl, V TI Problems and promises of targeted therapy for Hodgkin's lymphoma SO NATURE CLINICAL PRACTICE ONCOLOGY LA English DT Editorial Material ID KAPPA-B; CELL-LINES; DISEASE; PROLIFERATION; ACTIVATION; INHIBITOR; SURVIVAL; CD30; CD40; RANK C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Univ Hosp Cologne, Dept Hematol & Oncol, Cologne, Germany. Univ Cologne, Dept Med, Cologne, Germany. RP Re, D (reprint author), Univ Cologne, Dept Internal Med, Joseph Stelzmann Str 9, D-50924 Cologne, Germany. EM daniel.re@uni-koeln.de NR 10 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA SN 1743-4254 J9 NAT CLIN PRACT ONCOL JI Nat. Clin. Pract. Oncol. PD JAN PY 2005 VL 2 IS 1 BP 2 EP 3 DI 10.1038/ncponc0073 PG 2 WC Oncology SC Oncology GA 926JF UT WOS:000229118800002 PM 16264830 ER PT J AU Plotkin, SR Dorfman, MV Loeffler, JS AF Plotkin, SR Dorfman, MV Loeffler, JS TI Facial numbness in a man with inguinal and retroperitoneal masses SO NATURE CLINICAL PRACTICE ONCOLOGY LA English DT Article DE demyelination; Ma2; paraneoplastic; seminoma; testicular ID BRAIN; ENCEPHALITIS; DISORDER; CANCER; TESTIS AB Background A 37-year-old Brazilian man was admitted to Massachusetts General Hospital for evaluation of left-sided facial numbness, left-sided ataxia, dizziness, and vertigo. Seven weeks prior to admission, he reported numbness of the left oral cavity and tongue after a dental procedure. Three weeks prior to presentation, he developed left-sided incoordination with dizziness and vertigo. One week later, he noticed difficulty using a box cutter at work and presented to the emergency department for evaluation. A CT scan without contrast revealed no abnormalities and he was discharged home. Three days prior to admission, the patient developed diplopia. Cranial MRI revealed a 1.6 cm irregular enhancing mass in the left middle cerebellar peduncle. Neurologic examination was significant for diminished sensation over the left face to pinprick, left-sided dysmetria, and mild lateral instability of the trunk while walking. Investigations MRI, lumbar puncture, CT scans of the abdomen and pelvis, needle biopsy of the lymph node, and paraneoplastic antibodies. Diagnosis Possible paraneoplastic demyelination. Management Orchiectomy, adjuvant radiation, and corticosteroids. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. RP Plotkin, SR (reprint author), Massachusetts Gen Hosp, Brain Tumor Ctr, 55 Fruit St,Cox 315, Boston, MA 02114 USA. EM splotkin@partners.org NR 12 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA SN 1743-4254 J9 NAT CLIN PRACT ONCOL JI Nat. Clin. Pract. Oncol. PD JAN PY 2005 VL 2 IS 1 BP 54 EP 58 DI 10.1038/ncponc0059 PG 5 WC Oncology SC Oncology GA 926JF UT WOS:000229118800015 PM 16264857 ER PT J AU Bastepe, M Frohlich, LF Linglart, A Abu-Zahra, HS Tojo, K Ward, LM Juppner, H AF Bastepe, M Frohlich, LF Linglart, A Abu-Zahra, HS Tojo, K Ward, LM Juppner, H TI Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib SO NATURE GENETICS LA English DT Article ID G-PROTEINS; LOCUS; GENE; IDENTIFICATION; TRANSCRIPT; ANTISENSE; ELEMENT; CLUSTER; DEFECT; MARK AB Epigenetic defects in the imprinted GNAS cluster are associated with pseudohypoparathyroidism type Ib. In two kindreds with this disorder, we now report deletions that remove the differentially methylated region encompassing exon NESP55 and exons 3 and 4 of the antisense transcript. When inherited from a female, either deletion abolishes all maternal GNAS imprints and derepresses maternally silenced transcripts, suggesting that the deleted region contains a cis-acting element that controls imprinting of the maternal GNAS allele. C1 Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Jikei Univ, Sch Med, Dept Internal Med, Div Diabet & Endocrinol, Tokyo, Japan. Childrens Hosp Eastern Ontario, Div Endocrinol & Metab, Ottawa, ON, Canada. Massachusetts Gen Hosp, Massgen Hosp Children, Pediat Nephrol Unit, Boston, MA USA. RP Bastepe, M (reprint author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA. EM bastepe@helix.mgh.harvard.edu; jueppner@helix.mgh.harvard.edu NR 15 TC 149 Z9 156 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JAN PY 2005 VL 37 IS 1 BP 25 EP 27 DI 10.1038/ng1487 PG 3 WC Genetics & Heredity SC Genetics & Heredity GA 883FX UT WOS:000225997500016 PM 15592469 ER PT J AU Sweet-Cordero, A Mukherjee, S Subramanian, A You, H Roix, JJ Ladd-Acosta, C Mesirov, J Golub, TR Jacks, T AF Sweet-Cordero, A Mukherjee, S Subramanian, A You, H Roix, JJ Ladd-Acosta, C Mesirov, J Golub, TR Jacks, T TI An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis SO NATURE GENETICS LA English DT Article ID ACUTE LYMPHOBLASTIC-LEUKEMIA; GROWTH-FACTOR; LUNG ADENOCARCINOMA; BREAST-CANCER; RAS; CLASSIFICATION; MUTATIONS; PATTERNS; PROTEIN; TUMORS AB Using advanced gene targeting methods, generating mouse models of cancer that accurately reproduce the genetic alterations present in human tumors is now relatively straightforward. The challenge is to determine to what extent such models faithfully mimic human disease with respect to the underlying molecular mechanisms that accompany tumor progression. Here we describe a method for comparing mouse models of cancer with human tumors using gene-expression profiling. We applied this method to the analysis of a model of Kras2-mediated lung cancer and found a good relationship to human lung adenocarcinoma, thereby validating the model. Furthermore, we found that whereas a gene-expression signature of KRAS2 activation was not identifiable when analyzing human tumors with known KRAS2 mutation status alone, integrating mouse and human data uncovered a gene-expression signature of KRAS2 mutation in human lung cancer. We confirmed the importance of this signature by gene-expression analysis of short hairpin RNA-mediated inhibition of oncogenic Kras2. These experiments identified both a pattern of gene expression indicative of KRAS2 mutation and potential effectors of oncogenic KRAS2 activity in human cancer. This approach provides a strategy for using genomic analysis of animal models to probe human disease. C1 MIT, Ctr Canc Res, Cambridge, MA 02139 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. MIT, Eli & Edyth L Broad Inst, Cambridge, MA 02141 USA. Harvard Univ, Eli & Edyth L Broad Inst, Cambridge, MA 02141 USA. RP Jacks, T (reprint author), MIT, Ctr Canc Res, Bldg E17-517,40 Ames St, Cambridge, MA 02139 USA. EM tjacks@mit.edu OI Mukherjee, Sayan/0000-0002-6715-3920 NR 36 TC 277 Z9 285 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JAN PY 2005 VL 37 IS 1 BP 48 EP 55 DI 10.1038/ng1490 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 883FX UT WOS:000225997500020 PM 15608639 ER PT J AU McCarty, N Paust, S Ikizawa, K Dan, I Li, XY Cantor, H AF McCarty, N Paust, S Ikizawa, K Dan, I Li, XY Cantor, H TI Signaling by the kinase MINK is essential in the negative selection of autoreactive thymocytes SO NATURE IMMUNOLOGY LA English DT Article ID T-CELL-RECEPTOR; JUN NH2-TERMINAL KINASE; BCL-2 FAMILY MEMBER; POSITIVE SELECTION; C-JUN; MAMMALIAN-CELLS; GENE-EXPRESSION; JNK PATHWAY; APOPTOSIS; ACTIVATION AB Signaling through the T cell antigen receptor leading to elimination (negative selection) or differentiation (positive selection) of developing thymocytes generates a self-tolerant T cell repertoire. Here we report that the serine-threonine kinase MINK selectively connects the T cell receptor to a signaling pathway that mediates negative but not positive selection. Analysis of this pathway suggested that the essential function of MINK in the elimination of self-reactive thymocytes may be associated with 'downstream' activation of Jun kinase and enhancement of expression of the proapoptotic molecule Bim. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Natl Food Res Inst, Div Food Engn, Tsukuba, Ibaraki 305, Japan. RP Cantor, H (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM harvey_cantor@dfci.harvard.edu RI Dan, Ippeita/F-9179-2011 OI Dan, Ippeita/0000-0002-1779-9205 FU NIAID NIH HHS [T32 AI07386] NR 36 TC 44 Z9 46 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 1529-2908 J9 NAT IMMUNOL JI Nat. Immunol. PD JAN PY 2005 VL 6 IS 1 BP 65 EP 72 DI 10.1038/ni1145 PG 8 WC Immunology SC Immunology GA 881SA UT WOS:000225888500019 PM 15608642 ER PT J AU Kuwaki, K Tseng, YL Dor, FJMF Shimizu, A Houser, SL Sanderson, TM Lancos, CJ Prabharasuth, DD Cheng, J Moran, K Hisashi, Y Mueller, N Yamada, K Greenstein, JL Hawley, RJ Patience, C Awwad, M Fishman, JA Robson, SC Schuurman, HJ Sachs, DH Cooper, DKC AF Kuwaki, K Tseng, YL Dor, FJMF Shimizu, A Houser, SL Sanderson, TM Lancos, CJ Prabharasuth, DD Cheng, J Moran, K Hisashi, Y Mueller, N Yamada, K Greenstein, JL Hawley, RJ Patience, C Awwad, M Fishman, JA Robson, SC Schuurman, HJ Sachs, DH Cooper, DKC TI Heart transplantation in baboons using 1,3-galactosyl transferase gene-knockout pigs as donors: initial experience SO NATURE MEDICINE LA English DT Article ID ORGAN XENOTRANSPLANTATION; ANTI-GAL-ALPHA-1-3GAL IGM; MONOCLONAL-ANTIBODY; NATURAL ANTIBODIES; VASCULAR REJECTION; NONHUMAN-PRIMATES; HUMANS; COAGULATION; ACTIVATION AB Hearts from alpha1,3-galactosyltransferase knockout pigs (GalT-KO, n = 8) were transplanted heterotopically into baboons using an anti-CD154 monoclonal antibody-based regimen. The elimination of the galactose-alpha1,3-galactose epitope prevented hyperacute rejection and extended survival of pig hearts in baboons for 2-6 months (median, 78 d); the predominant lesion associated with graft failure was a thrombotic microangiopathy, with resulting ischemic injury. There were no infectious complications directly related to the immunosuppressive regimen. The transplantation of hearts from GalT-KO pigs increased graft survival over previous studies. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02129 USA. Immerge BioTherapeut Inc, Cambridge, MA 02139 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Immunobiol, Boston, MA 02215 USA. RP Cooper, DKC (reprint author), Univ Pittsburgh, Med Ctr, Starzl Transplantat Inst, Biomed Sci Tower E,Room E1550A,200 Lothrop St, Pittsburgh, PA 15261 USA. EM cooperdk@upmc.edu RI Dor, Frank/E-1032-2013; Mueller, Nicolas/B-6864-2013 OI Dor, Frank/0000-0001-7845-3075; Mueller, Nicolas/0000-0002-1059-3191 FU PHS HHS [1PO1A45897] NR 15 TC 401 Z9 418 U1 2 U2 19 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2005 VL 11 IS 1 BP 29 EP 31 DI 10.1038/nm1171 PG 3 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 884ZJ UT WOS:000226124900028 PM 15619628 ER PT J AU Yamada, K Yazawa, K Shimizu, A Iwanaga, T Hisashi, Y Nuhn, M O'Malley, P Nobori, S Vagefi, PA Patience, C Fishman, J Cooper, DKC Hawley, RJ Greenstein, J Schuurman, HJ Awwad, M Sykes, M Sachs, DH AF Yamada, K Yazawa, K Shimizu, A Iwanaga, T Hisashi, Y Nuhn, M O'Malley, P Nobori, S Vagefi, PA Patience, C Fishman, J Cooper, DKC Hawley, RJ Greenstein, J Schuurman, HJ Awwad, M Sykes, M Sachs, DH TI Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha 1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue SO NATURE MEDICINE LA English DT Article ID MINIATURE SWINE; COMPOSITE THYMOKIDNEYS; LOBE TRANSPLANTATION; TOLERANCE INDUCTION; MISMATCHED BARRIERS; NUCLEAR TRANSFER; PIGS; THYMOPOIESIS; ANTIBODIES AB The use of animal organs could potentially alleviate the critical worldwide shortage of donor organs for clinical transplantation. Because of the strong immune response to xenografts, success will probably depend upon new strategies of immune suppression and induction of tolerance. Here we report our initial results using alpha-1,3-galactosyltransferase knockout (GalT-KO) donors and a tolerance induction approach. We have achieved life-supporting pig-to-baboon renal xenograft survivals of up to 83 d with normal creatinine levels. C1 Massachusetts Gen Hosp East, Transplantat Biol Res Ctr, Boston, MA 02129 USA. Immerge Biotherapeut, Cambridge, MA 02139 USA. Massachusetts Gen Hosp East, Infect Dis Unit, Boston, MA 02129 USA. RP Sachs, DH (reprint author), Massachusetts Gen Hosp East, Transplantat Biol Res Ctr, Boston, MA 02129 USA. EM sachs@helix.mgh.harvard.edu RI Sano, Michael/E-1715-2011 FU PHS HHS [1P01A45897] NR 15 TC 367 Z9 381 U1 3 U2 15 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2005 VL 11 IS 1 BP 32 EP 34 DI 10.1038/nm1172 PG 3 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 884ZJ UT WOS:000226124900029 PM 15619627 ER PT J AU Chabner, BA Roberts, TG AF Chabner, BA Roberts, TG TI Timeline - Chemotherapy and the war on cancer SO NATURE REVIEWS CANCER LA English DT Article ID CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; CHRONIC MYELOID-LEUKEMIA; COMBINATION SEQUENTIAL CHEMOTHERAPY; COLONY-STIMULATING FACTOR; PHASE-II TRIAL; BREAST-CANCER; TYROSINE KINASE; HODGKINS DISEASE; PLUS IRINOTECAN AB The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs. Cancer drug development since then has transformed from a low-budget, government-supported research effort to a high-stakes, multi-billion dollar industry. The targeted-therapy revolution has arrived, but the principles and limitations of chemotherapy discovered by the early researchers still apply. This article chronicles the history of modern chemotherapy and identifies remaining challenges for the next generation of researchers. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. RP Chabner, BA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. EM bchabner@partners.org RI Bell, Tiffany/F-4403-2010 NR 91 TC 514 Z9 529 U1 24 U2 123 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-175X J9 NAT REV CANCER JI Nat. Rev. Cancer PD JAN PY 2005 VL 5 IS 1 BP 65 EP 72 DI 10.1038/nrc1529 PG 8 WC Oncology SC Oncology GA 884TO UT WOS:000226109500015 PM 15630416 ER PT J AU Zon, LI Peterson, RT AF Zon, LI Peterson, RT TI In vivo drug discovery in the zebrafish SO NATURE REVIEWS DRUG DISCOVERY LA English DT Article ID TRANSGENIC ZEBRAFISH; DANIO-RERIO; GENETIC-ANALYSIS; MUTATIONS; SCREEN; MODEL; EXPRESSION; EXPOSURE; GENOME; CARDIOMYOPATHY AB The zebrafish has become a widely used model organism because of its fecundity, its morphological and physiological similarity to mammals, the existence of many genomic tools and the ease with which large, phenotype-based screens can be performed. Because of these attributes, the zebrafish might also provide opportunities to accelerate the process of drug discovery. By combining the scale and throughput of in vitro screens with the physiological complexity of animal studies, the zebrafish promises to contribute to several aspects of the drug development process, including target identification, disease modelling, lead discovery and toxicology. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr,Dev Biol Lab, Charlestown, MA 02129 USA. Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst,Div Hematol Oncol, Boston, MA 02115 USA. RP Peterson, RT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr,Dev Biol Lab, Charlestown, MA 02129 USA. EM peterson@cvrc.mgh.harvard.edu NR 76 TC 659 Z9 693 U1 7 U2 88 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-1776 J9 NAT REV DRUG DISCOV JI Nat. Rev. Drug Discov. PD JAN PY 2005 VL 4 IS 1 BP 35 EP 44 DI 10.1038/nrd1606 PG 10 WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy GA 885JP UT WOS:000226153200016 PM 15688071 ER PT J AU Merabet, LB Rizzo, JF Amedi, A Somers, DC Pascual-Leone, A AF Merabet, LB Rizzo, JF Amedi, A Somers, DC Pascual-Leone, A TI What blindness can tell us about seeing again: merging neuroplasticity and neuroprostheses SO NATURE REVIEWS NEUROSCIENCE LA English DT Review ID CROSS-MODAL PLASTICITY; TRANSCRANIAL MAGNETIC STIMULATION; VISUAL-CORTEX; ELECTRICAL-STIMULATION; RETINAL PROSTHESIS; AUDITORY-CORTEX; RETINITIS-PIGMENTOSA; CONGENITALLY BLIND; CEREBRAL-CORTEX; PERCEPTION AB Significant progress has been made in the development of visual neuroprostheses to restore vision in blind individuals. Appropriate delivery of electrical stimulation to intact visual structures can evoke patterned sensations of light in those who have been blind for many years. However, success in developing functional visual prostheses requires an understanding of how to communicate effectively with the visually deprived brain in order to merge what is perceived visually with what is generated electrically. C1 Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Noninvas Brain Stimulat,Dept Ophthalmol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Noninvas Brain Stimulat,Dept Neurol, Boston, MA 02215 USA. Boston VA Hlth Care Syst, Ctr Innovat Visual Rehabil, Boston Retinal Implant Project, Boston, MA USA. Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Cambridge, MA 02138 USA. Univ Autonama, Hosp Neurorahabilitacio Inst Guttman, Barcelona, Spain. Boston Univ, Dept Psychol, Boston, MA 02215 USA. Boston Univ, Program Neurosci, Boston, MA 02215 USA. MGH Martinos Neuroimaging Ctr, Boston, MA USA. RP Merabet, LB (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Noninvas Brain Stimulat,Dept Ophthalmol, Boston, MA 02115 USA. EM lmerabet@bidmc.harvard.edu RI Somers, David/G-5802-2010; OI Somers, David/0000-0002-4169-5895 NR 67 TC 97 Z9 100 U1 1 U2 29 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-0048 J9 NAT REV NEUROSCI JI Nat. Rev. Neurosci. PD JAN PY 2005 VL 6 IS 1 BP 71 EP 77 DI 10.1038/nrn1586 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 885KI UT WOS:000226155100016 PM 15611728 ER PT J AU Barker, FG Curry, WT Carter, BS AF Barker, FG Curry, WT Carter, BS TI Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: The effect of provider caseload and centralization of care SO NEURO-ONCOLOGY LA English DT Article ID IN-HOSPITAL MORTALITY; UNRUPTURED INTRACRANIAL ANEURYSMS; ACADEMIC REFERRAL CENTERS; STEREOTACTIC BIOPSY; MALIGNANT GLIOMA; PHYSICIAN VOLUME; TREAT TUMORS; HEALTH-CARE; OUTCOMES; MORBIDITY AB Contemporary reports of patient outcomes after biopsy or resection of primary brain tumors typically reflect results at specialized centers. Such reports may not be representative of practices in nonspecialized settings. This analysis uses a nationwide hospital discharge database to examine trends in mortality and outcome at hospital discharge in 38,028 admissions for biopsy or resection of supratentorial primary brain tumors in adults between 1988 and 2000, particularly in relation to provider caseload. Multivariate analyses showed that largo-volume centers had lower in-hospital postoperative mortality rates than centers with lighter caseloads, both for craniotomies (odds ratio [OR] 0.75 for a tenfold larger caseload) and for needle (closed) biopsies (OR 0.54). Adverse discharge disposition was also less likely at high-volume hospitals, both for craniotomies (OR 0.77) and for needle biopsies (OR 0.67). The annual number of surgical admissions increased by 53% during the 12-year study period, and in-hospital mortality rates decreased during this period, from 4.8% to 1.8%. Mortality rates decreased over time, both for craniotomies and for needle biopsies. Subgroup analyses showed larger relative mortality rate reductions at large-volume centers than at small-volume centers (73% vs. 43%, respectively). The number of U.S. hospitals performing one or more craniotomies annually for primary brain tumors decreased slightly, and the number performing needle biopsies increased. There was little change in median hospital annual craniotomy caseloads, but the largest centers had disproportionate growth in volume. The 100 highest-caseload U.S. hospitals accounted for an estimated 30% of the total U.S. surgical primary brain tumor caseload in 1988 and 41% in 2000. Our findings do not establish minimum volume thresholds for acceptable surgical care of primary brain tumors. However, they do suggest a trend toward progressive centralization of craniotomies for primary brain tumor toward large-volume U.S. centers during this interval. C1 Massachusetts Gen Hosp, Brain Tumor Ctr, Neurol Serv, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Surg, Boston, MA 02114 USA. RP Barker, FG (reprint author), Massachusetts Gen Hosp, Brain Tumor Ctr, Neurol Serv, Stephen E & Catherine Pappas Ctr Neurooncol, Cox 315,Fruit St, Boston, MA 02114 USA. EM barker@helix.mgh.harvard.edu NR 57 TC 66 Z9 68 U1 0 U2 0 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JAN PY 2005 VL 7 IS 1 BP 49 EP 63 DI 10.1215/S1152851704000146 PG 15 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 894SY UT WOS:000226813100006 PM 15701282 ER PT J AU Voloschin, AD Louis, DN Cosgrove, GR Batchelor, TT AF Voloschin, AD Louis, DN Cosgrove, GR Batchelor, TT TI Neoadjuvant temozolomide followed by complete resection of a 1p-and 19q-deleted anaplastic oligoastrocytoma: Case study SO NEURO-ONCOLOGY LA English DT Article ID OLIGODENDROGLIAL TUMORS; SUCCESSFUL CHEMOTHERAPY; PCV CHEMOTHERAPY; ASTROCYTOMAS; SURVIVAL; PREDICTORS; IMPACT; 1P AB A 38-year-old woman presented with an infiltrative tumor of the right frontal lobe and genu of the corpus callosum that was deemed only partially resectable. A stereotactic biopsy was performed, which revealed a right frontal oligoastrocytoma that had some anaplastic features as well as allelic loss of chromosome arms 1p and 19q. The patient was treated with temozolomide for 24 months. The partial response of the tumor to chemotherapy rendered the lesion amenable to gross total resection, which was performed subsequently. The patient rem ins alive and well without evidence of recurrence 7 months after resection and 48 months after initial diagnosis. Thus, preoperative chemotherapy decreased tumor mass to a degree that subsequently enabled a gross total resection. This treatment strategy, although common in the treatment of other solid tumors, is rarely utilized in adult neuro-oncology and raises another potential role for chromosome testing in oligodendroglial tumor managentment. C1 Massachusetts Gen Hosp, Brain Tumor Ctr, Dept Neurol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Batchelor, TT (reprint author), Massachusetts Gen Hosp, Brain Tumor Ctr, Dept Neurol, Cox 345,55 Fruit St, Boston, MA 02114 USA. EM tbatchelor@partners.org FU NCI NIH HHS [R01 CA057683, CA57683] NR 17 TC 12 Z9 13 U1 0 U2 0 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JAN PY 2005 VL 7 IS 1 BP 97 EP 100 DI 10.1215/S1152851704000560 PG 4 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 894SY UT WOS:000226813100011 PM 15701287 ER PT J AU Stone, WS Thermenos, HW Tarbox, SI Poldrack, RA Seidman, LJ AF Stone, WS Thermenos, HW Tarbox, SI Poldrack, RA Seidman, LJ TI Medial temporal and prefrontal lobe activation during verbal encoding following glucose ingestion in schizophrenia: A pilot fMRI study SO NEUROBIOLOGY OF LEARNING AND MEMORY LA English DT Article ID HIPPOCAMPAL ACETYLCHOLINE-RELEASE; MEMORY PERFORMANCE; CONSCIOUS RECOLLECTION; RECOGNITION MEMORY; DECLARATIVE MEMORY; BRAIN ACTIVITY; INSULIN LEVELS; LONG-TERM; DYSFUNCTION; DEFICITS AB Verbal declarative memory is one of the most reliably impaired cognitive functions in schizophrenia. Important issues are whether the problem is reversible, and which brain regions underlie improvement. We showed previously that glucose administration improved declarative memory in patients with schizophrenia, and Sought in this pilot study to identify whether glucose affects the location or degree of activation of brain regions involved in a verbal encoding task. Seven clinically stable and medicated patients with schizophrenia or schizoaffective disorder, who showed deficits on a clinical test of memory, participated in the study. Subjects served as their own controls in a double-blind, crossover protocol that consisted of two sessions about a week apart. In each session, subjects ingested a beverage flavored with lemonade that contained 50 g of glucose on one occasion, and saccharin on the other. Blood glucose was measured before and 15, 50, and 75 min after ingestion. After ingesting the beverage, they performed a verbal encoding task while undergoing brain functional magnetic resonance imaging. The results showed significantly greater activation of the left parahippocampus during novel sentence encoding in the glucose condition, compared to the saccharin condition, despite no change in memory performance. A trend towards greater activation of the left dorsolateral prefrontal cortex (p < .07) was also evident in the glucose condition. These pilot findings emphasize the sensitivity of both the medial temporal and prefrontal regions to effects of glucose administration during encoding, and are consistent with the hypothesis that these regions also participate in declarative memory improvements following glucose administration. (C) 2004 Elsevier Inc. All rights reserved. C1 Harvard Univ, Sch Med, MMHC, Dept Psychiat, Cambridge, MA 02138 USA. Harvard Univ, Inst Psychiat Epidemiol & Genet, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Cambridge, MA 02138 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. RP Stone, WS (reprint author), Harvard Univ, Sch Med, MMHC, Dept Psychiat, Cambridge, MA 02138 USA. EM william_stone@hms.harvard.edu FU NIMH NIH HHS [R01 MH 63951, R25 MH 60485] NR 79 TC 22 Z9 22 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1074-7427 J9 NEUROBIOL LEARN MEM JI Neurobiol. Learn. Mem. PD JAN PY 2005 VL 83 IS 1 BP 54 EP 64 DI 10.1016/j.nlm.2004.07.009 PG 11 WC Behavioral Sciences; Neurosciences; Psychology; Psychology, Multidisciplinary SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 887TB UT WOS:000226327300007 PM 15607689 ER PT J AU Singhal, AB Bernstein, RA AF Singhal, AB Bernstein, RA TI Postpartum angiopathy and other cerebral vasoconstriction syndromes SO NEUROCRITICAL CARE LA English DT Editorial Material DE postpartum angiopathy; benign angiopathy of the CNS; Call-Fleming syndrome; cerebral vasospasm; headache; migraine; cerebral ischemia; reversible posterior leukoencephalopathy; cerebral angiography ID CENTRAL-NERVOUS-SYSTEM; MIGRAINOUS VASOSPASM; CORTICAL BLINDNESS; POSTERIOR LEUKOENCEPHALOPATHY; INTRACEREBRAL HEMORRHAGE; TRANSCRANIAL DOPPLER; THUNDERCLAP HEADACHE; BENIGN ANGIOPATHY; ARTERIAL SPASM; VASCULITIS AB The phenomenon of reversible cerebral arterial segmental vasoconstriction has been associated with several conditions, including pregnancy and puerperium ("postpartum angiopathy"), thunderclap headache, and use of vasoconstrictive medications. Patients with cerebral vasoconstriction typically present with sudden, severe, and recurrent ("thunderclap") headaches and can develop strokes. Cerebral vasoconstriction syndromes are under-recognized, are poorly characterized, and are frequently misdiagnosed as primary cerebral vasculitis. This article presents an illustrative case report and reviews the historical aspects, clinical and imaging characteristics, etiology, differential diagnosis, management, and prognosis of cerebral vasoconstriction syndromes. C1 Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Northwestern Univ, Feinberg Sch Med, Ken & Ruth Davee Dept Neurol & Clin Neurol Sci, Chicago, IL 60611 USA. RP Singhal, AB (reprint author), Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, VBK-802, Boston, MA 02114 USA. EM asinghal@partners.org NR 49 TC 65 Z9 68 U1 0 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 J9 NEUROCRIT CARE JI Neurocrit. Care PY 2005 VL 3 IS 1 BP 91 EP 97 DI 10.1385/Neurocrit.Care2005;3:91-97 PG 7 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA 967HM UT WOS:000232082300019 PM 16159105 ER PT J AU Kumar, MA Urrutia, VC Thomas, CE Abou-Khaled, KJ Schwartzman, RJ AF Kumar, MA Urrutia, VC Thomas, CE Abou-Khaled, KJ Schwartzman, RJ TI The syndrome of irreversible acidosis after prolonged propofol infusion SO NEUROCRITICAL CARE LA English DT Article DE anesthetics; cardiac failure; hypotension; metabolic acidosis; arrhythmia; side effects ID INTENSIVE-CARE UNIT; METABOLIC-ACIDOSIS; CHILDREN; RHABDOMYOLYSIS; FAILURE; PATIENT AB Introduction: Propofol infusion syndrome is described in the pediatric literature as metabolic acidosis, rhabdomyolysis, and bradycardia that results in death. The pathogenesis of this syndrome is thought to be activation of the systemic inflammatory response, which culminates in acidosis and muscle necrosis. Materials and Methods: Retrospective chart review of three patients in the Neurological Critical Care Units at Hahnemann and Massachusetts General Hospitals between October 2001 and September 2004. Results: Patient 1: A 27-year-old woman had seizures secondary to hemorrhage from an arteriovenous malformation. Propofol coma was induced for sedation. After initiation of propofol, she developed a metabolic acidosis, hypotension, and bradycardia and expired. Patient 2: A 64-year-old man presented in status epilepticus. After prolonged propofol administration, he developed metabolic acidosis, hypotension, and rhabdomyolysis and expired. Patient 3: A 24-year-old woman presented in status epilepticus secondary to encephalitis. Propofol was added for seizure control. She developed hypotension, metabolic acidosis, and bradyarrhythmias. Despite transvenous pacing, she expired. Conclusion: These data show an association between extended propofol use and metabolic acidosis, rhabdomyolysis, and death in adults, as well as children. Risk factors for propofol infusion syndrome in adults include lean body mass index, high dose, and administration of more than 24-hour duration. Creatine phosphokinase, lactic acid levels, electrolytes, and arterial blood gases should be monitored frequently. Both bacterial and fungal cultures should be obtained. If this syndrome is suspected, hemodialysis should be considered. In fatal cases, autopsy should include electron microscopy of cardiac and skeletal muscle to look for mitochondrial dysfunction. Further study is warranted. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurol & Neurosurg Intens Care Unit, Boston, MA 02114 USA. Drexel Univ, Coll Med, Hahnemann Hosp, Dept Neurol, Philadelphia, PA 19104 USA. RP Kumar, MA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurol & Neurosurg Intens Care Unit, Blake 12,45 Fruit St, Boston, MA 02114 USA. EM mkumar@partners.org OI Urrutia, Victor/0000-0002-4995-6949 NR 18 TC 28 Z9 28 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 J9 NEUROCRIT CARE JI Neurocrit. Care PY 2005 VL 3 IS 3 BP 257 EP 259 DI 10.1385/Neurocrit.Care2005;03:257-259 PG 3 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA 995PG UT WOS:000234115700013 PM 16377841 ER PT J AU Kelly, S Cheng, DY Steinberg, GK Yenari, MA AF Kelly, S Cheng, DY Steinberg, GK Yenari, MA TI Mild hypothermia decreases GSK3 beta expression following global cerebral ischemia SO NEUROCRITICAL CARE LA English DT Article DE global cerebral ischemia; mild hypothermia; GSK3 beta; phos-GSK3 beta; neuroprotection ID GLYCOGEN-SYNTHASE KINASE-3-BETA; RABBIT SKELETAL-MUSCLE; PHOSPHORYLASE-KINASE; FOREBRAIN ISCHEMIA; CARDIAC-ARREST; BRAIN-INJURY; RATS; LITHIUM; BCL-2 AB Introduction: The serine/threonine kinase glycogen synthase kinase 3 beta (GSK3 beta) is abundant in the central nervous system and is neuron-specific. GSK3 beta plays a pivotal role in the regulation of numerous cellular functions (including phosphorylation) and, thereby, regulation of many metabolic, signaling, and structural proteins as well as transcription factors that can influence cell survival. This article reports that GSK3 beta expression following global cerebral ischemia (GCI) is altered by the neuroprotectant, mild hypothermia (33 degrees C). Methods: Male Sprague-Dawley rats were anesthetized and subjected to GCI; arterial blood pressure was reduced to 30 mmHg by blood withdrawal via the jugular vein, and both common carotid arteries were occluded with aneurysm clips for 8 minutes. Hypothermia (33 degrees C) was induced in half the rats 10 minutes prior to GCI and was maintained for 3 hours. Rats were killed 24 or 72 hours later to assess cell death and GSK3 beta expression. Results: At 72 hours post-GCI, levels of GSK3 beta expression were significantly lower in hypothermic rats than in normothermic rats. This reduction in GSK3 beta correlated with marked neuroprotection and reduced terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end labeling staining in hippocampal CA1 neurons. No significant changes in phosphorylated GSK3 beta expression were observed. Conclusion: These data suggest that GSK3 beta plays a role in GCI pathology that can be altered by mild hypothermia. C1 Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Yenari, MA (reprint author), UCSF & SF VAMC, Dept Neurol, 4150 Clement St,MC127, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu RI Kelly, Stephen/A-8307-2010 FU NINDS NIH HHS [R01 NS40516]; PHS HHS [R01 27292] NR 27 TC 2 Z9 4 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 J9 NEUROCRIT CARE JI Neurocrit. Care PY 2005 VL 2 IS 2 BP 212 EP 217 DI 10.1385/Neurocrit.Care2005;2:212-217 PG 6 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA 947JI UT WOS:000230639100018 PM 16159068 ER PT J AU Atri, A Locascio, JJ Lin, JM Yap, L Dickerson, BC Grodstein, F Irizarry, MC Growdon, JH Greenberg, SM AF Atri, Alireza Locascio, Joseph J. Lin, Jenny M. Yap, Liang Dickerson, Bradford C. Grodstein, Francine Irizarry, Michael C. Growdon, John H. Greenberg, S. M. TI Prevalence and Effects of Lobar Microhemorrhages in Early-Stage Dementia SO NEURODEGENERATIVE DISEASES LA English DT Article DE Alzheimer's disease; Microbleed; Cerebral amyloid angiopathy; Neuroimaging; Magnetic resonance imaging; gradient echo AB Background: 80-100% of patients with Alzheimer's disease have vascular pathology related to cerebral amyloid angiopathy (CAA), and 5-7% have CAA-related lobar microhemorrhages (LMH) at autopsy. The prevalence and effects of LMH detectable by gradient echo MRI (GE-MRI) in early-stage dementia are unknown. Objective: To obtain, using GE-MRI, a prevalence estimate for LMH in patients with early-stage dementia and to assess the effects of LMH on dementia severity. Methods: Eighty-four subjects aged >= 55 years (range 58-89; mean 76) underwent cognitive and GE-MRI evaluation. The 84 subjects consisted of 61 consecutive subjects evaluated as part of an initial clinical evaluation for dementia and 23 consecutively evaluated healthy older subjects (controls). Data were analyzed for presence and number of LMH on GE-MRI and the effect of number of LMH on dementia severity. Results: Nine (15%) of the 61 dementia patients versus 1 (4%) of the 23 control subjects demonstrated LMH on GE-MRI. Multiple (>= 2) LMH were found in 7 of the 9 (88%) dementia subjects with LMH (range of LMH counts 1-330) and no (0%) control subjects. Multivariable causal modeling indicated that number of LMH (p < 0.02), age (p < 0.01) and duration of symptoms (p < 0.001) significantly increased dementia severity while higher educational level (p < 0.001) was protective. Conclusions: LMH were detected by GE-MRI in 15% of patients with early-stage dementia and may contribute to dementia severity. Copyright (C) 2005 S. Karger AG, Basel C1 [Atri, Alireza; Locascio, Joseph J.; Lin, Jenny M.; Yap, Liang; Dickerson, Bradford C.; Irizarry, Michael C.; Growdon, John H.; Greenberg, S. M.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Dickerson, Bradford C.; Grodstein, Francine] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA. RP Atri, A (reprint author), MGH Memory Disorders Unit, 15 Parkman St,WACC 830, Boston, MA 02114 USA. EM aatri@partners.org OI Atri, Alireza/0000-0003-4405-6973 FU MADRC Pilot Grant; NIA [5 P50AG05134, AG15424]; MADRC Neuroimaging Core; Clinical Investigator Training Program (Harvard/MIT Health Sciences & Technology and Beth Israel Deaconess Medical Center; Pfizer Inc. FX The study was supported by a MADRC Pilot Grant (to A. A.), NIA 5 P50AG05134 (to J.H.G.) and the MADRC Neuroimaging Core, and the Clinical Investigator Training Program (Harvard/MIT Health Sciences & Technology and Beth Israel Deaconess Medical Center, in collaboration with Pfizer Inc.; to A. A. and B. C. D.) and NIA AG15424 (to F. G.). We would like to acknowledge Mary-Theresa Shore for assistance with digitized MRI, Dr. Reisa Sperling for valuable comments on drafts of the manuscript and especially thank the patients and subjects without whose contributions this study would not have been possible. NR 19 TC 24 Z9 24 U1 1 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2854 J9 NEURODEGENER DIS JI Neurodegener. Dis. PY 2005 VL 2 IS 6 BP 305 EP 312 DI 10.1159/000092317 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V24IO UT WOS:000208404300004 PM 16909013 ER PT J AU Rosano, C Simonsick, EM Harris, TB Kritchevsky, SB Brach, J Visser, M Yaffe, K Newman, AB AF Rosano, C Simonsick, EM Harris, TB Kritchevsky, SB Brach, J Visser, M Yaffe, K Newman, AB CA Hlth ABC Collaborative Res Grp TI Association between physical and cognitive function in healthy elderly: The health, aging and body composition study SO NEUROEPIDEMIOLOGY LA English DT Article DE physical function; cognitive performance; gait speed; well-functioning elderly ID STROKE REHABILITATION; EXTRAPYRAMIDAL SIGNS; SENILE DEMENTIA; ALZHEIMER-TYPE; OLDER ADULTS; PERFORMANCE; IMPAIRMENT; WOMEN; MOTOR; DECLINE AB Performance measures of physical function ( gait speed, chair stands, standing balance) and cognitive function [Teng-modified Mini-Mental Status Exam (3MS) and digit symbol substitution test (DSST)] were assessed at baseline in 3,075 participants in the Health, Aging and Body Composition Study. Each physical function measure was examined for the strength and magnitude of association with cognitive function. All physical function measures were associated with both the 3MS and DSST scores (p < 0.001), and in multivariate analysis each relationship was independent of demographic characteristics, weight, physical activity and comorbid health conditions of participants. The association of motor performance was consistently greater for the DSST than the 3MS and, among the motor tests, gait speed retained a significant association with both cognitive measures independent of demographic, weight, physical activity and comorbid health conditions. In this large cohort of high-functioning older adults, the correlation between physical and cognitive function was not entirely explained by demographics. Longitudinal studies are needed to determine the direction of causality in this relationship. Copyright (C) 2005 S. Karger AG, Basel. C1 Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA 15260 USA. NIA, Intramural Res Program, Baltimore, MD 21224 USA. NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA. Univ Tennessee, Dept Prevent Med, Memphis, TN USA. Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Phys Therapy, Pittsburgh, PA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands. RP Rosano, C (reprint author), Univ Pittsburgh, Dept Med, Div Geriatr Med, 930 Scaife Hall, Pittsburgh, PA 15260 USA. EM RosanoC@edc.pitt.edu RI Brach, Jennifer/A-6912-2009; Newman, Anne/C-6408-2013; OI Newman, Anne/0000-0002-0106-1150; Rosano, Caterina/0000-0002-0909-1506; Rosano, Caterina/0000-0002-4271-6010 NR 31 TC 116 Z9 118 U1 0 U2 9 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0251-5350 J9 NEUROEPIDEMIOLOGY JI Neuroepidemiology PY 2005 VL 24 IS 1-2 BP 8 EP 14 DI 10.1159/000081043 PG 7 WC Public, Environmental & Occupational Health; Clinical Neurology SC Public, Environmental & Occupational Health; Neurosciences & Neurology GA 883OC UT WOS:000226021500002 PM 15459503 ER PT J AU Savino, W Cotta-de-Almeida, V van Buul-Offers, SC Koster, JG Dardenne, M AF Savino, W Cotta-de-Almeida, V van Buul-Offers, SC Koster, JG Dardenne, M TI Abnormal thymic microenvironment in insulin-like growth factor-II rransgenic mice SO NEUROIMMUNOMODULATION LA English DT Article DE insulin-like growth factor-II; transgenic mice; thymic epithelium; cytokeratins; perivascular spaces; fibronectin; laminin; beta 1 integrins; thymocytes ID EXTRACELLULAR-MATRIX COMPONENTS; T-CELL DEVELOPMENT; TRANSGENIC MICE; EPITHELIAL-CELLS; MONOCLONAL-ANTIBODY; MOUSE THYMUS; IGF-II; EXPRESSION; THYMOCYTES; DIFFERENTIATION AB Objectives: Intrathymic T cell differentiation is driven by the thymic microenvironment, a tridimensional network of cells and extracellular matrix (ECM). Previous data showed that lymphoid and microenvironmental compartments are under the control of hormones and growth factors. We then attempted to define if insulin-like growth factor-II (IGF-II) was also involved in such a control. Methods: We used IGF-II transgenic (Tg) mice and studied their thymic microenvironment by immunohistochemistry. Moreover, we evaluated thymocytes in terms of their ability to adhere to thymic epithelial cells and to migrate through epithelial cells and ECM. Results: Transgenic IGF-II expression results in abnormalities of the thymic epithelium. Terminal differentiation of thymic epithelial cells (TEC) is modified, with the appearance of large clusters of cells immunoreactive to the monoclonal antibody KL1, which specifically recognizes highly differentiated TEC. Accordingly, treatment of cultured TEC with exogenous IGF-II induces the appearance of KL1+ cells and increases TEC proliferation. IGF-II Tg animals exhibit increased serum levels of the TEC-derived hormone thymulin. These effects were seen even when the IGF-II transgene was inserted in dwarf mice. Moreover, deposition of fibronectin and laminin is also enhanced in IGF-II Tg mouse thymus and in IGF-II-treated TEC cultures. Furthermore, ECM-mediated interactions between thymocytes and TEC are affected by exogenous IGF-II, as exemplified by the enhancement of thymocyte adhesion to TEC monolayers and thymocyte migration in thymic nurse cell complexes. Conclusions: Our data indicate that IGF-II pleiotropically affects the thymic epithelium, both in vivo and in vitro, and that some of these changes may have consequences on thymocyte/TEC interactions. Copyright (C) 2005 S. Karger AG, Basel. C1 Oswaldo Cruz Fdn, Inst Oswaldo Cruz, Dept Immunol, Lab Thymus Res, BR-21045900 Rio De Janeiro, Brazil. Oswaldo Cruz Fdn, Inst Oswaldo Cruz, Dept Ultrastruct & Cell Biol, BR-21045900 Rio De Janeiro, Brazil. Univ Paris 05, Necker Hosp, INSERM, U344, Paris, France. Univ Paris 05, Necker Hosp, CNRS UMR 8147, Paris, France. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Univ Utrecht, Med Ctr, Dept Metab & Endocrine Dis, Utrecht, Netherlands. RP Savino, W (reprint author), Oswaldo Cruz Fdn, Inst Oswaldo Cruz, Dept Immunol, Lab Thymus Res, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil. EM savino@fiocruz.br RI Cotta-de-Almeida, Vinicius/G-3939-2012 NR 26 TC 8 Z9 9 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1021-7401 J9 NEUROIMMUNOMODULAT JI Neuroimmunomodulation PY 2005 VL 12 IS 2 BP 100 EP 112 DI 10.1159/000083582 PG 13 WC Endocrinology & Metabolism; Immunology; Neurosciences SC Endocrinology & Metabolism; Immunology; Neurosciences & Neurology GA 908LV UT WOS:000227789400005 PM 15785112 ER PT J AU Pernar, LIM Dunah, AW Curley, AC Young, AB Orlando, LR AF Pernar, LIM Dunah, AW Curley, AC Young, AB Orlando, LR TI Huntingtin is associated with glutamate receptor complexes in the postsynaptic density SO NEUROPHARMACOLOGY LA English DT Meeting Abstract CT 5th International Meeting on Metabotropic Glutamate Receptors CY SEP 18-23, 2005 CL Taormina, ITALY C1 Massachusetts Gen Hosp, Orlando LR MassGen Inst Neurodegenerat Dis, Boston, MA 02129 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 J9 NEUROPHARMACOLOGY JI Neuropharmacology PY 2005 VL 49 SU 1 MA 106 BP 264 EP 264 PG 1 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 964MJ UT WOS:000231884900128 ER PT J AU Lee, JK Won, JS Singh, AK Singh, I AF Lee, JK Won, JS Singh, AK Singh, I TI Adenosine kinase inhibitor attenuates the expression of inducible nitric oxide synthase in glial cells SO NEUROPHARMACOLOGY LA English DT Article DE adenosine; adenosine kinase inhibitor; adenosine receptor; C6 glioma cells; inducible nitric oxide synthase ID ACTIVATED PROTEIN-KINASE; RAT PRIMARY ASTROCYTES; MIDDLE CEREBRAL-ARTERY; KAPPA-B; ANTISEIZURE ACTIVITY; ENZYME-INHIBITION; NERVOUS-SYSTEM; RECEPTORS; INDUCTION; PHARMACOLOGY AB The present study demonstrates the anti-inflammatory effect of adenosine kinase inhibitor (ADKI) in glial cells. Treatment of glial cells with IC51, an ADKI. simulated the extracellular adenosine release and reduced the LPS/IFNgamma-mediated production of NO, and induction of iNOS and TNF-alpha gene expression. The recovery of IC51-mediated inhibition of iNOS expression by adenosine transport inhibitor. S-(4-nitrobenzyl)-6-thioinosine (NBTI), and (lie inhibition of LPS/IFNgamma-(-induced iNOS gene expression by exogenous adenosine indicate a role for adenosine release in IC51-mediated iNOS expression. The rescue of IC51-mediated inhibition of iNOS expression by adenosine receptor antagonist for A(2A). 8-(3-chlorostyryl)caffeine (CSC) and alloxazine for A(2B), further supports a role for interaction of adenosine and its receptors in anti-inflammatory, activity. The IC51-mediated induction of cAMP levels, downstream target of A(2A) and A(2B). and inhibition of LPS/IFNgamma-induced expression of iNOS by forskolin. a cAMP activator. document a role for cAMP mediated pathway in anti-inflammatory activity of IC51. Taken together, these studies document that IC51-mediated inhibition of iNOS expression is through activation of adenosine receptors, which activates A(2A) and A(2B) resulting in increased cAMP levels following LPS/IFNgamma stimulation. Moreover, the lack of effect of IC51 or adenosine on NFkappaB DNA binding activity and its transactivity indicates that the inhibition of iNOS expression mediated by IC51 may be through an NFkappaB independent pathway. (C) 2004 Elsevier Ltd. All rights reserved. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 96 Jonathan Lucas St,316 Clin Sci Bldg, Charleston, SC 29425 USA. EM singhi@musc.edu FU NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144] NR 45 TC 10 Z9 10 U1 2 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD JAN PY 2005 VL 48 IS 1 BP 151 EP 160 DI 10.1016/j.neuropharm.2004.09.006 PG 10 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 887RY UT WOS:000226324400014 PM 15617735 ER PT S AU Yenari, MA Liu, JL Zheng, Z Vexler, ZS Lee, JE Giffard, RG AF Yenari, MA Liu, JL Zheng, Z Vexler, ZS Lee, JE Giffard, RG BE Slikker, W Andrews, RJ Trembly, B TI Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection SO NEUROPROTECTIVE AGENTS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 7th International Conference on Neuroprotective Agents CY NOV 14-19, 2004 CL Pacific Grove, CA SP Cent Arkansas Chapter SIGMA XI, Natl Ctr Toxicol Res, FDA, US EPA DE heat-shock proteins; neuroprotection; apoptosis; cerebral ischemia; inflammation ID APOPTOSIS-INDUCING FACTOR; STRESS-INDUCED APOPTOSIS; KAPPA-B ACTIVATION; NITRIC-OXIDE; CEREBRAL-ISCHEMIA; FOCAL ISCHEMIA; RAT HEAT-SHOCK-PROTEIN-70; DIFFERENTIAL INDUCTION; TRANSCRIPTION FACTOR; APAF-1 APOPTOSOME AB We and others have previously shown that heat-shock proteins (HSPs) are involved in protecting the brain from a variety of insults including stroke, epilepsy, and other related insults. While the mechanism of this protection has largely been thought to be due to their chaperone functions (i.e., preventing abnormal protein folding or aggregation), recent work has shown that HSPs may also directly interfere with other cell death pathways such as apoptosis and inflammation. Using models of cerebral ischemic and ischemia-like injury, we overexpressed the 70-kDa heat-shock protein (HSP70) using gene transfer or by studying a transgenic mouse model. HSP70 protected neurons and astrocytes from experimental stroke and stroke-like insults. HSP70 transgenic mice also had better neurological scores following experimental stroke compared to their wild-type littermates. Overexpressing HSP70 was associated with less apoptotic cell death and increased expression of the antiapoptotic protein, Bcl-2. Furthermore, HSP70 suppressed microglial/monocyte activation following experimental stroke. HSP70 overexpression also led to the reduction of matrix metalloproteinases. We suggest that HSPs are capable of protecting brain cells from lethal insults through a variety of mechanisms and should be explored as a potential therapy against stroke and other neurodegenerative diseases. C1 Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94121 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Yonsei Univ, Dept Anat, Seoul 120749, South Korea. Yonsei Univ, Project BK21, Seoul 120749, South Korea. Stanford Univ, Dept Anesthesia, Sch Med, Stanford, CA 94305 USA. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu RI Liu, Jialing/A-8627-2012; OI Liu, Jialing/0000-0003-4420-4382; Lee, Jong Eun/0000-0001-6203-7413 FU NIGMS NIH HHS [GM49831]; NINDS NIH HHS [NS35902, NS40469, NS40516, NS44025, P01 NS37520] NR 60 TC 170 Z9 197 U1 1 U2 19 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-578-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1053 BP 74 EP 83 DI 10.1196/annals.1344.007 PG 10 WC Multidisciplinary Sciences; Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy GA BDR63 UT WOS:000235109800010 PM 16179510 ER PT S AU Tam, D Tam, M Maynard, KI AF Tam, D Tam, M Maynard, KI BE Slikker, W Andrews, RJ Trembly, B TI Nicotinamide modulates energy utilization and improves functional recovery from ischemia in the in vitro rabbit retina SO NEUROPROTECTIVE AGENTS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 7th International Conference on Neuroprotective Agents CY NOV 14-19, 2004 CL Pacific Grove, CA SP Cent Arkansas Chapter SIGMA XI, Natl Ctr Toxicol Res, FDA, US EPA DE nicotinamide (NAm); neuroprotection; stroke; hypoxia; niacin; neuronal energy metabolism ID MAGNESIUM PLUS MEXILETINE; FOCAL CEREBRAL-ISCHEMIA; CELL-DEATH; CNS ISCHEMIA; NAD(+); INJURY; NEUROPROTECTION; MECHANISMS; FAILURE; PATHOPHYSIOLOGY AB The central nervous system depends critically on a regular supply of oxygen and glucose for the formation of adenosine triphosphate (ATP) and the sustenance of its energy metabolism. Consequently, a significant reduction in the supply of oxygen and glucose to neuronal tissue causes an imbalance between the energy supply and demand, inducing the onset of neuronal ischemia and triggering many metabolic cascades leading to irreversible injury and cell death. Nicotinamide (NAm), an essential precursor to nicotinamide adenine dinucleotide (NAD(+)), which raises brain ATP levels, may improve cerebral blood flow and is neuroprotective against ischemia-induced injury. We therefore chose to examine the metabolic and electrophysiologic/functional effects of NAm (0.1 mM, 1.0 mM, 10.0 mM) under normal, control, and ischemic conditions, as well as following the early stages of reperfusion ("return-to-control" conditions) using an in vitro rabbit retina model where blood flow effects are 4 A excluded. Under nonischemic, control conditions, the protective concentration of NAm (10.0 mM) increased glucose utilization (34%, P < 0.01) and decreased lactate production (44%, P < 0.01), but had no significant effect on electrophysiologic function. After 2 h of ischemia, glucose utilization was significantly decreased (41%, P < 0.01) and lactate production was unaffected by NAm (10 mM). Following 3 h of "reperfusion", NAm (10 mM) significantly improved glucose utilization (217%, P < 0.01), lactate production (40%, P < 0.01), and electrophysiologic function (264%, P < 0.01) relative to controls. Thus, the functional neuroprotective effects of NAm may be independent of blood flow effects, but related, at least in part, to its improvement of tissue glucose A utilization and lactate production. C1 Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Calif San Francisco, Beckman Vis Ctr, Dept Ophthalmol, San Francisco, CA 94143 USA. Royal Coll Surgeons Ireland, Dublin 2, Ireland. RP Maynard, KI (reprint author), Sanofi Aventis Inc, 200 Crossing Blvd,BX2-306A, Bridgewater, NJ 08807 USA. EM kenneth.maynard@sanofi-aventis.com NR 26 TC 14 Z9 19 U1 0 U2 4 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-578-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1053 BP 258 EP 268 DI 10.1196/annals.1344.023 PG 11 WC Multidisciplinary Sciences; Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy GA BDR63 UT WOS:000235109800028 PM 16179531 ER PT S AU Imam, SZ Duhart, HM Skinner, JT Ali, SF AF Imam, SZ Duhart, HM Skinner, JT Ali, SF BE Slikker, W Andrews, RJ Trembly, B TI Cocaine induces a differential dose-dependent alteration in the expression profile of immediate early genes, transcription factors, and caspases in PC12 cells: A possible mechanism of neurotoxic damage in cocaine addiction SO NEUROPROTECTIVE AGENTS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 7th International Conference on Neuroprotective Agents CY NOV 14-19, 2004 CL Pacific Grove, CA SP Cent Arkansas Chapter SIGMA XI, Natl Ctr Toxicol Res, FDA, US EPA DE cocaine; psychostimulants; dopamine; immediate early genes; apoptosis; transcription ID DOPAMINE NEURONS; BRAIN; TRANSPORTERS; METABOLISM; EXPOSURE; ABUSERS; USERS AB Cocaine is a widely used drug of abuse and psychostimulant that acts on the central nervous system by blocking the dopamine reuptake sites. PC12 cells, a rat pheochromocytoma clonal line, in the presence of nerve growth factor (NGF), multiply and differentiate into competent neurons that can synthesize, store, and secrete the neurotransmitter dopamine (DA). In the present study, we evaluated the effect of increasing doses of cocaine on the expression of immediate early genes (IEGs), c-fos and c-jun, and closely related transcription factors, SP-1 and NF-k beta, at 24 h after the exposure to cocaine (50, 100, 200, 500, 1000, 2500 mu M) in NGF-differentiated PC12 cells. Cocaine (50-500 mu M) resulted in significant induction of the expression of c-jos, c-jun, SP-1, and NF-k beta. However, higher concentrations of cocaine (1000 and 2500 mu M) resulted in the downregulation of these expressions after 24 h. To further understand the role of dose-dependent changes in the mechanisms of cell death, we evaluated the protein expression of apoptotic markers. A concentration-dependent increase in the expression of caspase-9 and -3 was observed up to 500 mu M cocaine. However, the higher dose did not show any expression. We also evaluated the effect of increasing doses of cocaine on DA concentration and the expression of dopamine transporter (DAT). A significant dose-dependent decrease in the concentration of DA as well as the expression of DAT was observed 24 h after the exposure of PC12 cells to cocaine. Therefore, in the present study, we reported that cocaine has both upstream and downstream regulatory actions on some IEGs and transcription factors that can regulate the mechanism of cell death, and these effects on gene expression are independent of its action on the dopaminergic system. C1 S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. US FDA, Natl Ctr Toxicol Res, Div Neurotoxicol, Jefferson, AR 72079 USA. RP Imam, SZ (reprint author), S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. EM simam@satx.rr.com; sali@nctr.fda.gov NR 23 TC 19 Z9 19 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-578-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2005 VL 1053 BP 482 EP 490 DI 10.1196/annals.1344.042 PG 9 WC Multidisciplinary Sciences; Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy GA BDR63 UT WOS:000235109800049 PM 16179556 ER PT J AU Dackis, CA Kampman, KM Lynch, KG Pettinati, HM O'Brien, CP AF Dackis, CA Kampman, KM Lynch, KG Pettinati, HM O'Brien, CP TI A double-blind, placebo-controlled trial of modafinil for cocaine dependence SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE modafinil; cocaine; glutamate; pharmacotherapy; abstinence; addiction ID QUALITY-OF-LIFE; GLUTAMATE TRANSMISSION; WITHDRAWAL SYMPTOMS; NUCLEUS-ACCUMBENS; CONSCIOUS RAT; DRUG; NARCOLEPSY; ADDICTION; METHYLPHENIDATE; AMPHETAMINE AB Despite years of active research, there are still no approved medications for the treatment of cocaine dependence. Modafinil is a glutamate-enhancing agent that blunts cocaine euphoria under controlled conditions, and the current study assessed whether modafinil would improve clinical outcome in cocaine-dependent patients receiving standardized psychosocial treatment. This was a randomized, double-blind, placebo-controlled trial conducted at a university outpatient center (from 2002 to 2003) on a consecutive sample of 62 (predominantly African American) cocaine-dependent patients (aged 25-63) free of significant medical and psychiatric conditions. After screening, eligible patients were randomized to a single morning dose of modafinil (400 mg), or matching placebo tablets, for 8 weeks while receiving manual-guided, twice-weekly cognitive behavioral therapy. The primary efficacy measure was cocaine abstinence based on urine benzoylecgonine levels. Secondary measures were craving, cocaine withdrawal, retention, and adverse events. Modafinil-treated patients provided significantly more BE-negative urine samples (p = 0.03) over the 8-week trial when compared to placebos, and were more likely to achieve a protracted period (greater than or equal to3 weeks) of cocaine abstinence (p = 0.05). There were no serious adverse events, and none of the patients failed to complete the study as a result of adverse events. This study provides preliminary evidence, which should be confirmed by a larger study, that modafinil improves clinical outcome when combined with psychosocial treatment for cocaine dependence. C1 Univ Penn, Sch Med, Treatment Res Ctr, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Dackis, CA (reprint author), Univ Penn, Sch Med, Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM dackis@mail.med.upenn.edu FU NIDA NIH HHS [DA P60-05186, DA P50-12756] NR 44 TC 220 Z9 224 U1 4 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2005 VL 30 IS 1 BP 205 EP 211 DI 10.1038/sj.npp.1300600 PG 7 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 880WD UT WOS:000225819700023 PM 15525998 ER PT J AU Diaz, N Bronstein, JM AF Diaz, N Bronstein, JM TI Parkinson's disease research education and Clinical Centers (PADRECC): Background and overview SO NEUROREHABILITATION LA English DT Article ID QUALITY-OF-LIFE; REHABILITATION; THERAPY AB Parkinson's disease (PD) afflicts more than 1,000,000 people in the United States and over 50,000 veterans obtain their medical care for PD within the Veterans Health Care System. In an effort to improve care for this growing population of veterans suffering from PD, the Veteran's Health Administration established 6 Parkinson's disease Research, Education, and Clinical Centers (PADRECC) based on merit. These 6 centers offer state of the art diagnosis and treatment of PD and other movement disorders. The PADRECC also provide education for both the professional community and patients not only at the 6 sites, but also throughout the VA system through the development of a national consortium. Improving veterans' health care through research is also a priority for the PADRECC. All 6 PADRECC are participating in the largest surgical trial for the treatment of PD ever performed. Heath service researchers have already identified quality of care indicators that are now being used to evaluate care for veterans with PD. Basic researchers at the PADRECC are studying the cause of PD and are developing new therapies including stem cells. The development of the PADRECC has created an important infrastructure and attracted expertise into the VA system. They have already made great improvements in caring for veterans with PD and promises to push the field further with their research efforts. C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA. RP Bronstein, JM (reprint author), Univ Calif Los Angeles, Sch Med, Dept Neurol, 710 Westwood Blvd, Los Angeles, CA 90095 USA. EM jbronste@ucla.edu NR 15 TC 6 Z9 6 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2005 VL 20 IS 3 BP 153 EP 160 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 005KB UT WOS:000234820000002 PM 16340096 ER PT J AU Protas, EJ Mitchell, K Williams, A Qureshy, H Caroline, K Lai, EC AF Protas, EJ Mitchell, K Williams, A Qureshy, H Caroline, K Lai, EC TI Gait and step training to reduce falls in Parkinson's disease SO NEUROREHABILITATION LA English DT Article DE Parkinson's disease; falls; gait training; rehabilitation ID BODY-WEIGHT SUPPORT; PHYSICAL-THERAPY; STROKE PATIENTS; CONTROLLED-TRIAL; TREADMILL; BALANCE; PEOPLE; INDIVIDUALS; STIMULATION; RELIABILITY AB Introduction: Frequent falls and risk of injury are evident in individuals with Parkinson's disease (PD) as the disease progresses. There have been no reports of any interventions that reduce the incidence of falls in idiopathic PD. Purpose: Assess the benefit of gait and step perturbation training in individuals with PD. Design: Randomized, controlled trial. Setting: Outpatient research, education and clinical center in a tertiary care Veterans Affairs Medical Center. Outcome measures: Gait parameters, 5-step test, report of falls Subjects: Eighteen men with idiopathic PD in stage 2 or 3 of the Hoehn and Yahr staging Methods: Subjects were randomly assigned to a trained or control group. They were asked about any falls 2 weeks prior to and after an 8 week period. Gait speed, cadence, and step length were tested on an instrumented walkway. Subjects were timed while stepping onto and back down from an 8.8 cm step for 5 consecutive steps. Gait training consisted of walking on a treadmill at a speed greater than over ground walking speed while walking in 4 directions and while supported in a harness for safety. Step training consisted of suddenly turning the treadmill on and off while the subject stood in the safety harness facing either forwards, backwards, or sideways. Training occurred 1 hour per day, three times per week for 8 weeks. A two-factor (time and group) analysis of variance with repeated measures was used to compare the groups. Results: Substantial reduction occurred in falls in the trained group, but not in the control group. Gait speed increased in the trained group from 1.28 +/- 0.33 meters/sec to 1.45 +/- 0.37 meters/sec, but not in the control group (from 1.26 to 1.27 m/s). The cadence increased for both groups: from 112.8 to 120.3 steps/min for the trained group and 117.7 to 124.3 steps/min for the control group. Stride lengths increased for the trained group, but not the control group. The 5- step test speed increased in the trained group from 0.40 +/- 0.08 steps/sec to 0.51 +/- 0.12 steps/sec, and in the control group (0.36 +/- 0.11 steps/sec to 0.42 +/- 0.11 steps/ sec). Conclusion: Gait and step perturbation training resulted in a reduction in falls and improvements in gait and dynamic balance. This is a promising approach to reduce falls for patients with PD. C1 Univ Texas, Med Branch, Dept Phys Therapy, Galveston, TX 77555 USA. Michael E DeBakey Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Houston, TX USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. Texas Womans Univ, Sch Phys Therapy, Houston, TX USA. RP Protas, EJ (reprint author), Univ Texas, Med Branch, Dept Phys Therapy, Galveston, TX 77555 USA. EM ejprotas@utmb.edu RI Nathalie, Zimmermann/M-2179-2014 FU NIA NIH HHS [P30 AG024832] NR 48 TC 146 Z9 151 U1 4 U2 27 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2005 VL 20 IS 3 BP 183 EP 190 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 005KB UT WOS:000234820000005 PM 16340099 ER PT J AU Trail, M Fox, C Ramig, LO Sapir, S Howard, J Lai, EC AF Trail, M Fox, C Ramig, LO Sapir, S Howard, J Lai, EC TI Speech treatment for Parkinson's disease SO NEUROREHABILITATION LA English DT Review DE Parkinson's disease; speech and voice disorders; speech and voice treatment; hypokinetic dysarthria; hypophonia ID INTENSIVE VOICE TREATMENT; BASAL GANGLIA DISORDERS; OF-THE-LITERATURE; L-DOPA THERAPY; TREATMENT LSVT(R); BEHAVIORAL RECOVERY; FUNCTIONAL-ANATOMY; ACOUSTIC ANALYSIS; VOCAL INTENSITY; WRIST MOVEMENTS AB Researchers estimate that 89% of people with Parkinson's disease (PD) have a speech or voice disorder including disorders of laryngeal, respiratory, and articulatory function. Despite the high incidence of speech and voice impairment, studies suggest that only 3-4% of people with PD receive speech treatment. The authors review the literature on the characteristics and features of speech and voice disorders in people with PD, the types of treatment techniques available, including medical, surgical, and behavioral therapies, and provide recommendations for the current efficacy of treatment interventions and directions of future research. C1 Michael E DeBakey VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Natl Ctr Voice & Speech, Denver, CO USA. Univ Colorado, Dept Speech Language Hearing Sci, Boulder, CO 80309 USA. Univ Haifa, Dept Commun Sci & Disorders, Fac Social Welf & Hlth Sci, Haifa, Israel. Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. RP Trail, M (reprint author), Michael E DeBakey VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, 2002 Holcombe Blvd,127 PD, Houston, TX 77030 USA. EM mtrail@bcm.tmc.edu NR 171 TC 40 Z9 41 U1 6 U2 29 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2005 VL 20 IS 3 BP 205 EP 221 PG 17 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 005KB UT WOS:000234820000007 PM 16340101 ER PT J AU Piper, M Abrams, GM Marks, WJ AF Piper, M Abrams, GM Marks, WJ TI Deep brain stimulation for the treatment of Parkinson's disease: Overview and impact on gait and mobility SO NEUROREHABILITATION LA English DT Article DE Parkinson's disease; gait; gait analysis; deep brain stimulation; rehabilitation ID SUBTHALAMIC NUCLEUS STIMULATION; HIGH-FREQUENCY STIMULATION; GLOBUS-PALLIDUS; PARS INTERNA; FOLLOW-UP; LEVODOPA AB Abnormality in gait is a cardinal feature of Parkinson's disease. Walking is characterized by relatively preserved sequencing of trunk and limb movements, but diminished velocity, shortened stride length, increased base, and diminished double stance support time. The principle problem producing the gait abnormalities is dopamine deficiency, which is hypothesized to disrupt pallido-thalamic modulation of cortical motor regions that automatically regulate walking. Deep brain stimulation currently is directed at either the globus pallidum internus (GPi) or subthalamic nucleus (STN) and improves many of the abnormal characteristics of parkinsonian gait with efficacy similar to dopamine replacement. The optimal target for stimulation remains uncertain and is currently being addressed in a large VA cooperative study. Our studies show that unilateral stimulation of GPi or STN improves gait to a similar extent. Functional and quantitative gait analyses confirm sustained improvement in gait dynamics with bilateral stimulation for periods for more than several years. Parkinsonian gait is also improved with rehabilitation training, primarily using external visual or auditory cues. The combination of deep brain stimulation, pharmacotherapy, and rehabilitation training may result in more effective comprehensive approaches to the reduced mobility associated with Parkinson's disease. C1 San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Abrams, GM (reprint author), San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM abrams@itsa.ucsf.edu NR 22 TC 20 Z9 22 U1 0 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2005 VL 20 IS 3 BP 223 EP 232 PG 10 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 005KB UT WOS:000234820000008 PM 16340102 ER PT J AU Song, B Marvizon, JCG AF Song, B Marvizon, JCG TI N-methyl-D-aspartate receptors and large conductance calcium-sensitive potassium channels inhibit the release of opioid peptides that induce mu-opioid receptor internalization in the rat spinal cord SO NEUROSCIENCE LA English DT Article DE dorsal horn; dynorphin; enkephalin; internalization; mu-opioid receptor; opioid ID DORSAL-HORN NEURONS; ENKEPHALIN-DEGRADING ENZYMES; EXTRASYNAPTIC NMDA RECEPTORS; MEDIAL PREOPTIC NUCLEUS; PRIMARY AFFERENT-FIBERS; NEUROPEPTIDE FF ANALOG; CORTICAL CELL-CULTURE; SMOOTH-MUSCLE-CELLS; MIXED INHIBITOR; SUBSTANCE-P AB Endogenous opioids in the spinal cord play an important role in nociception, but the mechanisms that control their release are poorly understood. To simultaneously detect all opiolds able to activate the mu-opioid receptor, we measured mu-opioid receptor internalization in rat spinal cord slices stimulated electrically or chemically to evoke opioid release. Electrical stimulation of the dorsal horn in the presence of peptidase inhibitors produced mu-opioid receptor internalization in half of the mu-opioid receptor neurons. This internalization was rapidly abolished by N-methyl-D-aspartate (IC50=2 mu M), and N-methyl-D-aspartate antagonists prevented this effect. mu-Opioid receptor internalization evoked by high K+ or veratridine was also inhibited by N-methyl-D-aspartate receptor activation. N-methyl-D-aspartate did not affect mu-opioid receptor internalization induced by exogenous endomorphins, confirming that the effect of N-methyl-D-aspartate was on opioid release. We hypothesized that this inhibition was mediated by large conductance Cal(2+)-sensitive K+ channels BK(Ca2+). Indeed, inhibition by N-methyl-D-aspartate was prevented by tetraethylammonium and by the selective BK(Ca2+) blockers paxilline, penitrem A and verruculogen. Paxilline did not increase mu-opiold receptor internalization in the absence of N-methyl-D-aspartate, indicating that it does not produce an increase in opioid release unrelated to the inhibition by h-methyl-D-aspartate. The BK(Ca2+) involved appears to be a subtype with slow association kinetics for iberiotoxin, which was effective only with long incubations. The BK(Ca2+) opener NS-1619 also inhibited the evoked mu-opioid receptor internalization, and iberiotoxin prevented this effect. We concluded that Ca2+ influx through N-methyl-D-aspartate receptors causes the opening of BK(Ca2+) and hyperpolarization in opioid-containing dorsal horn neurons, resulting in the inhibition of opioid release. Since g-opioid receptors in the dorsal horn mediate analgesia, inhibition of spinal opioid release could contribute to the hyperalgesic actions of spinal N-methyl-D-aspartate receptors. (c) 2005 Published by Elsevier Ltd on behalf of IBRO. C1 Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, CURE, Digest Dis Res Ctr, Div Digest Dis,Dept Med,David Geffen Sch Med, Los Angeles, CA 90073 USA. Vet Affairs greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Marvizon, JCG (reprint author), Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Bldg 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM marvizon@ucla.edu FU NIDA NIH HHS [R01 DA012609, 1 R01 DA12609, P50 DA005010] NR 77 TC 16 Z9 16 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2005 VL 136 IS 2 BP 549 EP 562 DI 10.1016/j.neuroscience.2005.08.032 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 991RY UT WOS:000233832600018 PM 16203108 ER PT J AU Calcina, F Barocelli, E Bertoni, S Furukawa, O Kaunitz, J Impicciatore, M Sternini, C AF Calcina, F Barocelli, E Bertoni, S Furukawa, O Kaunitz, J Impicciatore, M Sternini, C TI Effect of N-methyl-D-aspartate receptor blockade on neuronal plasticity and gastromtestinal transit delay induced by ischemia/reperfusion in rats SO NEUROSCIENCE LA English DT Article DE ascending pathway; descending pathway; excitatory motor neurons; inhibitory motor neurons; nitric oxide ID NITRIC-OXIDE SYNTHASE; ISCHEMIA-REPERFUSION INJURY; GENE-RELATED PEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; ENTERIC NERVOUS-SYSTEM; FELINE SMALL-INTESTINE; SUBSTANCE-P; NECROTIZING ENTEROCOLITIS; INTERSTITIAL-CELLS; PROTEIN NITRATION AB intestinal ischemia impairs gastrointestinal motility. The aims of this study were to investigate the effect of intestinal ischemia on gastrointestinal transit and on the expression of enteric transmitters in the rat, and whether the glutamate N-methyl-D-aspartate receptors influence these effects. Ischemia (11 h), induced by occluding the superior mesenteric artery, was followed by 0 or 24 h of reperfusion. Normal and sham-operated rats served as controls. Serosal blood flow was measured with laser Doppler flow meter. Gastrointestinal transit was measured as time of appearance of a marker in fecal pellets. Immunohistochemistry was used to evaluate the number of neurons immunoreactive for neuronal nitric oxide synthase (NOS) or vasoactive intestinal polypeptide and the density of substance P immunoreactive fibers in the myenteric plexus. The N-methyl-D-aspartate receptors antagonist, (+)-5-methyl-10,11-dihydro-5HT-[a,b] cyclohepten-5,10-imine (MK-801) (1 mg/kg i.v.) or the NOS inhibitor, N-nitro-L-arginine (10 mg/kg i.v.) was administered prior to ischemia. Serosal blood flow was decreased by 70% during ischemia, but it was not altered in sham-operated rats. Gastrointestinal transit was significantly prolonged in ischemic/reper-fused rats compared with controls. There was a significant increase in the number of vasoactive intestinal polypeptide and neuronal nitric oxide synthase immunoreactive neurons, and a marked decrease of substance P immunoreactive fibers in ischemia followed by 24 h of reperfusion animals compared with controls. These alterations were not observed in ischemia without reperfusion. A significant delay of gastrointestinal transit and increase of vasoactive intestinal polypeptide neurons were also observed in sham-operated rats. The changes in transmitter expression and gastrointestinal transit in ischemic/reperfused rats were prevented by pre-treatment with the NOS inhibitor, N-nitro-L-arginine or the N-methyl-D-aspartate receptors antagonist, MK-801. This study suggests an involvement of the glutamatergic system and its interaction with nitric oxide in intestinal ischemia/reperfusion. Ischemia/reperfusion might induce local release of glutamate that activates N-methyl-D-aspartate receptors leading to increased production of nitric oxide and adaptive changes in enteric transmitters that might contribute to gastrointestinal dysmotility. (c) 2005 Published by Elsevier Ltd on behalf of IBRO. C1 Vet Adm Greater Los Angeles Hlth Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. Univ Parma, Dept Pharmacol Biol & Appl Chem Sci, I-43100 Parma, Italy. RP Sternini, C (reprint author), Vet Adm Greater Los Angeles Hlth Syst, CURE Digest Dis Res Ctr, CURE Bldg 115,Room 224,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM csternin@ucla.edu RI Barocelli, Elisabetta/C-4509-2013 FU NIDDK NIH HHS [DK41301, DK54155, DK54221, DK57037] NR 60 TC 28 Z9 28 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2005 VL 134 IS 1 BP 39 EP 49 DI 10.1016/j.neuroscience.2005.03.052 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 949SK UT WOS:000230808200005 PM 15939544 ER PT J AU Zhang, TA Hendricson, AW Wilkemeyer, MF Lippmann, MJ Charness, ME Morrisett, RA AF Zhang, TA Hendricson, AW Wilkemeyer, MF Lippmann, MJ Charness, ME Morrisett, RA TI Synergistic effects of the peptide fragment D-NAPVSIPQ on ethanol inhibition of synaptic plasticity and NMDA receptors in rat hippocampus SO NEUROSCIENCE LA English DT Article DE cell adhesion molecule; LTP; fetal alcohol syndrome; development ID LONG-TERM POTENTIATION; FETAL ALCOHOL SYNDROME; ADHESION MOLECULE L1; METHYL-D-ASPARTATE; CELL-CELL ADHESION; PRENATAL EXPOSURE; ADULT-RAT; MICE; SENSITIVITY; ANTAGONISTS AB The L1 cell adhesion molecule has been implicated in ethanol teratogenesis as well as NMDAR-dependent long-term potentiation (LTP) of synaptic transmission, a process thought to be critical for neural development. Ethanol inhibits LTP at least in part by interacting with NMDA receptors. Ethanol also inhibits L1-mediated cell adhesion in a manner that is prevented by an octapepticle, D-NAPVSIPQ (D-NAP), as well as long chain alcohols such as 1-octanol. Here we analyzed the effects of D-NAP and I-octanol on ethanol modulation of LTP induced by theta burst stimulation in two subfields of the rat hippocampus, the dentate gyrus and area CA1. When theta burst stimulation was delivered in ethanol (50 mM), LTP was inhibited by about 50%. Surprisingly, when D-NAP (10(-7)M) and ethanol were co-applied or applied sequentially, LTP was completely absent. The effects of D-NAP were persistent, since delivery of a second theta burst stimulation following washout of D-NAP and ethanol elicited minimal plasticity. Application of D-NAP alone had no effect on LTP induction or expression. The synergistic effect of D-NAP on ethanol inhibition of LTP was concentration-dependent since D-NAP (10(-10)M) had an intermediate effect, while D-NAP (10(-13)M) had no effect on ethanol suppression of LTP. These observations were also replicated with a different ethanol antagonist, 1-octanol, in area CA1. To address the mechanisms underlying this long-lasting suppression of LTP, the sensitivity of pharmacologically isolated NMDAR extracellular field potentials to combinations of D-NAP and ethanol was determined. D-NAP (10(-7)M) alone had no effect on NMDA extracellular field potentials; however, the peptide significantly increased the inhibitory action of ethanol on NMDA extracellular field potential. The findings suggest that D-NAP and 1-octanol selectively interact with NMDA receptors in an ethanol-dependent manner, further implicating the L1 cell adhesion molecule in alcohol-related brain disorders. (c) 2005 Published by Elsevier Ltd on behalf of IBRO. C1 Univ Texas, Coll Pharm, Austin, TX 78712 USA. Univ Texas, Waggoner Ctr Alcohol & Addict Res, Austin, TX 78712 USA. Harvard Univ, Sch Med, Dept Neurol 127, VA Boston Healthcare Syst, W Roxbury, MA 02132 USA. RP Morrisett, RA (reprint author), Univ Texas, Coll Pharm, Austin, TX 78712 USA. EM ramorris@mail.utexas.edu OI Charness, Michael/0000-0002-3301-8966 FU NIAAA NIH HHS [R37AA12974, F32AA014068, U01AA14397, R01AA09230] NR 37 TC 9 Z9 9 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2005 VL 134 IS 2 BP 583 EP 593 DI 10.1016/j.neuroscience.2005.04.010 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 957MI UT WOS:000231373500022 PM 15963648 ER PT J AU Thompson, KW AF Thompson, KW TI Genetically engineered cells with regulatable GABA production can affect afterdischarges and behavioral seizures after transplantation into the dentate gyrus SO NEUROSCIENCE LA English DT Article DE transplantation; epilepsy; seizures; GAD; GABA; hippocampus ID TEMPORAL-LOBE EPILEPSY; KINDLING EPILEPSY; PIRIFORM CORTEX; NEURAL TRANSPLANTATION; NEURONS; GRAFTS; RATS; SUPPRESSION; MODEL; TERM AB Intractable seizures originating in the mesial temporal lobe can often be controlled by resection. An alternative to removing hippocampal tissue may be transplantation of GABA-producing cells. Neural cell transplantation has been performed in hundreds of patients, including some with temporal lobe epilepsy. This study evaluates the seizure-suppressing capabilities of engineered GABA-producing cells transplanted into the dentate gyrus. Immortalized neurons were engineered to produce GABA under the control of doxycycline. The cells were characterized for GABA production in vitro and for their ability to raise GABA concentrations in vivo. Cells were transplanted bilaterally into the dentate gyrus of rats and tested in two separate paradigms. Afterdischarge thresholds and durations were tested with granule cell stimulation, and the development of behavioral seizures, induced by daily electrical stimulation of the major excitatory input pathway into the dentate gyrus, was assessed in the presence, or the absence, of doxycycline. GABA production was under the tight control of doxycycline. Cells engineered to produce GABA raised tissue GABA concentrations in the hippocampus compared with non GABA-producing cells, and this was abolished when doxycycline was administered. GABA-producing cells raised the threshold, and shortened the duration of hippocampal afterdischarges elicited by granule cell stimulation. Lastly, the appearance of stage 5 seizures was slowed in the kindling paradigm, compared with a group that received non-GABA-producing cells, and compared with a group that received GABA-producing cells but was administered doxycycline. This study shows that targeted hippocampal implants of genetically engineered cells have the potential to raise GABA levels and to affect seizure development. The ability to suppress the production of GABA, and to modulate the physiological effects of the transplanted cells provides an important level of experimental control. These techniques, combined with stem cell technology, may advance cell-based therapies for epilepsy and other diseases of the CNS. (c) 2005 Published by Elsevier Ltd on behalf of IBRO. C1 Univ Calif Los Angeles, Dept Neurol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Univ Calif Los Angeles, Dept Neurol, VA Greater Los Angeles Healthcare Syst, Bldg 114,Room 137,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM kthompso@ucla.edu NR 40 TC 46 Z9 50 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PY 2005 VL 133 IS 4 BP 1029 EP 1037 DI 10.1016/j.neuroscience.2005.03.003 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 942FO UT WOS:000230268500016 PM 15927406 ER PT J AU Mutai, H Mann, S Heller, S AF Mutai, H Mann, S Heller, S TI Identification of chicken transmembrane channel-like (TMC) genes: Expression analysis in the cochlea SO NEUROSCIENCE LA English DT Article DE deafness gene; hearing; hair cell; vestibular; basilar papilla; tonotopic ID HAIR-CELLS; INNER-EAR; EPIDERMODYSPLASIA-VERRUCIFORMIS; DOSAGE COMPENSATION; POTASSIUM CURRENTS; HEARING-LOSS; MUTATIONS; VARIANTS; PROTEINS; DOMINANT AB Mutations of the human gene encoding transmembrane channel-like protein (TMC)1 cause dominant and recessive nonsyndromic hearing disorders, suggesting that this protein plays an important role in the inner ear. In this study, we cloned chicken Tmc2 (GgTmc2) from a cochlear cDNA library and we annotated four additional TMC family members: GgTmc1, GgTmc3, GgTmc6, and GgTmc7. All chicken TMCs possess the defining TMC signature motif and display high conservation of their genomic structure when compared with other vertebrate TMC genes. GgTmc1 is localized on the chicken sex chromosome Z at a locus that displays conserved synteny with the loci of mammalian orthologues residing on autosomes. In contrast, the locus of GgTmc2 does not exhibit conserved synteny with its mammalian orthologues. Because murine TMC1 and TMC2 are restrictively expressed in cochlear hair cells, we determined the expression of the chicken orthologues in the basilar papilla, the avian equivalent of the organ of Corti. While GgTmc2 was present throughout the basilar papilla and in other tissues, GgTmc1 transcript was detected specifically in the basal portion of the basilar papilla and was not detectable in any other tissue or organ studied. GgTmc3 and GgTmc6 were detectable in all organs analyzed. Antibody labeling revealed that GgTmc2 is predominantly associated with the lateral membranes of hair and supporting cells. The expression of GgTmc2 by both cell types was further confirmed by RT-PCR using isolated cells. This expression and sulacellular localization of GgTmc2 is in agreement with the proposed potential role of this novel class of transmembrane proteins in ion transport. © 2005 IBRO. Published by Elsevier Ltd. All rights reserved. C1 Harvard Univ, Sch Med, Dept Otolaryngol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA. Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. RP Heller, S (reprint author), Harvard Univ, Sch Med, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM stefan_heller@meei.harvard.edu FU NIDCD NIH HHS [DC04563, P30 DC05209] NR 29 TC 11 Z9 13 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2005 VL 132 IS 4 BP 1115 EP 1122 DI 10.1016/j.neuroscience.2005.01.046 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 924NV UT WOS:000228986400022 PM 15857715 ER PT J AU Imamura, S Adams, JC AF Imamura, S Adams, JC TI Selective gentamicin uptake by cytochemical subpopulations of guinea-pig geniculate ganglion cells SO NEUROSCIENCE LA English DT Article DE immunohistochernistry; peptide 19; PMCA-ATPase; aminoglycoside; gentamicin; guinea-pig ID RAT INNER-EAR; VESTIBULAR GANGLION; SPIRAL GANGLION; BIOPHYSICAL PROPERTIES; TRIGEMINAL GANGLION; HAIR-CELLS; PEPTIDE 19; ADULT-RAT; IN-SITU; NEURONS AB Cytochemical subpopulations of geniculate ganglion (GG) cells were identified in guinea-pigs using immunohistochemistry and selective gentamicin accumulation. Two subpopulations of GG cells were evident based upon their location and immunoreactivity for peptide 19 (PEP 19), for plasma membrane Ca2+-ATPase (PMCA-ATPase), and for neurofilament proteins. Cells within the posterior part of GG were positive for PEP 19 and PMCA-ATPase, but not for 68 kD or 160 kD neurofilament proteins. Cells within the anterior part showed complementary staining properties. Cells within these populations showed differences in accumulation of gentamicin, depending upon the administration route. Cells within the posterior part showed avid accumulation of gentamicin when animals received the drug systemically. When the drug was administered directly into the middle ear, cells within the anterior part showed avid gentamicin accumulation. Immunostaining for gentamicin in both cell populations was much more extreme and remained so for longer post-administration times when compared with spiral ganglion and vestibular ganglion cells. The results suggest that cells in the anterior part of GG have little exposure to gentamicin in the serum and that perhaps they innervate the middle ear mucosa or they absorb the drug through their axons within the middle ear. In contrast, cells in the posterior part of GG have greater access to systemically administered gentamicin either directly or via their axon terminals. (C) 2005 Published by Elsevier Ltd on behalf of IBRO. C1 Yamanashi Univ, Dept Otorhinolaryngol, Yamanashi 4093898, Japan. Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Imamura, S (reprint author), Yamanashi Univ, Dept Otorhinolaryngol, 1110 Shimokato, Yamanashi 4093898, Japan. EM imamuras@res.yamanashi-med.ac.jp FU NIDCD NIH HHS [DC00269] NR 49 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2005 VL 131 IS 1 BP 125 EP 133 DI 10.1016/j.neuroscience.2004.11.009 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 896RM UT WOS:000226951200011 PM 15680697 ER PT J AU Lao, L Marvizon, JCG AF Lao, L Marvizon, JCG TI GABA(A) receptor facilitation of neurokinin release from primary afferent terminals in the rat spinal cord SO NEUROSCIENCE LA English DT Article DE C-fiber; dorsal horn; GABA; internalization; neurokinin 1 receptor; substance P ID GAMMA-AMINOBUTYRIC-ACID; PRIMARY SENSORY NEURONS; SUBSTANCE-P RELEASE; METHYL-D-ASPARTATE; CALCIUM-CHANNEL BLOCKERS; SUPERFICIAL DORSAL HORN; ROOT GANGLION NEURONS; BINDING-SITES; NMDA-RECEPTOR; N-TYPE AB Our goal was to test the following hypotheses: 1) GABA(A) receptors facilitate neurokinin release from primary afferent terminals; 2) they do this by suppressing an inhibitory effect of GABA(B) receptors; 3) the activation of these two receptors is controlled by the firing frequency of primary afferents. We evoked neurokinin release by stimulating the dorsal root attached to spinal cord slices, and measured it using neurokinin 1 receptor (NK1R) internalization. Internalization evoked by root stimulation at 1 Hz (but not at 100 Hz) was increased by the GABAA receptor agonists muscimol (effective concentration of drug for 50% of the increase [EC50] 3 muM) and isoguvacine (EC50 4.5 muM). Internalization evoked by root stimulation at 100 Hz was inhibited by the GABAA receptor antagonists bicuculline (effective concentration of drug for 50% of the inhibition [IC50] 2 muM) and picrotoxin (IC50 243 nM). Internalization evoked by incubating the root with capsaicin (to selectively recruit nociceptive fibers) was increased by isoguvacine and abolished by picrotoxin. Therefore, GABAA receptors facilitate neurokinin release. Isoguvacine-facilitated neurokinin release was inhibited by picrotoxin, low Cl-, low Ca2+, Ca2+ channel blockers and N-methyl-D-aspartate receptor antagonists. Bumetanide, an inhibitor of the Na+-K+-2Cl(-) cotransporter, inhibited isoguvacine-facilitated neurokinin release, but this could be attributed to a direct inhibition of GABAA receptors. The GABAB agonist baclofen inhibited NK1R internalization evoked by 100 Hz root stimulation (IC50 1.5 muM), whereas the GABAB receptor antagonist (2S)-3-[[(1S)-1-(3+ dichlorophenyl)ethyl]amino-2-hydroxypropyl](phenylmethyl) phosphinic acid (CGP-55845) increased NK1R internalization evoked by 1 Hz root stimulation (EC50 21 nM). Importantly, baclofen inhibited isoguvacine-facilitated neurokinin release, and CGP-55845 reversed the inhibition of neurokinin release by bicuculline. In conclusion, 1) GABAB receptors located presynaptically in primary afferent terminals inhibit neurakinin release; 2) GABAA receptors located in GABAergic interneurons facilitate neurokinin release by suppressing GABA release onto these GABA(B) receptors; 3) high frequency firing of C-fibers stimulates neurokinin release by activating GABA(A) receptors and inhibiting GABA(B) receptors, whereas low frequency firing inhibits neurokinin release by the converse mechanisms. (C) 2005 IBRO. Published by Elsevier Ltd. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med,Dept Med,Div Digest Dis, CURE Digest Dis Res Ctr, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA. RP Marvizon, JCG (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 115,Room 119,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM marvizon@ucla.edu FU NIDA NIH HHS [R01-DA12609] NR 93 TC 16 Z9 16 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2005 VL 130 IS 4 BP 1013 EP 1027 DI 10.1016/j.neuroscience.2004.10.019 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 894BW UT WOS:000226766000018 PM 15652997 ER PT J AU Frazer, A Morilak, DA AF Frazer, A Morilak, DA TI What should animal models of depression model? SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review ID GENERALIZED ANXIETY DISORDER; FORCED SWIMMING TEST; TRUE DRUG RESPONSE; MAJOR DEPRESSION; ANTIDEPRESSANT DRUGS; DOUBLE-BLIND; CLINICAL-TRIALS; MOOD DISORDERS; NEUROENDOCRINE RESPONSES; EARLY IMPROVEMENT AB In this article, we discuss what animal models of depression should be attempting to 'model'. One must first determine if the goal is to model the regulatory mechanisms by which antidepressant treatments alleviate the various symptoms of depression, or to model the dysregulatory mechanisms underlying the etiology of those symptoms. When modeling the mechanisms of antidepressant effects, a key feature that is often overlooked is the time course required for behavioral efficacy. Even in the clinical literature, there is considerable confusion and inconsistency in defining and identifying 'time of onset' of clinical effect. Although the 'therapeutic tag' may not be as long as has been commonly believed, it does occur. Observable improvement in either global symptomatology or specific symptoms becomes evident after 7-14 days of treatment, and more complete recovery takes considerably longer. Thus, any model addressing potential mechanisms of antidepressant action should exhibit a similar time-dependency. Second, whether attempting to address mechanisms underlying behavioral effects of antidepressants, or the neurobiological substrates underlying the development and manifestation of depression, it is essential to recognize that the syndrome of depression is a diagnostic construct that includes a variety of disparate symptoms, some of which may be related mechanistically, and others that may not be specific to depression, but may cut across categorical diagnostic schemes. Further, it is critical to recognize the close relationship of depression and anxiety. Psychological studies have suggested that the myriad symptoms of depression and anxiety may be subsumed within a more limited number of distinct behavioral dimensions, such as negative affect (neuroticism), positive affect, or physiologic hyperarousal. These dimensions may be related to the functioning of specific neurobiological systems. Thus, rather than trying to recreate or mimic the entire spectrum of symptoms comprising the syndrome of depression, it may be more informative to develop animal models for these behavioral dimensions. Such models may then provide access not only to the neural regulatory mechanisms underlying effective antidepressant treatment, but may also provide clues to the processes underlying the development and manifestation of depression. (c) 2005 Elsevier Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Frazer, A (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, MC 7764,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM frazer@uthscsa.edu FU NIMH NIH HHS [MH53851] NR 88 TC 69 Z9 74 U1 3 U2 19 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PY 2005 VL 29 IS 4-5 SI SI BP 515 EP 523 DI 10.1016/j.neubiorev.2005.03.006 PG 9 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 939JL UT WOS:000230068700003 PM 15893377 ER PT J AU Kliethermes, CL AF Kliethermes, CL TI Anxiety-like behaviors following chronic ethanol exposure SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE ethanol withdrawal; anxiety; elevated plus maze; light/dark box; open field; locomotor activity; mice; rats ID ELEVATED PLUS-MAZE; CORTICOTROPIN-RELEASING-FACTOR; WITHDRAWAL-INDUCED ANXIETY; OPEN-FIELD BEHAVIOR; ONE-TRIAL TOLERANCE; PHYSICAL-DEPENDENCE; ALCOHOL-WITHDRAWAL; EXPLORATORY-BEHAVIOR; ANXIOGENIC RESPONSE; LOCOMOTOR-ACTIVITY AB Rodent models of ethanol withdrawal-induced anxiety have been used to explore the neurobiology underlying withdrawal and to evaluate the utility of therapeutic agents aimed at reducing withdrawal severity. Of the many tests of anxiety-like behavior, the elevated plus maze, light/dark box, and open field are the most commonly used. In general, ethanol withdrawal decreases most or all of the individual behaviors recorded in these tasks, indicating the occurrence of an anxiogenic-like effect of withdrawal in rodents, although these effects of withdrawal have not always been found. Potential problems with interpreting the effects of withdrawal as being indicative of an anxiety-like state include the effects of withdrawal on motivation to explore an apparatus, non-specific effects of withdrawal on locomotion, and the use of test parameters that have not been pharmacologically validated. For example, most of the published studies interpreted as having shown increased anxiety-like behavior during ethanol withdrawal have also observed concurrent decreases in locomotion. At a minimum, a given test of anxiety-like behavior during withdrawal should be responsive to the dose and duration of ethanol exposure that was used to produce physical dependence, and should not non-specifically decrease locomotion. In addition, standard anxiolytic drugs should ameliorate the anxiogenic-like effects of withdrawal, preferably in multiple tests of anxiety-like behavior. (C) 2004 Elsevier Ltd. All rights reserved. C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Dept Vet Affairs Med Ctr,Portland VA Med Ctr, Portland, OR 97239 USA. RP Kliethermes, CL (reprint author), Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Dept Vet Affairs Med Ctr,Portland VA Med Ctr, R&D 12,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM kliether@ohsu.edu FU NIAAA NIH HHS [AA015015, AA10760]; NIDA NIH HHS [DA01762] NR 103 TC 95 Z9 96 U1 2 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PD JAN PY 2005 VL 28 IS 8 BP 837 EP 850 DI 10.1013/j.neubiorev.2004.11.001 PG 14 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 893FH UT WOS:000226704200005 PM 15642625 ER EF